<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Disclosure Solutions PROFILE 3.2.0.0 Copyright 1995 - 2015 Thomson Reuters Accelus. All rights reserved.-->
<xbrl xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2014-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:country="http://xbrl.sec.gov/country/2013-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2014-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2014-01-31" xmlns:ebs="http://emergentbiosolutions.com/20141231" xmlns="http://www.xbrl.org/2003/instance">
  <link:schemaRef xlink:type="simple" xlink:href="ebs-20141231.xsd" />
  <xbrli:context id="c20140101to20141231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20141231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150227">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-02-27</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20131231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130101to20131231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20120101to20121231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20111231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20121231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20111231_StatementEquityComponentsAxis_NoncontrollingInterestMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20111231_StatementEquityComponentsAxis_RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20111231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20111231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20111231_StatementEquityComponentsAxis_TreasuryStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20111231_StatementEquityComponentsAxis_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130101to20131231_StatementEquityComponentsAxis_RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231_StatementEquityComponentsAxis_NoncontrollingInterestMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20120101to20121231_StatementEquityComponentsAxis_RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20120101to20121231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20120101to20121231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130101to20131231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20120101to20121231_StatementEquityComponentsAxis_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130101to20131231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231_StatementEquityComponentsAxis_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20120101to20121231_StatementEquityComponentsAxis_NoncontrollingInterestMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231_StatementEquityComponentsAxis_RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130101to20131231_StatementEquityComponentsAxis_NoncontrollingInterestMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130101to20131231_StatementEquityComponentsAxis_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130101to20131231_StatementEquityComponentsAxis_TreasuryStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231_StatementEquityComponentsAxis_TreasuryStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20120101to20121231_StatementEquityComponentsAxis_TreasuryStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20131231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20141231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20131231_StatementEquityComponentsAxis_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20121231_StatementEquityComponentsAxis_TreasuryStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20141231_StatementEquityComponentsAxis_RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20131231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20131231_StatementEquityComponentsAxis_RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20141231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20131231_StatementEquityComponentsAxis_TreasuryStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20141231_StatementEquityComponentsAxis_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20141231_StatementEquityComponentsAxis_TreasuryStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20121231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20121231_StatementEquityComponentsAxis_RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20131231_StatementEquityComponentsAxis_NoncontrollingInterestMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20121231_StatementEquityComponentsAxis_NoncontrollingInterestMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20121231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20141231_StatementEquityComponentsAxis_NoncontrollingInterestMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20121231_StatementEquityComponentsAxis_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231_BusinessAcquisitionAxis_EvolvaHoldingSA035Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:EvolvaHoldingSA035Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231_BusinessAcquisitionAxis_CangeneMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:CangeneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231_BusinessAcquisitionAxis_HppdMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:HppdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130101to20131231_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20120101to20121231_ConcentrationRiskByBenchmarkAxis_SalesRevenueGoodsNetMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130101to20131231_ConcentrationRiskByBenchmarkAxis_SalesRevenueGoodsNetMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231_ConcentrationRiskByBenchmarkAxis_SalesRevenueGoodsNetMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20131231_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis_UnbilledRevenuesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20141231_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis_UnbilledRevenuesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember_RangeAxis_MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231_PropertyPlantAndEquipmentByTypeAxis_BuildingImprovementsMember_RangeAxis_MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingImprovementsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231_PropertyPlantAndEquipmentByTypeAxis_BuildingMember_RangeAxis_MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231_PropertyPlantAndEquipmentByTypeAxis_BuildingImprovementsMember_RangeAxis_MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingImprovementsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember_RangeAxis_MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231_PropertyPlantAndEquipmentByTypeAxis_BuildingMember_RangeAxis_MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231_PropertyPlantAndEquipmentByTypeAxis_LeaseholdsAndLeaseholdImprovementsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231_PropertyPlantAndEquipmentByTypeAxis_ComputerSoftwareIntangibleAssetMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20141231_PlanNameAxis_EmergentPlansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ebs:EmergentPlansMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ebs:EmergentBiosolutionsInc2006StockIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20141231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ebs:EmergentBiosolutionsInc2006StockIncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20141231_AwardTypeAxis_RestrictedStockUnitsRSUMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ebs:EmergentBiosolutionsInc2006StockIncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember_RangeAxis_MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ebs:EmergentBiosolutionsInc2006StockIncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20141231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember_RangeAxis_MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ebs:EmergentBiosolutionsInc2006StockIncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ebs:EmergentBiosolutionsInc2006StockIncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20120101to20121231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ebs:EmergentBiosolutionsInc2006StockIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130101to20131231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ebs:EmergentBiosolutionsInc2006StockIncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20120101to20121231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember_RangeAxis_MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ebs:EmergentBiosolutionsInc2006StockIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130101to20131231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember_RangeAxis_MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ebs:EmergentBiosolutionsInc2006StockIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20120101to20121231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember_RangeAxis_MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ebs:EmergentBiosolutionsInc2006StockIncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130101to20131231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember_RangeAxis_MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ebs:EmergentBiosolutionsInc2006StockIncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember_RangeAxis_MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ebs:EmergentBiosolutionsInc2006StockIncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140221_BusinessAcquisitionAxis_CangeneMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:CangeneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-02-21</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130801_BusinessAcquisitionAxis_HppdMember_FiniteLivedIntangibleAssetsByMajorClassAxis_RsdlMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ebs:RsdlMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:HppdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-08-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130801_BusinessAcquisitionAxis_HppdMember_FiniteLivedIntangibleAssetsByMajorClassAxis_ManufacturingAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:HppdMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ebs:ManufacturingAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-08-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20141231_BusinessAcquisitionAxis_CangeneMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:CangeneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140221to20140221_BusinessAcquisitionAxis_CangeneMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:CangeneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-02-21</xbrli:startDate>
      <xbrli:endDate>2014-02-21</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140221_BusinessAcquisitionAxis_CangeneMember_FiniteLivedIntangibleAssetsByMajorClassAxis_BiodefenseIntangibleAssetMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:CangeneMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ebs:BiodefenseIntangibleAssetMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-02-21</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140221_BusinessAcquisitionAxis_CangeneMember_FiniteLivedIntangibleAssetsByMajorClassAxis_TradeNamesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:CangeneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-02-21</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140221_BusinessAcquisitionAxis_CangeneMember_FiniteLivedIntangibleAssetsByMajorClassAxis_CustomerContractsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerContractsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:CangeneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-02-21</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140221_BusinessAcquisitionAxis_CangeneMember_FiniteLivedIntangibleAssetsByMajorClassAxis_LicensingAgreementsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:CangeneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-02-21</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140221_BusinessAcquisitionAxis_CangeneMember_FiniteLivedIntangibleAssetsByMajorClassAxis_MarketingRelatedIntangibleAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:CangeneMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:MarketingRelatedIntangibleAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-02-21</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140221to20140221_BusinessAcquisitionAxis_CangeneMember_FiniteLivedIntangibleAssetsByMajorClassAxis_LicensingAgreementsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:CangeneMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-02-21</xbrli:startDate>
      <xbrli:endDate>2014-02-21</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140221to20140221_BusinessAcquisitionAxis_CangeneMember_FiniteLivedIntangibleAssetsByMajorClassAxis_MarketingRelatedIntangibleAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:MarketingRelatedIntangibleAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:CangeneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-02-21</xbrli:startDate>
      <xbrli:endDate>2014-02-21</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140221to20140221_BusinessAcquisitionAxis_CangeneMember_FiniteLivedIntangibleAssetsByMajorClassAxis_CustomerContractsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:CangeneMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerContractsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-02-21</xbrli:startDate>
      <xbrli:endDate>2014-02-21</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140221to20140221_BusinessAcquisitionAxis_CangeneMember_FiniteLivedIntangibleAssetsByMajorClassAxis_TradeNamesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:CangeneMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-02-21</xbrli:startDate>
      <xbrli:endDate>2014-02-21</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140221to20140221_BusinessAcquisitionAxis_CangeneMember_FiniteLivedIntangibleAssetsByMajorClassAxis_BiodefenseIntangibleAssetMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:CangeneMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ebs:BiodefenseIntangibleAssetMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-02-21</xbrli:startDate>
      <xbrli:endDate>2014-02-21</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20141217to20141217_BusinessAcquisitionAxis_EvolvaHoldingSA035Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:EvolvaHoldingSA035Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-12-17</xbrli:startDate>
      <xbrli:endDate>2014-12-17</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231_FiniteLivedIntangibleAssetsByMajorClassAxis_BiodefenseIntangibleAssetMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ebs:BiodefenseIntangibleAssetMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231_BusinessAcquisitionAxis_CangeneMember_FiniteLivedIntangibleAssetsByMajorClassAxis_CustomerContractsMember_IncomeStatementLocationAxis_CostOfSalesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:CangeneMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerContractsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231_BusinessAcquisitionAxis_CangeneMember_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:CangeneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231_FiniteLivedIntangibleAssetsByMajorClassAxis_BiosciencesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ebs:BiosciencesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20131231_BusinessAcquisitionAxis_CangeneMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:CangeneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20141217_BusinessAcquisitionAxis_EvolvaHoldingSA035Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:EvolvaHoldingSA035Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-17</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20141217_BusinessAcquisitionAxis_EvolvaHoldingSA035Member_RangeAxis_MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:EvolvaHoldingSA035Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-17</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20141217_BusinessAcquisitionAxis_EvolvaHoldingSA035Member_RangeAxis_MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:EvolvaHoldingSA035Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-17</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130801_BusinessAcquisitionAxis_HppdMember_RangeAxis_MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:HppdMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-08-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130801_BusinessAcquisitionAxis_HppdMember_RangeAxis_MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:HppdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-08-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130731to20130801_BusinessAcquisitionAxis_HppdMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:HppdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-07-31</xbrli:startDate>
      <xbrli:endDate>2013-08-01</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130801_BusinessAcquisitionAxis_HppdMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:HppdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-08-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130731to20130801_BusinessAcquisitionAxis_HppdMember_FiniteLivedIntangibleAssetsByMajorClassAxis_ManufacturingAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ebs:ManufacturingAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:HppdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-07-31</xbrli:startDate>
      <xbrli:endDate>2013-08-01</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130731to20130801_BusinessAcquisitionAxis_HppdMember_FiniteLivedIntangibleAssetsByMajorClassAxis_RsdlMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:HppdMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ebs:RsdlMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-07-31</xbrli:startDate>
      <xbrli:endDate>2013-08-01</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20131231_BusinessAcquisitionAxis_HppdMember_FiniteLivedIntangibleAssetsByMajorClassAxis_RsdlMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ebs:RsdlMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:HppdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20131231_BusinessAcquisitionAxis_HppdMember_FiniteLivedIntangibleAssetsByMajorClassAxis_ManufacturingAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ebs:ManufacturingAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:HppdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20141231_BusinessAcquisitionAxis_HppdMember_FiniteLivedIntangibleAssetsByMajorClassAxis_RsdlMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:HppdMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ebs:RsdlMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20141231_BusinessAcquisitionAxis_HppdMember_FiniteLivedIntangibleAssetsByMajorClassAxis_ManufacturingAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:HppdMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ebs:ManufacturingAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231_BusinessAcquisitionAxis_HppdMember_FiniteLivedIntangibleAssetsByMajorClassAxis_RsdlMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:HppdMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ebs:RsdlMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231_BusinessAcquisitionAxis_HppdMember_FiniteLivedIntangibleAssetsByMajorClassAxis_ManufacturingAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:HppdMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ebs:ManufacturingAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20141231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20131231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20131231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20141231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20141231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20131231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20131231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20141231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231_TypeOfArrangementAxis_MorphosysMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ebs:MorphosysMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20141231_TypeOfArrangementAxis_MorphosysMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ebs:MorphosysMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20131231_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis_BilledRevenuesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20141231_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis_BilledRevenuesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20141231_PropertyPlantAndEquipmentByTypeAxis_LandAndLandImprovementsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandAndLandImprovementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20141231_PropertyPlantAndEquipmentByTypeAxis_ComputerSoftwareIntangibleAssetMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20141231_PropertyPlantAndEquipmentByTypeAxis_ConstructionInProgressMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20131231_PropertyPlantAndEquipmentByTypeAxis_ComputerSoftwareIntangibleAssetMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20131231_PropertyPlantAndEquipmentByTypeAxis_ConstructionInProgressMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20131231_PropertyPlantAndEquipmentByTypeAxis_LandAndLandImprovementsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandAndLandImprovementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20131231_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20141231_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20131231_PropertyPlantAndEquipmentByTypeAxis_BuildingAndBuildingImprovementsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20141231_PropertyPlantAndEquipmentByTypeAxis_BuildingAndBuildingImprovementsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20131231_FiniteLivedIntangibleAssetsByMajorClassAxis_BiodefenseProductsMember_StatementBusinessSegmentsAxis_BiodefenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ebs:BiodefenseProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:BiodefenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20131231_FiniteLivedIntangibleAssetsByMajorClassAxis_ContractualRightsMember_StatementBusinessSegmentsAxis_BiosciencesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:BiosciencesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20131231_FiniteLivedIntangibleAssetsByMajorClassAxis_ManufacturingAgreementMember_StatementBusinessSegmentsAxis_BiodefenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:BiodefenseMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ebs:ManufacturingAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20131231_FiniteLivedIntangibleAssetsByMajorClassAxis_TradeNamesMember_StatementBusinessSegmentsAxis_BiosciencesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:BiosciencesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20131231_FiniteLivedIntangibleAssetsByMajorClassAxis_LicensingAgreementsMember_StatementBusinessSegmentsAxis_BiosciencesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:BiosciencesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20131231_FiniteLivedIntangibleAssetsByMajorClassAxis_RsdlMember_StatementBusinessSegmentsAxis_BiodefenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ebs:RsdlMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:BiodefenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20131231_FiniteLivedIntangibleAssetsByMajorClassAxis_MarketedProductsMember_StatementBusinessSegmentsAxis_BiosciencesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:BiosciencesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ebs:MarketedProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231_FiniteLivedIntangibleAssetsByMajorClassAxis_ContractualRightsMember_StatementBusinessSegmentsAxis_BiosciencesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:BiosciencesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231_FiniteLivedIntangibleAssetsByMajorClassAxis_MarketedProductsMember_StatementBusinessSegmentsAxis_BiosciencesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ebs:MarketedProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:BiosciencesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231_FiniteLivedIntangibleAssetsByMajorClassAxis_BiodefenseProductsMember_StatementBusinessSegmentsAxis_BiodefenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:BiodefenseMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ebs:BiodefenseProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231_FiniteLivedIntangibleAssetsByMajorClassAxis_ManufacturingAgreementMember_StatementBusinessSegmentsAxis_BiodefenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ebs:ManufacturingAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:BiodefenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231_FiniteLivedIntangibleAssetsByMajorClassAxis_RsdlMember_StatementBusinessSegmentsAxis_BiodefenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:BiodefenseMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ebs:RsdlMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231_FiniteLivedIntangibleAssetsByMajorClassAxis_TradeNamesMember_StatementBusinessSegmentsAxis_BiosciencesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:BiosciencesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231_FiniteLivedIntangibleAssetsByMajorClassAxis_LicensingAgreementsMember_StatementBusinessSegmentsAxis_BiosciencesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:BiosciencesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20141231_FiniteLivedIntangibleAssetsByMajorClassAxis_LicensingAgreementsMember_StatementBusinessSegmentsAxis_BiosciencesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:BiosciencesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20141231_FiniteLivedIntangibleAssetsByMajorClassAxis_ManufacturingAgreementMember_StatementBusinessSegmentsAxis_BiodefenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:BiodefenseMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ebs:ManufacturingAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20141231_FiniteLivedIntangibleAssetsByMajorClassAxis_RsdlMember_StatementBusinessSegmentsAxis_BiodefenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:BiodefenseMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ebs:RsdlMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20141231_FiniteLivedIntangibleAssetsByMajorClassAxis_MarketedProductsMember_StatementBusinessSegmentsAxis_BiosciencesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:BiosciencesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ebs:MarketedProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20141231_FiniteLivedIntangibleAssetsByMajorClassAxis_BiodefenseProductsMember_StatementBusinessSegmentsAxis_BiodefenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:BiodefenseMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ebs:BiodefenseProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20141231_FiniteLivedIntangibleAssetsByMajorClassAxis_ContractualRightsMember_StatementBusinessSegmentsAxis_BiosciencesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:BiosciencesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20141231_FiniteLivedIntangibleAssetsByMajorClassAxis_TradeNamesMember_StatementBusinessSegmentsAxis_BiosciencesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:BiosciencesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20141231_FiniteLivedIntangibleAssetsByMajorClassAxis_ManufacturingAgreementMember_StatementBusinessSegmentsAxis_BiosciencesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:BiosciencesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ebs:ManufacturingAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20131231_StatementBusinessSegmentsAxis_BiosciencesMember_SubsegmentsAxis_BiosciencesContractsManufacturingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ebs:BiosciencesContractsManufacturingMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:BiosciencesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20131231_StatementBusinessSegmentsAxis_BiodefenseMember_SubsegmentsAxis_BiodefenseTherapeuticsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ebs:BiodefenseTherapeuticsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:BiodefenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20131231_StatementBusinessSegmentsAxis_BiosciencesMember_SubsegmentsAxis_BiosciencesTherapeuticsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ebs:BiosciencesTherapeuticsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:BiosciencesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20131231_StatementBusinessSegmentsAxis_BiodefenseMember_SubsegmentsAxis_BiodefenseMedicalDevicesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ebs:BiodefenseMedicalDevicesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:BiodefenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231_StatementBusinessSegmentsAxis_BiodefenseMember_SubsegmentsAxis_BiodefenseTherapeuticsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:BiodefenseMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ebs:BiodefenseTherapeuticsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231_StatementBusinessSegmentsAxis_BiosciencesMember_SubsegmentsAxis_BiosciencesTherapeuticsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ebs:BiosciencesTherapeuticsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:BiosciencesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231_StatementBusinessSegmentsAxis_BiodefenseMember_SubsegmentsAxis_BiodefenseMedicalDevicesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:BiodefenseMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ebs:BiodefenseMedicalDevicesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231_StatementBusinessSegmentsAxis_BiosciencesMember_SubsegmentsAxis_BiosciencesContractsManufacturingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ebs:BiosciencesContractsManufacturingMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:BiosciencesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20141231_StatementBusinessSegmentsAxis_BiosciencesMember_SubsegmentsAxis_BiosciencesContractsManufacturingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:BiosciencesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ebs:BiosciencesContractsManufacturingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20141231_StatementBusinessSegmentsAxis_BiodefenseMember_SubsegmentsAxis_BiodefenseTherapeuticsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ebs:BiodefenseTherapeuticsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:BiodefenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20141231_StatementBusinessSegmentsAxis_BiodefenseMember_SubsegmentsAxis_BiodefenseMedicalDevicesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:BiodefenseMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ebs:BiodefenseMedicalDevicesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20141231_StatementBusinessSegmentsAxis_BiosciencesMember_SubsegmentsAxis_BiosciencesTherapeuticsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:BiosciencesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ebs:BiosciencesTherapeuticsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20141231_StatementBusinessSegmentsAxis_BiosciencesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:BiosciencesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20141231_StatementBusinessSegmentsAxis_BiodefenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:BiodefenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140129_LongtermDebtTypeAxis_ConvertibleSeniorNotesDue2021Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ebs:ConvertibleSeniorNotesDue2021Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-01-29</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231_LongtermDebtTypeAxis_EbsBamlTermLoanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ebs:EbsBamlTermLoanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20140129_LongtermDebtTypeAxis_ConvertibleSeniorNotesDue2021Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ebs:ConvertibleSeniorNotesDue2021Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-01-29</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231_LongtermDebtTypeAxis_RevolvingCreditLoanDatedDecember2013DueInDecember2018Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ebs:RevolvingCreditLoanDatedDecember2013DueInDecember2018Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231_LongtermDebtTypeAxis_CreditAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ebs:CreditAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20141231_LongtermDebtTypeAxis_EbsBamlTermLoanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ebs:EbsBamlTermLoanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140331_LongtermDebtTypeAxis_RevolvingCreditLoanDatedDecember2013DueInDecember2018Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ebs:RevolvingCreditLoanDatedDecember2013DueInDecember2018Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130101to20131231_LongtermDebtTypeAxis_RevolvingCreditLoanDatedDecember2013DueInDecember2018Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ebs:RevolvingCreditLoanDatedDecember2013DueInDecember2018Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20140331_LongtermDebtTypeAxis_CreditAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ebs:CreditAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20140930_LongtermDebtTypeAxis_CreditAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ebs:CreditAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20141231_LongtermDebtTypeAxis_CreditAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ebs:CreditAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20141231_ShareRepurchaseProgramAxis_StockRepurchasePlanOf2012Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">ebs:StockRepurchasePlanOf2012Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231_ShareRepurchaseProgramAxis_StockRepurchasePlanOf2012Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">ebs:StockRepurchasePlanOf2012Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231_RelatedPartyTransactionsByRelatedPartyAxis_ChiefExecutiveOfficerMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231_PlanNameAxis_EmployeeStockPurchasePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ebs:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20141231_PlanNameAxis_EmployeeStockPurchasePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ebs:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20141231_PlanNameAxis_EmployeeStockPurchasePlanMember_RangeAxis_MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ebs:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20141231_PlanNameAxis_EmployeeStockPurchasePlanMember_RangeAxis_MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ebs:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20131231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EmergentBiosolutionsEmployeeStockOptionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ebs:EmergentBiosolutionsEmployeeStockOptionPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20131231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ebs:EmergentBiosolutionsInc2006StockIncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EmergentBiosolutionsEmployeeStockOptionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ebs:EmergentBiosolutionsEmployeeStockOptionPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20141231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EmergentBiosolutionsEmployeeStockOptionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ebs:EmergentBiosolutionsEmployeeStockOptionPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20131231_AwardTypeAxis_EmployeeStockOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20141231_AwardTypeAxis_EmployeeStockOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20131231_AwardTypeAxis_RestrictedStockUnitsRSUMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ebs:EmergentBiosolutionsInc2006StockIncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231_AwardTypeAxis_RestrictedStockUnitsRSUMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ebs:EmergentBiosolutionsInc2006StockIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231_AwardTypeAxis_EmployeeStockOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130101to20131231_AwardTypeAxis_EmployeeStockOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20120101to20121231_AwardTypeAxis_EmployeeStockOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20120101to20121231_IncomeStatementLocationAxis_CostOfSalesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231_IncomeStatementLocationAxis_CostOfSalesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20120101to20121231_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130101to20131231_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130101to20131231_IncomeStatementLocationAxis_CostOfSalesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130101to20131231_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20120101to20121231_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20141231_IncomeTaxAuthorityAxis_ForeignCountryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20141231_IncomeTaxAuthorityAxis_InternalRevenueServiceIRSMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20141231_IncomeTaxAuthorityAxis_StateAndLocalJurisdictionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231_IncomeTaxAuthorityAxis_InternalRevenueServiceIRSMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231_IncomeTaxAuthorityAxis_StateAndLocalJurisdictionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231_IncomeTaxAuthorityAxis_ForeignCountryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20141231_TaxCreditCarryforwardAxis_EBSManitobaScientificResearchAndExperimentalDevelopmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">ebs:EBSManitobaScientificResearchAndExperimentalDevelopmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20141231_TaxCreditCarryforwardAxis_EBSCanadianFederalScientificResearchAndDevelopmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">ebs:EBSCanadianFederalScientificResearchAndDevelopmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20141231_TaxCreditCarryforwardAxis_ResearchMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231_TaxCreditCarryforwardAxis_EBSCanadianFederalScientificResearchAndDevelopmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">ebs:EBSCanadianFederalScientificResearchAndDevelopmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231_TaxCreditCarryforwardAxis_ResearchMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231_TaxCreditCarryforwardAxis_EBSManitobaScientificResearchAndExperimentalDevelopmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">ebs:EBSManitobaScientificResearchAndExperimentalDevelopmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231_IncomeTaxAuthorityAxis_InternalRevenueServiceIRSMember_RangeAxis_MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231_IncomeTaxAuthorityAxis_ForeignCountryMember_RangeAxis_MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231_IncomeTaxAuthorityAxis_InternalRevenueServiceIRSMember_RangeAxis_MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231_IncomeTaxAuthorityAxis_ForeignCountryMember_RangeAxis_MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20141231_RestructuringCostAndReserveAxis_SpecialTerminationBenefitsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:SpecialTerminationBenefitsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20141231_RestructuringCostAndReserveAxis_ContractTerminationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:ContractTerminationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20141231_RestructuringCostAndReserveAxis_OtherRestructuringMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20121231_RestructuringCostAndReserveAxis_ContractTerminationMember_RestructuringPlanAxis_EpduRestructuringPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:ContractTerminationMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:EpduRestructuringPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20121231_RestructuringPlanAxis_EpduRestructuringPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:EpduRestructuringPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20121231_RestructuringCostAndReserveAxis_SpecialTerminationBenefitsMember_RestructuringPlanAxis_EpduRestructuringPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:SpecialTerminationBenefitsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:EpduRestructuringPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231_RestructuringPlanAxis_EpduRestructuringPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:EpduRestructuringPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130101to20131231_RestructuringCostAndReserveAxis_SpecialTerminationBenefitsMember_RestructuringPlanAxis_EpduRestructuringPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:SpecialTerminationBenefitsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:EpduRestructuringPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130101to20131231_RestructuringCostAndReserveAxis_ContractTerminationMember_RestructuringPlanAxis_EpduRestructuringPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:ContractTerminationMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:EpduRestructuringPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231_RestructuringCostAndReserveAxis_SpecialTerminationBenefitsMember_RestructuringPlanAxis_EpduRestructuringPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:SpecialTerminationBenefitsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:EpduRestructuringPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231_RestructuringCostAndReserveAxis_ContractTerminationMember_RestructuringPlanAxis_EpduRestructuringPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:ContractTerminationMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:EpduRestructuringPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130101to20131231_RestructuringPlanAxis_EpduRestructuringPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:EpduRestructuringPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20141231_RestructuringCostAndReserveAxis_SpecialTerminationBenefitsMember_RestructuringPlanAxis_EpduRestructuringPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:EpduRestructuringPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:SpecialTerminationBenefitsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20141231_RestructuringPlanAxis_EpduRestructuringPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:EpduRestructuringPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20141231_RestructuringCostAndReserveAxis_ContractTerminationMember_RestructuringPlanAxis_EpduRestructuringPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:EpduRestructuringPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:ContractTerminationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231_PropertyPlantAndEquipmentByTypeAxis_OfficeSpaceWokinghamEnglandMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ebs:OfficeSpaceWokinghamEnglandMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231_PropertyPlantAndEquipmentByTypeAxis_OfficeAndLaboratorySpaceSeattleWashingtonMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ebs:OfficeAndLaboratorySpaceSeattleWashingtonMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231_PropertyPlantAndEquipmentByTypeAxis_OfficeAndLaboratorySpaceRockvilleMarylandMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ebs:OfficeAndLaboratorySpaceRockvilleMarylandMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231_PropertyPlantAndEquipmentByTypeAxis_OfficeAndLaboratorySpaceMunichGermanyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ebs:OfficeAndLaboratorySpaceMunichGermanyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20141231_PropertyPlantAndEquipmentByTypeAxis_OfficeAndLaboratorySpaceRockvilleMarylandMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ebs:OfficeAndLaboratorySpaceRockvilleMarylandMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231_StatementGeographicalAxis_AE">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:AE</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231_StatementGeographicalAxis_QA">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:QA</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231_StatementGeographicalAxis_SA">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:SA</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130101to20131231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20120101to20121231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20141231_StatementGeographicalAxis_EBSForeignJurisdictionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">ebs:EBSForeignJurisdictionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20121231_StatementGeographicalAxis_EBSForeignJurisdictionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">ebs:EBSForeignJurisdictionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20131231_StatementGeographicalAxis_EBSForeignJurisdictionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">ebs:EBSForeignJurisdictionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20120101to20121231_StatementBusinessSegmentsAxis_BiosciencesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:BiosciencesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231_StatementBusinessSegmentsAxis_BiosciencesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:BiosciencesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20120101to20121231_StatementBusinessSegmentsAxis_BiodefenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:BiodefenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130101to20131231_ConsolidationItemsAxis_IntersegmentEliminationMember_StatementBusinessSegmentsAxis_AllOtherSegmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20120101to20121231_ConsolidationItemsAxis_IntersegmentEliminationMember_StatementBusinessSegmentsAxis_BiodefenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:BiodefenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231_ConsolidationItemsAxis_IntersegmentEliminationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130101to20131231_ConsolidationItemsAxis_IntersegmentEliminationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20120101to20121231_StatementBusinessSegmentsAxis_AllOtherSegmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231_StatementBusinessSegmentsAxis_AllOtherSegmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231_ConsolidationItemsAxis_IntersegmentEliminationMember_StatementBusinessSegmentsAxis_BiosciencesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:BiosciencesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130101to20131231_StatementBusinessSegmentsAxis_BiosciencesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:BiosciencesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130101to20131231_ConsolidationItemsAxis_IntersegmentEliminationMember_StatementBusinessSegmentsAxis_BiosciencesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:BiosciencesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20120101to20121231_ConsolidationItemsAxis_IntersegmentEliminationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130101to20131231_StatementBusinessSegmentsAxis_BiodefenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:BiodefenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20120101to20121231_ConsolidationItemsAxis_IntersegmentEliminationMember_StatementBusinessSegmentsAxis_BiosciencesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:BiosciencesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20120101to20121231_ConsolidationItemsAxis_IntersegmentEliminationMember_StatementBusinessSegmentsAxis_AllOtherSegmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130101to20131231_StatementBusinessSegmentsAxis_AllOtherSegmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231_ConsolidationItemsAxis_IntersegmentEliminationMember_StatementBusinessSegmentsAxis_AllOtherSegmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231_ConsolidationItemsAxis_IntersegmentEliminationMember_StatementBusinessSegmentsAxis_BiodefenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:BiodefenseMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231_StatementBusinessSegmentsAxis_BiodefenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:BiodefenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130101to20131231_ConsolidationItemsAxis_IntersegmentEliminationMember_StatementBusinessSegmentsAxis_BiodefenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:BiodefenseMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20131231_StatementBusinessSegmentsAxis_AllOtherSegmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20131231_StatementBusinessSegmentsAxis_BiodefenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:BiodefenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20131231_StatementBusinessSegmentsAxis_BiosciencesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:BiosciencesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20141231_StatementBusinessSegmentsAxis_AllOtherSegmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20121231_StatementBusinessSegmentsAxis_BiosciencesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:BiosciencesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20121231_StatementBusinessSegmentsAxis_BiodefenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:BiodefenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20121231_StatementBusinessSegmentsAxis_AllOtherSegmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20141001to20141231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-10-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130701to20130930">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-07-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130101to20130331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140701to20140930">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-07-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20140331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140401to20140630">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-04-01</xbrli:startDate>
      <xbrli:endDate>2014-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20131001to20131231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-10-01</xbrli:startDate>
      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130401to20130630">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-04-01</xbrli:startDate>
      <xbrli:endDate>2013-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:unit id="U001">
    <xbrli:measure>iso4217:USD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U002">
    <xbrli:measure>xbrli:shares</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U003">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>
      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>
  <xbrli:unit id="U004">
    <xbrli:measure>utr:acre</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U005">
    <xbrli:measure>xbrli:pure</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U006">
    <xbrli:measure>ebs:Dose</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U007">
    <xbrli:measure>ebs:Plan</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U008">
    <xbrli:measure>ebs:Unit</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U009">
    <xbrli:measure>ebs:Employee</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U010">
    <xbrli:measure>ebs:Segment</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U011">
    <xbrli:measure>ebs:BusinessUnit</xbrli:measure>
  </xbrli:unit>
  <!--Amendment Flag-->
  <dei:AmendmentFlag contextRef="c20140101to20141231">false</dei:AmendmentFlag>
  <!--Current Fiscal Year End Date-->
  <dei:CurrentFiscalYearEndDate contextRef="c20140101to20141231">--12-31</dei:CurrentFiscalYearEndDate>
  <!--Document Period End Date-->
  <dei:DocumentPeriodEndDate contextRef="c20140101to20141231">2014-12-31</dei:DocumentPeriodEndDate>
  <!--Entity Well-known Seasoned Issuer-->
  <dei:EntityWellKnownSeasonedIssuer contextRef="c20140101to20141231">Yes</dei:EntityWellKnownSeasonedIssuer>
  <!--Entity Voluntary Filers-->
  <dei:EntityVoluntaryFilers contextRef="c20140101to20141231">No</dei:EntityVoluntaryFilers>
  <!--Entity Current Reporting Status-->
  <dei:EntityCurrentReportingStatus contextRef="c20140101to20141231">Yes</dei:EntityCurrentReportingStatus>
  <!--Entity Filer Category-->
  <dei:EntityFilerCategory contextRef="c20140101to20141231">Accelerated Filer</dei:EntityFilerCategory>
  <!--Entity Public Float-->
  <dei:EntityPublicFloat contextRef="c20141231" unitRef="U001" decimals="-6">0</dei:EntityPublicFloat>
  <!--Entity Registrant Name-->
  <dei:EntityRegistrantName contextRef="c20140101to20141231">Emergent BioSolutions Inc.</dei:EntityRegistrantName>
  <!--Entity Central Index Key-->
  <dei:EntityCentralIndexKey contextRef="c20140101to20141231">0001367644</dei:EntityCentralIndexKey>
  <!--Entity Common Stock, Shares Outstanding-->
  <dei:EntityCommonStockSharesOutstanding contextRef="c20150227" unitRef="U002" decimals="0">37918377</dei:EntityCommonStockSharesOutstanding>
  <!--Document Fiscal Year Focus-->
  <dei:DocumentFiscalYearFocus contextRef="c20140101to20141231">2014</dei:DocumentFiscalYearFocus>
  <!--Document Fiscal Period Focus-->
  <dei:DocumentFiscalPeriodFocus contextRef="c20140101to20141231">FY</dei:DocumentFiscalPeriodFocus>
  <!--Document Type-->
  <dei:DocumentType contextRef="c20140101to20141231">10-K</dei:DocumentType>
  <!--Area of land in Lansing, Michigan (in acres)-->
  <us-gaap:AreaOfLand contextRef="c20141231" unitRef="U004" decimals="1">12.5</us-gaap:AreaOfLand>
  <!--Unbilled accounts receivable-->
  <us-gaap:AccountsReceivableNetCurrent contextRef="c20131231" unitRef="U001" decimals="-3">60587000</us-gaap:AccountsReceivableNetCurrent>
  <!--Unbilled accounts receivable-->
  <us-gaap:AccountsReceivableNetCurrent contextRef="c20141231" unitRef="U001" decimals="-3">58834000</us-gaap:AccountsReceivableNetCurrent>
  <!--Unbilled accounts receivable-Unbilled [Member]-->
  <us-gaap:AccountsReceivableNetCurrent contextRef="c20131231_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis_UnbilledRevenuesMember" unitRef="U001" decimals="-3">14830000</us-gaap:AccountsReceivableNetCurrent>
  <!--Unbilled accounts receivable-Unbilled [Member]-->
  <us-gaap:AccountsReceivableNetCurrent contextRef="c20141231_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis_UnbilledRevenuesMember" unitRef="U001" decimals="-3">18886000</us-gaap:AccountsReceivableNetCurrent>
  <!--Unbilled accounts receivable-Billed [Member]-->
  <us-gaap:AccountsReceivableNetCurrent contextRef="c20131231_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis_BilledRevenuesMember" unitRef="U001" decimals="-3">45757000</us-gaap:AccountsReceivableNetCurrent>
  <!--Unbilled accounts receivable-Billed [Member]-->
  <us-gaap:AccountsReceivableNetCurrent contextRef="c20141231_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis_BilledRevenuesMember" unitRef="U001" decimals="-3">39948000</us-gaap:AccountsReceivableNetCurrent>
  <!--Accounts Receivable, Net-Morphosys [Member]-->
  <us-gaap:AccountsReceivableNet contextRef="c20141231_TypeOfArrangementAxis_MorphosysMember" unitRef="U001" decimals="0">972000</us-gaap:AccountsReceivableNet>
  <!--Accounts Payable, Current-->
  <us-gaap:AccountsPayableCurrent contextRef="c20141231" unitRef="U001" decimals="-3">40930000</us-gaap:AccountsPayableCurrent>
  <!--Accounts Payable, Current-->
  <us-gaap:AccountsPayableCurrent contextRef="c20131231" unitRef="U001" decimals="-3">27521000</us-gaap:AccountsPayableCurrent>
  <!--Accrued expenses and other current liabilities-->
  <us-gaap:AccruedLiabilitiesCurrent contextRef="c20141231" unitRef="U001" decimals="-3">6274000</us-gaap:AccruedLiabilitiesCurrent>
  <!--Accrued expenses and other current liabilities-->
  <us-gaap:AccruedLiabilitiesCurrent contextRef="c20131231" unitRef="U001" decimals="-3">1252000</us-gaap:AccruedLiabilitiesCurrent>
  <!--Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment-->
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c20131231" unitRef="U001" decimals="-3">57371000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <!--Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment-->
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c20141231" unitRef="U001" decimals="-3">79430000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <!--Accumulated other comprehensive loss-->
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c20141231" unitRef="U001" decimals="-3">-3008000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <!--Accumulated other comprehensive loss-->
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c20131231" unitRef="U001" decimals="-3">-3465000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <!--Weighted average amortization period of intangible assets-HPPD [Member]-->
  <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife contextRef="c20140101to20141231_BusinessAcquisitionAxis_HppdMember">P72M</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
  <!--Additional paid-in capital-->
  <us-gaap:AdditionalPaidInCapital contextRef="c20141231" unitRef="U001" decimals="-3">274222000</us-gaap:AdditionalPaidInCapital>
  <!--Additional paid-in capital-->
  <us-gaap:AdditionalPaidInCapital contextRef="c20131231" unitRef="U001" decimals="-3">247637000</us-gaap:AdditionalPaidInCapital>
  <!--Allocated Share-based Compensation Expense-->
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c20120101to20121231" unitRef="U001" decimals="-3">11115000</us-gaap:AllocatedShareBasedCompensationExpense>
  <!--Allocated Share-based Compensation Expense-Cost of Sales [Member]-->
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c20120101to20121231_IncomeStatementLocationAxis_CostOfSalesMember" unitRef="U001" decimals="-3">513000</us-gaap:AllocatedShareBasedCompensationExpense>
  <!--Allocated Share-based Compensation Expense-Cost of Sales [Member]-->
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c20140101to20141231_IncomeStatementLocationAxis_CostOfSalesMember" unitRef="U001" decimals="-3">1145000</us-gaap:AllocatedShareBasedCompensationExpense>
  <!--Allocated Share-based Compensation Expense-Selling, General and Administrative Expenses [Member]-->
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c20120101to20121231_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember" unitRef="U001" decimals="-3">7151000</us-gaap:AllocatedShareBasedCompensationExpense>
  <!--Allocated Share-based Compensation Expense-Research and Development Expense [Member]-->
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c20140101to20141231_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember" unitRef="U001" decimals="-3">3606000</us-gaap:AllocatedShareBasedCompensationExpense>
  <!--Allocated Share-based Compensation Expense-Research and Development Expense [Member]-->
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c20130101to20131231_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember" unitRef="U001" decimals="-3">3283000</us-gaap:AllocatedShareBasedCompensationExpense>
  <!--Allocated Share-based Compensation Expense-->
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c20130101to20131231" unitRef="U001" decimals="-3">11238000</us-gaap:AllocatedShareBasedCompensationExpense>
  <!--Allocated Share-based Compensation Expense-Cost of Sales [Member]-->
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c20130101to20131231_IncomeStatementLocationAxis_CostOfSalesMember" unitRef="U001" decimals="-3">575000</us-gaap:AllocatedShareBasedCompensationExpense>
  <!--Allocated Share-based Compensation Expense-Selling, General and Administrative Expenses [Member]-->
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c20140101to20141231_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember" unitRef="U001" decimals="-3">8078000</us-gaap:AllocatedShareBasedCompensationExpense>
  <!--Allocated Share-based Compensation Expense-Selling, General and Administrative Expenses [Member]-->
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c20130101to20131231_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember" unitRef="U001" decimals="-3">7380000</us-gaap:AllocatedShareBasedCompensationExpense>
  <!--Allocated Share-based Compensation Expense-->
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c20140101to20141231" unitRef="U001" decimals="-3">12829000</us-gaap:AllocatedShareBasedCompensationExpense>
  <!--Allocated Share-based Compensation Expense-Research and Development Expense [Member]-->
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c20120101to20121231_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember" unitRef="U001" decimals="-3">3451000</us-gaap:AllocatedShareBasedCompensationExpense>
  <!--Amortization of Financing Costs-->
  <us-gaap:AmortizationOfFinancingCosts contextRef="c20120101to20121231" unitRef="U001" decimals="-3">0</us-gaap:AmortizationOfFinancingCosts>
  <!--Amortization of Financing Costs-->
  <us-gaap:AmortizationOfFinancingCosts contextRef="c20140101to20141231" unitRef="U001" decimals="-3">-735000</us-gaap:AmortizationOfFinancingCosts>
  <!--Amortization of Financing Costs-->
  <us-gaap:AmortizationOfFinancingCosts contextRef="c20130101to20131231" unitRef="U001" decimals="-3">0</us-gaap:AmortizationOfFinancingCosts>
  <!--Amortization-Biodefense Intangible Asset [Member]-->
  <us-gaap:AmortizationOfIntangibleAssets contextRef="c20140101to20141231_FiniteLivedIntangibleAssetsByMajorClassAxis_BiodefenseIntangibleAssetMember" unitRef="U001" decimals="-5">1200000</us-gaap:AmortizationOfIntangibleAssets>
  <!--Amortization-Cangene [Member]-Contract Manufacturing [Member]-Cost of Sales [Member]-->
  <us-gaap:AmortizationOfIntangibleAssets contextRef="c20140101to20141231_BusinessAcquisitionAxis_CangeneMember_FiniteLivedIntangibleAssetsByMajorClassAxis_CustomerContractsMember_IncomeStatementLocationAxis_CostOfSalesMember" unitRef="U001" decimals="-5">2800000</us-gaap:AmortizationOfIntangibleAssets>
  <!--Amortization-Selling, General and Administrative Expenses [Member]-Cangene [Member]-->
  <us-gaap:AmortizationOfIntangibleAssets contextRef="c20140101to20141231_BusinessAcquisitionAxis_CangeneMember_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember" unitRef="U001" decimals="0">478000</us-gaap:AmortizationOfIntangibleAssets>
  <!--Amortization-Biosciences [Member]-->
  <us-gaap:AmortizationOfIntangibleAssets contextRef="c20140101to20141231_FiniteLivedIntangibleAssetsByMajorClassAxis_BiosciencesMember" unitRef="U001" decimals="-5">2100000</us-gaap:AmortizationOfIntangibleAssets>
  <!--Amortization-Cangene [Member]-->
  <us-gaap:AmortizationOfIntangibleAssets contextRef="c20140101to20141231_BusinessAcquisitionAxis_CangeneMember" unitRef="U001" decimals="-5">3300000</us-gaap:AmortizationOfIntangibleAssets>
  <!--Amortization-HPPD [Member]-RSDL [Member]-->
  <us-gaap:AmortizationOfIntangibleAssets contextRef="c20140101to20141231_BusinessAcquisitionAxis_HppdMember_FiniteLivedIntangibleAssetsByMajorClassAxis_RsdlMember" unitRef="U001" decimals="-3">-3519000</us-gaap:AmortizationOfIntangibleAssets>
  <!--Amortization-HPPD [Member]-Manufacturing Agreement [Member]-->
  <us-gaap:AmortizationOfIntangibleAssets contextRef="c20140101to20141231_BusinessAcquisitionAxis_HppdMember_FiniteLivedIntangibleAssetsByMajorClassAxis_ManufacturingAgreementMember" unitRef="U001" decimals="-3">-1159000</us-gaap:AmortizationOfIntangibleAssets>
  <!--Amortization-Licensed Products [Member]-Biosciences [Member]-->
  <us-gaap:AmortizationOfIntangibleAssets contextRef="c20140101to20141231_FiniteLivedIntangibleAssetsByMajorClassAxis_LicensingAgreementsMember_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U001" decimals="-3">-378000</us-gaap:AmortizationOfIntangibleAssets>
  <!--Amortization-->
  <us-gaap:AmortizationOfIntangibleAssets contextRef="c20140101to20141231" unitRef="U001" decimals="-3">-8004000</us-gaap:AmortizationOfIntangibleAssets>
  <!--Amortization-Biosciences [Member]-Contractual Rights [Member]-->
  <us-gaap:AmortizationOfIntangibleAssets contextRef="c20140101to20141231_FiniteLivedIntangibleAssetsByMajorClassAxis_ContractualRightsMember_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U001" decimals="-3">-587000</us-gaap:AmortizationOfIntangibleAssets>
  <!--Amortization-Biosciences [Member]-Corporate Trade Name [Member]-->
  <us-gaap:AmortizationOfIntangibleAssets contextRef="c20140101to20141231_FiniteLivedIntangibleAssetsByMajorClassAxis_TradeNamesMember_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U001" decimals="-3">-478000</us-gaap:AmortizationOfIntangibleAssets>
  <!--Amortization-Marketed Products [Member]-Biosciences [Member]-->
  <us-gaap:AmortizationOfIntangibleAssets contextRef="c20140101to20141231_FiniteLivedIntangibleAssetsByMajorClassAxis_MarketedProductsMember_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U001" decimals="-3">-692000</us-gaap:AmortizationOfIntangibleAssets>
  <!--Amortization-Biodefense [Member]-RSDL [Member]-->
  <us-gaap:AmortizationOfIntangibleAssets contextRef="c20140101to20141231_FiniteLivedIntangibleAssetsByMajorClassAxis_RsdlMember_StatementBusinessSegmentsAxis_BiodefenseMember" unitRef="U001" decimals="-3">-3519000</us-gaap:AmortizationOfIntangibleAssets>
  <!--Amortization-Biodefense [Member]-Biodefense Products [Member]-->
  <us-gaap:AmortizationOfIntangibleAssets contextRef="c20140101to20141231_FiniteLivedIntangibleAssetsByMajorClassAxis_BiodefenseProductsMember_StatementBusinessSegmentsAxis_BiodefenseMember" unitRef="U001" decimals="-3">-1191000</us-gaap:AmortizationOfIntangibleAssets>
  <!--Amortization-Manufacturing Agreement [Member]-Biodefense [Member]-->
  <us-gaap:AmortizationOfIntangibleAssets contextRef="c20140101to20141231_FiniteLivedIntangibleAssetsByMajorClassAxis_ManufacturingAgreementMember_StatementBusinessSegmentsAxis_BiodefenseMember" unitRef="U001" decimals="-3">-1159000</us-gaap:AmortizationOfIntangibleAssets>
  <!--Antidilutive shares excluded from calculation (in shares)-Stock Options [Member]-->
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c20130101to20131231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember" unitRef="U002" decimals="-5">1500000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <!--Antidilutive shares excluded from calculation (in shares)-Stock Options [Member]-->
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c20120101to20121231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember" unitRef="U002" decimals="-5">2900000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <!--Antidilutive shares excluded from calculation (in shares)-Stock Options [Member]-->
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c20140101to20141231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember" unitRef="U002" decimals="-5">1400000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <!--Impairment related to equipment-->
  <us-gaap:AssetImpairmentCharges contextRef="c20130101to20131231" unitRef="U001" decimals="-3">1172000</us-gaap:AssetImpairmentCharges>
  <!--Impairment related to equipment-->
  <us-gaap:AssetImpairmentCharges contextRef="c20140101to20141231" unitRef="U001" decimals="-6">0</us-gaap:AssetImpairmentCharges>
  <!--Assets-->
  <us-gaap:Assets contextRef="c20141231" unitRef="U001" decimals="-3">945262000</us-gaap:Assets>
  <!--Assets-->
  <us-gaap:Assets contextRef="c20131231" unitRef="U001" decimals="-3">626630000</us-gaap:Assets>
  <!--Assets-EBS_ForeignJurisdictions [Member]-->
  <us-gaap:Assets contextRef="c20141231_StatementGeographicalAxis_EBSForeignJurisdictionsMember" unitRef="U001" decimals="-5">242500000</us-gaap:Assets>
  <!--Assets-EBS_ForeignJurisdictions [Member]-->
  <us-gaap:Assets contextRef="c20121231_StatementGeographicalAxis_EBSForeignJurisdictionsMember" unitRef="U001" decimals="-5">5500000</us-gaap:Assets>
  <!--Assets-EBS_ForeignJurisdictions [Member]-->
  <us-gaap:Assets contextRef="c20131231_StatementGeographicalAxis_EBSForeignJurisdictionsMember" unitRef="U001" decimals="-5">56700000</us-gaap:Assets>
  <!--Assets-Biodefense [Member]-->
  <us-gaap:Assets contextRef="c20121231_StatementBusinessSegmentsAxis_BiodefenseMember" unitRef="U001" decimals="-3">354010000</us-gaap:Assets>
  <!--Assets-->
  <us-gaap:Assets contextRef="c20121231" unitRef="U001" decimals="-3">564230000</us-gaap:Assets>
  <!--Assets-Biosciences [Member]-->
  <us-gaap:Assets contextRef="c20121231_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U001" decimals="-3">56148000</us-gaap:Assets>
  <!--Assets-All Other [Member]-->
  <us-gaap:Assets contextRef="c20141231_StatementBusinessSegmentsAxis_AllOtherSegmentsMember" unitRef="U001" decimals="-3">161045000</us-gaap:Assets>
  <!--Assets-Biodefense [Member]-->
  <us-gaap:Assets contextRef="c20141231_StatementBusinessSegmentsAxis_BiodefenseMember" unitRef="U001" decimals="-3">439797000</us-gaap:Assets>
  <!--Assets-Biosciences [Member]-->
  <us-gaap:Assets contextRef="c20131231_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U001" decimals="-3">98510000</us-gaap:Assets>
  <!--Assets-All Other [Member]-->
  <us-gaap:Assets contextRef="c20131231_StatementBusinessSegmentsAxis_AllOtherSegmentsMember" unitRef="U001" decimals="-3">196293000</us-gaap:Assets>
  <!--Assets-Biosciences [Member]-->
  <us-gaap:Assets contextRef="c20141231_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U001" decimals="-3">344420000</us-gaap:Assets>
  <!--Assets-All Other [Member]-->
  <us-gaap:Assets contextRef="c20121231_StatementBusinessSegmentsAxis_AllOtherSegmentsMember" unitRef="U001" decimals="-3">154072000</us-gaap:Assets>
  <!--Assets-Biodefense [Member]-->
  <us-gaap:Assets contextRef="c20131231_StatementBusinessSegmentsAxis_BiodefenseMember" unitRef="U001" decimals="-3">331827000</us-gaap:Assets>
  <!--Assets, Fair Value Disclosure-Fair Value, Inputs, Level 2 [Member]-Fair Value, Measurements, Recurring [Member]-->
  <us-gaap:AssetsFairValueDisclosure contextRef="c20131231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="-3">0</us-gaap:AssetsFairValueDisclosure>
  <!--Assets, Fair Value Disclosure-Fair Value, Inputs, Level 1 [Member]-Fair Value, Measurements, Recurring [Member]-->
  <us-gaap:AssetsFairValueDisclosure contextRef="c20131231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="-3">37701000</us-gaap:AssetsFairValueDisclosure>
  <!--Assets, Fair Value Disclosure-Fair Value, Inputs, Level 1 [Member]-Fair Value, Measurements, Recurring [Member]-->
  <us-gaap:AssetsFairValueDisclosure contextRef="c20141231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="-3">111912000</us-gaap:AssetsFairValueDisclosure>
  <!--Assets, Fair Value Disclosure-Fair Value, Measurements, Recurring [Member]-Fair Value, Inputs, Level 3 [Member]-->
  <us-gaap:AssetsFairValueDisclosure contextRef="c20131231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="-3">0</us-gaap:AssetsFairValueDisclosure>
  <!--Assets, Fair Value Disclosure-Fair Value, Measurements, Recurring [Member]-Fair Value, Inputs, Level 2 [Member]-->
  <us-gaap:AssetsFairValueDisclosure contextRef="c20141231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="-3">0</us-gaap:AssetsFairValueDisclosure>
  <!--Assets, Fair Value Disclosure-Fair Value, Measurements, Recurring [Member]-->
  <us-gaap:AssetsFairValueDisclosure contextRef="c20131231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="-3">37701000</us-gaap:AssetsFairValueDisclosure>
  <!--Assets, Fair Value Disclosure-Fair Value, Measurements, Recurring [Member]-Fair Value, Inputs, Level 3 [Member]-->
  <us-gaap:AssetsFairValueDisclosure contextRef="c20141231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="-3">0</us-gaap:AssetsFairValueDisclosure>
  <!--Assets, Fair Value Disclosure-Fair Value, Measurements, Recurring [Member]-->
  <us-gaap:AssetsFairValueDisclosure contextRef="c20141231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="-3">111912000</us-gaap:AssetsFairValueDisclosure>
  <!--Assets, Current-->
  <us-gaap:AssetsCurrent contextRef="c20141231" unitRef="U001" decimals="-3">432175000</us-gaap:AssetsCurrent>
  <!--Assets, Current-->
  <us-gaap:AssetsCurrent contextRef="c20131231" unitRef="U001" decimals="-3">273115000</us-gaap:AssetsCurrent>
  <!--Prepaid expenses and other assets-Cangene [Member]-->
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets contextRef="c20140221_BusinessAcquisitionAxis_CangeneMember" unitRef="U001" decimals="-3">2375000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
  <!--Accounts receivable-Cangene [Member]-->
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables contextRef="c20140221_BusinessAcquisitionAxis_CangeneMember" unitRef="U001" decimals="-3">19652000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
  <!--Deferred taxes, net-Cangene [Member]-->
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssetsNoncurrent contextRef="c20140221_BusinessAcquisitionAxis_CangeneMember" unitRef="U001" decimals="-3">21337000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssetsNoncurrent>
  <!--Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue-Cangene [Member]-->
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue contextRef="c20140221_BusinessAcquisitionAxis_CangeneMember" unitRef="U001" decimals="-3">6378000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue>
  <!--Price paid per share of acquisition (in dollars per share)-Cangene [Member]-->
  <us-gaap:BusinessAcquisitionSharePrice contextRef="c20140221_BusinessAcquisitionAxis_CangeneMember" unitRef="U003" decimals="2">3.24</us-gaap:BusinessAcquisitionSharePrice>
  <!--Cash-Cangene [Member]-->
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents contextRef="c20140221_BusinessAcquisitionAxis_CangeneMember" unitRef="U001" decimals="-3">43631000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
  <!--Business Acquisition, Pro Forma Information [Table Text Block]-->
  <us-gaap:BusinessAcquisitionProFormaInformationTextBlock contextRef="c20140101to20141231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;The following pro forma information is presented as if the acquisition had occurred on January 1, 2013, and combines the historical results of operations of the Company and Cangene for the year ended December 31, 2014 and 2013.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;(in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;2014&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;2013&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Pro forma revenue&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;462,446&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;428,194&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Pro forma net income&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;34,624&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;10,994&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BusinessAcquisitionProFormaInformationTextBlock>
  <!--Business Combination, Contingent Consideration, Liability-Evolva Holding SA 035 [Member]-->
  <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c20141217_BusinessAcquisitionAxis_EvolvaHoldingSA035Member" unitRef="U001" decimals="-3">28200000</us-gaap:BusinessCombinationContingentConsiderationLiability>
  <!--Business Combination, Contingent Consideration, Liability-HPPD [Member]-->
  <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c20130801_BusinessAcquisitionAxis_HppdMember" unitRef="U001" decimals="-3">16232000</us-gaap:BusinessCombinationContingentConsiderationLiability>
  <!--Acquired intangible assets-Cangene [Member]-->
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="c20140221_BusinessAcquisitionAxis_CangeneMember" unitRef="U001" decimals="-3">36200000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
  <!--Acquired intangible assets-RSDL [Member]-HPPD [Member]-->
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="c20130801_BusinessAcquisitionAxis_HppdMember_FiniteLivedIntangibleAssetsByMajorClassAxis_RsdlMember" unitRef="U001" decimals="-5">28600000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
  <!--Acquired intangible assets-HPPD [Member]-Manufacturing Agreement [Member]-->
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="c20130801_BusinessAcquisitionAxis_HppdMember_FiniteLivedIntangibleAssetsByMajorClassAxis_ManufacturingAgreementMember" unitRef="U001" decimals="-5">3500000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
  <!--Acquired intangible assets-Cangene [Member]-Biodefense Intangible Asset [Member]-->
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="c20140221_BusinessAcquisitionAxis_CangeneMember_FiniteLivedIntangibleAssetsByMajorClassAxis_BiodefenseIntangibleAssetMember" unitRef="U001" decimals="-3">16700000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
  <!--Acquired intangible assets-Corporate Trade Name [Member]-Cangene [Member]-->
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="c20140221_BusinessAcquisitionAxis_CangeneMember_FiniteLivedIntangibleAssetsByMajorClassAxis_TradeNamesMember" unitRef="U001" decimals="-3">2800000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
  <!--Acquired intangible assets-Contract Manufacturing [Member]-Cangene [Member]-->
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="c20140221_BusinessAcquisitionAxis_CangeneMember_FiniteLivedIntangibleAssetsByMajorClassAxis_CustomerContractsMember" unitRef="U001" decimals="-3">5500000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
  <!--Acquired intangible assets-Licensed Products [Member]-Cangene [Member]-->
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="c20140221_BusinessAcquisitionAxis_CangeneMember_FiniteLivedIntangibleAssetsByMajorClassAxis_LicensingAgreementsMember" unitRef="U001" decimals="-3">3100000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
  <!--Acquired intangible assets-Cangene [Member]-Marketing-Related Intangible Assets [Member]-->
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="c20140221_BusinessAcquisitionAxis_CangeneMember_FiniteLivedIntangibleAssetsByMajorClassAxis_MarketingRelatedIntangibleAssetsMember" unitRef="U001" decimals="-3">8100000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
  <!--Acquired intangible assets-Evolva Holding SA 035 [Member]-->
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="c20141217_BusinessAcquisitionAxis_EvolvaHoldingSA035Member" unitRef="U001" decimals="-3">27700000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
  <!--Acquired intangible assets-HPPD [Member]-->
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="c20130801_BusinessAcquisitionAxis_HppdMember" unitRef="U001" decimals="-3">32099000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
  <!--Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities-HPPD [Member]-->
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities contextRef="c20130801_BusinessAcquisitionAxis_HppdMember" unitRef="U001" decimals="-3">1464000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
  <!--Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets-HPPD [Member]-->
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets contextRef="c20130801_BusinessAcquisitionAxis_HppdMember" unitRef="U001" decimals="-3">11000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets>
  <!--Business Acquisition, Percentage of Voting Interests Acquired-Cangene [Member]-->
  <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired contextRef="c20140221_BusinessAcquisitionAxis_CangeneMember" unitRef="U005" decimals="0">1</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
  <!--Fair value adjustment for contingent obligations-->
  <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c20140101to20141231" unitRef="U001" decimals="-5">3100000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
  <!--Fair value adjustment for contingent obligations-->
  <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c20130101to20131231" unitRef="U001" decimals="1">735000.0</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
  <!--Business Acquisition, Pro Forma Revenue-->
  <us-gaap:BusinessAcquisitionsProFormaRevenue contextRef="c20140101to20141231" unitRef="U001" decimals="-3">462446000</us-gaap:BusinessAcquisitionsProFormaRevenue>
  <!--Business Acquisition, Pro Forma Revenue-->
  <us-gaap:BusinessAcquisitionsProFormaRevenue contextRef="c20130101to20131231" unitRef="U001" decimals="-3">428194000</us-gaap:BusinessAcquisitionsProFormaRevenue>
  <!--Business Acquisition, Pro Forma Net Income (Loss)-->
  <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss contextRef="c20140101to20141231" unitRef="U001" decimals="-3">34624000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
  <!--Business Acquisition, Pro Forma Net Income (Loss)-->
  <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss contextRef="c20130101to20131231" unitRef="U001" decimals="-3">10994000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
  <!--Transaction costs-Cangene [Member]-->
  <us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts contextRef="c20131231_BusinessAcquisitionAxis_CangeneMember" unitRef="U001" decimals="-5">3300000</us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts>
  <!--Transaction costs-Cangene [Member]-->
  <us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts contextRef="c20141231_BusinessAcquisitionAxis_CangeneMember" unitRef="U001" decimals="-5">3700000</us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts>
  <!--Transaction costs-Evolva Holding SA 035 [Member]-->
  <us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts contextRef="c20141217_BusinessAcquisitionAxis_EvolvaHoldingSA035Member" unitRef="U001" decimals="-6">0</us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts>
  <!--Total purchase price-Cangene [Member]-->
  <us-gaap:BusinessCombinationConsiderationTransferred1 contextRef="c20140221to20140221_BusinessAcquisitionAxis_CangeneMember" unitRef="U001" decimals="-3">221510000</us-gaap:BusinessCombinationConsiderationTransferred1>
  <!--Total purchase price-HPPD [Member]-->
  <us-gaap:BusinessCombinationConsiderationTransferred1 contextRef="c20130731to20130801_BusinessAcquisitionAxis_HppdMember" unitRef="U001" decimals="-3">42105000</us-gaap:BusinessCombinationConsiderationTransferred1>
  <!--Total purchase price-Evolva Holding SA 035 [Member]-->
  <us-gaap:BusinessCombinationConsiderationTransferred1 contextRef="c20141217to20141217_BusinessAcquisitionAxis_EvolvaHoldingSA035Member" unitRef="U001" decimals="-3">29700000</us-gaap:BusinessCombinationConsiderationTransferred1>
  <!--Inventory-Cangene [Member]-->
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory contextRef="c20140221_BusinessAcquisitionAxis_CangeneMember" unitRef="U001" decimals="-3" id="Item-1">55259000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory>
  <!--Acquisitions-->
  <us-gaap:BusinessCombinationDisclosureTextBlock contextRef="c20140101to20141231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;&lt;font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;3.&lt;/font&gt;&amp;#160;&lt;font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Acquisitions&lt;/font&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; margin-top: 3pt; text-indent: 18pt; font-family: 'Times New Roman', Times, serif; margin-bottom: 3pt; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Cangene Corporation&lt;/div&gt;&lt;div style="margin-top: 3pt; margin-bottom: 3pt;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; margin-top: 3pt; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; margin-bottom: 3pt; color: #000000; font-size: 10pt;"&gt;On February 21, 2014, the Company acquired 100% of the voting interest of Cangene for $3.24 per share in cash (on a fully-diluted basis), which represents a total purchase price of $221.5 million. This transaction was accounted for by the Company under the acquisition method of accounting, with the Company as the acquirer. Under the acquisition method of accounting, the assets and liabilities of Cangene were recorded as of the acquisition date, at their respective fair values, and combined with those of the Company. This acquisition diversified the product portfolio of the Company's Biodefense and Biosciences divisions and expanded the Company's manufacturing capabilities.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; margin-top: 3pt; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; margin-bottom: 3pt; color: #000000; font-size: 10pt;"&gt;The table below summarizes the allocation of the purchase price based upon estimated fair values of assets acquired and liabilities assumed at February 21, 2014.&lt;/div&gt;&lt;div style="margin-top: 3pt; margin-bottom: 3pt;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;(in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Fair value of tangible assets acquired and liabilities assumed:&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Cash&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;43,631&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Accounts receivable&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;19,652&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Inventory (i)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;55,259&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Prepaid expenses and other assets&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;2,375&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Property, plant and equipment&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;40,264&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Deferred taxes, net&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;21,337&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Income tax receivable&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;2,452&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Accounts payable and accrued liabilities&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(22,918&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Provision for chargebacks&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(1,946&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Contingent purchase consideration&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(1,284&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Deferred revenue&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(6,378&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Total fair value of tangible assets acquired and liabilities assumed&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;152,444&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Acquired in-process research and development&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;8,300&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Acquired intangible assets&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;36,200&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Goodwill&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;24,566&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Total purchase price&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;221,510&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top: 3pt; margin-bottom: 3pt;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; margin-top: 3pt; font-family: 'Times New Roman', Times, serif; margin-bottom: 3pt; color: #000000; font-size: 10pt;"&gt;(i) Acquired inventory reflects a $8.8 million adjustment to record inventory at fair value, referred to as a step-up adjustment. The $8.8 million step-up is estimated to be amortized through cost of product sales and contract manufacturing over the next five years based on expected inventory turnover, which will increase cost of product sales and contract manufacturing during such period.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; margin-top: 3pt; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; margin-bottom: 3pt; color: #000000; font-size: 10pt;"&gt;The table below summarizes the preliminary estimated fair value of intangible assets acquired and the estimated amortization periods:&lt;/div&gt;&lt;div style="margin-top: 3pt; margin-bottom: 3pt;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: middle;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="3" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Amortization&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: middle;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" valign="bottom" style="vertical-align: middle;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="3" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Period&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;( in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Amount&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="3" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;in years&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="3" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Corporate Trade Name&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;2,800&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;5.0&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Marketed Products&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;8,100&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;10.0&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Licensed Products&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;3,100&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;7.0&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Biodefense Products&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;16,700&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;12.0&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Contract Manufacturing&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;5,500&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;8.0&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Total identified intangible assets&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;36,200&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; padding-bottom: 4px; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; margin-top: 3pt; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; margin-bottom: 3pt; color: #000000; font-size: 10pt;"&gt;The Company determined the estimated fair value of the intangible assets using the income approach, which is based on the present value of future cash flows. The fair value measurements are based on significant unobservable inputs that are developed by the Company using estimates and assumptions of the respective market and market penetration of the Company's products.&lt;/div&gt;&lt;div style="margin-top: 3pt; margin-bottom: 3pt;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;A portion of the assets acquired from Cangene consisted of intangible assets. The Marketed Products intangible asset consists of WinRho&lt;sup&gt;&amp;#174;&lt;/sup&gt; SDF [Rh&lt;sub&gt;o&lt;/sub&gt;(D) Immune Globulin Intravenous (Human)] and VARIZIG&lt;sup&gt;&amp;#174;&lt;/sup&gt; (Varicella Zoster Immune Globulin (Human)]. The Licensed Products intangible asset primarily consists of HepaGam B&lt;sup&gt;&amp;#174;&lt;/sup&gt; (Hepatitis B Immune Globulin Intravenous (Human). The Biodefense intangible asset consist of BAT&lt;sup&gt;TM&lt;/sup&gt; [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G)-Equine], &lt;font style="background-color: #ffffff; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Anthrasil&lt;/font&gt; (Anthrax Immune Globulin Intravenous (Human)) and VIGIV (Vaccinia Immune Globulin Intravenous (Human)). The Contract Manufacturing intangible asset is primarily related to contract manufacturing contracts with current and expected future third-party customers.&lt;/div&gt;&lt;div style="margin-top: 3pt; margin-bottom: 3pt;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; margin-top: 3pt; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; margin-bottom: 3pt; color: #000000; font-size: 10pt;"&gt;The Company estimated the fair value of the Marketed, Licensed and Biodefense Product intangible assets using the income approach with a present value discount rate of 15%, which is based on the estimated weighted-average cost of capital for companies with profiles substantially similar to that of Cangene. This is comparable to the estimated internal rate of return for the acquisition and represents the rate that market participants would use to value these intangible assets. The projected cash flows from these Marketed, Licensed and Biodefense Product intangible assets were based on key assumptions including: estimates of revenues and operating profits; the life of the potential commercialized product and associated risks; and risks related to the viability of and potential alternative treatments in any future target markets.&lt;/div&gt;&lt;div style="margin-top: 3pt; margin-bottom: 3pt;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; margin-top: 3pt; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; margin-bottom: 3pt; color: #000000; font-size: 10pt;"&gt;The Company estimated the fair value of the Contract Manufacturing intangible asset using the income approach with a present value discount rate of 15%, which is based on the estimated weighted-average cost of capital for companies with profiles substantially similar to that of Cangene. This is comparable to the estimated internal rate of return for the acquisition and represents the rate that market participants would use to value this intangible asset. The projected cash flows from the Contract Manufacturing intangible asset were based on key assumptions including: estimates of revenues and operating profits; and viability of attaining/maintaining future third-party manufacturing relationships with the Company's customers.&lt;/div&gt;&lt;div style="margin-top: 3pt; margin-bottom: 3pt;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; margin-top: 3pt; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; margin-bottom: 3pt; color: #000000; font-size: 10pt;"&gt;The Company estimated the fair value of the Corporate Trade Name intangible asset using the relief of royalty method with a present value discount rate of 15%, which is based on the estimated weighted-average cost of capital for companies with profiles substantially similar to that of Cangene. This is comparable to the estimated internal rate of return for the acquisition and represents the rate that market participants would use to value this intangible asset.&lt;/div&gt;&lt;div style="margin-top: 3pt; margin-bottom: 3pt;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; margin-top: 3pt; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; margin-bottom: 3pt; color: #000000; font-size: 10pt;"&gt;The weighted average amortization period of the intangible assets from the Cangene acquisition is 110 months. For the year ended December 31, 2014, the Company recorded amortization expense of $3.3 million for intangible assets acquired from Cangene, of which $478,000 and $2.8 million, respectively, has been recorded in selling, general and administrative and cost of product sales and contract manufacturing. Amortization expense of $2.1 million and $1.2 million, respectively, was recorded within the Biosciences and Biodefense segments for the year ended December 31, 2014.&lt;/div&gt;&lt;div style="margin-top: 3pt; margin-bottom: 3pt;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; margin-top: 3pt; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; margin-bottom: 3pt; color: #000000; font-size: 10pt;"&gt;The intangible asset associated with IPR&amp;amp;D acquired from Cangene is the IXINITY product candidate. Management determined that the estimated acquisition-date fair value of intangible assets related to IPR&amp;amp;D was $8.3 million. The estimated fair value was determined using the income approach, which discounts expected future cash flows to present value. The Company estimated the fair value using a present value discount rate of 16%, which is based on the estimated weighted-average cost of capital for companies with that profiles substantially similar to that of Cangene and IPR&amp;amp;D assets at a similar stage of development as IXINITY. This is comparable to the estimated internal rate of return for the acquisition and represents the rate that market participants would use to value the IPR&amp;amp;D. The projected cash flows for IXINITY was based on key assumptions including: estimates of revenues and operating profits, considering its stage of development on the acquisition date; the time and resources needed to complete the development and approval of the product candidate; the life of the potential commercialized product and associated risks, including the inherent difficulties and uncertainties in developing a product candidate, such as obtaining marketing approval from the U.S. Food and Drug Administration ("FDA") and other regulatory agencies; and risks related to the viability of and potential for alternative treatments in any future target markets. IPR&amp;amp;D assets are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts (see Note 9).&lt;/div&gt;&lt;div style="margin-top: 3pt; margin-bottom: 3pt;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; margin-top: 3pt; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; margin-bottom: 3pt; color: #000000; font-size: 10pt;"&gt;The Company recorded approximately $24.6 million in goodwill related to the Cangene acquisition, representing the purchase price paid in the acquisition that was in excess of the fair value of the tangible and intangible assets acquired. None of the goodwill generated from the Cangene acquisition is expected to be deductible for tax purposes.&lt;/div&gt;&lt;div style="margin-top: 3pt; margin-bottom: 3pt;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; margin-top: 3pt; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; margin-bottom: 3pt; color: #000000; font-size: 10pt;"&gt;The Company has incurred transaction costs related to the Cangene acquisition of approximately $3.7 million and $3.3 million for the years ended December 31, 2014 and 2013, respectively, which has been recorded in selling, general and administrative expenses within the Company's Biosciences segment.&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;The following pro forma information is presented as if the acquisition had occurred on January 1, 2013, and combines the historical results of operations of the Company and Cangene for the year ended December 31, 2014 and 2013.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;(in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;2014&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;2013&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Pro forma revenue&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;462,446&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;428,194&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Pro forma net income&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;34,624&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;10,994&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; margin-top: 3pt; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; margin-bottom: 3pt; color: #000000; font-size: 10pt; font-weight: bold;"&gt;EV-035 Molecules&lt;/div&gt;&lt;div style="margin-top: 3pt; margin-bottom: 3pt;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; margin-top: 3pt; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; margin-bottom: 3pt; color: #000000; font-size: 10pt;"&gt;On December 17, 2014, the Company acquired the EV-035 series of molecules from Evolva Holding SA ("Evolva") for approximately $1.5 million in cash along with contingent purchase consideration obligations to Evolva. EV-035 is a series of novel small molecule broad spectrum antibiotics of the 4-oxoquinolizine class and targets bacterial type IIa topoisomerase. The lead molecule in the series, GC-072, has demonstrated protection &lt;font style="font-style: italic; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;in vivo&lt;/font&gt; from lethal &lt;font style="font-style: italic; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;B. pseudomallei&lt;/font&gt; infection when administered orally. GC-072 is being developed as a potential oral and IV treatment for &lt;font style="font-style: italic; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;B. pseudomallei&lt;/font&gt; under a three-year, $15 million contract with the Defense Threat Reduction Agency ("DTRA") of the U.S. Department of Defense. &lt;font style="font-style: italic; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;B. pseudomallei&lt;/font&gt; is a gram-negative pathogen classified by the CDC as a Category B bioterrorism agent and a priority threat capable of being easily weaponized and disseminated. The acquisition diversifies the Biodefense segment by adding a clinical stage product that is currently being funded through preclinical development and has been accounted for a business acquisition.&lt;/div&gt;&lt;div style="background-color: #ffffff;"&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;The contingent values rights are based on the novation of the DTRA contract ($4.0 million) along with the achievement of certain development ($15.0 million) and regulatory filing ($50.0 million) milestones. In addition, the Company is required to make sales-based royalty payments of between 5 %-10 % based on levels of annual net sales.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="background-color: #ffffff;"&gt;&lt;div style="text-align: left; text-indent: 18pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;The total preliminary purchase price is summarized below:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;(in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Amount of cash paid to Evolva Holdings SA&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;1,500&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Fair value of contingent consideration&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;28,200&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Total purchase price&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;29,700&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 18pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;The table below summarizes the preliminary allocation of the purchase price based upon fair values of assets acquired. As of the date of this filing, the valuation of acquired intangible assets and other fair value adjustments are not complete as the Company is obtaining and analyzing additional information related to the aforementioned items.&amp;#160; As such, the purchase price allocation is subject to change.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;(in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Acquired intangible assets&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;27,700&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Goodwill&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;2,000&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Total purchase price&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;29,700&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; background-color: #ffffff; text-indent: 18pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;The assets acquired from Evolva consisted of the EV-035 molecules IPR&amp;amp;D asset. Management determined that the estimated acquisition-date fair value of intangible assets related to IPR&amp;amp;D was $27.7 million. The estimated fair value was determined using the income approach, which discounts expected future cash flows to present value. The Company estimated the fair value using a present value discount rate of 12%. This is comparable to the estimated internal rate of return for the acquisition and represents the rate that market participants would use to value the IPR&amp;amp;D. The projected cash flows for EV-035 was based on key assumptions including: estimates of revenues and operating profits, considering its stage of development on the acquisition date; the time and resources needed to complete the development and approval of the product candidate; the life of the potential commercialized product and associated risks, including the inherent difficulties and uncertainties in developing a product candidate, such as obtaining marketing approval from the FDA and other regulatory agencies; and risks related to the viability of and potential for alternative treatments in any future target markets. IPR&amp;amp;D assets are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts. From the acquisition date through the year ended December 31, 2014, there were no indicators present that would require the Company to complete an interim impairment assessment.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; margin-top: 3pt; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; margin-bottom: 3pt; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Healthcare Protective Products Division&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; background-color: #ffffff; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;In August 2013, the Company acquired substantially all of the assets of the HPPD, a division of Bracco, for approximately $25.9 million in cash along with contingent purchase consideration obligations to Bracco. The assets acquired in this acquisition include HPPD's product, RSDL, and a majority of the customer and distributor agreements associated with RSDL along with approximately $1.5 million of manufacturing equipment. The acquisition diversifies the Biodefense segment by adding product sales from RSDL. In addition, the Company assumed a $1.5 million liability associated with the Canadian Technology Development Fund ("TDF").&lt;/div&gt;&lt;div style="background-color: #ffffff;"&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;The contingent purchase consideration obligation is based on a percentage of RSDL net sales, ranging from 5 %-10%, for the period August 1, 2013 through July 31, 2028. At August 1, 2013, the contingent purchase consideration obligation was recorded at a fair value of $16.2 million. The Level 3 fair value of this obligation is based on management's assessment of the potential future realization of the contingent purchase consideration payments. This assessment is based on inputs that have no observable market. The obligation is measured using the income approach (a discounted cash flow model).&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="background-color: #ffffff;"&gt;&lt;div style="text-align: left; text-indent: 18pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;The total purchase price is summarized below:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;(in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Amount of cash paid to Bracco Diagnostics Inc.&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;25,873&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Fair value of contingent purchase consideration&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;16,232&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Total purchase price&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;42,105&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;The table below summarizes the allocation of the purchase price based upon fair values of assets acquired and liabilities assumed at August 1, 2013.&amp;#160;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;(in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Acquired intangible assets&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;32,099&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Goodwill&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;9,916&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Acquired equipment&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;1,543&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Other&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;11&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Assumed liabilities&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(1,464&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Total purchase price&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;42,105&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="background-color: #ffffff;"&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;During the year ended December 31, 2014, the Company updated its purchase price to include an assumed liability from the TDF resulting in additional goodwill of $1.5 million.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;A substantial portion of the assets acquired from Bracco consisted of intangible assets associated with the RSDL product.&amp;#160; &lt;font style="background-color: #ffffff; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;As of the date of acquisition, the Company has recorded intangible assets of approximately $28.6 million related to RSDL, which is being amortized over 8 years, and $3.5 million related to a manufacturing agreement with Bracco, which is being amortized over 3 years. For the year ended December 31, 2014 and 2013, respectively, the Company recorded $4.7 million and $2.0 million in amortization for intangible assets, which have been recorded in &lt;/font&gt;cost of product sales and contract manufacturing within the Company's Biodefense segment&lt;font style="background-color: #ffffff; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;. The weighted average amortization period for the intangible assets is 72 months.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;The Company recorded approximately $9.9 million in goodwill related to the HPPD acquisition representing the purchase price paid in the acquisition in excess of the fair value of the tangible and intangible assets acquired. This goodwill is included in the Company's Biodefense segment. None of the goodwill generated from the HPPD acquisition is expected to be deductible for tax purposes.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;The Company has determined the historical results of the EV-035 Series and HPPD were not significant to the Company's results of operations, and as such no proforma disclosures have been presented.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
  <!--Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment-Cangene [Member]-->
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment contextRef="c20140221_BusinessAcquisitionAxis_CangeneMember" unitRef="U001" decimals="-3">40264000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
  <!--Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment-HPPD [Member]-->
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment contextRef="c20130801_BusinessAcquisitionAxis_HppdMember" unitRef="U001" decimals="-3">1543000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
  <!--Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net-Cangene [Member]-->
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet contextRef="c20140221_BusinessAcquisitionAxis_CangeneMember" unitRef="U001" decimals="-3">152444000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
  <!--Contingent value rights-->
  <us-gaap:BusinessCombinationsPolicy contextRef="c20140101to20141231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Contingent value rights&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;The Company records contingent value right ("CVR") obligations at fair value. Obligations generally become due and payable only upon achievement of certain developmental, regulatory or commercial milestones. The fair value model used for the CVR obligations are based on a discounted cash flow model that has been risk adjusted based on the probability of achievement of the milestones.&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;The Company believes that the inputs it uses for determining the fair value of the CVR obligations are Level 3 fair value measurements. The Company re-evaluates the fair value on a quarterly basis. Changes in the fair value of the CVR obligations can result from adjustments to the discount rates, updates in the assumed timing of achievement of any development milestones or changes in the probability of certain events and changes in the assumed probability associated with approval. Any future increase in the fair value of the CVR obligations, based on an increased likelihood that the underlying milestones will be achieved and the associated payment or payments will therefore become due and payable, will result in a charge to research and development expense in the period in which the increase is determined. Similarly, any future decrease in the fair value of the CVR obligations will result in a reduction in research and development expense.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BusinessCombinationsPolicy>
  <!--Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net-HPPD [Member]-->
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet contextRef="c20130801_BusinessAcquisitionAxis_HppdMember" unitRef="U001" decimals="-3">42105000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
  <!--Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net-Evolva Holding SA 035 [Member]-->
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet contextRef="c20141217_BusinessAcquisitionAxis_EvolvaHoldingSA035Member" unitRef="U001" decimals="-3">29700000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
  <!--Purchases of property, plant and equipment unpaid at year end-->
  <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c20120101to20121231" unitRef="U001" decimals="-3">5612000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
  <!--Purchases of property, plant and equipment unpaid at year end-->
  <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c20130101to20131231" unitRef="U001" decimals="-3">2755000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
  <!--Purchases of property, plant and equipment unpaid at year end-->
  <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c20140101to20141231" unitRef="U001" decimals="-3">5394000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
  <!--Capitalized Computer Software, Additions-->
  <us-gaap:CapitalizedComputerSoftwareAdditions contextRef="c20140101to20141231" unitRef="U001" decimals="-5">2400000</us-gaap:CapitalizedComputerSoftwareAdditions>
  <!--Cash and Cash Equivalents, Policy [Policy Text Block]-->
  <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c20140101to20141231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Cash and cash equivalents&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Cash equivalents are highly liquid investments with a maturity of 90 days or less at the date of purchase and consist of time deposits and investments in money market funds with commercial banks and financial institutions. Also, the Company maintains cash balances with financial institutions in excess of insured limits. The Company does not anticipate any losses with such cash balances.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
  <!--Cash and Cash Equivalents, Period Increase (Decrease)-->
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="c20120101to20121231" unitRef="U001" decimals="-3">-2235000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <!--Cash and Cash Equivalents, Period Increase (Decrease)-->
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="c20130101to20131231" unitRef="U001" decimals="-3">37672000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <!--Cash and Cash Equivalents, Period Increase (Decrease)-->
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="c20140101to20141231" unitRef="U001" decimals="-3">101161000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <!--Cash and cash equivalents-->
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c20141231" unitRef="U001" decimals="-3">280499000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <!--Cash and cash equivalents-->
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c20131231" unitRef="U001" decimals="-3">179338000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <!--Cash and cash equivalents-->
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c20111231" unitRef="U001" decimals="-3">143901000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <!--Cash and cash equivalents-->
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c20121231" unitRef="U001" decimals="-3">141666000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <!--Description of rights and obligations-Morphosys [Member]-->
  <us-gaap:CollaborativeArrangementRightsAndObligations contextRef="c20140101to20141231_TypeOfArrangementAxis_MorphosysMember">MorphoSys and the Company will jointly fund further development of MOR209/ES414, with the Company responsible for 36% of the total development cost and MorphoSys responsible for the remainder</us-gaap:CollaborativeArrangementRightsAndObligations>
  <!--Collaborative Arrangement Disclosure [Text Block]-->
  <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="c20140101to20141231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;5. MorphoSys collaboration agreement&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;In August 2014, the Company entered into a collaboration agreement ("MorphoSys Agreement") with MorphoSys AG ("MorphoSys") for the joint worldwide development and commercialization of MOR209/ES414, a targeted immunotherapeutic protein, constructed using the Company's proprietary ADAPTIR technology platform, which activates host T-cell immunity specifically against cells expressing prostate specific membrane antigen, an antigen commonly overexpressed on prostate cancer cells.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;In accordance with the terms of the MorphoSys Agreement, the Company received a nonrefundable $20 million upfront payment and may receive up to $163 million in additional contingent payments, of which $80.0 million and $83.0 million, respectively, are due upon the achievement of specified development and regulatory milestones. The Company has determined that payments for the achievement of the development and regulatory milestones are substantive milestones and will be accounted for as revenue in the period in which the milestone is achieved.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;MorphoSys and the Company will jointly fund further development of MOR209/ES414, with the Company responsible for 36% of the total development cost and MorphoSys responsible for the remainder. The Company's funding requirement is capped at $186 million. The Company will retain commercialization rights in the U.S. and Canada, with a tiered royalty obligation to MorphoSys, ranging from mid-single digits up to 20%. MorphoSys will gain worldwide commercialization rights excluding the United States and Canada, with a low single digit royalty obligation to the Company. The Company's current obligations under the collaboration includes the performance of non-clinical, clinical, manufacturing and regulatory activities.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;The Company has evaluated the MorphoSys Agreement and determined that it is a revenue arrangement with multiple deliverables, or performance obligations. The Company determined there were two units of accounting under the collaboration agreement with MorphoSys: (1) the delivered license to further develop and commercialize MOR209/ES414 and (2) undelivered items related to development services. The Company determined that the license had standalone value as the drug candidate has been (1) developed and is currently Phase 1 clinical trial ready, (2) MorphoSys possesses the knowledge, technology, skills, experience and infrastructure necessary to complete all further development of the drug through commercialization, and (3) MorphoSys has the right to further sublicense the product. The Company allocated the $20.0 million upfront payment to the two units of accounting using the relative selling price method. The Company determined the estimated selling price for the license using the income approach and a discount rate of 12%. The estimated selling price includes unobservable inputs (Level 3), such as estimates of revenues and operating margins; the time and resources needed to complete the development and approval of the product candidate; and the risk related to the viability of and potential for alternative treatments. The Company determined the estimated selling price of the development services unit of accounting based on the estimated number of full-time equivalent personnel at the contractual rate as defined in the MorphoSys Agreement, which represents the approximate terms of other service related contracts both entered by the Company and observed generally through other collaboration negotiations. The allocation resulted in $15.3 million of the upfront payment being allocated to the license and $4.7 million being allocated to the development services. The Company determined the license fee unit of accounting was delivered on the date the MorphoSys agreement was executed and therefore has recognized revenue of $15.3 million, which is included in contracts, grants and collaborations revenues within the Company's Biosciences segment. Revenue related to the undelivered item will be recognized as the services are performed. The current estimated service period for the undelivered item under the MorphoSys Agreement is through 2022.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;The amount allocable to the units of accounting is limited to the amount that is not contingent upon the delivery of additional items or meeting other specified performance conditions (the noncontingent amount). As such, the Company excluded from the allocable arrangement consideration the milestone payments and royalties regardless of the probability of receipt.&lt;/div&gt;&lt;div style="text-align: justify;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;&lt;font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;The collaboration provides for sharing of development and clinical costs, with the Company responsible for 36% of such costs and MorphoSys responsible for the remainder. In the event the Company's share of the total cost for a given quarter exceeds 36% of the total costs for the project, the Company records a net receivable in its financial statements equal to the difference between the Company's costs and 36% of the total costs for the period, and reduces research and development expense in this amount. &lt;/font&gt;For the year ended December 31, 2014, the Company has recorded a reduction to research and development expense of $1.5 million. As of December 31, 2014, accounts receivable from MorphoSys was $972,000.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;As of December 31, 2014, deferred revenue related to the MorphoSys Agreement consisted of $890,000 and $3.5 million of current and long-term deferred revenue, respectively.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
  <!--Commitments and contingencies-->
  <us-gaap:CommitmentsAndContingencies contextRef="c20131231" unitRef="U001" xsi:nil="true" />
  <!--Commitments and contingencies-->
  <us-gaap:CommitmentsAndContingencies contextRef="c20141231" unitRef="U001" xsi:nil="true" />
  <!--Purchase commitment [Text Block]-->
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c20140101to20141231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;&lt;font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;15&lt;/font&gt;. &lt;font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Purchase commitment&lt;/font&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;During the year ended December 31, 2014, the Company entered into a contract with Norwood Laboratories Inc. ("Norwood") to purchase $15.2 million of raw materials related to the Company's RSDL product. For the year ended December 31, 2014, the Company has purchased $1.5 million of materials under this commitment.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <!--Common stock, par value (in dollars per share)-->
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="c20131231" unitRef="U003" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <!--Common stock, par value (in dollars per share)-->
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="c20141231" unitRef="U003" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <!--Common stock, $0.001 par value; 100,000,000 shares authorized, 38,129,872 shares issued and 37,709,683, shares outstanding at December 31, 2014; 37,036,996 shares issued and 36,624,043, shares outstanding at December 31, 2013-->
  <us-gaap:CommonStockValue contextRef="c20141231" unitRef="U001" decimals="-3">38000</us-gaap:CommonStockValue>
  <!--Common stock, $0.001 par value; 100,000,000 shares authorized, 38,129,872 shares issued and 37,709,683, shares outstanding at December 31, 2014; 37,036,996 shares issued and 36,624,043, shares outstanding at December 31, 2013-->
  <us-gaap:CommonStockValue contextRef="c20131231" unitRef="U001" decimals="-3">37000</us-gaap:CommonStockValue>
  <!--Common stock, shares issued (in shares)-->
  <us-gaap:CommonStockSharesIssued contextRef="c20131231" unitRef="U002" decimals="0">37036996</us-gaap:CommonStockSharesIssued>
  <!--Common stock, shares issued (in shares)-->
  <us-gaap:CommonStockSharesIssued contextRef="c20141231" unitRef="U002" decimals="0">38129872</us-gaap:CommonStockSharesIssued>
  <!--Common stock, voting rights-->
  <us-gaap:CommonStockVotingRights contextRef="c20140101to20141231">1</us-gaap:CommonStockVotingRights>
  <!--Common stock, shares authorized (in shares)-->
  <us-gaap:CommonStockSharesAuthorized contextRef="c20141231" unitRef="U002" decimals="0">100000000</us-gaap:CommonStockSharesAuthorized>
  <!--Common stock, shares authorized (in shares)-->
  <us-gaap:CommonStockSharesAuthorized contextRef="c20131231" unitRef="U002" decimals="0">100000000</us-gaap:CommonStockSharesAuthorized>
  <!--Common stock, shares outstanding (in shares)-->
  <us-gaap:CommonStockSharesOutstanding contextRef="c20131231" unitRef="U002" decimals="0">36624043</us-gaap:CommonStockSharesOutstanding>
  <!--Common stock, shares outstanding (in shares)-->
  <us-gaap:CommonStockSharesOutstanding contextRef="c20141231" unitRef="U002" decimals="0">37709683</us-gaap:CommonStockSharesOutstanding>
  <!--Common stock, shares outstanding (in shares)-Treasury Stock [Member]-->
  <us-gaap:CommonStockSharesOutstanding contextRef="c20111231_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="U002" decimals="0">0</us-gaap:CommonStockSharesOutstanding>
  <!--Common stock, shares outstanding (in shares)-Common Stock [Member]-->
  <us-gaap:CommonStockSharesOutstanding contextRef="c20111231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0">36002698</us-gaap:CommonStockSharesOutstanding>
  <!--Common stock, shares outstanding (in shares)-Common Stock [Member]-->
  <us-gaap:CommonStockSharesOutstanding contextRef="c20121231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0">36272550</us-gaap:CommonStockSharesOutstanding>
  <!--Common stock, shares outstanding (in shares)-Treasury Stock [Member]-->
  <us-gaap:CommonStockSharesOutstanding contextRef="c20121231_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="U002" decimals="0">-403158</us-gaap:CommonStockSharesOutstanding>
  <!--Common stock, shares outstanding (in shares)-Common Stock [Member]-->
  <us-gaap:CommonStockSharesOutstanding contextRef="c20131231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0">37036996</us-gaap:CommonStockSharesOutstanding>
  <!--Common stock, shares outstanding (in shares)-Treasury Stock [Member]-->
  <us-gaap:CommonStockSharesOutstanding contextRef="c20141231_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="U002" decimals="0">-420189</us-gaap:CommonStockSharesOutstanding>
  <!--Common stock, shares outstanding (in shares)-Common Stock [Member]-->
  <us-gaap:CommonStockSharesOutstanding contextRef="c20141231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0">38129872</us-gaap:CommonStockSharesOutstanding>
  <!--Common stock, shares outstanding (in shares)-Treasury Stock [Member]-->
  <us-gaap:CommonStockSharesOutstanding contextRef="c20131231_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="U002" decimals="0">-412953</us-gaap:CommonStockSharesOutstanding>
  <!--Comprehensive income-->
  <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="c20140101to20141231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Comprehensive income&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Comprehensive income is comprised of net income and other changes in equity that are excluded from net income. The Company includes translation gains and losses incurred when converting its subsidiaries' financial statements from their functional currency to the U.S. dollar in accumulated other comprehensive income.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
  <!--Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest-->
  <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c20120101to20121231" unitRef="U001" decimals="-3">22708000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
  <!--Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest-->
  <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c20130101to20131231" unitRef="U001" decimals="-3">31799000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
  <!--Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest-->
  <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c20140101to20141231" unitRef="U001" decimals="-3">37198000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
  <!--Concentrations of credit risk-->
  <us-gaap:ConcentrationRiskCreditRisk contextRef="c20140101to20141231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Concentrations of credit risk&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. The Company places its cash and cash equivalents with high quality financial institutions. Management believes that the financial risks associated with its cash and cash equivalents are minimal. Because accounts receivable consist primarily of amounts due from the U.S. government for product sales and from government agencies under government grants and development contracts, management deems there to be minimal credit risk.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
  <!--Concentration Risk, Percentage-Customer Concentration Risk [Member]-Accounts Receivable [Member]-->
  <us-gaap:ConcentrationRiskPercentage1 contextRef="c20130101to20131231_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember" unitRef="U005" decimals="3">0.962</us-gaap:ConcentrationRiskPercentage1>
  <!--Concentration Risk, Percentage-Customer Concentration Risk [Member]-Accounts Receivable [Member]-->
  <us-gaap:ConcentrationRiskPercentage1 contextRef="c20140101to20141231_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember" unitRef="U005" decimals="3">0.404</us-gaap:ConcentrationRiskPercentage1>
  <!--Concentration Risk, Percentage-Sales Revenue, Goods, Net [Member]-Customer Concentration Risk [Member]-->
  <us-gaap:ConcentrationRiskPercentage1 contextRef="c20120101to20121231_ConcentrationRiskByBenchmarkAxis_SalesRevenueGoodsNetMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember" unitRef="U005" decimals="3">0.979</us-gaap:ConcentrationRiskPercentage1>
  <!--Concentration Risk, Percentage-Sales Revenue, Goods, Net [Member]-Customer Concentration Risk [Member]-->
  <us-gaap:ConcentrationRiskPercentage1 contextRef="c20130101to20131231_ConcentrationRiskByBenchmarkAxis_SalesRevenueGoodsNetMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember" unitRef="U005" decimals="3">0.955</us-gaap:ConcentrationRiskPercentage1>
  <!--Concentration Risk, Percentage-Sales Revenue, Goods, Net [Member]-Customer Concentration Risk [Member]-->
  <us-gaap:ConcentrationRiskPercentage1 contextRef="c20140101to20141231_ConcentrationRiskByBenchmarkAxis_SalesRevenueGoodsNetMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember" unitRef="U005" decimals="3">0.743</us-gaap:ConcentrationRiskPercentage1>
  <!--Basis of presentation and consolidation-->
  <us-gaap:ConsolidationPolicyTextBlock contextRef="c20140101to20141231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Basis of presentation and consolidation&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;The accompanying consolidated financial statements include the accounts of Emergent and its wholly-owned and majority-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. For investments in variable interest entities, the Company consolidates when it is determined to be the primary beneficiary.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
  <!--Contracts, grants and collaborations-->
  <us-gaap:ContractsRevenue contextRef="c20130101to20131231" unitRef="U001" decimals="-3">54823000</us-gaap:ContractsRevenue>
  <!--Contracts, grants and collaborations-->
  <us-gaap:ContractsRevenue contextRef="c20120101to20121231" unitRef="U001" decimals="-3">66009000</us-gaap:ContractsRevenue>
  <!--Contracts, grants and collaborations-->
  <us-gaap:ContractsRevenue contextRef="c20140101to20141231" unitRef="U001" decimals="-3">110849000</us-gaap:ContractsRevenue>
  <!--Cost of product sales-->
  <us-gaap:CostOfGoodsSold contextRef="c20140101to20141231" unitRef="U001" decimals="-3">118412000</us-gaap:CostOfGoodsSold>
  <!--Cost of product sales-->
  <us-gaap:CostOfGoodsSold contextRef="c20130101to20131231" unitRef="U001" decimals="-3">62127000</us-gaap:CostOfGoodsSold>
  <!--Cost of product sales-->
  <us-gaap:CostOfGoodsSold contextRef="c20120101to20121231" unitRef="U001" decimals="-3">46077000</us-gaap:CostOfGoodsSold>
  <!--State-->
  <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c20130101to20131231" unitRef="U001" decimals="-3">-173000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
  <!--State-->
  <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c20120101to20121231" unitRef="U001" decimals="-3">-1045000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
  <!--State-->
  <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c20140101to20141231" unitRef="U001" decimals="-3">479000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
  <!--International-->
  <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c20130101to20131231" unitRef="U001" decimals="-3">300000</us-gaap:CurrentForeignTaxExpenseBenefit>
  <!--International-->
  <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c20120101to20121231" unitRef="U001" decimals="-3">103000</us-gaap:CurrentForeignTaxExpenseBenefit>
  <!--International-->
  <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c20140101to20141231" unitRef="U001" decimals="-3">112000</us-gaap:CurrentForeignTaxExpenseBenefit>
  <!--Federal-->
  <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c20140101to20141231" unitRef="U001" decimals="-3">10412000</us-gaap:CurrentFederalTaxExpenseBenefit>
  <!--Federal-->
  <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c20120101to20121231" unitRef="U001" decimals="-3">11481000</us-gaap:CurrentFederalTaxExpenseBenefit>
  <!--Federal-->
  <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c20130101to20131231" unitRef="U001" decimals="-3">-878000</us-gaap:CurrentFederalTaxExpenseBenefit>
  <!--Current Income Tax Expense (Benefit)-->
  <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c20130101to20131231" unitRef="U001" decimals="-3">-751000</us-gaap:CurrentIncomeTaxExpenseBenefit>
  <!--Current Income Tax Expense (Benefit)-->
  <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c20120101to20121231" unitRef="U001" decimals="-3">10539000</us-gaap:CurrentIncomeTaxExpenseBenefit>
  <!--Current Income Tax Expense (Benefit)-->
  <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c20140101to20141231" unitRef="U001" decimals="-3">11003000</us-gaap:CurrentIncomeTaxExpenseBenefit>
  <!--Face amount of debt instrument-Convertible Senior Notes Due 2021 [Member]-->
  <us-gaap:DebtInstrumentFaceAmount contextRef="c20140129_LongtermDebtTypeAxis_ConvertibleSeniorNotesDue2021Member" unitRef="U001" decimals="-5">250000000</us-gaap:DebtInstrumentFaceAmount>
  <!--Debt and Capital Leases Disclosures [Text Block]-->
  <us-gaap:DebtAndCapitalLeasesDisclosuresTextBlock contextRef="c20140101to20141231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;&lt;font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;10.&lt;/font&gt;&lt;font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Long-term debt&lt;/font&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; margin-top: 3pt; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; margin-bottom: 3pt; color: #000000; font-size: 10pt;"&gt;On January 29, 2014, the Company issued $250.0 million aggregate principal amount of 2.875% Convertible Senior Notes due 2021 (the "Notes"). The Notes bear interest at a rate of 2.875% per year, payable semi-annually in arrears on January 15 and July 15 of each year. The Notes mature on January 15, 2021, unless earlier purchased by the Company or converted. The conversion rate is equal to 30.8821 shares of common stock per $1,000 principal amount of notes (which is equivalent to an initial conversion price of approximately $32.38 per share of common stock). The conversion rate is subject to adjustment upon the occurrence of certain specified events but will not be adjusted for accrued and unpaid interest. The Company incurred approximately $8.3 million in debt issuance costs associated with the Notes, which has been capitalized on the consolidated balance sheets and is being amortized over seven years, using the effective interest method.&lt;/div&gt;&lt;div style="margin-top: 3pt; margin-bottom: 3pt;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; margin-top: 3pt; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; margin-bottom: 3pt; color: #000000; font-size: 10pt;"&gt;On December 11, 2013, the Company entered into a senior secured credit agreement (the "Credit Agreement") with three lending financial institutions (the "Lenders"), led by Bank of America, N.A., as administrative agent. The Credit Agreement originally provided for a revolving credit facility of up to $100.0 million through December 11, 2018 (or such earlier date required by the terms of the Credit Agreement) and a term loan facility of up to $125.0 million to be drawn in full, if at all, on or prior to March 31, 2014. In connection with the Credit Agreement,&amp;#160;the Company borrowed $62.0 million under the revolving credit facility primarily to repay obligations under existing loan agreements. On January 29, 2014, in connection with the Company's issuance of the Notes, the unused $125.0 million term loan portion of the Credit Agreement terminated automatically in accordance with the terms of the Credit Agreement. In addition, following the closing of the Notes offering, the Company repaid the $62.0 million outstanding indebtedness under the revolving credit facility, which restored the full $100.0 million revolving credit capacity under this facility. Under the revolving credit facility, the Company is required to pay an unused fee of approximately 0.6% per quarter. In addition, during the year ended December 31, 2014, the Company expensed $1.8 million of debt issuance cost associated with the term loan facility. As of December 31, 2014, no amounts were drawn under the revolving credit facility.&lt;/div&gt;&lt;div style="margin-top: 3pt; margin-bottom: 3pt;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; margin-top: 3pt; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; margin-bottom: 3pt; color: #000000; font-size: 10pt;"&gt;The Company's payment obligations under the Credit Agreement are secured by a lien on substantially all of the Company's assets, including the stock of all of the Company's subsidiaries, and the assets of the subsidiary guarantors, including mortgages over certain of their real properties, including the Company's large-scale vaccine manufacturing facility in Lansing, Michigan and the Company's product development and manufacturing facility in Baltimore, Maryland.&lt;/div&gt;&lt;div style="margin-top: 3pt; margin-bottom: 3pt;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;The Credit Agreement, as amended, contains affirmative and negative covenants customary for financings of this type. Negative covenants in the Credit Agreement limit the Company's ability to, among other things: incur indebtedness (other than the issuance of the Notes) and liens; dispose of assets; make investments including loans, advances or guarantees; and enter into certain mergers or similar transactions. The Credit Agreement also contains financial covenants, tested quarterly and in connection with any triggering events under the Credit Agreement that include the maintenance of: (1) a minimum consolidated debt service coverage ratio of 2.50 to 1.00, (2) a maximum consolidated leverage ratio for the period ending on or prior to September 30, 2014 of 4.00 to 1.00, for the measurement period ending December 31, 2014 of 3.75 to 1.00, and thereafter of 3.50 to 1.00, (3) a maximum consolidated senior leverage ratio of 2.00 to 1.00 and (4) a minimum liquidity requirement of $50 million. Upon the occurrence and continuance of an event of default under the Credit Agreement, the commitments of the lenders to make loans under the Credit Agreement may be terminated and the Company's payment obligations under the Credit Agreement may be accelerated. The events of default under the Credit Agreement include, among others, subject in some cases to specified cure periods: payment defaults; inaccuracy of representations and warranties in any material respect; defaults in the observance or performance of covenants; bankruptcy and insolvency related defaults; the entry of a final judgment in excess of a threshold amount; change of control; and the invalidity of loan documents relating to the Credit Agreement. The Company was in compliance with these covenants as of December 31, 2014.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DebtAndCapitalLeasesDisclosuresTextBlock>
  <!--Conversion price per share (in dollars per share)-Convertible Senior Notes Due 2021 [Member]-->
  <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="c20140129_LongtermDebtTypeAxis_ConvertibleSeniorNotesDue2021Member" unitRef="U003" decimals="INF">32.38</us-gaap:DebtInstrumentConvertibleConversionPrice1>
  <!--Debt issuance costs-Convertible Senior Notes Due 2021 [Member]-->
  <us-gaap:DebtIssuanceCosts contextRef="c20140101to20140129_LongtermDebtTypeAxis_ConvertibleSeniorNotesDue2021Member" unitRef="U001" decimals="10">8300000.0000000000</us-gaap:DebtIssuanceCosts>
  <!--Interest rate, stated percentage (in hundredths)-Convertible Senior Notes Due 2021 [Member]-->
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c20140129_LongtermDebtTypeAxis_ConvertibleSeniorNotesDue2021Member" unitRef="U005" decimals="INF">0.02875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <!--Maturity date-EBS BAML Term Loan [Member]-->
  <us-gaap:DebtInstrumentMaturityDate contextRef="c20140101to20141231_LongtermDebtTypeAxis_EbsBamlTermLoanMember">2018-12-11</us-gaap:DebtInstrumentMaturityDate>
  <!--Maturity date-Convertible Senior Notes Due 2021 [Member]-->
  <us-gaap:DebtInstrumentMaturityDate contextRef="c20140101to20140129_LongtermDebtTypeAxis_ConvertibleSeniorNotesDue2021Member">2021-01-15</us-gaap:DebtInstrumentMaturityDate>
  <!--Maturity date-Revolving Credit Loan dated December 2013, due in December 2018 [Member]-->
  <us-gaap:DebtInstrumentMaturityDate contextRef="c20140101to20141231_LongtermDebtTypeAxis_RevolvingCreditLoanDatedDecember2013DueInDecember2018Member">2018-12-11</us-gaap:DebtInstrumentMaturityDate>
  <!--Deferred tax liability, net-->
  <us-gaap:DeferredTaxLiabilitiesGrossCurrent contextRef="c20131231" unitRef="U001" decimals="-3">88000</us-gaap:DeferredTaxLiabilitiesGrossCurrent>
  <!--Deferred tax liability, net-->
  <us-gaap:DeferredTaxLiabilitiesGrossCurrent contextRef="c20141231" unitRef="U001" decimals="-3">0</us-gaap:DeferredTaxLiabilitiesGrossCurrent>
  <!--Deferred Tax Liabilities, Gross, Noncurrent-->
  <us-gaap:DeferredTaxLiabilitiesGrossNoncurrent contextRef="c20141231" unitRef="U001" decimals="-3">0</us-gaap:DeferredTaxLiabilitiesGrossNoncurrent>
  <!--Deferred Tax Liabilities, Gross, Noncurrent-->
  <us-gaap:DeferredTaxLiabilitiesGrossNoncurrent contextRef="c20131231" unitRef="U001" decimals="-3">1419000</us-gaap:DeferredTaxLiabilitiesGrossNoncurrent>
  <!--Deferred Tax Liabilities, Gross-->
  <us-gaap:DeferredIncomeTaxLiabilities contextRef="c20141231" unitRef="U001" decimals="-3">52268000</us-gaap:DeferredIncomeTaxLiabilities>
  <!--Deferred Tax Liabilities, Gross-->
  <us-gaap:DeferredIncomeTaxLiabilities contextRef="c20131231" unitRef="U001" decimals="-3">38302000</us-gaap:DeferredIncomeTaxLiabilities>
  <!--Deferred Federal Income Tax Expense (Benefit)-->
  <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c20120101to20121231" unitRef="U001" decimals="-3">3758000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
  <!--Deferred Federal Income Tax Expense (Benefit)-->
  <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c20130101to20131231" unitRef="U001" decimals="-3">12679000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
  <!--Deferred Federal Income Tax Expense (Benefit)-->
  <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c20140101to20141231" unitRef="U001" decimals="-3">7693000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
  <!--Deferred Foreign Income Tax Expense (Benefit)-->
  <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="c20120101to20121231" unitRef="U001" decimals="-3">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
  <!--Deferred Foreign Income Tax Expense (Benefit)-->
  <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="c20130101to20131231" unitRef="U001" decimals="-3">152000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
  <!--Deferred Foreign Income Tax Expense (Benefit)-->
  <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="c20140101to20141231" unitRef="U001" decimals="-3">-2503000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
  <!--Deferred income taxes-->
  <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c20130101to20131231" unitRef="U001" decimals="-3">13858000</us-gaap:DeferredIncomeTaxExpenseBenefit>
  <!--Deferred income taxes-->
  <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c20140101to20141231" unitRef="U001" decimals="-3">16493000</us-gaap:DeferredIncomeTaxExpenseBenefit>
  <!--Deferred income taxes-->
  <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c20120101to20121231" unitRef="U001" decimals="-3">3383000</us-gaap:DeferredIncomeTaxExpenseBenefit>
  <!--Deferred State and Local Income Tax Expense (Benefit)-->
  <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c20120101to20121231" unitRef="U001" decimals="-3">-375000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
  <!--Deferred State and Local Income Tax Expense (Benefit)-->
  <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c20130101to20131231" unitRef="U001" decimals="-3">1028000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
  <!--Deferred State and Local Income Tax Expense (Benefit)-->
  <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c20140101to20141231" unitRef="U001" decimals="-3">128000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
  <!--Deferred Tax Assets, Net-->
  <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c20131231" unitRef="U001" decimals="-3">-1507000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
  <!--Deferred Tax Assets, Net-->
  <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c20141231" unitRef="U001" decimals="-3">14474000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
  <!--Deferred Revenue, Current-->
  <us-gaap:DeferredRevenueCurrent contextRef="c20141231" unitRef="U001" decimals="-3">5345000</us-gaap:DeferredRevenueCurrent>
  <!--Deferred Revenue, Current-->
  <us-gaap:DeferredRevenueCurrent contextRef="c20131231" unitRef="U001" decimals="-3">1834000</us-gaap:DeferredRevenueCurrent>
  <!--Deferred Revenue, Current-Morphosys [Member]-->
  <us-gaap:DeferredRevenueCurrent contextRef="c20141231_TypeOfArrangementAxis_MorphosysMember" unitRef="U001" decimals="0">890000</us-gaap:DeferredRevenueCurrent>
  <!--Deferred revenue-->
  <us-gaap:DeferredTaxAssetsDeferredIncome contextRef="c20131231" unitRef="U001" decimals="-3">0</us-gaap:DeferredTaxAssetsDeferredIncome>
  <!--Deferred revenue-->
  <us-gaap:DeferredTaxAssetsDeferredIncome contextRef="c20141231" unitRef="U001" decimals="-3">244000</us-gaap:DeferredTaxAssetsDeferredIncome>
  <!--Deferred revenue, net of current portion-->
  <us-gaap:DeferredRevenueNoncurrent contextRef="c20141231" unitRef="U001" decimals="-3">5713000</us-gaap:DeferredRevenueNoncurrent>
  <!--Deferred revenue, net of current portion-->
  <us-gaap:DeferredRevenueNoncurrent contextRef="c20131231" unitRef="U001" decimals="-3">0</us-gaap:DeferredRevenueNoncurrent>
  <!--Deferred revenue, net of current portion-Morphosys [Member]-->
  <us-gaap:DeferredRevenueNoncurrent contextRef="c20141231_TypeOfArrangementAxis_MorphosysMember" unitRef="U001" decimals="-5">3500000</us-gaap:DeferredRevenueNoncurrent>
  <!--Deferred Tax Assets, Gross-->
  <us-gaap:DeferredTaxAssetsGross contextRef="c20141231" unitRef="U001" decimals="-3">159116000</us-gaap:DeferredTaxAssetsGross>
  <!--Deferred Tax Assets, Gross-->
  <us-gaap:DeferredTaxAssetsGross contextRef="c20131231" unitRef="U001" decimals="-3">105641000</us-gaap:DeferredTaxAssetsGross>
  <!--Stock compensation-->
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c20141231" unitRef="U001" decimals="-3">8196000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
  <!--Stock compensation-->
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c20131231" unitRef="U001" decimals="-3">6378000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
  <!--Other-->
  <us-gaap:DeferredTaxAssetsOther contextRef="c20141231" unitRef="U001" decimals="-3">7219000</us-gaap:DeferredTaxAssetsOther>
  <!--Other-->
  <us-gaap:DeferredTaxAssetsOther contextRef="c20131231" unitRef="U001" decimals="-3">1222000</us-gaap:DeferredTaxAssetsOther>
  <!--Deferred Tax Assets, Net of Valuation Allowance, Current-->
  <us-gaap:DeferredTaxAssetsNetCurrent contextRef="c20131231" unitRef="U001" decimals="-3">0</us-gaap:DeferredTaxAssetsNetCurrent>
  <!--Deferred Tax Assets, Net of Valuation Allowance, Current-->
  <us-gaap:DeferredTaxAssetsNetCurrent contextRef="c20141231" unitRef="U001" decimals="-3">1710000</us-gaap:DeferredTaxAssetsNetCurrent>
  <!--Research and development carryforward-->
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="c20141231" unitRef="U001" decimals="-3">8049000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
  <!--Research and development carryforward-->
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="c20131231" unitRef="U001" decimals="-3">7395000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
  <!--Deferred Tax Assets, Operating Loss Carryforwards, Foreign-->
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign contextRef="c20131231" unitRef="U001" decimals="-3">64090000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign>
  <!--Deferred Tax Assets, Operating Loss Carryforwards, Foreign-->
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign contextRef="c20141231" unitRef="U001" decimals="-3">75511000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign>
  <!--Deferred Tax Assets, Net of Valuation Allowance, Noncurrent-->
  <us-gaap:DeferredTaxAssetsNetNoncurrent contextRef="c20131231" unitRef="U001" decimals="-3">0</us-gaap:DeferredTaxAssetsNetNoncurrent>
  <!--Deferred Tax Assets, Net of Valuation Allowance, Noncurrent-->
  <us-gaap:DeferredTaxAssetsNetNoncurrent contextRef="c20141231" unitRef="U001" decimals="-3">12764000</us-gaap:DeferredTaxAssetsNetNoncurrent>
  <!--Net operating loss carryforward-->
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c20131231" unitRef="U001" decimals="-3">23256000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <!--Net operating loss carryforward-->
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c20141231" unitRef="U001" decimals="-3">20530000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <!--Deferred Tax Assets, Valuation Allowance-->
  <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c20141231" unitRef="U001" decimals="-3">92374000</us-gaap:DeferredTaxAssetsValuationAllowance>
  <!--Deferred Tax Assets, Valuation Allowance-->
  <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c20131231" unitRef="U001" decimals="-3">68846000</us-gaap:DeferredTaxAssetsValuationAllowance>
  <!--Deferred Tax Liabilities, Other-->
  <us-gaap:DeferredTaxLiabilitiesOther contextRef="c20141231" unitRef="U001" decimals="-3">10891000</us-gaap:DeferredTaxLiabilitiesOther>
  <!--Deferred Tax Liabilities, Other-->
  <us-gaap:DeferredTaxLiabilitiesOther contextRef="c20131231" unitRef="U001" decimals="-3">5714000</us-gaap:DeferredTaxLiabilitiesOther>
  <!--Deferred Tax Liabilities, Property, Plant and Equipment-->
  <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="c20131231" unitRef="U001" decimals="-3">32588000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
  <!--Deferred Tax Liabilities, Property, Plant and Equipment-->
  <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="c20141231" unitRef="U001" decimals="-3">34839000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
  <!--Matching contributions made by employer-->
  <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount contextRef="c20140101to20141231" unitRef="U001" decimals="-5">2400000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
  <!--Matching contributions made by employer-->
  <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount contextRef="c20120101to20121231" unitRef="U001" decimals="-5">1900000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
  <!--Matching contributions made by employer-->
  <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount contextRef="c20130101to20131231" unitRef="U001" decimals="-5">2000000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
  <!--Matching of qualified deferrals by employer, maximum (in hundredths)-->
  <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent contextRef="c20140101to20141231" unitRef="U005" decimals="INF">0.5</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
  <!--Depreciation and amortization-->
  <us-gaap:DepreciationDepletionAndAmortization contextRef="c20140101to20141231" unitRef="U001" decimals="-3">23006000</us-gaap:DepreciationDepletionAndAmortization>
  <!--Depreciation and amortization-->
  <us-gaap:DepreciationDepletionAndAmortization contextRef="c20120101to20121231" unitRef="U001" decimals="-3">11197000</us-gaap:DepreciationDepletionAndAmortization>
  <!--Depreciation and amortization-->
  <us-gaap:DepreciationDepletionAndAmortization contextRef="c20130101to20131231" unitRef="U001" decimals="-3">17008000</us-gaap:DepreciationDepletionAndAmortization>
  <!--Depreciation and amortization-All Other [Member]-->
  <us-gaap:DepreciationDepletionAndAmortization contextRef="c20140101to20141231_StatementBusinessSegmentsAxis_AllOtherSegmentsMember" unitRef="U001" decimals="-3">267000</us-gaap:DepreciationDepletionAndAmortization>
  <!--Depreciation and amortization-Biodefense [Member]-->
  <us-gaap:DepreciationDepletionAndAmortization contextRef="c20120101to20121231_StatementBusinessSegmentsAxis_BiodefenseMember" unitRef="U001" decimals="-3">8951000</us-gaap:DepreciationDepletionAndAmortization>
  <!--Depreciation and amortization-Biosciences [Member]-->
  <us-gaap:DepreciationDepletionAndAmortization contextRef="c20140101to20141231_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U001" decimals="-3">5070000</us-gaap:DepreciationDepletionAndAmortization>
  <!--Depreciation and amortization-Biosciences [Member]-->
  <us-gaap:DepreciationDepletionAndAmortization contextRef="c20130101to20131231_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U001" decimals="-3">1238000</us-gaap:DepreciationDepletionAndAmortization>
  <!--Depreciation and amortization-Biodefense [Member]-->
  <us-gaap:DepreciationDepletionAndAmortization contextRef="c20130101to20131231_StatementBusinessSegmentsAxis_BiodefenseMember" unitRef="U001" decimals="-3">15584000</us-gaap:DepreciationDepletionAndAmortization>
  <!--Depreciation and amortization-All Other [Member]-->
  <us-gaap:DepreciationDepletionAndAmortization contextRef="c20120101to20121231_StatementBusinessSegmentsAxis_AllOtherSegmentsMember" unitRef="U001" decimals="-3">99000</us-gaap:DepreciationDepletionAndAmortization>
  <!--Depreciation and amortization-Biosciences [Member]-->
  <us-gaap:DepreciationDepletionAndAmortization contextRef="c20120101to20121231_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U001" decimals="-3">2147000</us-gaap:DepreciationDepletionAndAmortization>
  <!--Depreciation and amortization-All Other [Member]-->
  <us-gaap:DepreciationDepletionAndAmortization contextRef="c20130101to20131231_StatementBusinessSegmentsAxis_AllOtherSegmentsMember" unitRef="U001" decimals="-3">186000</us-gaap:DepreciationDepletionAndAmortization>
  <!--Depreciation and amortization-Biodefense [Member]-->
  <us-gaap:DepreciationDepletionAndAmortization contextRef="c20140101to20141231_StatementBusinessSegmentsAxis_BiodefenseMember" unitRef="U001" decimals="-3">17669000</us-gaap:DepreciationDepletionAndAmortization>
  <!--Assets held for sale [Text Block]-->
  <us-gaap:DisclosureOfLongLivedAssetsHeldForSaleTextBlock contextRef="c20140101to20141231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;&lt;font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;14&lt;/font&gt;. &lt;font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Assets held for sale&lt;/font&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;The Company currently owns a manufacturing and development facility in Winnipeg, Manitoba, Canada that it is actively seeking to sell. In October 2014, the Company determined that this facility, along with associated equipment, would not be placed into service and committed to a plan to sell the facility. Therefore, this facility and related equipment are classified on the Company's balance sheet as an asset held for sale within the prepaid and other current assets line item. The Company recorded the assets held for sale at fair market value of $2.4 million, based on factors that include recent purchase offers less estimated selling costs.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DisclosureOfLongLivedAssetsHeldForSaleTextBlock>
  <!--Facility and equipment held for sale in Winnipeg, Manitoba, Canada-->
  <us-gaap:DisposalGroupIncludingDiscontinuedOperationLongLivedAssets contextRef="c20141231" unitRef="U001" decimals="-5">2400000</us-gaap:DisposalGroupIncludingDiscontinuedOperationLongLivedAssets>
  <!--Earnings Per Share [Text Block]-->
  <us-gaap:EarningsPerShareTextBlock contextRef="c20140101to20141231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;&lt;font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;20.&lt;/font&gt;&lt;font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Earnings per share&lt;/font&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;The following table presents the calculation of basic and diluted net income per share:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="10" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt; font-weight: bold;"&gt;(in thousands, except share and per share data)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;2014&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;2013&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;2012&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Numerator:&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Net income&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;36,741&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;31,135&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;23,524&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Interest expense applicable to convertible debt, net of tax&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;2,879&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Amortization of debt issuance costs, net of tax&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;735&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Adjusted net income&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;40,355&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;31,135&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;23,524&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 64%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Denominator:&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Weighted-average number of shares&amp;#8212;basic&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;37,344,891&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;36,201,283&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;36,080,495&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Dilutive securities&amp;#8212;equity awards&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;737,391&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;546,273&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;340,167&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Dilutive securities&amp;#8212;convertible debt&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;7,720,525&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Weighted-average number of shares&amp;#8212;diluted&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;45,802,807&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;36,747,556&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;36,420,662&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 64%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Earnings per share-basic&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;0.98&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;0.86&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;0.65&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Earnings per share-diluted&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;0.88&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;0.85&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;0.65&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;For the years ending December 31, 2014, 2013 and 2012, outstanding stock options to purchase approximately 1.4 million, 1.5 million and 2.9 million shares of common stock, respectively, are not considered in the diluted earnings per share calculation because the exercise price of these options is greater than the average per share closing price during the year.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
  <!--Earnings per share - basic (in dollars per share)-->
  <us-gaap:EarningsPerShareBasic contextRef="c20120101to20121231" unitRef="U003" decimals="2">0.65</us-gaap:EarningsPerShareBasic>
  <!--Earnings per share - basic (in dollars per share)-->
  <us-gaap:EarningsPerShareBasic contextRef="c20130101to20131231" unitRef="U003" decimals="2">0.86</us-gaap:EarningsPerShareBasic>
  <!--Earnings per share - basic (in dollars per share)-->
  <us-gaap:EarningsPerShareBasic contextRef="c20140101to20141231" unitRef="U003" decimals="2">0.98</us-gaap:EarningsPerShareBasic>
  <!--Earnings per share - basic (in dollars per share)-->
  <us-gaap:EarningsPerShareBasic contextRef="c20130101to20130331" unitRef="U003" decimals="2">-0.22</us-gaap:EarningsPerShareBasic>
  <!--Earnings per share - basic (in dollars per share)-->
  <us-gaap:EarningsPerShareBasic contextRef="c20141001to20141231" unitRef="U003" decimals="2">0.80</us-gaap:EarningsPerShareBasic>
  <!--Earnings per share - basic (in dollars per share)-->
  <us-gaap:EarningsPerShareBasic contextRef="c20140101to20140331" unitRef="U003" decimals="2">-0.55</us-gaap:EarningsPerShareBasic>
  <!--Earnings per share - basic (in dollars per share)-->
  <us-gaap:EarningsPerShareBasic contextRef="c20130701to20130930" unitRef="U003" decimals="2">0.37</us-gaap:EarningsPerShareBasic>
  <!--Earnings per share - basic (in dollars per share)-->
  <us-gaap:EarningsPerShareBasic contextRef="c20131001to20131231" unitRef="U003" decimals="2">0.42</us-gaap:EarningsPerShareBasic>
  <!--Earnings per share - basic (in dollars per share)-->
  <us-gaap:EarningsPerShareBasic contextRef="c20140701to20140930" unitRef="U003" decimals="2">0.58</us-gaap:EarningsPerShareBasic>
  <!--Earnings per share - basic (in dollars per share)-->
  <us-gaap:EarningsPerShareBasic contextRef="c20130401to20130630" unitRef="U003" decimals="2">0.29</us-gaap:EarningsPerShareBasic>
  <!--Earnings per share - basic (in dollars per share)-->
  <us-gaap:EarningsPerShareBasic contextRef="c20140401to20140630" unitRef="U003" decimals="2">0.13</us-gaap:EarningsPerShareBasic>
  <!--Earnings Per Share-->
  <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c20140101to20141231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Earnings per share&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;The Company calculates basic earnings per share by dividing net income by the weighted average number of shares of common stock outstanding during the period.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;During the year ended December 31, 2014, the Company issued 2.875% Convertible Senior Notes due 2021 (the "Notes"). Due to the issuance, the Company calculates diluted earnings per share using the if-converted method by dividing the adjusted net income by the weighted average number of shares of common stock outstanding during the period. The adjusted net income is adjusted for interest expense and amortization of debt issuance cost, both net of tax, associated with the Notes. The weighted average number of shares-diluted is adjusted for the potential dilutive effect of the exercise of stock options and the vesting of restricted stock units along with the assumption of the conversion of the Notes, at the beginning of the period.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;For the years ended December 31, 2013 and 2012, diluted earnings per share is computed using the treasury method by dividing net income by the weighted average number of shares of common stock outstanding during the period, adjusted for the potential dilutive effect of other securities if such securities were converted or exercised.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <!--Earnings per share - diluted (in dollars per share)-->
  <us-gaap:EarningsPerShareDiluted contextRef="c20130101to20131231" unitRef="U003" decimals="2">0.85</us-gaap:EarningsPerShareDiluted>
  <!--Earnings per share - diluted (in dollars per share)-->
  <us-gaap:EarningsPerShareDiluted contextRef="c20120101to20121231" unitRef="U003" decimals="2">0.65</us-gaap:EarningsPerShareDiluted>
  <!--Earnings per share - diluted (in dollars per share)-->
  <us-gaap:EarningsPerShareDiluted contextRef="c20140101to20141231" unitRef="U003" decimals="2">0.88</us-gaap:EarningsPerShareDiluted>
  <!--Earnings per share - diluted (in dollars per share)-->
  <us-gaap:EarningsPerShareDiluted contextRef="c20130101to20130331" unitRef="U003" decimals="2">-0.22</us-gaap:EarningsPerShareDiluted>
  <!--Earnings per share - diluted (in dollars per share)-->
  <us-gaap:EarningsPerShareDiluted contextRef="c20130401to20130630" unitRef="U003" decimals="2">0.29</us-gaap:EarningsPerShareDiluted>
  <!--Earnings per share - diluted (in dollars per share)-->
  <us-gaap:EarningsPerShareDiluted contextRef="c20140401to20140630" unitRef="U003" decimals="2">0.13</us-gaap:EarningsPerShareDiluted>
  <!--Earnings per share - diluted (in dollars per share)-->
  <us-gaap:EarningsPerShareDiluted contextRef="c20131001to20131231" unitRef="U003" decimals="2">0.41</us-gaap:EarningsPerShareDiluted>
  <!--Earnings per share - diluted (in dollars per share)-->
  <us-gaap:EarningsPerShareDiluted contextRef="c20140101to20140331" unitRef="U003" decimals="2">-0.55</us-gaap:EarningsPerShareDiluted>
  <!--Earnings per share - diluted (in dollars per share)-->
  <us-gaap:EarningsPerShareDiluted contextRef="c20130701to20130930" unitRef="U003" decimals="2">0.36</us-gaap:EarningsPerShareDiluted>
  <!--Earnings per share - diluted (in dollars per share)-->
  <us-gaap:EarningsPerShareDiluted contextRef="c20141001to20141231" unitRef="U003" decimals="2">0.66</us-gaap:EarningsPerShareDiluted>
  <!--Earnings per share - diluted (in dollars per share)-->
  <us-gaap:EarningsPerShareDiluted contextRef="c20140701to20140930" unitRef="U003" decimals="2">0.49</us-gaap:EarningsPerShareDiluted>
  <!--Effect of exchange rate changes on cash and cash equivalents-->
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="c20120101to20121231" unitRef="U001" decimals="-3">1000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <!--Effect of exchange rate changes on cash and cash equivalents-->
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="c20130101to20131231" unitRef="U001" decimals="-3">-14000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <!--Effect of exchange rate changes on cash and cash equivalents-->
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="c20140101to20141231" unitRef="U001" decimals="-3">21000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <!--Effective annual tax rate (in hundredths)-->
  <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c20130101to20131231" unitRef="U005" decimals="1">0.3</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
  <!--Effective annual tax rate (in hundredths)-->
  <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c20140101to20141231" unitRef="U005" decimals="2">0.31</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
  <!--Effective annual tax rate (in hundredths)-->
  <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c20120101to20121231" unitRef="U005" decimals="2">0.37</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
  <!--Employee-related Liabilities, Current-->
  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c20131231" unitRef="U001" decimals="-3">24615000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <!--Employee-related Liabilities, Current-->
  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c20141231" unitRef="U001" decimals="-3">31654000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <!--Excess Tax Benefit from Share-based Compensation, Operating Activities-->
  <us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities contextRef="c20130101to20131231" unitRef="U001" decimals="-3">3099000</us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities>
  <!--Excess Tax Benefit from Share-based Compensation, Operating Activities-->
  <us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities contextRef="c20140101to20141231" unitRef="U001" decimals="-3">5987000</us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities>
  <!--Excess Tax Benefit from Share-based Compensation, Operating Activities-->
  <us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities contextRef="c20120101to20121231" unitRef="U001" decimals="-3">1588000</us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities>
  <!--Excess tax benefits from stock-based compensation-->
  <us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities contextRef="c20140101to20141231" unitRef="U001" decimals="-3">5987000</us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities>
  <!--Excess tax benefits from stock-based compensation-->
  <us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities contextRef="c20130101to20131231" unitRef="U001" decimals="-3">3099000</us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities>
  <!--Excess tax benefits from stock-based compensation-->
  <us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities contextRef="c20120101to20121231" unitRef="U001" decimals="-3">1588000</us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities>
  <!--Additions-Biosciences [Member]-Contractual Rights [Member]-->
  <us-gaap:FinitelivedIntangibleAssetsAcquired1 contextRef="c20140101to20141231_FiniteLivedIntangibleAssetsByMajorClassAxis_ContractualRightsMember_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U001" decimals="-3">5500000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
  <!--Additions-Marketed Products [Member]-Biosciences [Member]-->
  <us-gaap:FinitelivedIntangibleAssetsAcquired1 contextRef="c20140101to20141231_FiniteLivedIntangibleAssetsByMajorClassAxis_MarketedProductsMember_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U001" decimals="-3">8100000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
  <!--Additions-Biodefense [Member]-Biodefense Products [Member]-->
  <us-gaap:FinitelivedIntangibleAssetsAcquired1 contextRef="c20140101to20141231_FiniteLivedIntangibleAssetsByMajorClassAxis_BiodefenseProductsMember_StatementBusinessSegmentsAxis_BiodefenseMember" unitRef="U001" decimals="-3">16700000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
  <!--Additions-Manufacturing Agreement [Member]-Biodefense [Member]-->
  <us-gaap:FinitelivedIntangibleAssetsAcquired1 contextRef="c20140101to20141231_FiniteLivedIntangibleAssetsByMajorClassAxis_ManufacturingAgreementMember_StatementBusinessSegmentsAxis_BiodefenseMember" unitRef="U001" decimals="-3">0</us-gaap:FinitelivedIntangibleAssetsAcquired1>
  <!--Additions-Biodefense [Member]-RSDL [Member]-->
  <us-gaap:FinitelivedIntangibleAssetsAcquired1 contextRef="c20140101to20141231_FiniteLivedIntangibleAssetsByMajorClassAxis_RsdlMember_StatementBusinessSegmentsAxis_BiodefenseMember" unitRef="U001" decimals="-3">0</us-gaap:FinitelivedIntangibleAssetsAcquired1>
  <!--Additions-Biosciences [Member]-Corporate Trade Name [Member]-->
  <us-gaap:FinitelivedIntangibleAssetsAcquired1 contextRef="c20140101to20141231_FiniteLivedIntangibleAssetsByMajorClassAxis_TradeNamesMember_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U001" decimals="-3">2800000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
  <!--Additions-Licensed Products [Member]-Biosciences [Member]-->
  <us-gaap:FinitelivedIntangibleAssetsAcquired1 contextRef="c20140101to20141231_FiniteLivedIntangibleAssetsByMajorClassAxis_LicensingAgreementsMember_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U001" decimals="-3">3100000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
  <!--Additions-->
  <us-gaap:FinitelivedIntangibleAssetsAcquired1 contextRef="c20140101to20141231" unitRef="U001" decimals="-3">36200000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
  <!--Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements-->
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements contextRef="c20130101to20131231" unitRef="U001" decimals="-3">348000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
  <!--Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements-->
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements contextRef="c20140101to20141231" unitRef="U001" decimals="-3">1579000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
  <!--Present value discount rate (in hundredths)-Cangene [Member]-Contract Manufacturing [Member]-->
  <us-gaap:FairValueInputsDiscountRate contextRef="c20140221to20140221_BusinessAcquisitionAxis_CangeneMember_FiniteLivedIntangibleAssetsByMajorClassAxis_CustomerContractsMember" unitRef="U005" decimals="2">0.15</us-gaap:FairValueInputsDiscountRate>
  <!--Present value discount rate (in hundredths)-Cangene [Member]-Licensed Products [Member]-->
  <us-gaap:FairValueInputsDiscountRate contextRef="c20140221to20140221_BusinessAcquisitionAxis_CangeneMember_FiniteLivedIntangibleAssetsByMajorClassAxis_LicensingAgreementsMember" unitRef="U005" decimals="2">0.15</us-gaap:FairValueInputsDiscountRate>
  <!--Present value discount rate (in hundredths)-Evolva Holding SA 035 [Member]-->
  <us-gaap:FairValueInputsDiscountRate contextRef="c20141217to20141217_BusinessAcquisitionAxis_EvolvaHoldingSA035Member" unitRef="U005" decimals="2">0.12</us-gaap:FairValueInputsDiscountRate>
  <!--Present value discount rate (in hundredths)-Cangene [Member]-Biodefense Intangible Asset [Member]-->
  <us-gaap:FairValueInputsDiscountRate contextRef="c20140221to20140221_BusinessAcquisitionAxis_CangeneMember_FiniteLivedIntangibleAssetsByMajorClassAxis_BiodefenseIntangibleAssetMember" unitRef="U005" decimals="2">0.15</us-gaap:FairValueInputsDiscountRate>
  <!--Present value discount rate (in hundredths)-Cangene [Member]-Corporate Trade Name [Member]-->
  <us-gaap:FairValueInputsDiscountRate contextRef="c20140221to20140221_BusinessAcquisitionAxis_CangeneMember_FiniteLivedIntangibleAssetsByMajorClassAxis_TradeNamesMember" unitRef="U005" decimals="2">0.15</us-gaap:FairValueInputsDiscountRate>
  <!--Present value discount rate (in hundredths)-Marketing-Related Intangible Assets [Member]-Cangene [Member]-->
  <us-gaap:FairValueInputsDiscountRate contextRef="c20140221to20140221_BusinessAcquisitionAxis_CangeneMember_FiniteLivedIntangibleAssetsByMajorClassAxis_MarketingRelatedIntangibleAssetsMember" unitRef="U005" decimals="2">0.15</us-gaap:FairValueInputsDiscountRate>
  <!--Present value discount rate (in hundredths)-Cangene [Member]-->
  <us-gaap:FairValueInputsDiscountRate contextRef="c20140221to20140221_BusinessAcquisitionAxis_CangeneMember" unitRef="U005" decimals="2">0.16</us-gaap:FairValueInputsDiscountRate>
  <!--Fair value of measurements-->
  <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c20140101to20141231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Fair value of measurements&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;The Company measures and records cash equivalents and investment securities considered available-for-sale at fair value in the accompanying financial statements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability, an exit price, in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value include:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify;"&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td style="width: 36pt;"&gt;&lt;/td&gt;&lt;td style="width: 72pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; vertical-align: top; align: right;"&gt;Level 1 &amp;#8212;&lt;/td&gt;&lt;td style="text-align: justify; width: auto; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; vertical-align: top;"&gt;Observable inputs for identical assets or liabilities such as quoted prices in active markets;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align: justify;"&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td style="width: 36pt;"&gt;&lt;/td&gt;&lt;td style="width: 72pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; vertical-align: top; align: right;"&gt;Level 2 &amp;#8212;&lt;/td&gt;&lt;td style="text-align: justify; width: auto; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; vertical-align: top;"&gt;Inputs other than quoted prices in active markets that are either directly or indirectly observable; and&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align: justify;"&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td style="width: 36pt;"&gt;&lt;/td&gt;&lt;td style="width: 72pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; vertical-align: top; align: right;"&gt;Level 3 &amp;#8212;&lt;/td&gt;&lt;td style="text-align: justify; width: auto; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; vertical-align: top;"&gt;Unobservable inputs in which little or no market data exists, which are therefore developed by the Company using estimates and assumptions that reflect those that a market participant would use.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;The carrying amounts of the Company's short-term financial instruments, which include cash and cash equivalents, accounts receivable and accounts payable, approximate their fair values due to their short maturities.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
  <!--Transfers in/(out) of Level 3-->
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3 contextRef="c20130101to20131231" unitRef="U001" decimals="-3">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3>
  <!--Transfers in/(out) of Level 3-->
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3 contextRef="c20140101to20141231" unitRef="U001" decimals="-3">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3>
  <!--Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value-->
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c20121231" unitRef="U001" decimals="-3">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
  <!--Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value-->
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c20141231" unitRef="U001" decimals="-3">47657000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
  <!--Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value-->
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c20131231" unitRef="U001" decimals="-3">16619000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
  <!--Fair Value Disclosures [Text Block]-->
  <us-gaap:FairValueDisclosuresTextBlock contextRef="c20140101to20141231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;&lt;font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;4.&lt;/font&gt;&lt;font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Fair value measurements&lt;/font&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;&amp;#160;&amp;#160;The following table represents the Company's fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="15" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;At December 31, 2014&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;(in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Level 1&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Level 2&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Level 3&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Total&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Assets:&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Investment in money market funds (1)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;111,912&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;111,912&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Total assets&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;111,912&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;111,912&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Liabilities:&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Contingent consideration&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;47,657&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;47,657&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Total liabilities&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;47,657&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;47,657&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="15" valign="bottom" style="border-bottom: #000000 2px solid; background-color: #ffffff; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;At December 31, 2013&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #ffffff; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;(in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; background-color: #cceeff; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Level 1&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #cceeff; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; background-color: #cceeff; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Level 2&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #cceeff; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; background-color: #cceeff; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Level 3&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #cceeff; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; background-color: #cceeff; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Total&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #cceeff; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Assets:&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Investment in money market funds (1)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;37,701&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;37,701&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Total assets&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;37,701&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;37,701&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Liabilities:&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Contingent price consideration&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;16,619&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;16,619&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Total liabilities&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;16,619&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;16,619&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(1) Included in cash and cash equivalents in accompanying consolidated balance sheets.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;As of December 31, 2014 and 2013, the Company did not have any transfers between Level 1 and Level 2 assets or liabilities.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;The fair value of contingent purchase consideration obligations are based on management's assessment of changes as a result of adjustments to the discount rates and updates in the assumed and actual achievement of future net sales for RSDL and HepaGam B, which are inputs that have no observable market (Level 3). For the years ended December 31, 2014 and 2013, the contingent purchase consideration obligation increased by $3.1 million and $735,000, respectively, primarily due to an adjustment to the actual and expected timing of RSDL and HepaGam B sales. This increase resulted in a charge that is classified in the Company's statement of operations as cost of product sales and contract manufacturing. In addition, contingent value rights increased for the year ended December 31, 2014 due to the acquisition of EV-035 series (see Note 3).&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; margin-top: 8pt; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; margin-bottom: 8pt; color: #000000; font-size: 10pt;"&gt;The following table is a reconciliation of the beginning and ending balance of the liabilities measured at fair value using significant unobservable inputs (Level 3) during the years ended December 31, 2014 and 2013.&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;(in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Balance at December 31, 2012&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Expense (income) included in earnings&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;735&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Settlements&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(348&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Purchases, sales and issuances&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;16,232&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Transfers in/(out) of Level 3&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Balance at December 31, 2013&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;16,619&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Expense (income) included in earnings&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;3,133&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Settlements&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(1,579&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Purchases, sales and issuances&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;29,484&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Transfers in/(out) of Level 3&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Balance at December 31, 2014&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;47,657&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Separate disclosure is required for assets and liabilities measured at fair value on a recurring basis, as documented above, from those measured at fair value on a nonrecurring basis. During the year ended December 31, 2014, the assets acquired and liabilities assumed as part of the Cangene and EV-035 molecules acquisitions (Note 3) and the evaluation of the IXINITY IPR&amp;amp;D asset for impairment (Note 9) were measured at fair value on a nonrecurring basis. For the year ended December 31, 2013, some of the Company's equipment was measured at fair value on a non-recurring basis (see Note 7), which is categorized as a Level 3 fair value measurement.&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
  <!--Reconciliation of Liabilities Measured at Fair Value Using Significant Unobservable Inputs (Level 3)-->
  <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="c20140101to20141231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; margin-top: 8pt; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; margin-bottom: 8pt; color: #000000; font-size: 10pt;"&gt;The following table is a reconciliation of the beginning and ending balance of the liabilities measured at fair value using significant unobservable inputs (Level 3) during the years ended December 31, 2014 and 2013.&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;(in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Balance at December 31, 2012&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Expense (income) included in earnings&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;735&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Settlements&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(348&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Purchases, sales and issuances&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;16,232&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Transfers in/(out) of Level 3&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Balance at December 31, 2013&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;16,619&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Expense (income) included in earnings&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;3,133&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Settlements&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(1,579&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Purchases, sales and issuances&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;29,484&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Transfers in/(out) of Level 3&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Balance at December 31, 2014&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;47,657&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
  <!--Expense (income) included in earnings-->
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="c20140101to20141231" unitRef="U001" decimals="-3">3133000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
  <!--Expense (income) included in earnings-->
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="c20130101to20131231" unitRef="U001" decimals="-3">735000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
  <!--Finite-Lived Intangible Assets, Amortization Expense, Year Four-->
  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="c20141231" unitRef="U001" decimals="-3">7470000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
  <!--Amortization period of intangible assets-Cangene [Member]-Licensed Products [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c20140221to20140221_BusinessAcquisitionAxis_CangeneMember_FiniteLivedIntangibleAssetsByMajorClassAxis_LicensingAgreementsMember">P7Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
  <!--Amortization period of intangible assets-Marketing-Related Intangible Assets [Member]-Cangene [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c20140221to20140221_BusinessAcquisitionAxis_CangeneMember_FiniteLivedIntangibleAssetsByMajorClassAxis_MarketingRelatedIntangibleAssetsMember">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
  <!--Amortization period of intangible assets-Cangene [Member]-Contract Manufacturing [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c20140221to20140221_BusinessAcquisitionAxis_CangeneMember_FiniteLivedIntangibleAssetsByMajorClassAxis_CustomerContractsMember">P8Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
  <!--Amortization period of intangible assets-Cangene [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c20140101to20141231_BusinessAcquisitionAxis_CangeneMember">P110M</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
  <!--Amortization period of intangible assets-Cangene [Member]-Corporate Trade Name [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c20140221to20140221_BusinessAcquisitionAxis_CangeneMember_FiniteLivedIntangibleAssetsByMajorClassAxis_TradeNamesMember">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
  <!--Amortization period of intangible assets-Cangene [Member]-Biodefense Intangible Asset [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c20140221to20140221_BusinessAcquisitionAxis_CangeneMember_FiniteLivedIntangibleAssetsByMajorClassAxis_BiodefenseIntangibleAssetMember">P12Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
  <!--Amortization period of intangible assets-Manufacturing Agreement [Member]-HPPD [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c20130731to20130801_BusinessAcquisitionAxis_HppdMember_FiniteLivedIntangibleAssetsByMajorClassAxis_ManufacturingAgreementMember">P3Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
  <!--Amortization period of intangible assets-HPPD [Member]-RSDL [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c20130731to20130801_BusinessAcquisitionAxis_HppdMember_FiniteLivedIntangibleAssetsByMajorClassAxis_RsdlMember">P8Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
  <!--Finite-Lived Intangible Assets, Gross-RSDL [Member]-HPPD [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c20131231_BusinessAcquisitionAxis_HppdMember_FiniteLivedIntangibleAssetsByMajorClassAxis_RsdlMember" unitRef="U001" decimals="-3">28621000</us-gaap:FiniteLivedIntangibleAssetsGross>
  <!--Finite-Lived Intangible Assets, Gross-Manufacturing Agreement [Member]-HPPD [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c20131231_BusinessAcquisitionAxis_HppdMember_FiniteLivedIntangibleAssetsByMajorClassAxis_ManufacturingAgreementMember" unitRef="U001" decimals="-3">3478000</us-gaap:FiniteLivedIntangibleAssetsGross>
  <!--Finite-Lived Intangible Assets, Gross-HPPD [Member]-RSDL [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c20141231_BusinessAcquisitionAxis_HppdMember_FiniteLivedIntangibleAssetsByMajorClassAxis_RsdlMember" unitRef="U001" decimals="-3">28621000</us-gaap:FiniteLivedIntangibleAssetsGross>
  <!--Finite-Lived Intangible Assets, Gross-HPPD [Member]-Manufacturing Agreement [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c20141231_BusinessAcquisitionAxis_HppdMember_FiniteLivedIntangibleAssetsByMajorClassAxis_ManufacturingAgreementMember" unitRef="U001" decimals="-3">3478000</us-gaap:FiniteLivedIntangibleAssetsGross>
  <!--Finite-Lived Intangible Assets, Gross-Biodefense Products [Member]-Biodefense [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c20131231_FiniteLivedIntangibleAssetsByMajorClassAxis_BiodefenseProductsMember_StatementBusinessSegmentsAxis_BiodefenseMember" unitRef="U001" decimals="-3">0</us-gaap:FiniteLivedIntangibleAssetsGross>
  <!--Finite-Lived Intangible Assets, Gross-->
  <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c20131231" unitRef="U001" decimals="-3">32099000</us-gaap:FiniteLivedIntangibleAssetsGross>
  <!--Finite-Lived Intangible Assets, Gross-Biosciences [Member]-Contractual Rights [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c20131231_FiniteLivedIntangibleAssetsByMajorClassAxis_ContractualRightsMember_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U001" decimals="-3">0</us-gaap:FiniteLivedIntangibleAssetsGross>
  <!--Finite-Lived Intangible Assets, Gross-Biodefense [Member]-Manufacturing Agreement [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c20131231_FiniteLivedIntangibleAssetsByMajorClassAxis_ManufacturingAgreementMember_StatementBusinessSegmentsAxis_BiodefenseMember" unitRef="U001" decimals="-3">3478000</us-gaap:FiniteLivedIntangibleAssetsGross>
  <!--Finite-Lived Intangible Assets, Gross-Biosciences [Member]-Corporate Trade Name [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c20131231_FiniteLivedIntangibleAssetsByMajorClassAxis_TradeNamesMember_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U001" decimals="-3">0</us-gaap:FiniteLivedIntangibleAssetsGross>
  <!--Finite-Lived Intangible Assets, Gross-Licensed Products [Member]-Biosciences [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c20131231_FiniteLivedIntangibleAssetsByMajorClassAxis_LicensingAgreementsMember_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U001" decimals="-3">0</us-gaap:FiniteLivedIntangibleAssetsGross>
  <!--Finite-Lived Intangible Assets, Gross-RSDL [Member]-Biodefense [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c20131231_FiniteLivedIntangibleAssetsByMajorClassAxis_RsdlMember_StatementBusinessSegmentsAxis_BiodefenseMember" unitRef="U001" decimals="-3">28621000</us-gaap:FiniteLivedIntangibleAssetsGross>
  <!--Finite-Lived Intangible Assets, Gross-Biosciences [Member]-Marketed Products [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c20131231_FiniteLivedIntangibleAssetsByMajorClassAxis_MarketedProductsMember_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U001" decimals="-3">0</us-gaap:FiniteLivedIntangibleAssetsGross>
  <!--Finite-Lived Intangible Assets, Gross-Licensed Products [Member]-Biosciences [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c20141231_FiniteLivedIntangibleAssetsByMajorClassAxis_LicensingAgreementsMember_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U001" decimals="-3">3100000</us-gaap:FiniteLivedIntangibleAssetsGross>
  <!--Finite-Lived Intangible Assets, Gross-->
  <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c20141231" unitRef="U001" decimals="-3">68299000</us-gaap:FiniteLivedIntangibleAssetsGross>
  <!--Finite-Lived Intangible Assets, Gross-Biodefense [Member]-Manufacturing Agreement [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c20141231_FiniteLivedIntangibleAssetsByMajorClassAxis_ManufacturingAgreementMember_StatementBusinessSegmentsAxis_BiodefenseMember" unitRef="U001" decimals="-3">3478000</us-gaap:FiniteLivedIntangibleAssetsGross>
  <!--Finite-Lived Intangible Assets, Gross-Biodefense [Member]-RSDL [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c20141231_FiniteLivedIntangibleAssetsByMajorClassAxis_RsdlMember_StatementBusinessSegmentsAxis_BiodefenseMember" unitRef="U001" decimals="-3">28621000</us-gaap:FiniteLivedIntangibleAssetsGross>
  <!--Finite-Lived Intangible Assets, Gross-Biosciences [Member]-Marketed Products [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c20141231_FiniteLivedIntangibleAssetsByMajorClassAxis_MarketedProductsMember_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U001" decimals="-3">8100000</us-gaap:FiniteLivedIntangibleAssetsGross>
  <!--Finite-Lived Intangible Assets, Gross-Biodefense [Member]-Biodefense Products [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c20141231_FiniteLivedIntangibleAssetsByMajorClassAxis_BiodefenseProductsMember_StatementBusinessSegmentsAxis_BiodefenseMember" unitRef="U001" decimals="-3">16700000</us-gaap:FiniteLivedIntangibleAssetsGross>
  <!--Finite-Lived Intangible Assets, Gross-Biosciences [Member]-Contractual Rights [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c20141231_FiniteLivedIntangibleAssetsByMajorClassAxis_ContractualRightsMember_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U001" decimals="-3">5500000</us-gaap:FiniteLivedIntangibleAssetsGross>
  <!--Finite-Lived Intangible Assets, Gross-Corporate Trade Name [Member]-Biosciences [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c20141231_FiniteLivedIntangibleAssetsByMajorClassAxis_TradeNamesMember_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U001" decimals="-3">2800000</us-gaap:FiniteLivedIntangibleAssetsGross>
  <!--Finite-Lived Intangible Assets, Accumulated Amortization-Manufacturing Agreement [Member]-HPPD [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c20131231_BusinessAcquisitionAxis_HppdMember_FiniteLivedIntangibleAssetsByMajorClassAxis_ManufacturingAgreementMember" unitRef="U001" decimals="-3">-483000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <!--Finite-Lived Intangible Assets, Accumulated Amortization-HPPD [Member]-RSDL [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c20131231_BusinessAcquisitionAxis_HppdMember_FiniteLivedIntangibleAssetsByMajorClassAxis_RsdlMember" unitRef="U001" decimals="-3">-1468000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <!--Finite-Lived Intangible Assets, Accumulated Amortization-Manufacturing Agreement [Member]-HPPD [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c20141231_BusinessAcquisitionAxis_HppdMember_FiniteLivedIntangibleAssetsByMajorClassAxis_ManufacturingAgreementMember" unitRef="U001" decimals="-3">-1642000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <!--Finite-Lived Intangible Assets, Accumulated Amortization-RSDL [Member]-HPPD [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c20141231_BusinessAcquisitionAxis_HppdMember_FiniteLivedIntangibleAssetsByMajorClassAxis_RsdlMember" unitRef="U001" decimals="-3">-4987000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <!--Finite-Lived Intangible Assets, Accumulated Amortization-->
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c20131231" unitRef="U001" decimals="-3">-1951000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <!--Finite-Lived Intangible Assets, Accumulated Amortization-Manufacturing Agreement [Member]-Biodefense [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c20131231_FiniteLivedIntangibleAssetsByMajorClassAxis_ManufacturingAgreementMember_StatementBusinessSegmentsAxis_BiodefenseMember" unitRef="U001" decimals="-3">-483000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <!--Finite-Lived Intangible Assets, Accumulated Amortization-Biodefense Products [Member]-Biodefense [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c20131231_FiniteLivedIntangibleAssetsByMajorClassAxis_BiodefenseProductsMember_StatementBusinessSegmentsAxis_BiodefenseMember" unitRef="U001" decimals="-3">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <!--Finite-Lived Intangible Assets, Accumulated Amortization-Marketed Products [Member]-Biosciences [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c20131231_FiniteLivedIntangibleAssetsByMajorClassAxis_MarketedProductsMember_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U001" decimals="-3">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <!--Finite-Lived Intangible Assets, Accumulated Amortization-Biosciences [Member]-Corporate Trade Name [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c20131231_FiniteLivedIntangibleAssetsByMajorClassAxis_TradeNamesMember_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U001" decimals="-3">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <!--Finite-Lived Intangible Assets, Accumulated Amortization-Biodefense [Member]-RSDL [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c20131231_FiniteLivedIntangibleAssetsByMajorClassAxis_RsdlMember_StatementBusinessSegmentsAxis_BiodefenseMember" unitRef="U001" decimals="-3">-1468000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <!--Finite-Lived Intangible Assets, Accumulated Amortization-Biosciences [Member]-Contractual Rights [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c20131231_FiniteLivedIntangibleAssetsByMajorClassAxis_ContractualRightsMember_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U001" decimals="-3">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <!--Finite-Lived Intangible Assets, Accumulated Amortization-Biosciences [Member]-Licensed Products [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c20131231_FiniteLivedIntangibleAssetsByMajorClassAxis_LicensingAgreementsMember_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U001" decimals="-3">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <!--Finite-Lived Intangible Assets, Accumulated Amortization-Marketed Products [Member]-Biosciences [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c20141231_FiniteLivedIntangibleAssetsByMajorClassAxis_MarketedProductsMember_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U001" decimals="-3">-692000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <!--Finite-Lived Intangible Assets, Accumulated Amortization-Biodefense [Member]-Biodefense Products [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c20141231_FiniteLivedIntangibleAssetsByMajorClassAxis_BiodefenseProductsMember_StatementBusinessSegmentsAxis_BiodefenseMember" unitRef="U001" decimals="-3">-1191000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <!--Finite-Lived Intangible Assets, Accumulated Amortization-Biodefense [Member]-RSDL [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c20141231_FiniteLivedIntangibleAssetsByMajorClassAxis_RsdlMember_StatementBusinessSegmentsAxis_BiodefenseMember" unitRef="U001" decimals="-3">-4987000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <!--Finite-Lived Intangible Assets, Accumulated Amortization-Corporate Trade Name [Member]-Biosciences [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c20141231_FiniteLivedIntangibleAssetsByMajorClassAxis_TradeNamesMember_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U001" decimals="-3">-478000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <!--Finite-Lived Intangible Assets, Accumulated Amortization-Biosciences [Member]-Contractual Rights [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c20141231_FiniteLivedIntangibleAssetsByMajorClassAxis_ContractualRightsMember_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U001" decimals="-3">-587000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <!--Finite-Lived Intangible Assets, Accumulated Amortization-->
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c20141231" unitRef="U001" decimals="-3">-9955000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <!--Finite-Lived Intangible Assets, Accumulated Amortization-Manufacturing Agreement [Member]-Biodefense [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c20141231_FiniteLivedIntangibleAssetsByMajorClassAxis_ManufacturingAgreementMember_StatementBusinessSegmentsAxis_BiodefenseMember" unitRef="U001" decimals="-3">-1642000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <!--Finite-Lived Intangible Assets, Accumulated Amortization-Biosciences [Member]-Licensed Products [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c20141231_FiniteLivedIntangibleAssetsByMajorClassAxis_LicensingAgreementsMember_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U001" decimals="-3">-378000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <!--Net book value of intangible assets-HPPD [Member]-Manufacturing Agreement [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c20141231_BusinessAcquisitionAxis_HppdMember_FiniteLivedIntangibleAssetsByMajorClassAxis_ManufacturingAgreementMember" unitRef="U001" decimals="-3">1836000</us-gaap:FiniteLivedIntangibleAssetsNet>
  <!--Net book value of intangible assets-HPPD [Member]-RSDL [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c20141231_BusinessAcquisitionAxis_HppdMember_FiniteLivedIntangibleAssetsByMajorClassAxis_RsdlMember" unitRef="U001" decimals="-3">23634000</us-gaap:FiniteLivedIntangibleAssetsNet>
  <!--Net book value of intangible assets-Corporate Trade Name [Member]-Biosciences [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c20141231_FiniteLivedIntangibleAssetsByMajorClassAxis_TradeNamesMember_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U001" decimals="-3">2322000</us-gaap:FiniteLivedIntangibleAssetsNet>
  <!--Net book value of intangible assets-->
  <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c20141231" unitRef="U001" decimals="-3">58344000</us-gaap:FiniteLivedIntangibleAssetsNet>
  <!--Net book value of intangible assets-RSDL [Member]-Biodefense [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c20141231_FiniteLivedIntangibleAssetsByMajorClassAxis_RsdlMember_StatementBusinessSegmentsAxis_BiodefenseMember" unitRef="U001" decimals="-3">23634000</us-gaap:FiniteLivedIntangibleAssetsNet>
  <!--Net book value of intangible assets-Marketed Products [Member]-Biosciences [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c20141231_FiniteLivedIntangibleAssetsByMajorClassAxis_MarketedProductsMember_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U001" decimals="-3">7408000</us-gaap:FiniteLivedIntangibleAssetsNet>
  <!--Net book value of intangible assets-Biosciences [Member]-Manufacturing Agreement [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c20141231_FiniteLivedIntangibleAssetsByMajorClassAxis_ManufacturingAgreementMember_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U001" decimals="-3">1836000</us-gaap:FiniteLivedIntangibleAssetsNet>
  <!--Net book value of intangible assets-Biosciences [Member]-Contractual Rights [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c20141231_FiniteLivedIntangibleAssetsByMajorClassAxis_ContractualRightsMember_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U001" decimals="-3">4913000</us-gaap:FiniteLivedIntangibleAssetsNet>
  <!--Net book value of intangible assets-Biosciences [Member]-Licensed Products [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c20141231_FiniteLivedIntangibleAssetsByMajorClassAxis_LicensingAgreementsMember_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U001" decimals="-3">2722000</us-gaap:FiniteLivedIntangibleAssetsNet>
  <!--Net book value of intangible assets-Biodefense Products [Member]-Biodefense [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c20141231_FiniteLivedIntangibleAssetsByMajorClassAxis_BiodefenseProductsMember_StatementBusinessSegmentsAxis_BiodefenseMember" unitRef="U001" decimals="-3">15509000</us-gaap:FiniteLivedIntangibleAssetsNet>
  <!--Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months-->
  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="c20141231" unitRef="U001" decimals="-3">8629000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
  <!--Finite-Lived Intangible Assets, Amortization Expense, Year Two-->
  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="c20141231" unitRef="U001" decimals="-3">8146000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
  <!--Finite-Lived Intangible Assets, Amortization Expense, Year Three-->
  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="c20141231" unitRef="U001" decimals="-3">7470000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
  <!--Foreign currencies-->
  <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="c20140101to20141231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Foreign currencies&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Except for the Company's Canadian subsidiaries, the local currency is the functional currency for the Company's foreign subsidiaries and, as such, assets and liabilities are translated into U.S. dollars at year-end exchange rates. Income and expense items are translated at average exchange rates during the year. Translation adjustments resulting from this process are charged or credited to other comprehensive income. The Company's Canadian subsidiaries local currency is U.S. dollars due to substantially all the transactions of the subsidiaries being denominated in U.S. dollars.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
  <!--Goodwill, net book value-->
  <us-gaap:Goodwill contextRef="c20141231" unitRef="U001" decimals="-3">41984000</us-gaap:Goodwill>
  <!--Goodwill, net book value-->
  <us-gaap:Goodwill contextRef="c20131231" unitRef="U001" decimals="-3">13954000</us-gaap:Goodwill>
  <!--Goodwill, net book value-Cangene [Member]-->
  <us-gaap:Goodwill contextRef="c20140221_BusinessAcquisitionAxis_CangeneMember" unitRef="U001" decimals="-3">24566000</us-gaap:Goodwill>
  <!--Goodwill, net book value-Cangene [Member]-->
  <us-gaap:Goodwill contextRef="c20141231_BusinessAcquisitionAxis_CangeneMember" unitRef="U001" decimals="-5">24600000</us-gaap:Goodwill>
  <!--Goodwill, net book value-HPPD [Member]-->
  <us-gaap:Goodwill contextRef="c20130801_BusinessAcquisitionAxis_HppdMember" unitRef="U001" decimals="-3">9916000</us-gaap:Goodwill>
  <!--Goodwill, net book value-Evolva Holding SA 035 [Member]-->
  <us-gaap:Goodwill contextRef="c20141217_BusinessAcquisitionAxis_EvolvaHoldingSA035Member" unitRef="U001" decimals="-3">2000000</us-gaap:Goodwill>
  <!--Goodwill, net book value-Biosciences [Member]-->
  <us-gaap:Goodwill contextRef="c20141231_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U001" decimals="-3">21346000</us-gaap:Goodwill>
  <!--Goodwill, net book value-Biodefense [Member]-->
  <us-gaap:Goodwill contextRef="c20141231_StatementBusinessSegmentsAxis_BiodefenseMember" unitRef="U001" decimals="-3">20638000</us-gaap:Goodwill>
  <!--Goodwill, net book value-->
  <us-gaap:Goodwill contextRef="c20121231" unitRef="U001" decimals="-3">5502000</us-gaap:Goodwill>
  <!--Goodwill, net book value-Biosciences [Member]-->
  <us-gaap:Goodwill contextRef="c20121231_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U001" decimals="-3">5502000</us-gaap:Goodwill>
  <!--Goodwill, net book value-Biodefense [Member]-->
  <us-gaap:Goodwill contextRef="c20121231_StatementBusinessSegmentsAxis_BiodefenseMember" unitRef="U001" decimals="-3">0</us-gaap:Goodwill>
  <!--Goodwill, net book value-Biodefense [Member]-->
  <us-gaap:Goodwill contextRef="c20131231_StatementBusinessSegmentsAxis_BiodefenseMember" unitRef="U001" decimals="-3">8452000</us-gaap:Goodwill>
  <!--Goodwill, net book value-Biosciences [Member]-->
  <us-gaap:Goodwill contextRef="c20131231_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U001" decimals="-3">5502000</us-gaap:Goodwill>
  <!--Goodwill, net book value-All Other [Member]-->
  <us-gaap:Goodwill contextRef="c20121231_StatementBusinessSegmentsAxis_AllOtherSegmentsMember" unitRef="U001" decimals="-3">0</us-gaap:Goodwill>
  <!--Goodwill, net book value-All Other [Member]-->
  <us-gaap:Goodwill contextRef="c20131231_StatementBusinessSegmentsAxis_AllOtherSegmentsMember" unitRef="U001" decimals="-3">0</us-gaap:Goodwill>
  <!--Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]-->
  <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy contextRef="c20140101to20141231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Goodwill&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;The Company assesses the carrying value of goodwill on an annual basis, or whenever events or changes in circumstances indicate the carrying value of goodwill may not be recoverable,&lt;font style="font-style: italic; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;to determine whether any impairment in this asset may exist and, if so, the extent of such impairment. The provisions of the relevant accounting guidance require that the Company perform a two-step impairment test. In the first step, the Company compares the fair value of its reporting unit to the carrying value of the reporting unit. If the carrying value of the reporting unit exceeds the fair value of the reporting unit, then the second step of the impairment test is performed in order to determine the implied fair value of the reporting unit's goodwill. If the carrying value of the reporting unit's goodwill exceeds its implied fair value, an impairment loss equal to the difference is recognized. The Company calculates the fair value of the reporting unit utilizing the income approach. The income approach utilizes a discounted cash flow model, using a discount rate based on the Company's estimated weighted average cost of capital. The Company also evaluates goodwill for certain reporting units using the qualitative assessment method, which permits companies to qualitatively assess whether it is more-likely-than-not that the fair value of a reporting unit is less than its carrying amount. The Company considers developments in its operations, the industry in which it operates and overall macroeconomic factors that could have affected the fair value of the reporting unit since the date of the most recent quantitative analysis of a reporting unit's fair value.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;The determination of the fair value of a reporting unit is judgmental in nature and involves the use of significant estimates and assumptions. The estimates and assumptions used in calculating fair value include identifying future cash flows, which requires that the Company makes a number of critical legal, economic, market and business assumptions that reflect best estimates as of the testing date. The Company's assumptions and estimates may differ significantly from actual results, or circumstances could change that would cause the Company to conclude that an impairment now exists or that it previously understated the extent of impairment. The Company selected October 1&lt;sup&gt;st&lt;/sup&gt; as its annual impairment test date.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
  <!--In-process research and development and goodwill-->
  <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="c20140101to20141231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;9. Intangible assets, in-process research and development and goodwill&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;&lt;font style="background-color: #ffffff; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;The Company completed its annual impairment assessments for its IPR&amp;amp;D asset and goodwill as of October 1, 2014 and 2013, respectively, and determined that the fair value of the Company's IPR&amp;amp;D assets and reporting units was significantly in excess of carrying value. &lt;/font&gt;The Company performed a quantitative assessment of goodwill associated with the Bioscience Therapeutics and Contract Manufacturing reporting units, components of the Biosciences segment along with the Biodefense medical device reporting unit, a component of the Biodefense segment. The Company performed a qualitative assessment of goodwill associated with the Biodefense Therapeutics and Vaccines reporting unit, a component of the Biodefense segment.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;On July 29, 2014, the FDA issued a complete response letter for the New Drug Application ("NDA") of IXINITY. The complete response letter requested additional analyses of data from completed studies and noted deficiencies in the chemistry, manufacturing, and controls section of the license application, all of which must be resolved before approval can be granted by the FDA. The Company determined that the FDA's response to its NDA is a potential indicator of impairment of the related IXINITY IPR&amp;amp;D asset. The Company performed its interim impairment analysis and concluded its estimated fair value for the IXINITY IPR&amp;amp;D asset was in excess of carrying value, therefore the Company determined there was no impairment of the IXINITY IPR&amp;amp;D asset as of December 31, 2014. The determination of fair value involved unobservable inputs, such as estimates of future revenues and operating profits, probabilities of success and discount rates. The Company believes these inputs represent the highest and best use of the IXINITY IPR&amp;amp;D asset.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;&lt;font style="background-color: #ffffff; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;During the year ended December 31, 2012, Pfizer Inc. ("Pfizer") terminated its development programs with respect to the Company's SBI-087 product candidate. The Company considered this termination a potential indicator of impairment of the related SBI-087 IPR&amp;amp;D asset, and assessed the fair value of this asset. As part of the assessment, the Company considered the impact of Pfizer's decision, along with the Company's decision to no longer pursue further development of this asset due to reduced overall probability of success and increased development costs for the product candidate. As a result, the Company recorded an impairment charge of $9.6 million during the year ended December 31, 2012, which represented the entire carrying value of the SBI-087 IPR&amp;amp;D asset. &lt;/font&gt;This charge is classified in the Company's statement of operations as impairment of in-process research and development, within the Company's Biosciences segment.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; margin-top: 3pt; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; margin-bottom: 3pt; color: #000000; font-size: 10pt;"&gt;Intangible assets consist of the following:&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Manufacturing&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Corporate&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Marketed&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Licensed&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Biodefense&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Contract&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;&lt;font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;(in thousands)&lt;/font&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;RSDL&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Agreement&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Tradename&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Products&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Products&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Products&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Manufacturing&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Total&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Cost basis&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 20%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Balance at December 31, 2013&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;28,621&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;3,478&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;32,099&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 20%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Additions&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;2,800&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;8,100&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;3,100&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;16,700&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;5,500&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;36,200&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 20%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Balance at December 31, 2014&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;28,621&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;3,478&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;2,800&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;8,100&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;3,100&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;16,700&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;5,500&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;68,299&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 20%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 20%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Accumulated amortization&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 20%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Balance at December 31, 2013&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(1,468&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(483&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(1,951&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 20%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Amortization&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(3,519&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(1,159&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(478&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(692&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(378&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(1,191&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(587&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(8,004&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 20%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Balance at December 31, 2014&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(4,987&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(1,642&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(478&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(692&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(378&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(1,191&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(587&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(9,955&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 20%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 20%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Net book value at December 31, 2014&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;23,634&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;1,836&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;2,322&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;7,408&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;2,722&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;15,509&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;4,913&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;58,344&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="margin-top: 3pt; margin-bottom: 3pt;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Future amortization expense as of December 31, 2014 is as follows:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;(in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;2015&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;8,629&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;2016&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;8,146&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;2017&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;7,470&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;2018&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;7,470&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;2019 and beyond&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;26,629&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Total remaining amortization&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;58,344&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="margin-top: 3pt; margin-bottom: 3pt;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; margin-top: 3pt; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; margin-bottom: 3pt; color: #000000; font-size: 10pt;"&gt;The following table is a summary of changes in goodwill by reporting unit:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;(in thousands)&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Biosciences therapeutics&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Biosciences contracts manufacturing&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Biodefense therapeutics&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Biodefense medical device(s)&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Total&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Cost Basis&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 40%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Balance at December 31, 2013&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;5,502&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;8,452&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;13,954&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 40%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Additions&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;8,400&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;6,736&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;11,430&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;1,464&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;28,030&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 40%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Balance at December 31, 2014&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;13,902&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;6,736&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;11,430&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;9,916&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;41,984&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 40%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
  <!--Goodwill, Gross-->
  <us-gaap:GoodwillGross contextRef="c20131231" unitRef="U001" decimals="-3">13954000</us-gaap:GoodwillGross>
  <!--Goodwill, Gross-Biosciences contracts manufacturing [Member]-Biosciences [Member]-->
  <us-gaap:GoodwillGross contextRef="c20131231_StatementBusinessSegmentsAxis_BiosciencesMember_SubsegmentsAxis_BiosciencesContractsManufacturingMember" unitRef="U001" decimals="-3">0</us-gaap:GoodwillGross>
  <!--Goodwill, Gross-Biodefense therapeutics [Member]-Biodefense [Member]-->
  <us-gaap:GoodwillGross contextRef="c20131231_StatementBusinessSegmentsAxis_BiodefenseMember_SubsegmentsAxis_BiodefenseTherapeuticsMember" unitRef="U001" decimals="-3">0</us-gaap:GoodwillGross>
  <!--Goodwill, Gross-Biosciences Therapeutics [Member]-Biosciences [Member]-->
  <us-gaap:GoodwillGross contextRef="c20131231_StatementBusinessSegmentsAxis_BiosciencesMember_SubsegmentsAxis_BiosciencesTherapeuticsMember" unitRef="U001" decimals="-3">5502000</us-gaap:GoodwillGross>
  <!--Goodwill, Gross-Biodefense medical devices [Member]-Biodefense [Member]-->
  <us-gaap:GoodwillGross contextRef="c20131231_StatementBusinessSegmentsAxis_BiodefenseMember_SubsegmentsAxis_BiodefenseMedicalDevicesMember" unitRef="U001" decimals="-3">8452000</us-gaap:GoodwillGross>
  <!--Goodwill, Gross-->
  <us-gaap:GoodwillGross contextRef="c20141231" unitRef="U001" decimals="-3">41984000</us-gaap:GoodwillGross>
  <!--Goodwill, Gross-Biosciences [Member]-Biosciences contracts manufacturing [Member]-->
  <us-gaap:GoodwillGross contextRef="c20141231_StatementBusinessSegmentsAxis_BiosciencesMember_SubsegmentsAxis_BiosciencesContractsManufacturingMember" unitRef="U001" decimals="-3">6736000</us-gaap:GoodwillGross>
  <!--Goodwill, Gross-Biodefense therapeutics [Member]-Biodefense [Member]-->
  <us-gaap:GoodwillGross contextRef="c20141231_StatementBusinessSegmentsAxis_BiodefenseMember_SubsegmentsAxis_BiodefenseTherapeuticsMember" unitRef="U001" decimals="-3">11430000</us-gaap:GoodwillGross>
  <!--Goodwill, Gross-Biodefense [Member]-Biodefense medical devices [Member]-->
  <us-gaap:GoodwillGross contextRef="c20141231_StatementBusinessSegmentsAxis_BiodefenseMember_SubsegmentsAxis_BiodefenseMedicalDevicesMember" unitRef="U001" decimals="-3">9916000</us-gaap:GoodwillGross>
  <!--Goodwill, Gross-Biosciences [Member]-Biosciences Therapeutics [Member]-->
  <us-gaap:GoodwillGross contextRef="c20141231_StatementBusinessSegmentsAxis_BiosciencesMember_SubsegmentsAxis_BiosciencesTherapeuticsMember" unitRef="U001" decimals="-3">13902000</us-gaap:GoodwillGross>
  <!--Goodwill, Acquired During Period-Biodefense [Member]-Biodefense therapeutics [Member]-->
  <us-gaap:GoodwillAcquiredDuringPeriod contextRef="c20140101to20141231_StatementBusinessSegmentsAxis_BiodefenseMember_SubsegmentsAxis_BiodefenseTherapeuticsMember" unitRef="U001" decimals="-3">11430000</us-gaap:GoodwillAcquiredDuringPeriod>
  <!--Goodwill, Acquired During Period-Biosciences Therapeutics [Member]-Biosciences [Member]-->
  <us-gaap:GoodwillAcquiredDuringPeriod contextRef="c20140101to20141231_StatementBusinessSegmentsAxis_BiosciencesMember_SubsegmentsAxis_BiosciencesTherapeuticsMember" unitRef="U001" decimals="-3">8400000</us-gaap:GoodwillAcquiredDuringPeriod>
  <!--Goodwill, Acquired During Period-Biodefense [Member]-Biodefense medical devices [Member]-->
  <us-gaap:GoodwillAcquiredDuringPeriod contextRef="c20140101to20141231_StatementBusinessSegmentsAxis_BiodefenseMember_SubsegmentsAxis_BiodefenseMedicalDevicesMember" unitRef="U001" decimals="-3">1464000</us-gaap:GoodwillAcquiredDuringPeriod>
  <!--Goodwill, Acquired During Period-Biosciences contracts manufacturing [Member]-Biosciences [Member]-->
  <us-gaap:GoodwillAcquiredDuringPeriod contextRef="c20140101to20141231_StatementBusinessSegmentsAxis_BiosciencesMember_SubsegmentsAxis_BiosciencesContractsManufacturingMember" unitRef="U001" decimals="-3">6736000</us-gaap:GoodwillAcquiredDuringPeriod>
  <!--Goodwill, Acquired During Period-->
  <us-gaap:GoodwillAcquiredDuringPeriod contextRef="c20140101to20141231" unitRef="U001" decimals="-3">28030000</us-gaap:GoodwillAcquiredDuringPeriod>
  <!--Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]-->
  <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="c20140101to20141231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Impairment of in process research and development and long-lived assets&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;The Company assesses IPR&amp;amp;D assets for impairment on an annual basis or more frequently if indicators of impairment are present. The Company's annual assessment includes a comparison of the fair value of IPR&amp;amp;D assets to existing carrying value, and recognizes an impairment when the carrying value is greater than the determined fair value. The Company believes that the assumptions used in valuing the intangible and IPR&amp;amp;D assets are reasonable and are based upon its best estimate of likely outcomes of sales and clinical development. The underlying assumptions and estimates used to value these assets are subject to change in the future, and actual results may differ significantly from the assumptions and estimates. The Company has selected October 1&lt;sup&gt;st&lt;/sup&gt; as its annual impairment test date for indefinite-lived intangible assets.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;The Company assesses the recoverability of its long-lived assets or asset groups for which an indicator of impairment exists by determining whether the carrying value of such assets can be recovered through undiscounted future operating cash flows. If the Company concludes that the carrying value will not be recovered, the Company measures the amount of such impairment by comparing the fair value to the carrying value of the assets or asset groups.&lt;/div&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
  <!--Impairment of in-process research and development-->
  <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill contextRef="c20140101to20141231" unitRef="U001" decimals="-3">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
  <!--Impairment of in-process research and development-->
  <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill contextRef="c20120101to20121231" unitRef="U001" decimals="-3">9600000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
  <!--Impairment of in-process research and development-->
  <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill contextRef="c20130101to20131231" unitRef="U001" decimals="-3">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
  <!--Impairment of IPR&D assets-->
  <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="c20130101to20131231" unitRef="U001" decimals="-5">9600000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
  <!--Impairment of long-lived assets-->
  <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf contextRef="c20130101to20131231" unitRef="U001" decimals="-3">1172000</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
  <!--Impairment of long-lived assets-->
  <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf contextRef="c20140101to20141231" unitRef="U001" decimals="-3">0</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
  <!--Impairment of long-lived assets-->
  <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf contextRef="c20120101to20121231" unitRef="U001" decimals="-3">0</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
  <!--In Process Research and Development, Policy [Policy Text Block]-->
  <us-gaap:InProcessResearchAndDevelopmentPolicy contextRef="c20140101to20141231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Mergers and Acquisitions&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;In a business combination, the acquisition method of accounting requires that the assets acquired and liabilities assumed be recorded as of the date of the merger or acquisition at their respective fair values with limited exceptions. Assets acquired and liabilities assumed in a business combination that arise from contingencies are recognized at fair value if fair value can reasonably be estimated. If the acquisition date fair value of an asset acquired or liability assumed that arises from a contingency cannot be determined, the asset or liability is recognized if probable and reasonably estimable; if these criteria are not met, no asset or liability is recognized. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Accordingly, the Company may be required to value assets at fair value measures that do not reflect our intended use of those assets. Any excess of the purchase price (consideration transferred) over the estimated fair values of net assets acquired is recorded as goodwill. Transaction costs and costs to restructure the acquired company are expensed as incurred. The operating results of the acquired business are reflected in our consolidated financial statements after the date of the merger or acquisition. If the Company determines the assets acquired do not meet the definition of a business under the acquisition method of accounting, the transaction will be accounted for as an acquisition of assets rather than a business combination and, therefore, no goodwill will be recorded. The fair values of intangible assets, including acquired in-process research and development, or IPR&amp;amp;D, are determined utilizing information available near the merger or acquisition date based on expectations and assumptions that are deemed reasonable by management. Given the considerable judgment involved in determining fair values, the Company typically obtains assistance from third-party valuation specialists for significant items. Amounts allocated to acquired IPR&amp;amp;D are capitalized and accounted for as indefinite-lived intangible assets. Upon successful completion of each project, the Company will make a separate determination as to the then useful life of the asset and begin amortization. The judgments made in determining estimated fair values assigned to assets acquired and liabilities assumed in a business combination, as well as asset lives, can materially affect the Company's results of operations.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;The fair values of identifiable intangible assets related to currently marketed products and product rights are primarily determined by using an "income approach" through which fair value is estimated based on each asset's discounted projected net cash flows. Our estimates of market participant net cash flows consider historical and projected pricing, margins and expense levels; the performance of competing products where applicable; relevant industry and therapeutic area growth drivers and factors; current and expected trends in technology and product life cycles; the time and investment that will be required to develop products and technologies; the ability to obtain marketing and regulatory approvals; the ability to manufacture and commercialize the products; the extent and timing of potential new product introductions by the Company's competitors; and the life of each asset's underlying patent, if any. The net cash flows are then probability-adjusted where appropriate to consider the uncertainties associated with the underlying assumptions, as well as the risk profile of the net cash flows utilized in the valuation. The probability-adjusted future net cash flows of each product are then discounted to present value utilizing an appropriate discount rate.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;The fair values of identifiable intangible assets related to IPR&amp;amp;D are determined using an income approach, through which fair value is estimated based on each asset's probability-adjusted future net cash flows, which reflect the different stages of development of each product and the associated probability of successful completion. The net cash flows are then discounted to present value using an appropriate discount rate. Indefinite-lived intangible assets are tested for impairment annually or whenever events or changes in circumstances indicate that its carrying amount may not be recoverable.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InProcessResearchAndDevelopmentPolicy>
  <!--Income (Loss), Including Portion Attributable to Noncontrolling Interest-->
  <us-gaap:IncomeLossIncludingPortionAttributableToNoncontrollingInterest contextRef="c20140101to20141231" unitRef="U001" decimals="-3">53062000</us-gaap:IncomeLossIncludingPortionAttributableToNoncontrollingInterest>
  <!--Income (Loss), Including Portion Attributable to Noncontrolling Interest-->
  <us-gaap:IncomeLossIncludingPortionAttributableToNoncontrollingInterest contextRef="c20120101to20121231" unitRef="U001" decimals="-3">37446000</us-gaap:IncomeLossIncludingPortionAttributableToNoncontrollingInterest>
  <!--Income (Loss), Including Portion Attributable to Noncontrolling Interest-->
  <us-gaap:IncomeLossIncludingPortionAttributableToNoncontrollingInterest contextRef="c20130101to20131231" unitRef="U001" decimals="-3">44243000</us-gaap:IncomeLossIncludingPortionAttributableToNoncontrollingInterest>
  <!--Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest-->
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="c20140101to20141231" unitRef="U001" decimals="-3">53062000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <!--Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest-->
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="c20130101to20131231" unitRef="U001" decimals="-3">43367000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <!--Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest-->
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="c20120101to20121231" unitRef="U001" decimals="-3">32065000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <!--Federal income tax year selected for audit-Minimum [Member]-Internal Revenue Service (IRS) [Member]-->
  <us-gaap:IncomeTaxExaminationYearUnderExamination contextRef="c20140101to20141231_IncomeTaxAuthorityAxis_InternalRevenueServiceIRSMember_RangeAxis_MinimumMember">2009</us-gaap:IncomeTaxExaminationYearUnderExamination>
  <!--Federal income tax year selected for audit-Maximum [Member]-Internal Revenue Service (IRS) [Member]-->
  <us-gaap:IncomeTaxExaminationYearUnderExamination contextRef="c20140101to20141231_IncomeTaxAuthorityAxis_InternalRevenueServiceIRSMember_RangeAxis_MaximumMember">2012</us-gaap:IncomeTaxExaminationYearUnderExamination>
  <!--Income (Loss) from Continuing Operations before Income Taxes, Foreign-->
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c20120101to20121231" unitRef="U001" decimals="-3">-14945000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
  <!--Income (Loss) from Continuing Operations before Income Taxes, Foreign-->
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c20130101to20131231" unitRef="U001" decimals="-3">-8506000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
  <!--Income (Loss) from Continuing Operations before Income Taxes, Foreign-->
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c20140101to20141231" unitRef="U001" decimals="-3">-6702000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
  <!--US-->
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c20130101to20131231" unitRef="U001" decimals="-3">52749000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
  <!--US-->
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c20120101to20121231" unitRef="U001" decimals="-3">52391000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
  <!--US-->
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c20140101to20141231" unitRef="U001" decimals="-3">59764000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
  <!--Provision for income taxes-->
  <us-gaap:IncomeTaxExpenseBenefit contextRef="c20140101to20141231" unitRef="U001" decimals="-3">16321000</us-gaap:IncomeTaxExpenseBenefit>
  <!--Provision for income taxes-->
  <us-gaap:IncomeTaxExpenseBenefit contextRef="c20120101to20121231" unitRef="U001" decimals="-3">13922000</us-gaap:IncomeTaxExpenseBenefit>
  <!--Provision for income taxes-->
  <us-gaap:IncomeTaxExpenseBenefit contextRef="c20130101to20131231" unitRef="U001" decimals="-3">13108000</us-gaap:IncomeTaxExpenseBenefit>
  <!--Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount-->
  <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c20120101to20121231" unitRef="U001" decimals="-3">4629000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <!--Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount-->
  <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c20130101to20131231" unitRef="U001" decimals="-3">1434000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <!--Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount-->
  <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c20140101to20141231" unitRef="U001" decimals="-3">1808000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <!--Permanent differences-->
  <us-gaap:IncomeTaxReconciliationDeductions contextRef="c20140101to20141231" unitRef="U001" decimals="-3">2511000</us-gaap:IncomeTaxReconciliationDeductions>
  <!--Permanent differences-->
  <us-gaap:IncomeTaxReconciliationDeductions contextRef="c20130101to20131231" unitRef="U001" decimals="-3">2912000</us-gaap:IncomeTaxReconciliationDeductions>
  <!--Permanent differences-->
  <us-gaap:IncomeTaxReconciliationDeductions contextRef="c20120101to20121231" unitRef="U001" decimals="-3">4657000</us-gaap:IncomeTaxReconciliationDeductions>
  <!--Income Tax Disclosure [Text Block]-->
  <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c20140101to20141231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;&lt;font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;12.&lt;/font&gt;&lt;font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Income taxes&lt;/font&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Significant components of the provisions for income taxes attributable to operations consist of the following:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="10" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Year ended December 31,&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;(in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;2014&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;2013&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;2012&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Current&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Federal&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;10,412&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(878&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;11,481&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;State&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;479&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(173&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(1,045&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;International&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;112&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;300&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;103&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Total current&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;11,003&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(751&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;10,539&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Deferred&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Federal&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;7,693&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;12,679&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;3,758&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;State&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;128&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;1,028&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(375&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;International&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(2,503&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;152&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Total deferred&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;5,318&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;13,859&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;3,383&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Total provision for income taxes&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;16,321&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;13,108&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;13,922&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 18pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;The Company's net deferred tax asset (liability) consists of the following:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt; font-weight: bold;"&gt;(in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;2014&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;2013&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Net operating loss carryforward&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;20,530&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;23,256&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Research and development carryforward&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;8,049&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;7,395&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Scientific research and experimental development credit carryforward&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;29,556&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Intangible assets&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;5,689&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;3,300&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Stock compensation&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;8,196&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;6,378&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Foreign deferrals&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;75,511&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;64,090&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Inventory reserves&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;4,122&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Deferred revenue&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;244&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Other&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;7,219&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;1,222&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Deferred tax asset&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;159,116&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;105,641&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Fixed assets&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(34,839&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(32,588&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Intangible assets&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(6,538&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Other&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(10,891&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(5,714&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Deferred tax liability&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(52,268&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(38,302&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Valuation allowance&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(92,374&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(68,846&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Net deferred tax (liabilities)/ asset&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;14,474&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(1,507&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;The Company currently has approximately $24.2 million in net operating loss carryforwards along with $8.1 million in research and development tax credit carryforwards for U.S. federal tax purposes that will begin to expire in 2026 and 2023, respectively. The U.S. federal tax carryforwards are recorded with no valuation allowance. The Company has $224.6 million in state net operating loss carryforwards, primarily in Maryland, that will begin to expire in 2018. The Company has approximately $274.4 million in net operating losses from foreign jurisdictions that will have an indefinite life unless the foreign entities have a change in the nature or conduct of the business in the three years following a change in ownership. The Company currently has approximately $9.3 million of Canadian federal scientific research and experimental development credit carryforwards that will begin to expire in 2032. In addition, the Company has approximately $22.9 million in Manitoba scientific research and experimental development credit carryforwards that will begin to expire in 2019. Due to the timing of the expiry of the Manitoba credits, the Company has recorded a valuation allowance with respect to the Manitoba credits in the amount of $22.9 million, as it is uncertain whether sufficient future taxable income will be generated in Manitoba during the carryforward period. The foreign and state net operating losses are recorded with a valuation allowance as their realization is not more-likely-than-not. The use of any of these net operating losses and research and development tax credit carryforwards may be restricted due to changes in the Company's ownership.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;The provision for income taxes differs from the amount of taxes determined by applying the U.S. federal statutory rate to loss before provision for income taxes as a result of the following:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="10" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Year ended December 31,&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt; font-weight: bold;"&gt;(in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;2014&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;2013&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;2012&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;US&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;59,764&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;52,749&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;52,391&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;International&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(6,702&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(8,506&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(14,945&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Earnings before taxes on income&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;53,062&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;44,243&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;37,446&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 64%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Federal tax at statutory rates&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;18,572&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;15,485&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;13,106&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;State taxes, net of federal benefit&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;257&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;538&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(2,079&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Impact of foreign operations&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;186&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(1,116&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(3,604&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Change in valuation allowance&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;1,808&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;1,434&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;4,629&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Effect of foreign rates&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(22&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Tax credits&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(7,137&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(5,918&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(2,904&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Other differences&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;124&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(227&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;139&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Permanent differences&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;2,511&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;2,912&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;4,657&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Provision for income taxes&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;16,321&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;13,108&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;13,922&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;The effective annual tax rate for the years ended December 31, 2014, 2013 and 2012 was 31%, 30% and 37%, respectively. The decrease in the effective annual tax rate in 2013 from 2012 is primarily related to research and development tax credits and orphan drug tax credits related to otlertuzumab (formerly TRU-016) product candidate.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;The Company recognizes interest in interest expense and recognizes potential penalties related to unrecognized tax benefits in selling, general and administrative expense. The Company accrued approximately $26,000 and $15,000 for the payment of interest and penalties as of December 31, 2014 and 2013, respectively. Of the total unrecognized tax benefits recorded at December 31, 2014 and 2013, $183,000 and $132,000, respectively, is classified as a current liability and $1.1 million and $991,000, respectively, is classified as a non-current liability on the balance sheet. As of December 31, 2014, $140,000 of unrecognized tax benefits will reverse within the next twelve months.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;The table below presents the gross unrecognized tax benefits activity for 2014, 2013 and 2012:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt; font-weight: bold;"&gt;(in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Gross unrecognized tax benefits at December 31, 2011&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;1,056&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Increases for tax positions for prior years&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;25&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Decreases for tax positions for prior years&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(65&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Increases for tax positions for current year&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Settlements&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Lapse of statute of limitations&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Gross unrecognized tax benefits at December 31, 2012&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;1,016&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Increases for tax positions for prior years&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;165&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Decreases for tax positions for prior years&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Increases for tax positions for current year&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;15&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Settlements&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Lapse of statute of limitations&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(75&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Gross unrecognized tax benefits at December 31, 2013&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;1,121&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Increases for tax positions for prior years&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;150&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Decreases for tax positions for prior years&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Increases for tax positions for current year&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;102&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Settlements&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Lapse of statute of limitations&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(125&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Gross unrecognized tax benefits at December 31, 2014&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;1,248&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;When resolved, substantially all of these reserves would impact the effective tax rate.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;The Company's federal and state income tax returns for the tax years 2011 to 2013 remain open to examination. The Company's tax returns in the United Kingdom remain open to examination for the tax years 2007 to 2013, and tax returns in Germany remain open indefinitely. The Company's tax returns for Canada remains open to examination for the tax years 2009 to 2013.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;As of December 31, 2014, the Company's 2009 and 2011 federal income tax returns are in appeals with the Internal Revenue service. The Company believes appropriate provisions have been made for any outstanding issues. As of December 31, 2014, the Company's 2011 and 2012 federal income tax returns are under audit.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <!--Cash paid during the year for income taxes-->
  <us-gaap:IncomeTaxesPaid contextRef="c20140101to20141231" unitRef="U001" decimals="-3">4711000</us-gaap:IncomeTaxesPaid>
  <!--Cash paid during the year for income taxes-->
  <us-gaap:IncomeTaxesPaid contextRef="c20120101to20121231" unitRef="U001" decimals="-3">6537000</us-gaap:IncomeTaxesPaid>
  <!--Cash paid during the year for income taxes-->
  <us-gaap:IncomeTaxesPaid contextRef="c20130101to20131231" unitRef="U001" decimals="-3">6331000</us-gaap:IncomeTaxesPaid>
  <!--Effective Income Tax Rate Reconciliation, Tax Credit, Amount-->
  <us-gaap:IncomeTaxReconciliationTaxCredits contextRef="c20130101to20131231" unitRef="U001" decimals="-3">5918000</us-gaap:IncomeTaxReconciliationTaxCredits>
  <!--Effective Income Tax Rate Reconciliation, Tax Credit, Amount-->
  <us-gaap:IncomeTaxReconciliationTaxCredits contextRef="c20140101to20141231" unitRef="U001" decimals="-3">7137000</us-gaap:IncomeTaxReconciliationTaxCredits>
  <!--Effective Income Tax Rate Reconciliation, Tax Credit, Amount-->
  <us-gaap:IncomeTaxReconciliationTaxCredits contextRef="c20120101to20121231" unitRef="U001" decimals="-3">2904000</us-gaap:IncomeTaxReconciliationTaxCredits>
  <!--Income tax receivable, net-->
  <us-gaap:IncomeTaxesReceivable contextRef="c20141231" unitRef="U001" decimals="-3">1357000</us-gaap:IncomeTaxesReceivable>
  <!--Income tax receivable, net-->
  <us-gaap:IncomeTaxesReceivable contextRef="c20131231" unitRef="U001" decimals="-3">5651000</us-gaap:IncomeTaxesReceivable>
  <!--Impact of foreign operations-->
  <us-gaap:IncomeTaxReconciliationRepatriationOfForeignEarnings contextRef="c20130101to20131231" unitRef="U001" decimals="-3">-1116000</us-gaap:IncomeTaxReconciliationRepatriationOfForeignEarnings>
  <!--Impact of foreign operations-->
  <us-gaap:IncomeTaxReconciliationRepatriationOfForeignEarnings contextRef="c20120101to20121231" unitRef="U001" decimals="-3">-3604000</us-gaap:IncomeTaxReconciliationRepatriationOfForeignEarnings>
  <!--Impact of foreign operations-->
  <us-gaap:IncomeTaxReconciliationRepatriationOfForeignEarnings contextRef="c20140101to20141231" unitRef="U001" decimals="-3">186000</us-gaap:IncomeTaxReconciliationRepatriationOfForeignEarnings>
  <!--Federal tax at statutory rates-->
  <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c20130101to20131231" unitRef="U001" decimals="-3">15485000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
  <!--Federal tax at statutory rates-->
  <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c20140101to20141231" unitRef="U001" decimals="-3">18572000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
  <!--Federal tax at statutory rates-->
  <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c20120101to20121231" unitRef="U001" decimals="-3">13106000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
  <!--Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount-->
  <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="c20140101to20141231" unitRef="U001" decimals="-3">257000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
  <!--Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount-->
  <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="c20130101to20131231" unitRef="U001" decimals="-3">538000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
  <!--Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount-->
  <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="c20120101to20121231" unitRef="U001" decimals="-3">-2079000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
  <!--Other differences-->
  <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="c20130101to20131231" unitRef="U001" decimals="-3">-227000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
  <!--Other differences-->
  <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="c20140101to20141231" unitRef="U001" decimals="-3">124000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
  <!--Other differences-->
  <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="c20120101to20121231" unitRef="U001" decimals="-3">139000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
  <!--Income taxes-->
  <us-gaap:IncomeTaxPolicyTextBlock contextRef="c20140101to20141231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Income taxes&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Income taxes are accounted for using the liability method. Deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between financial statement carrying amounts of existing assets and liabilities and their respective tax bases and net operating loss and research and development tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which those temporary differences are expected to be recovered or settled.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;The Company's ability to realize deferred tax assets depends upon future taxable income as well as the limitations discussed below. For financial reporting purposes, a deferred tax asset must be reduced by a valuation allowance if it is more likely than not that some portion or all of the deferred tax assets will not be realized prior to expiration. The Company considers future taxable income and ongoing tax planning strategies in assessing the need for valuation allowances. In general, if the Company determines that it is more likely than not to realize more than the recorded amounts of net deferred tax assets in the future, the Company will reverse all or a portion of the valuation allowance established against its deferred tax assets, resulting in a decrease to the provision for income taxes in the period in which the determination is made. Likewise, if the Company determines that it is not more likely than not to realize all or part of the net deferred tax asset in the future, the Company will establish a valuation allowance against deferred tax assets, with an offsetting increase to the provision for income taxes, in the period in which the determination is made.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Under sections 382 and 383 of the Internal Revenue Code, if an ownership change occurs with respect to a "loss corporation", as defined, there are annual limitations on the amount of net operating losses and deductions that are available. The Company believes the use of net operating losses and research and development tax credits acquired in the Trubion acquisition will not be significantly limited. Due to the acquisition of Microscience in 2005 and the Company's initial public offering, the Company believes the use of the operating losses incurred prior to 2005 will be significantly limited.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
  <!--Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount-->
  <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential contextRef="c20120101to20121231" unitRef="U001" decimals="-3">22000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
  <!--Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount-->
  <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential contextRef="c20140101to20141231" unitRef="U001" decimals="-3">0</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
  <!--Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount-->
  <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential contextRef="c20130101to20131231" unitRef="U001" decimals="-3">0</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
  <!--Increase (Decrease) in Accounts Receivable-->
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c20120101to20121231" unitRef="U001" decimals="-3">21890000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <!--Increase (Decrease) in Accounts Receivable-->
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c20140101to20141231" unitRef="U001" decimals="-3">-21405000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <!--Increase (Decrease) in Accounts Receivable-->
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c20130101to20131231" unitRef="U001" decimals="-3">-35456000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <!--Accounts payable-->
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c20130101to20131231" unitRef="U001" decimals="-3">-551000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <!--Accounts payable-->
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c20140101to20141231" unitRef="U001" decimals="-3">-9279000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <!--Accounts payable-->
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c20120101to20121231" unitRef="U001" decimals="-3">274000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <!--Accrued expenses and other liabilities-->
  <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c20120101to20121231" unitRef="U001" decimals="-3">169000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <!--Accrued expenses and other liabilities-->
  <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c20140101to20141231" unitRef="U001" decimals="-3">2685000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <!--Accrued expenses and other liabilities-->
  <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c20130101to20131231" unitRef="U001" decimals="-3">7000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <!--Increase (Decrease) in Deferred Revenue-->
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="c20120101to20121231" unitRef="U001" decimals="-3">449000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <!--Increase (Decrease) in Deferred Revenue-->
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="c20130101to20131231" unitRef="U001" decimals="-3">26000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <!--Increase (Decrease) in Deferred Revenue-->
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="c20140101to20141231" unitRef="U001" decimals="-3">2846000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <!--Increase (Decrease) in Inventories-->
  <us-gaap:IncreaseDecreaseInInventories contextRef="c20140101to20141231" unitRef="U001" decimals="-3">-4229000</us-gaap:IncreaseDecreaseInInventories>
  <!--Increase (Decrease) in Inventories-->
  <us-gaap:IncreaseDecreaseInInventories contextRef="c20130101to20131231" unitRef="U001" decimals="-3">-518000</us-gaap:IncreaseDecreaseInInventories>
  <!--Increase (Decrease) in Inventories-->
  <us-gaap:IncreaseDecreaseInInventories contextRef="c20120101to20121231" unitRef="U001" decimals="-3">500000</us-gaap:IncreaseDecreaseInInventories>
  <!--Accrued compensation-->
  <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="c20130101to20131231" unitRef="U001" decimals="-3">2092000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
  <!--Accrued compensation-->
  <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="c20140101to20141231" unitRef="U001" decimals="-3">4539000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
  <!--Accrued compensation-->
  <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="c20120101to20121231" unitRef="U001" decimals="-3">1649000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
  <!--Increase (Decrease) in Income Taxes Receivable-->
  <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable contextRef="c20120101to20121231" unitRef="U001" decimals="-3">-8055000</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
  <!--Increase (Decrease) in Income Taxes Receivable-->
  <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable contextRef="c20140101to20141231" unitRef="U001" decimals="-3">4711000</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
  <!--Increase (Decrease) in Income Taxes Receivable-->
  <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable contextRef="c20130101to20131231" unitRef="U001" decimals="-3">7179000</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
  <!--Increase (Decrease) in Prepaid Expense and Other Assets-->
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c20140101to20141231" unitRef="U001" decimals="-3">8472000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <!--Increase (Decrease) in Prepaid Expense and Other Assets-->
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c20120101to20121231" unitRef="U001" decimals="-3">1038000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <!--Increase (Decrease) in Prepaid Expense and Other Assets-->
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c20130101to20131231" unitRef="U001" decimals="-3">6226000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <!--Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities-->
  <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities contextRef="c20120101to20121231" unitRef="U002" decimals="0">0</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
  <!--Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities-->
  <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities contextRef="c20140101to20141231" unitRef="U002" decimals="0">7720525</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
  <!--Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities-->
  <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities contextRef="c20130101to20131231" unitRef="U002" decimals="0">0</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
  <!--Dilutive securities-equity awards (in shares)-->
  <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c20130101to20131231" unitRef="U002" decimals="0">546273</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
  <!--Dilutive securities-equity awards (in shares)-->
  <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c20120101to20121231" unitRef="U002" decimals="0">340167</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
  <!--Dilutive securities-equity awards (in shares)-->
  <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c20140101to20141231" unitRef="U002" decimals="0">737391</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
  <!--Intangible Assets, Net (Excluding Goodwill)-->
  <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c20131231" unitRef="U001" decimals="-3">30148000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <!--Intangible Assets, Net (Excluding Goodwill)-->
  <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c20141231" unitRef="U001" decimals="-3">58344000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <!--Intangible Assets, Net (Excluding Goodwill)-All Other [Member]-->
  <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c20131231_StatementBusinessSegmentsAxis_AllOtherSegmentsMember" unitRef="U001" decimals="-3">0</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <!--Intangible Assets, Net (Excluding Goodwill)-Biodefense [Member]-->
  <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c20131231_StatementBusinessSegmentsAxis_BiodefenseMember" unitRef="U001" decimals="-3">30148000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <!--Intangible Assets, Net (Excluding Goodwill)-Biosciences [Member]-->
  <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c20131231_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U001" decimals="-3">0</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <!--Intangible Assets, Net (Excluding Goodwill)-Biosciences [Member]-->
  <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c20141231_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U001" decimals="-3">17365000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <!--Intangible Assets, Net (Excluding Goodwill)-All Other [Member]-->
  <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c20141231_StatementBusinessSegmentsAxis_AllOtherSegmentsMember" unitRef="U001" decimals="-3">0</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <!--Intangible Assets, Net (Excluding Goodwill)-Biodefense [Member]-->
  <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c20141231_StatementBusinessSegmentsAxis_BiodefenseMember" unitRef="U001" decimals="-3">40979000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <!--Interest costs incurred-->
  <us-gaap:InterestCostsIncurred contextRef="c20140101to20141231" unitRef="U001" decimals="-5">7500000</us-gaap:InterestCostsIncurred>
  <!--Interest costs incurred-->
  <us-gaap:InterestCostsIncurred contextRef="c20130101to20131231" unitRef="U001" decimals="-5">2000000</us-gaap:InterestCostsIncurred>
  <!--Interest costs incurred-->
  <us-gaap:InterestCostsIncurred contextRef="c20120101to20121231" unitRef="U001" decimals="-5">2200000</us-gaap:InterestCostsIncurred>
  <!--Interest Expense-->
  <us-gaap:InterestExpense contextRef="c20140101to20141231" unitRef="U001" decimals="-3">8240000</us-gaap:InterestExpense>
  <!--Interest Expense-->
  <us-gaap:InterestExpense contextRef="c20130101to20131231" unitRef="U001" decimals="-3">0</us-gaap:InterestExpense>
  <!--Interest Expense-->
  <us-gaap:InterestExpense contextRef="c20120101to20121231" unitRef="U001" decimals="-3">6000</us-gaap:InterestExpense>
  <!--Interest Expense-Biodefense [Member]-->
  <us-gaap:InterestExpense contextRef="c20120101to20121231_StatementBusinessSegmentsAxis_BiodefenseMember" unitRef="U001" decimals="-3">0</us-gaap:InterestExpense>
  <!--Interest Expense-Biosciences [Member]-->
  <us-gaap:InterestExpense contextRef="c20120101to20121231_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U001" decimals="-3">0</us-gaap:InterestExpense>
  <!--Interest Expense-Biodefense [Member]-->
  <us-gaap:InterestExpense contextRef="c20140101to20141231_StatementBusinessSegmentsAxis_BiodefenseMember" unitRef="U001" decimals="-3">0</us-gaap:InterestExpense>
  <!--Interest Expense-Biosciences [Member]-->
  <us-gaap:InterestExpense contextRef="c20140101to20141231_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U001" decimals="-3">0</us-gaap:InterestExpense>
  <!--Interest Expense-Biodefense [Member]-->
  <us-gaap:InterestExpense contextRef="c20130101to20131231_StatementBusinessSegmentsAxis_BiodefenseMember" unitRef="U001" decimals="-3">0</us-gaap:InterestExpense>
  <!--Interest Expense-All Other [Member]-->
  <us-gaap:InterestExpense contextRef="c20130101to20131231_StatementBusinessSegmentsAxis_AllOtherSegmentsMember" unitRef="U001" decimals="-3">0</us-gaap:InterestExpense>
  <!--Interest Expense-Biosciences [Member]-->
  <us-gaap:InterestExpense contextRef="c20130101to20131231_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U001" decimals="-3">0</us-gaap:InterestExpense>
  <!--Interest Expense-All Other [Member]-->
  <us-gaap:InterestExpense contextRef="c20140101to20141231_StatementBusinessSegmentsAxis_AllOtherSegmentsMember" unitRef="U001" decimals="-3">8240000</us-gaap:InterestExpense>
  <!--Interest Expense-All Other [Member]-->
  <us-gaap:InterestExpense contextRef="c20120101to20121231_StatementBusinessSegmentsAxis_AllOtherSegmentsMember" unitRef="U001" decimals="-3">6000</us-gaap:InterestExpense>
  <!--Interest costs capitalized-->
  <us-gaap:InterestCostsCapitalized contextRef="c20120101to20121231" unitRef="U001" decimals="-5">2200000</us-gaap:InterestCostsCapitalized>
  <!--Interest costs capitalized-->
  <us-gaap:InterestCostsCapitalized contextRef="c20140101to20141231" unitRef="U001" decimals="-5">2500000</us-gaap:InterestCostsCapitalized>
  <!--Interest costs capitalized-->
  <us-gaap:InterestCostsCapitalized contextRef="c20130101to20131231" unitRef="U001" decimals="-5">2000000</us-gaap:InterestCostsCapitalized>
  <!--Interest Capitalization, Policy [Policy Text Block]-->
  <us-gaap:InterestCapitalizationPolicyPolicyTextBlock contextRef="c20140101to20141231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Capitalized interest&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;The Company capitalizes interest based on the cost of major ongoing capital projects which have not yet been placed in service. For the years ended December 31, 2014, 2013 and 2012, the Company incurred interest of $7.5 million, $2.0 million and $2.2 million, respectively. Of these amounts, the Company capitalized $2.5 million, $2.0 million and $2.2 million, respectively.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InterestCapitalizationPolicyPolicyTextBlock>
  <!--Cash paid during the year for interest-->
  <us-gaap:InterestPaid contextRef="c20130101to20131231" unitRef="U001" decimals="-3">2055000</us-gaap:InterestPaid>
  <!--Cash paid during the year for interest-->
  <us-gaap:InterestPaid contextRef="c20120101to20121231" unitRef="U001" decimals="-3">2137000</us-gaap:InterestPaid>
  <!--Cash paid during the year for interest-->
  <us-gaap:InterestPaid contextRef="c20140101to20141231" unitRef="U001" decimals="-3">3761000</us-gaap:InterestPaid>
  <!--Interest on Convertible Debt, Net of Tax-->
  <us-gaap:InterestOnConvertibleDebtNetOfTax contextRef="c20130101to20131231" unitRef="U001" decimals="-3">0</us-gaap:InterestOnConvertibleDebtNetOfTax>
  <!--Interest on Convertible Debt, Net of Tax-->
  <us-gaap:InterestOnConvertibleDebtNetOfTax contextRef="c20140101to20141231" unitRef="U001" decimals="-3">2879000</us-gaap:InterestOnConvertibleDebtNetOfTax>
  <!--Interest on Convertible Debt, Net of Tax-->
  <us-gaap:InterestOnConvertibleDebtNetOfTax contextRef="c20120101to20121231" unitRef="U001" decimals="-3">0</us-gaap:InterestOnConvertibleDebtNetOfTax>
  <!--Inventory, Net-->
  <us-gaap:InventoryNet contextRef="c20131231" unitRef="U001" decimals="-3">14643000</us-gaap:InventoryNet>
  <!--Inventory, Net-->
  <us-gaap:InventoryNet contextRef="c20141231" unitRef="U001" decimals="-3">65674000</us-gaap:InventoryNet>
  <!--Inventories-->
  <us-gaap:InventoryPolicyTextBlock contextRef="c20140101to20141231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Inventories&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Inventories are stated at the lower of cost or market with cost being determined using a standard cost method, which approximates average cost. Average cost consists primarily of material, labor and manufacturing overhead expenses (including fixed production-overhead costs) and includes the services and products of third party suppliers. The Company analyzes its inventory levels quarterly and writes down, in the applicable period, inventory that has become obsolete, inventory that has a cost basis in excess of its expected net realizable value and inventory in excess of expected customer demand. The Company also writes off, in the applicable period, the costs related to expired inventory.&amp;#160;Costs of purchased inventories are recorded using weighted-average costing. The Company determines normal capacity for each production facility and allocates fixed production-overhead costs on that basis.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
  <!--Finished goods-->
  <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="c20131231" unitRef="U001" decimals="-3">2168000</us-gaap:InventoryFinishedGoodsNetOfReserves>
  <!--Finished goods-->
  <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="c20141231" unitRef="U001" decimals="-3">14822000</us-gaap:InventoryFinishedGoodsNetOfReserves>
  <!--Inventory Disclosure [Text Block]-->
  <us-gaap:InventoryDisclosureTextBlock contextRef="c20140101to20141231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;&lt;font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;7.&lt;/font&gt;&lt;font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Inventories&lt;/font&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Inventories consist of the following:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt; font-weight: bold;"&gt;(in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;2014&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;2013&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Raw materials and supplies&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;17,375&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;2,656&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Work-in-process&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;33,477&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;9,819&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Finished goods&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;14,822&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;2,168&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Total inventories&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;65,674&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;14,643&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
  <!--Raw materials and supplies-->
  <us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves contextRef="c20141231" unitRef="U001" decimals="-3">17375000</us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves>
  <!--Raw materials and supplies-->
  <us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves contextRef="c20131231" unitRef="U001" decimals="-3">2656000</us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves>
  <!--Step up adjustment to inventory-Cangene [Member]-->
  <us-gaap:InventoryNoncurrentFairValueDisclosure contextRef="c20140221_BusinessAcquisitionAxis_CangeneMember" unitRef="U001" decimals="-5">8800000</us-gaap:InventoryNoncurrentFairValueDisclosure>
  <!--Work-in-process-->
  <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="c20141231" unitRef="U001" decimals="-3">33477000</us-gaap:InventoryWorkInProcessNetOfReserves>
  <!--Work-in-process-->
  <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="c20131231" unitRef="U001" decimals="-3">9819000</us-gaap:InventoryWorkInProcessNetOfReserves>
  <!--Interest income-->
  <us-gaap:InvestmentIncomeInterest contextRef="c20120101to20121231" unitRef="U001" decimals="-3">134000</us-gaap:InvestmentIncomeInterest>
  <!--Interest income-->
  <us-gaap:InvestmentIncomeInterest contextRef="c20140101to20141231" unitRef="U001" decimals="-3">320000</us-gaap:InvestmentIncomeInterest>
  <!--Interest income-->
  <us-gaap:InvestmentIncomeInterest contextRef="c20130101to20131231" unitRef="U001" decimals="-3">139000</us-gaap:InvestmentIncomeInterest>
  <!--Interest income-Biosciences [Member]-->
  <us-gaap:InvestmentIncomeInterest contextRef="c20120101to20121231_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U001" decimals="-3">0</us-gaap:InvestmentIncomeInterest>
  <!--Interest income-Biosciences [Member]-->
  <us-gaap:InvestmentIncomeInterest contextRef="c20140101to20141231_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U001" decimals="-3">0</us-gaap:InvestmentIncomeInterest>
  <!--Interest income-All Other [Member]-->
  <us-gaap:InvestmentIncomeInterest contextRef="c20120101to20121231_StatementBusinessSegmentsAxis_AllOtherSegmentsMember" unitRef="U001" decimals="-3">134000</us-gaap:InvestmentIncomeInterest>
  <!--Interest income-Biodefense [Member]-->
  <us-gaap:InvestmentIncomeInterest contextRef="c20120101to20121231_StatementBusinessSegmentsAxis_BiodefenseMember" unitRef="U001" decimals="-3">0</us-gaap:InvestmentIncomeInterest>
  <!--Interest income-Biodefense [Member]-->
  <us-gaap:InvestmentIncomeInterest contextRef="c20140101to20141231_StatementBusinessSegmentsAxis_BiodefenseMember" unitRef="U001" decimals="-3">62000</us-gaap:InvestmentIncomeInterest>
  <!--Interest income-All Other [Member]-->
  <us-gaap:InvestmentIncomeInterest contextRef="c20140101to20141231_StatementBusinessSegmentsAxis_AllOtherSegmentsMember" unitRef="U001" decimals="-3">258000</us-gaap:InvestmentIncomeInterest>
  <!--Interest income-Biosciences [Member]-->
  <us-gaap:InvestmentIncomeInterest contextRef="c20130101to20131231_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U001" decimals="-3">0</us-gaap:InvestmentIncomeInterest>
  <!--Interest income-Biodefense [Member]-->
  <us-gaap:InvestmentIncomeInterest contextRef="c20130101to20131231_StatementBusinessSegmentsAxis_BiodefenseMember" unitRef="U001" decimals="-3">0</us-gaap:InvestmentIncomeInterest>
  <!--Interest income-All Other [Member]-->
  <us-gaap:InvestmentIncomeInterest contextRef="c20130101to20131231_StatementBusinessSegmentsAxis_AllOtherSegmentsMember" unitRef="U001" decimals="-3">139000</us-gaap:InvestmentIncomeInterest>
  <!--Operating lease expiration date-Office space, Wokingham, England [Member]-->
  <us-gaap:LeaseExpirationDate1 contextRef="c20140101to20141231_PropertyPlantAndEquipmentByTypeAxis_OfficeSpaceWokinghamEnglandMember">2016-11-30</us-gaap:LeaseExpirationDate1>
  <!--Operating lease expiration date-Office and laboratory space, Seattle, Washington [Member]-->
  <us-gaap:LeaseExpirationDate1 contextRef="c20140101to20141231_PropertyPlantAndEquipmentByTypeAxis_OfficeAndLaboratorySpaceSeattleWashingtonMember">2020-04-30</us-gaap:LeaseExpirationDate1>
  <!--Operating lease expiration date-Office and laboratory space, Rockville, Maryland [Member]-->
  <us-gaap:LeaseExpirationDate1 contextRef="c20140101to20141231_PropertyPlantAndEquipmentByTypeAxis_OfficeAndLaboratorySpaceRockvilleMarylandMember">2016-12-31</us-gaap:LeaseExpirationDate1>
  <!--Operating lease expiration date-Office and laboratory space, Munich, Germany [Member]-->
  <us-gaap:LeaseExpirationDate1 contextRef="c20140101to20141231_PropertyPlantAndEquipmentByTypeAxis_OfficeAndLaboratorySpaceMunichGermanyMember">2015-06-30</us-gaap:LeaseExpirationDate1>
  <!--Leases of Lessee Disclosure [Text Block]-->
  <us-gaap:LeasesOfLesseeDisclosureTextBlock contextRef="c20140101to20141231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;&amp;#160;&lt;font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;17.&lt;/font&gt;&lt;font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Leases&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;The Company leases laboratory and office facilities, office equipment and vehicles under various operating lease agreements. The Company leases office and laboratory space in Seattle, Washington under a operating lease that contains a 2% escalation clause, which expires in April 2020. For the years ended December 31, 2014, 2013, and 2012, total lease expense was $4.6 million, $3.9 million and $3.6 million, respectively. For the year ended December 31, 2014 and 2013, the Company recorded lease income of $3.1 million and $446,000, respectively.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Future minimum lease payments under operating lease obligations as of December 31, 2014 were as follows:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;(in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;2015&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;2,558&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;2016&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;2,204&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;2017&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;1,950&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;2018&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;1,813&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;2019&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;1,697&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;2020 and beyond&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;904&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Total minimum lease payments&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;11,126&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Minimum lease receipts&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(1,388&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Total minimum lease payments&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$9,738&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:LeasesOfLesseeDisclosureTextBlock>
  <!--Liabilities, Current-->
  <us-gaap:LiabilitiesCurrent contextRef="c20131231" unitRef="U001" decimals="-3">56651000</us-gaap:LiabilitiesCurrent>
  <!--Liabilities, Current-->
  <us-gaap:LiabilitiesCurrent contextRef="c20141231" unitRef="U001" decimals="-3">92936000</us-gaap:LiabilitiesCurrent>
  <!--Liabilities and Equity-->
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c20131231" unitRef="U001" decimals="-3">626630000</us-gaap:LiabilitiesAndStockholdersEquity>
  <!--Liabilities and Equity-->
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c20141231" unitRef="U001" decimals="-3">945262000</us-gaap:LiabilitiesAndStockholdersEquity>
  <!--Financial and Nonfinancial Liabilities, Fair Value Disclosure-Fair Value, Measurements, Recurring [Member]-Fair Value, Inputs, Level 3 [Member]-->
  <us-gaap:LiabilitiesFairValueDisclosure contextRef="c20131231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="-3">16619000</us-gaap:LiabilitiesFairValueDisclosure>
  <!--Financial and Nonfinancial Liabilities, Fair Value Disclosure-Fair Value, Measurements, Recurring [Member]-->
  <us-gaap:LiabilitiesFairValueDisclosure contextRef="c20141231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="-3">47657000</us-gaap:LiabilitiesFairValueDisclosure>
  <!--Financial and Nonfinancial Liabilities, Fair Value Disclosure-Fair Value, Measurements, Recurring [Member]-Fair Value, Inputs, Level 1 [Member]-->
  <us-gaap:LiabilitiesFairValueDisclosure contextRef="c20141231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="-3">0</us-gaap:LiabilitiesFairValueDisclosure>
  <!--Financial and Nonfinancial Liabilities, Fair Value Disclosure-Fair Value, Measurements, Recurring [Member]-Fair Value, Inputs, Level 1 [Member]-->
  <us-gaap:LiabilitiesFairValueDisclosure contextRef="c20131231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="-3">0</us-gaap:LiabilitiesFairValueDisclosure>
  <!--Financial and Nonfinancial Liabilities, Fair Value Disclosure-Fair Value, Inputs, Level 2 [Member]-Fair Value, Measurements, Recurring [Member]-->
  <us-gaap:LiabilitiesFairValueDisclosure contextRef="c20141231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="-3">0</us-gaap:LiabilitiesFairValueDisclosure>
  <!--Financial and Nonfinancial Liabilities, Fair Value Disclosure-Fair Value, Inputs, Level 3 [Member]-Fair Value, Measurements, Recurring [Member]-->
  <us-gaap:LiabilitiesFairValueDisclosure contextRef="c20141231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="-3">47657000</us-gaap:LiabilitiesFairValueDisclosure>
  <!--Financial and Nonfinancial Liabilities, Fair Value Disclosure-Fair Value, Inputs, Level 2 [Member]-Fair Value, Measurements, Recurring [Member]-->
  <us-gaap:LiabilitiesFairValueDisclosure contextRef="c20131231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="-3">0</us-gaap:LiabilitiesFairValueDisclosure>
  <!--Financial and Nonfinancial Liabilities, Fair Value Disclosure-Fair Value, Measurements, Recurring [Member]-->
  <us-gaap:LiabilitiesFairValueDisclosure contextRef="c20131231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="-3">16619000</us-gaap:LiabilitiesFairValueDisclosure>
  <!--Liabilities-->
  <us-gaap:Liabilities contextRef="c20141231" unitRef="U001" decimals="-3">392061000</us-gaap:Liabilities>
  <!--Liabilities-->
  <us-gaap:Liabilities contextRef="c20131231" unitRef="U001" decimals="-3">137465000</us-gaap:Liabilities>
  <!--Revenue from license fee-Morphosys [Member]-->
  <us-gaap:LicenseAndServicesRevenue contextRef="c20140101to20141231_TypeOfArrangementAxis_MorphosysMember" unitRef="U001" decimals="-5">15300000</us-gaap:LicenseAndServicesRevenue>
  <!--Line of Credit Facility, Maximum Borrowing Capacity-EBS BAML Term Loan [Member]-->
  <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c20141231_LongtermDebtTypeAxis_EbsBamlTermLoanMember" unitRef="U001" decimals="-6">125000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
  <!--Line of Credit Facility, Maximum Borrowing Capacity-Revolving Credit Loan dated December 2013, due in December 2018 [Member]-->
  <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c20140331_LongtermDebtTypeAxis_RevolvingCreditLoanDatedDecember2013DueInDecember2018Member" unitRef="U001" decimals="-6">100000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
  <!--Loans, Notes, Trade and Other Receivables Disclosure [Text Block]-->
  <us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock contextRef="c20140101to20141231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;&lt;font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;6.&lt;/font&gt;&lt;font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Accounts receivable&lt;/font&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Accounts receivable consist of the following:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="7" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt; font-weight: bold;"&gt;(in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;2014&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="3" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;2013&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Billed&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;39,948&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;45,757&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Unbilled&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;18,886&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;14,830&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Total&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;58,834&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;60,587&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock>
  <!--Long-term Debt, Excluding Current Maturities-->
  <us-gaap:LongTermDebtNoncurrent contextRef="c20131231" unitRef="U001" decimals="-3">62000000</us-gaap:LongTermDebtNoncurrent>
  <!--Long-term Debt, Excluding Current Maturities-->
  <us-gaap:LongTermDebtNoncurrent contextRef="c20141231" unitRef="U001" decimals="-3">251000000</us-gaap:LongTermDebtNoncurrent>
  <!--Significant customers and accounts receivable-->
  <us-gaap:MajorCustomersPolicyPolicyTextBlock contextRef="c20140101to20141231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Significant customers and accounts receivable&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;For the years ended December 31, 2014, 2013 and 2012, the Company's primary customer was the U.S. Department of Health and Human Services ("HHS"). For the years ended December 31, 2014, 2013 and 2012, revenues from HHS and HHS agencies comprised 74.3%, 95.5% and 97.9%, respectively, of total revenues and are included in the Company's Biodefense segment. As of December 31, 2014 and 2013, the Company's receivable balances were comprised of 40.4% and 96.2%, respectively, from this customer. The overall decrease in the percentage of receivables attributed to HHS was due to the additional non-U.S. government revenue generating products from the Company's acquisition of Cangene in February 2014. Unbilled accounts receivable, included in accounts receivable, as of December 31, 2014 and 2013 were $18.9 million and $14.8 million, respectively, relates to various service contracts for which work has been performed, though invoicing has not yet occurred. Accounts receivable are stated at invoice amounts and consist primarily of amounts due from the U.S. government and collaborative partners as well as amounts due under reimbursement contracts with other government entities and non-government and philanthropic organizations. If necessary, the Company records a provision for doubtful receivables to allow for any amounts which may be unrecoverable. This provision is based upon an analysis of the Company's prior collection experience, customer creditworthiness and current economic trends. As of December 31, 2014 and 2013, an allowance for doubtful accounts was not recorded as the collection history from the Company's customers indicated that collection was probable.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:MajorCustomersPolicyPolicyTextBlock>
  <!--Noncontrolling interest in subsidiaries-->
  <us-gaap:MinorityInterest contextRef="c20131231" unitRef="U001" decimals="-3">-453000</us-gaap:MinorityInterest>
  <!--Noncontrolling interest in subsidiaries-->
  <us-gaap:MinorityInterest contextRef="c20141231" unitRef="U001" decimals="-3">0</us-gaap:MinorityInterest>
  <!--Nature of Operations [Text Block]-->
  <us-gaap:NatureOfOperations contextRef="c20140101to20141231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;&lt;font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;1.&lt;/font&gt;&amp;#160;&lt;font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Nature of the business and organization&lt;/font&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Emergent BioSolutions Inc. (the "Company" or "Emergent") is a &lt;font style="background-color: #ffffff; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;specialty pharmaceutical company seeking to protect and enhance life by offering specialized products to healthcare providers and governments for use in addressing medical needs and emerging health threats. &lt;/font&gt;The Company markets and develops products to be offered both to biodefense and commercial markets. The Company commenced operations as BioPort Corporation ("BioPort") in September 1998 through an acquisition from the Michigan Biologic Products Institute which includes: acquired rights to the marketed product BioThrax, vaccine manufacturing facilities at a multi-building campus on approximately 12.5 acres in Lansing, Michigan and vaccine development and production know-how. In December 2001, the U.S. Food and Drug Administration ("FDA") approved a supplement to the Company's manufacturing facility license for the manufacture of BioThrax at the renovated facilities. In June 2004, the Company completed a corporate reorganization ("Reorganization").&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;As a result of the Reorganization, BioPort became a wholly owned subsidiary of the Company. The Company subsequently renamed and converted this subsidiary to Emergent Biodefense Operations Lansing LLC ("Emergent Biodefense Operations"). The Company acquired a portion of its portfolio of vaccine and therapeutic product candidates through an acquisition of Microscience Limited ("Microscience") in a share exchange in June 2005, and acquisitions of substantially all of the assets, for cash, of Antex Biologics Inc. ("Antex") in May 2003 and ViVacs GmbH, Germany ("ViVacs") in July 2006. The Company renamed Microscience as Emergent Product Development UK Limited. The assets acquired from Antex are held in an entity incorporated as Emergent Product Development Gaithersburg Inc., and the assets acquired from ViVacs are held in an entity incorporated as Emergent Product Development Germany GmbH. On October 28, 2010, the Company acquired Trubion Pharmaceuticals, Inc. ("Trubion") for cash, equity and contingent value rights. Concurrent with the acquisition, the Company converted Trubion to Emergent Product Development Seattle, LLC. In August 2013, the Company acquired substantially all of the assets of the Health Protective Products Division ("HPPD") of Bracco Diagnostics Inc. ("Bracco") for cash along with contingent purchase consideration obligations. In February 2014, the Company acquired all the shares of Cangene Corporation ("Cangene") for cash.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
  <!--Net income (loss)-->
  <us-gaap:NetIncomeLoss contextRef="c20130101to20131231" unitRef="U001" decimals="-3">31135000</us-gaap:NetIncomeLoss>
  <!--Net income (loss)-->
  <us-gaap:NetIncomeLoss contextRef="c20140101to20141231" unitRef="U001" decimals="-3">36741000</us-gaap:NetIncomeLoss>
  <!--Net income (loss)-->
  <us-gaap:NetIncomeLoss contextRef="c20120101to20121231" unitRef="U001" decimals="-3">23524000</us-gaap:NetIncomeLoss>
  <!--Net income (loss)-Noncontrolling Interest in Subsidiary [Member]-->
  <us-gaap:NetIncomeLoss contextRef="c20130101to20131231_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U001" decimals="-3">0</us-gaap:NetIncomeLoss>
  <!--Net income (loss)-Retained Earnings [Member]-->
  <us-gaap:NetIncomeLoss contextRef="c20140101to20141231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3">36741000</us-gaap:NetIncomeLoss>
  <!--Net income (loss)-Retained Earnings [Member]-->
  <us-gaap:NetIncomeLoss contextRef="c20120101to20121231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3">23524000</us-gaap:NetIncomeLoss>
  <!--Net income (loss)-Accumulated Other Comprehensive Loss [Member]-->
  <us-gaap:NetIncomeLoss contextRef="c20130101to20131231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3">0</us-gaap:NetIncomeLoss>
  <!--Net income (loss)-Noncontrolling Interest in Subsidiary [Member]-->
  <us-gaap:NetIncomeLoss contextRef="c20120101to20121231_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U001" decimals="-3">0</us-gaap:NetIncomeLoss>
  <!--Net income (loss)-Retained Earnings [Member]-->
  <us-gaap:NetIncomeLoss contextRef="c20130101to20131231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3">31135000</us-gaap:NetIncomeLoss>
  <!--Net income (loss)-Accumulated Other Comprehensive Loss [Member]-->
  <us-gaap:NetIncomeLoss contextRef="c20140101to20141231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3">0</us-gaap:NetIncomeLoss>
  <!--Net income (loss)-Noncontrolling Interest in Subsidiary [Member]-->
  <us-gaap:NetIncomeLoss contextRef="c20140101to20141231_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U001" decimals="-3">0</us-gaap:NetIncomeLoss>
  <!--Net income (loss)-Biodefense [Member]-->
  <us-gaap:NetIncomeLoss contextRef="c20130101to20131231_StatementBusinessSegmentsAxis_BiodefenseMember" unitRef="U001" decimals="-3">87289000</us-gaap:NetIncomeLoss>
  <!--Net income (loss)-All Other [Member]-->
  <us-gaap:NetIncomeLoss contextRef="c20140101to20141231_StatementBusinessSegmentsAxis_AllOtherSegmentsMember" unitRef="U001" decimals="-3">-8925000</us-gaap:NetIncomeLoss>
  <!--Net income (loss)-Biodefense [Member]-->
  <us-gaap:NetIncomeLoss contextRef="c20120101to20121231_StatementBusinessSegmentsAxis_BiodefenseMember" unitRef="U001" decimals="-3">94865000</us-gaap:NetIncomeLoss>
  <!--Net income (loss)-Biosciences [Member]-->
  <us-gaap:NetIncomeLoss contextRef="c20130101to20131231_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U001" decimals="-3">-50925000</us-gaap:NetIncomeLoss>
  <!--Net income (loss)-All Other [Member]-->
  <us-gaap:NetIncomeLoss contextRef="c20120101to20121231_StatementBusinessSegmentsAxis_AllOtherSegmentsMember" unitRef="U001" decimals="-3">-7413000</us-gaap:NetIncomeLoss>
  <!--Net income (loss)-All Other [Member]-->
  <us-gaap:NetIncomeLoss contextRef="c20130101to20131231_StatementBusinessSegmentsAxis_AllOtherSegmentsMember" unitRef="U001" decimals="-3">-5229000</us-gaap:NetIncomeLoss>
  <!--Net income (loss)-Biosciences [Member]-->
  <us-gaap:NetIncomeLoss contextRef="c20120101to20121231_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U001" decimals="-3">-63928000</us-gaap:NetIncomeLoss>
  <!--Net income (loss)-Biodefense [Member]-->
  <us-gaap:NetIncomeLoss contextRef="c20140101to20141231_StatementBusinessSegmentsAxis_BiodefenseMember" unitRef="U001" decimals="-3">96966000</us-gaap:NetIncomeLoss>
  <!--Net income (loss)-Biosciences [Member]-->
  <us-gaap:NetIncomeLoss contextRef="c20140101to20141231_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U001" decimals="-3">-51300000</us-gaap:NetIncomeLoss>
  <!--Net income (loss)-->
  <us-gaap:NetIncomeLoss contextRef="c20130101to20130331" unitRef="U001" decimals="-3">-8062000</us-gaap:NetIncomeLoss>
  <!--Net income (loss)-->
  <us-gaap:NetIncomeLoss contextRef="c20130401to20130630" unitRef="U001" decimals="-3">10484000</us-gaap:NetIncomeLoss>
  <!--Net income (loss)-->
  <us-gaap:NetIncomeLoss contextRef="c20131001to20131231" unitRef="U001" decimals="-3">15222000</us-gaap:NetIncomeLoss>
  <!--Net income (loss)-->
  <us-gaap:NetIncomeLoss contextRef="c20140401to20140630" unitRef="U001" decimals="-3">5029000</us-gaap:NetIncomeLoss>
  <!--Net income (loss)-->
  <us-gaap:NetIncomeLoss contextRef="c20140101to20140331" unitRef="U001" decimals="-3">-20236000</us-gaap:NetIncomeLoss>
  <!--Net income (loss)-->
  <us-gaap:NetIncomeLoss contextRef="c20140701to20140930" unitRef="U001" decimals="-3">21832000</us-gaap:NetIncomeLoss>
  <!--Net income (loss)-->
  <us-gaap:NetIncomeLoss contextRef="c20141001to20141231" unitRef="U001" decimals="-3">30116000</us-gaap:NetIncomeLoss>
  <!--Net income (loss)-->
  <us-gaap:NetIncomeLoss contextRef="c20130701to20130930" unitRef="U001" decimals="-3">13491000</us-gaap:NetIncomeLoss>
  <!--Net Cash Provided by (Used in) Investing Activities-->
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c20130101to20131231" unitRef="U001" decimals="-3">-67894000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <!--Net Cash Provided by (Used in) Investing Activities-->
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c20140101to20141231" unitRef="U001" decimals="-3">-210052000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <!--Net Cash Provided by (Used in) Investing Activities-->
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c20120101to20121231" unitRef="U001" decimals="-3">-40114000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <!--Net Cash Provided by (Used in) Financing Activities-->
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c20140101to20141231" unitRef="U001" decimals="-3">198874000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <!--Net Cash Provided by (Used in) Financing Activities-->
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c20130101to20131231" unitRef="U001" decimals="-3">8612000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <!--Net Cash Provided by (Used in) Financing Activities-->
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c20120101to20121231" unitRef="U001" decimals="-3">-1765000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <!--Net Cash Provided by (Used in) Operating Activities-->
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c20130101to20131231" unitRef="U001" decimals="-3">96968000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <!--Net Cash Provided by (Used in) Operating Activities-->
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c20140101to20141231" unitRef="U001" decimals="-3">112318000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <!--Net Cash Provided by (Used in) Operating Activities-->
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c20120101to20121231" unitRef="U001" decimals="-3">39643000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <!--Net loss attributable to noncontrolling interest-->
  <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c20120101to20121231" unitRef="U001" decimals="-3">-5381000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
  <!--Net loss attributable to noncontrolling interest-->
  <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c20140101to20141231" unitRef="U001" decimals="-3">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
  <!--Net loss attributable to noncontrolling interest-->
  <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c20130101to20131231" unitRef="U001" decimals="-3">-876000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
  <!--Net loss attributable to noncontrolling interest-Retained Earnings [Member]-->
  <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c20120101to20121231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
  <!--Net loss attributable to noncontrolling interest-Retained Earnings [Member]-->
  <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c20130101to20131231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
  <!--Net loss attributable to noncontrolling interest-Accumulated Other Comprehensive Loss [Member]-->
  <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c20130101to20131231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
  <!--Net loss attributable to noncontrolling interest-Noncontrolling Interest in Subsidiary [Member]-->
  <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c20120101to20121231_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U001" decimals="-3">-5381000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
  <!--Net loss attributable to noncontrolling interest-Noncontrolling Interest in Subsidiary [Member]-->
  <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c20130101to20131231_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U001" decimals="-3">-876000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
  <!--Nonoperating Income (Expense)-->
  <us-gaap:NonoperatingIncomeExpense contextRef="c20120101to20121231" unitRef="U001" decimals="-3">2098000</us-gaap:NonoperatingIncomeExpense>
  <!--Nonoperating Income (Expense)-->
  <us-gaap:NonoperatingIncomeExpense contextRef="c20140101to20141231" unitRef="U001" decimals="-3">-4994000</us-gaap:NonoperatingIncomeExpense>
  <!--Nonoperating Income (Expense)-->
  <us-gaap:NonoperatingIncomeExpense contextRef="c20130101to20131231" unitRef="U001" decimals="-3">565000</us-gaap:NonoperatingIncomeExpense>
  <!--Number of business segments-->
  <us-gaap:NumberOfReportableSegments contextRef="c20140101to20141231" unitRef="U010" decimals="INF">2</us-gaap:NumberOfReportableSegments>
  <!--Open tax year-Minimum [Member]-Internal Revenue Service (IRS) [Member]-->
  <us-gaap:OpenTaxYear contextRef="c20140101to20141231_IncomeTaxAuthorityAxis_InternalRevenueServiceIRSMember_RangeAxis_MinimumMember">2011</us-gaap:OpenTaxYear>
  <!--Open tax year-Maximum [Member]-Foreign Tax Authority [Member]-->
  <us-gaap:OpenTaxYear contextRef="c20140101to20141231_IncomeTaxAuthorityAxis_ForeignCountryMember_RangeAxis_MaximumMember">2013</us-gaap:OpenTaxYear>
  <!--Open tax year-Maximum [Member]-Internal Revenue Service (IRS) [Member]-->
  <us-gaap:OpenTaxYear contextRef="c20140101to20141231_IncomeTaxAuthorityAxis_InternalRevenueServiceIRSMember_RangeAxis_MaximumMember">2013</us-gaap:OpenTaxYear>
  <!--Open tax year-Foreign Tax Authority [Member]-Minimum [Member]-->
  <us-gaap:OpenTaxYear contextRef="c20140101to20141231_IncomeTaxAuthorityAxis_ForeignCountryMember_RangeAxis_MinimumMember">2007</us-gaap:OpenTaxYear>
  <!--2019-->
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears contextRef="c20141231" unitRef="U001" decimals="-3">1697000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears>
  <!--2018-->
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears contextRef="c20141231" unitRef="U001" decimals="-3">1813000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
  <!--Rental income-->
  <us-gaap:OperatingLeasesRentExpenseSubleaseRentals1 contextRef="c20130101to20131231" unitRef="U001" decimals="0">446000</us-gaap:OperatingLeasesRentExpenseSubleaseRentals1>
  <!--Rental income-->
  <us-gaap:OperatingLeasesRentExpenseSubleaseRentals1 contextRef="c20140101to20141231" unitRef="U001" decimals="-5">3100000</us-gaap:OperatingLeasesRentExpenseSubleaseRentals1>
  <!--2017-->
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="c20141231" unitRef="U001" decimals="-3">1950000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
  <!--Total lease expense-->
  <us-gaap:OperatingLeasesRentExpenseNet contextRef="c20120101to20121231" unitRef="U001" decimals="-5">3600000</us-gaap:OperatingLeasesRentExpenseNet>
  <!--Total lease expense-->
  <us-gaap:OperatingLeasesRentExpenseNet contextRef="c20140101to20141231" unitRef="U001" decimals="-5">4600000</us-gaap:OperatingLeasesRentExpenseNet>
  <!--Total lease expense-->
  <us-gaap:OperatingLeasesRentExpenseNet contextRef="c20130101to20131231" unitRef="U001" decimals="-5">3900000</us-gaap:OperatingLeasesRentExpenseNet>
  <!--2016-->
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="c20141231" unitRef="U001" decimals="-3">2204000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
  <!--Income (loss) from operations-->
  <us-gaap:OperatingIncomeLoss contextRef="c20130101to20131231" unitRef="U001" decimals="-3">42802000</us-gaap:OperatingIncomeLoss>
  <!--Income (loss) from operations-->
  <us-gaap:OperatingIncomeLoss contextRef="c20140101to20141231" unitRef="U001" decimals="-3">58056000</us-gaap:OperatingIncomeLoss>
  <!--Income (loss) from operations-->
  <us-gaap:OperatingIncomeLoss contextRef="c20120101to20121231" unitRef="U001" decimals="-3">29967000</us-gaap:OperatingIncomeLoss>
  <!--Income (loss) from operations-->
  <us-gaap:OperatingIncomeLoss contextRef="c20140101to20140331" unitRef="U001" decimals="-3">-25458000</us-gaap:OperatingIncomeLoss>
  <!--Income (loss) from operations-->
  <us-gaap:OperatingIncomeLoss contextRef="c20130401to20130630" unitRef="U001" decimals="-3">14712000</us-gaap:OperatingIncomeLoss>
  <!--Income (loss) from operations-->
  <us-gaap:OperatingIncomeLoss contextRef="c20140701to20140930" unitRef="U001" decimals="-3">31032000</us-gaap:OperatingIncomeLoss>
  <!--Income (loss) from operations-->
  <us-gaap:OperatingIncomeLoss contextRef="c20130701to20130930" unitRef="U001" decimals="-3">18147000</us-gaap:OperatingIncomeLoss>
  <!--Income (loss) from operations-->
  <us-gaap:OperatingIncomeLoss contextRef="c20130101to20130331" unitRef="U001" decimals="-3">-13350000</us-gaap:OperatingIncomeLoss>
  <!--Income (loss) from operations-->
  <us-gaap:OperatingIncomeLoss contextRef="c20131001to20131231" unitRef="U001" decimals="-3">23293000</us-gaap:OperatingIncomeLoss>
  <!--Income (loss) from operations-->
  <us-gaap:OperatingIncomeLoss contextRef="c20141001to20141231" unitRef="U001" decimals="-3">44620000</us-gaap:OperatingIncomeLoss>
  <!--Income (loss) from operations-->
  <us-gaap:OperatingIncomeLoss contextRef="c20140401to20140630" unitRef="U001" decimals="-3">7862000</us-gaap:OperatingIncomeLoss>
  <!--Operating Leases, Future Minimum Payments Due, Future Minimum Sublease Rentals-->
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals contextRef="c20141231" unitRef="U001" decimals="-3">1388000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals>
  <!--Operating loss carryforwards, expiration year-Internal Revenue Service (IRS) [Member]-->
  <us-gaap:OperatingLossCarryforwardsExpirationDate contextRef="c20140101to20141231_IncomeTaxAuthorityAxis_InternalRevenueServiceIRSMember">2026-12-31</us-gaap:OperatingLossCarryforwardsExpirationDate>
  <!--Operating loss carryforwards, expiration year-State and Local Jurisdiction [Member]-->
  <us-gaap:OperatingLossCarryforwardsExpirationDate contextRef="c20140101to20141231_IncomeTaxAuthorityAxis_StateAndLocalJurisdictionMember">2018-12-31</us-gaap:OperatingLossCarryforwardsExpirationDate>
  <!--2020 and beyond-->
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter contextRef="c20141231" unitRef="U001" decimals="-3">904000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter>
  <!--2015-->
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent contextRef="c20141231" unitRef="U001" decimals="-3">2558000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
  <!--Operating Leases, Future Minimum Payments Due-->
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="c20141231" unitRef="U001" decimals="-3">11126000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
  <!--Net operating loss carryforwards-Foreign Tax Authority [Member]-->
  <us-gaap:OperatingLossCarryforwards contextRef="c20141231_IncomeTaxAuthorityAxis_ForeignCountryMember" unitRef="U001" decimals="-5">274400000</us-gaap:OperatingLossCarryforwards>
  <!--Net operating loss carryforwards-Internal Revenue Service (IRS) [Member]-->
  <us-gaap:OperatingLossCarryforwards contextRef="c20141231_IncomeTaxAuthorityAxis_InternalRevenueServiceIRSMember" unitRef="U001" decimals="-5">24200000</us-gaap:OperatingLossCarryforwards>
  <!--Net operating loss carryforwards-State and Local Jurisdiction [Member]-->
  <us-gaap:OperatingLossCarryforwards contextRef="c20141231_IncomeTaxAuthorityAxis_StateAndLocalJurisdictionMember" unitRef="U001" decimals="-5">224600000</us-gaap:OperatingLossCarryforwards>
  <!--Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation, before Tax-->
  <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax contextRef="c20130101to20131231" unitRef="U001" decimals="-3">-58000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax>
  <!--Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation, before Tax-->
  <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax contextRef="c20140101to20141231" unitRef="U001" decimals="-3">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax>
  <!--Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation, before Tax-->
  <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax contextRef="c20120101to20121231" unitRef="U001" decimals="-3">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax>
  <!--Foreign currency translations, net of tax-Accumulated Other Comprehensive Loss [Member]-->
  <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c20130101to20131231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3">664000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
  <!--Foreign currency translations, net of tax-->
  <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c20120101to20121231" unitRef="U001" decimals="-3">-816000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
  <!--Foreign currency translations, net of tax-Retained Earnings [Member]-->
  <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c20140101to20141231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
  <!--Foreign currency translations, net of tax-Noncontrolling Interest in Subsidiary [Member]-->
  <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c20120101to20121231_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U001" decimals="-3">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
  <!--Foreign currency translations, net of tax-Noncontrolling Interest in Subsidiary [Member]-->
  <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c20130101to20131231_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U001" decimals="-3">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
  <!--Foreign currency translations, net of tax-Noncontrolling Interest in Subsidiary [Member]-->
  <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c20140101to20141231_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U001" decimals="-3">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
  <!--Foreign currency translations, net of tax-->
  <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c20140101to20141231" unitRef="U001" decimals="-3">457000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
  <!--Foreign currency translations, net of tax-Retained Earnings [Member]-->
  <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c20130101to20131231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
  <!--Foreign currency translations, net of tax-Accumulated Other Comprehensive Loss [Member]-->
  <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c20140101to20141231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3">457000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
  <!--Foreign currency translations, net of tax-Retained Earnings [Member]-->
  <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c20120101to20121231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
  <!--Foreign currency translations, net of tax-Accumulated Other Comprehensive Loss [Member]-->
  <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c20120101to20121231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3">-816000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
  <!--Foreign currency translations, net of tax-->
  <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c20130101to20131231" unitRef="U001" decimals="-3">664000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
  <!--Other assets-->
  <us-gaap:OtherAssetsNoncurrent contextRef="c20131231" unitRef="U001" decimals="-3">3373000</us-gaap:OtherAssetsNoncurrent>
  <!--Other assets-->
  <us-gaap:OtherAssetsNoncurrent contextRef="c20141231" unitRef="U001" decimals="-3">8216000</us-gaap:OtherAssetsNoncurrent>
  <!--Other Noncash Income (Expense)-->
  <us-gaap:OtherNoncashIncomeExpense contextRef="c20140101to20141231" unitRef="U001" decimals="-3">-1284000</us-gaap:OtherNoncashIncomeExpense>
  <!--Other Noncash Income (Expense)-->
  <us-gaap:OtherNoncashIncomeExpense contextRef="c20130101to20131231" unitRef="U001" decimals="-3">-51000</us-gaap:OtherNoncashIncomeExpense>
  <!--Other Noncash Income (Expense)-->
  <us-gaap:OtherNoncashIncomeExpense contextRef="c20120101to20121231" unitRef="U001" decimals="-3">40000</us-gaap:OtherNoncashIncomeExpense>
  <!--Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax-->
  <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="c20130101to20131231" unitRef="U001" decimals="-3">606000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
  <!--Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax-->
  <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="c20120101to20121231" unitRef="U001" decimals="-3">-816000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
  <!--Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax-->
  <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="c20140101to20141231" unitRef="U001" decimals="-3">457000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
  <!--Other Depreciation and Amortization-->
  <us-gaap:OtherDepreciationAndAmortization contextRef="c20130101to20131231" unitRef="U001" decimals="-3">18958000</us-gaap:OtherDepreciationAndAmortization>
  <!--Other Depreciation and Amortization-->
  <us-gaap:OtherDepreciationAndAmortization contextRef="c20120101to20121231" unitRef="U001" decimals="-3">11197000</us-gaap:OtherDepreciationAndAmortization>
  <!--Other Depreciation and Amortization-->
  <us-gaap:OtherDepreciationAndAmortization contextRef="c20140101to20141231" unitRef="U001" decimals="-3">32453000</us-gaap:OtherDepreciationAndAmortization>
  <!--Non-cash development expenses from joint venture-->
  <us-gaap:OtherNoncashExpense contextRef="c20120101to20121231" unitRef="U001" decimals="-3">3670000</us-gaap:OtherNoncashExpense>
  <!--Non-cash development expenses from joint venture-->
  <us-gaap:OtherNoncashExpense contextRef="c20140101to20141231" unitRef="U001" decimals="-3">0</us-gaap:OtherNoncashExpense>
  <!--Non-cash development expenses from joint venture-->
  <us-gaap:OtherNoncashExpense contextRef="c20130101to20131231" unitRef="U001" decimals="-3">-347000</us-gaap:OtherNoncashExpense>
  <!--Other income (expense), net-->
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="c20120101to20121231" unitRef="U001" decimals="-3">1970000</us-gaap:OtherNonoperatingIncomeExpense>
  <!--Other income (expense), net-->
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="c20140101to20141231" unitRef="U001" decimals="-3">2926000</us-gaap:OtherNonoperatingIncomeExpense>
  <!--Other income (expense), net-->
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="c20130101to20131231" unitRef="U001" decimals="-3">426000</us-gaap:OtherNonoperatingIncomeExpense>
  <!--Other liabilities-->
  <us-gaap:OtherLiabilitiesNoncurrent contextRef="c20131231" unitRef="U001" decimals="-3">2117000</us-gaap:OtherLiabilitiesNoncurrent>
  <!--Other liabilities-->
  <us-gaap:OtherLiabilitiesNoncurrent contextRef="c20141231" unitRef="U001" decimals="-3">1242000</us-gaap:OtherLiabilitiesNoncurrent>
  <!--Payments for Repurchase of Common Stock-->
  <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c20140101to20141231" unitRef="U001" decimals="-3">200000</us-gaap:PaymentsForRepurchaseOfCommonStock>
  <!--Payments for Repurchase of Common Stock-->
  <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c20130101to20131231" unitRef="U001" decimals="-3">213000</us-gaap:PaymentsForRepurchaseOfCommonStock>
  <!--Payments for Repurchase of Common Stock-->
  <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c20120101to20121231" unitRef="U001" decimals="-3">5906000</us-gaap:PaymentsForRepurchaseOfCommonStock>
  <!--Payments to Acquire Businesses, Net of Cash Acquired-->
  <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c20140101to20141231" unitRef="U001" decimals="-3">179379000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
  <!--Payments to Acquire Businesses, Net of Cash Acquired-->
  <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c20120101to20121231" unitRef="U001" decimals="-3">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
  <!--Payments to Acquire Businesses, Net of Cash Acquired-->
  <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c20130101to20131231" unitRef="U001" decimals="-3">25873000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
  <!--Payments for Restructuring-->
  <us-gaap:PaymentsForRestructuring contextRef="c20140101to20141231" unitRef="U001" decimals="-3">454000</us-gaap:PaymentsForRestructuring>
  <!--Payments for Restructuring-Termination benefits [Member]-EPDU Restructuring Plan [Member]-->
  <us-gaap:PaymentsForRestructuring contextRef="c20130101to20131231_RestructuringCostAndReserveAxis_SpecialTerminationBenefitsMember_RestructuringPlanAxis_EpduRestructuringPlanMember" unitRef="U001" decimals="-3">1660000</us-gaap:PaymentsForRestructuring>
  <!--Payments for Restructuring-EPDU Restructuring Plan [Member]-->
  <us-gaap:PaymentsForRestructuring contextRef="c20140101to20141231_RestructuringPlanAxis_EpduRestructuringPlanMember" unitRef="U001" decimals="-3">0</us-gaap:PaymentsForRestructuring>
  <!--Payments for Restructuring-->
  <us-gaap:PaymentsForRestructuring contextRef="c20130101to20131231" unitRef="U001" decimals="-3">2225000</us-gaap:PaymentsForRestructuring>
  <!--Payments for Restructuring-Contract termination costs [Member]-EPDU Restructuring Plan [Member]-->
  <us-gaap:PaymentsForRestructuring contextRef="c20130101to20131231_RestructuringCostAndReserveAxis_ContractTerminationMember_RestructuringPlanAxis_EpduRestructuringPlanMember" unitRef="U001" decimals="-3">431000</us-gaap:PaymentsForRestructuring>
  <!--Payments for Restructuring-EPDU Restructuring Plan [Member]-->
  <us-gaap:PaymentsForRestructuring contextRef="c20130101to20131231_RestructuringPlanAxis_EpduRestructuringPlanMember" unitRef="U001" decimals="-3">134000</us-gaap:PaymentsForRestructuring>
  <!--Payments for Restructuring-Contract termination costs [Member]-EPDU Restructuring Plan [Member]-->
  <us-gaap:PaymentsForRestructuring contextRef="c20140101to20141231_RestructuringCostAndReserveAxis_ContractTerminationMember_RestructuringPlanAxis_EpduRestructuringPlanMember" unitRef="U001" decimals="-3">0</us-gaap:PaymentsForRestructuring>
  <!--Payments for Restructuring-Termination benefits [Member]-EPDU Restructuring Plan [Member]-->
  <us-gaap:PaymentsForRestructuring contextRef="c20140101to20141231_RestructuringCostAndReserveAxis_SpecialTerminationBenefitsMember_RestructuringPlanAxis_EpduRestructuringPlanMember" unitRef="U001" decimals="-3">454000</us-gaap:PaymentsForRestructuring>
  <!--Payments to Acquire Businesses, Gross-Evolva Holding SA 035 [Member]-->
  <us-gaap:PaymentsToAcquireBusinessesGross contextRef="c20141217to20141217_BusinessAcquisitionAxis_EvolvaHoldingSA035Member" unitRef="U001" decimals="-3">1500000</us-gaap:PaymentsToAcquireBusinessesGross>
  <!--Payments to Acquire Businesses, Gross-HPPD [Member]-->
  <us-gaap:PaymentsToAcquireBusinessesGross contextRef="c20130731to20130801_BusinessAcquisitionAxis_HppdMember" unitRef="U001" decimals="-3">25873000</us-gaap:PaymentsToAcquireBusinessesGross>
  <!--Payments to Acquire Property, Plant, and Equipment-->
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c20130101to20131231" unitRef="U001" decimals="-3">42021000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <!--Payments to Acquire Property, Plant, and Equipment-->
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c20140101to20141231" unitRef="U001" decimals="-3">30673000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <!--Payments to Acquire Property, Plant, and Equipment-->
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c20120101to20121231" unitRef="U001" decimals="-3">53845000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <!--Payments to Acquire Property, Plant, and Equipment-Biodefense [Member]-->
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c20130101to20131231_StatementBusinessSegmentsAxis_BiodefenseMember" unitRef="U001" decimals="-3">30700000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <!--Payments to Acquire Property, Plant, and Equipment-Biodefense [Member]-->
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c20120101to20121231_StatementBusinessSegmentsAxis_BiodefenseMember" unitRef="U001" decimals="-3">52957000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <!--Payments to Acquire Property, Plant, and Equipment-Biosciences [Member]-->
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c20140101to20141231_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U001" decimals="-3">2444000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <!--Payments to Acquire Property, Plant, and Equipment-Biosciences [Member]-->
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c20130101to20131231_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U001" decimals="-3">1343000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <!--Payments to Acquire Property, Plant, and Equipment-Biosciences [Member]-->
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c20120101to20121231_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U001" decimals="-3">810000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <!--Payments to Acquire Property, Plant, and Equipment-Biodefense [Member]-->
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c20140101to20141231_StatementBusinessSegmentsAxis_BiodefenseMember" unitRef="U001" decimals="-3">26736000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <!--Payments to Acquire Property, Plant, and Equipment-All Other [Member]-->
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c20140101to20141231_StatementBusinessSegmentsAxis_AllOtherSegmentsMember" unitRef="U001" decimals="-3">1493000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <!--Payments to Acquire Property, Plant, and Equipment-All Other [Member]-->
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c20130101to20131231_StatementBusinessSegmentsAxis_AllOtherSegmentsMember" unitRef="U001" decimals="-3">9978000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <!--Payments to Acquire Property, Plant, and Equipment-All Other [Member]-->
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c20120101to20121231_StatementBusinessSegmentsAxis_AllOtherSegmentsMember" unitRef="U001" decimals="-3">78000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <!--Pension and Other Postretirement Benefits Disclosure [Text Block]-->
  <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock contextRef="c20140101to20141231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;&lt;font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;16.&lt;/font&gt;&lt;font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;401(k) savings plan&lt;/font&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;The Company has established a defined contribution savings plan under Section 401(k) of the Internal Revenue Code. The 401(k) Plan covers substantially all U.S. employees. Under the 401(k) Plan, employees may make elective salary deferrals. The Company currently provides for matching of qualified deferrals up to 50% of the first 6% of the employee's salary. During the years ended December 31, 2014, 2013, and 2012, the Company made matching contributions of approximately $2.4 million, $2.0 million and $1.9 million, respectively.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
  <!--Preferred stock, par value (in dollars per share)-->
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="c20131231" unitRef="U003" decimals="INF">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <!--Preferred stock, par value (in dollars per share)-->
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="c20141231" unitRef="U003" decimals="INF">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <!--Preferred stock, $0.001 par value; 15,000,000 shares authorized, 0 shares issued and outstanding at December 31, 2014 and December 31, 2013, respectively-->
  <us-gaap:PreferredStockValue contextRef="c20141231" unitRef="U001" decimals="-3">0</us-gaap:PreferredStockValue>
  <!--Preferred stock, $0.001 par value; 15,000,000 shares authorized, 0 shares issued and outstanding at December 31, 2014 and December 31, 2013, respectively-->
  <us-gaap:PreferredStockValue contextRef="c20131231" unitRef="U001" decimals="-3">0</us-gaap:PreferredStockValue>
  <!--Preferred stock, shares issued (in shares)-->
  <us-gaap:PreferredStockSharesIssued contextRef="c20141231" unitRef="U002" decimals="0">0</us-gaap:PreferredStockSharesIssued>
  <!--Preferred stock, shares issued (in shares)-->
  <us-gaap:PreferredStockSharesIssued contextRef="c20131231" unitRef="U002" decimals="0">0</us-gaap:PreferredStockSharesIssued>
  <!--Preferred stock, shares authorized (in shares)-->
  <us-gaap:PreferredStockSharesAuthorized contextRef="c20141231" unitRef="U002" decimals="0">15000000</us-gaap:PreferredStockSharesAuthorized>
  <!--Preferred stock, shares authorized (in shares)-->
  <us-gaap:PreferredStockSharesAuthorized contextRef="c20131231" unitRef="U002" decimals="0">15000000</us-gaap:PreferredStockSharesAuthorized>
  <!--Preferred stock, shares outstanding (in shares)-->
  <us-gaap:PreferredStockSharesOutstanding contextRef="c20141231" unitRef="U002" decimals="0">0</us-gaap:PreferredStockSharesOutstanding>
  <!--Preferred stock, shares outstanding (in shares)-->
  <us-gaap:PreferredStockSharesOutstanding contextRef="c20131231" unitRef="U002" decimals="0">0</us-gaap:PreferredStockSharesOutstanding>
  <!--Prepaid expenses and other current assets-->
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c20131231" unitRef="U001" decimals="-3">12896000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <!--Prepaid expenses and other current assets-->
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c20141231" unitRef="U001" decimals="-3">24101000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <!--Proceeds from sale of assets-->
  <us-gaap:ProceedsFromSaleOfOtherAssets1 contextRef="c20120101to20121231" unitRef="U001" decimals="-3">11765000</us-gaap:ProceedsFromSaleOfOtherAssets1>
  <!--Proceeds from sale of assets-->
  <us-gaap:ProceedsFromSaleOfOtherAssets1 contextRef="c20140101to20141231" unitRef="U001" decimals="-3">0</us-gaap:ProceedsFromSaleOfOtherAssets1>
  <!--Proceeds from sale of assets-->
  <us-gaap:ProceedsFromSaleOfOtherAssets1 contextRef="c20130101to20131231" unitRef="U001" decimals="-3">0</us-gaap:ProceedsFromSaleOfOtherAssets1>
  <!--Restricted cash deposit-->
  <us-gaap:ProceedsFromRepaymentsOfRestrictedCashFinancingActivities contextRef="c20130101to20131231" unitRef="U001" decimals="-3">0</us-gaap:ProceedsFromRepaymentsOfRestrictedCashFinancingActivities>
  <!--Restricted cash deposit-->
  <us-gaap:ProceedsFromRepaymentsOfRestrictedCashFinancingActivities contextRef="c20140101to20141231" unitRef="U001" decimals="-3">0</us-gaap:ProceedsFromRepaymentsOfRestrictedCashFinancingActivities>
  <!--Restricted cash deposit-->
  <us-gaap:ProceedsFromRepaymentsOfRestrictedCashFinancingActivities contextRef="c20120101to20121231" unitRef="U001" decimals="-3">220000</us-gaap:ProceedsFromRepaymentsOfRestrictedCashFinancingActivities>
  <!--Proceeds from Convertible Debt-->
  <us-gaap:ProceedsFromConvertibleDebt contextRef="c20140101to20141231" unitRef="U001" decimals="-3">241588000</us-gaap:ProceedsFromConvertibleDebt>
  <!--Proceeds from Convertible Debt-->
  <us-gaap:ProceedsFromConvertibleDebt contextRef="c20130101to20131231" unitRef="U001" decimals="-3">0</us-gaap:ProceedsFromConvertibleDebt>
  <!--Proceeds from Convertible Debt-->
  <us-gaap:ProceedsFromConvertibleDebt contextRef="c20120101to20121231" unitRef="U001" decimals="-3">0</us-gaap:ProceedsFromConvertibleDebt>
  <!--Issuance of common stock subject to employee equity plans-->
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="c20130101to20131231" unitRef="U001" decimals="-3">6848000</us-gaap:ProceedsFromStockOptionsExercised>
  <!--Issuance of common stock subject to employee equity plans-->
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="c20120101to20121231" unitRef="U001" decimals="-3">761000</us-gaap:ProceedsFromStockOptionsExercised>
  <!--Issuance of common stock subject to employee equity plans-->
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="c20140101to20141231" unitRef="U001" decimals="-3">14078000</us-gaap:ProceedsFromStockOptionsExercised>
  <!--Proceeds from maturity of investments-->
  <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="c20140101to20141231" unitRef="U001" decimals="-3">0</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
  <!--Proceeds from maturity of investments-->
  <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="c20130101to20131231" unitRef="U001" decimals="-3">0</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
  <!--Proceeds from maturity of investments-->
  <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="c20120101to20121231" unitRef="U001" decimals="-3">1966000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
  <!--Net income-->
  <us-gaap:ProfitLoss contextRef="c20130101to20131231" unitRef="U001" decimals="-3">30259000</us-gaap:ProfitLoss>
  <!--Net income-->
  <us-gaap:ProfitLoss contextRef="c20120101to20121231" unitRef="U001" decimals="-3">18143000</us-gaap:ProfitLoss>
  <!--Net income-->
  <us-gaap:ProfitLoss contextRef="c20140101to20141231" unitRef="U001" decimals="-3">36741000</us-gaap:ProfitLoss>
  <!--Property, plant and equipment-->
  <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c20140101to20141231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Property, plant and equipment&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Property, plant and equipment are stated at cost. Depreciation is computed using the straight-line method over the following estimated useful lives:&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td style="width: 50.01%; vertical-align: top;"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Buildings&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 49.99%; vertical-align: top;"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;31-39 years&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width: 50.01%; vertical-align: top;"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Building improvements&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 49.99%; vertical-align: top;"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;10-39 years&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width: 50.01%; vertical-align: top;"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Furniture and equipment&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 49.99%; vertical-align: top;"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;3-15 years&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width: 50.01%; vertical-align: top;"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Software&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 49.99%; vertical-align: top;"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Lesser of 3-5 years or product life&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width: 50.01%; vertical-align: top;"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Leasehold improvements&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 49.99%; vertical-align: top;"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Lesser of the asset life or lease term&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is credited or charged to operations. Repairs and maintenance costs are expensed as incurred.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
  <!--Estimated useful lives-Minimum [Member]-Furniture and equipment [Member]-->
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c20140101to20141231_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember_RangeAxis_MinimumMember">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <!--Estimated useful lives-Building Improvements [Member]-Maximum [Member]-->
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c20140101to20141231_PropertyPlantAndEquipmentByTypeAxis_BuildingImprovementsMember_RangeAxis_MaximumMember">P39Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <!--Estimated useful lives-Building [Member]-Minimum [Member]-->
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c20140101to20141231_PropertyPlantAndEquipmentByTypeAxis_BuildingMember_RangeAxis_MinimumMember">P31Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <!--Estimated useful lives-Building Improvements [Member]-Minimum [Member]-->
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c20140101to20141231_PropertyPlantAndEquipmentByTypeAxis_BuildingImprovementsMember_RangeAxis_MinimumMember">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <!--Estimated useful lives-Furniture and equipment [Member]-Maximum [Member]-->
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c20140101to20141231_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember_RangeAxis_MaximumMember">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <!--Estimated useful lives-Maximum [Member]-Building [Member]-->
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c20140101to20141231_PropertyPlantAndEquipmentByTypeAxis_BuildingMember_RangeAxis_MaximumMember">P39Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <!--Property, Plant and Equipment, Gross-Land and improvements [Member]-->
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="c20141231_PropertyPlantAndEquipmentByTypeAxis_LandAndLandImprovementsMember" unitRef="U001" decimals="-3">12838000</us-gaap:PropertyPlantAndEquipmentGross>
  <!--Property, Plant and Equipment, Gross-Software [Member]-->
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="c20141231_PropertyPlantAndEquipmentByTypeAxis_ComputerSoftwareIntangibleAssetMember" unitRef="U001" decimals="-3">25354000</us-gaap:PropertyPlantAndEquipmentGross>
  <!--Property, Plant and Equipment, Gross-Construction-in-progress [Member]-->
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="c20141231_PropertyPlantAndEquipmentByTypeAxis_ConstructionInProgressMember" unitRef="U001" decimals="-3">117884000</us-gaap:PropertyPlantAndEquipmentGross>
  <!--Property, Plant and Equipment, Gross-Software [Member]-->
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="c20131231_PropertyPlantAndEquipmentByTypeAxis_ComputerSoftwareIntangibleAssetMember" unitRef="U001" decimals="-3">21832000</us-gaap:PropertyPlantAndEquipmentGross>
  <!--Property, Plant and Equipment, Gross-->
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="c20141231" unitRef="U001" decimals="-3">393409000</us-gaap:PropertyPlantAndEquipmentGross>
  <!--Property, Plant and Equipment, Gross-->
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="c20131231" unitRef="U001" decimals="-3">321611000</us-gaap:PropertyPlantAndEquipmentGross>
  <!--Property, Plant and Equipment, Gross-Construction-in-progress [Member]-->
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="c20131231_PropertyPlantAndEquipmentByTypeAxis_ConstructionInProgressMember" unitRef="U001" decimals="-3">98345000</us-gaap:PropertyPlantAndEquipmentGross>
  <!--Property, Plant and Equipment, Gross-Land and improvements [Member]-->
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="c20131231_PropertyPlantAndEquipmentByTypeAxis_LandAndLandImprovementsMember" unitRef="U001" decimals="-3">10605000</us-gaap:PropertyPlantAndEquipmentGross>
  <!--Property, Plant and Equipment, Gross-Furniture and equipment [Member]-->
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="c20131231_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember" unitRef="U001" decimals="-3">107006000</us-gaap:PropertyPlantAndEquipmentGross>
  <!--Property, Plant and Equipment, Gross-Furniture and equipment [Member]-->
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="c20141231_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember" unitRef="U001" decimals="-3">130131000</us-gaap:PropertyPlantAndEquipmentGross>
  <!--Property, Plant and Equipment, Gross-Buildings, building improvements and leasehold improvements [Member]-->
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="c20131231_PropertyPlantAndEquipmentByTypeAxis_BuildingAndBuildingImprovementsMember" unitRef="U001" decimals="-3">83823000</us-gaap:PropertyPlantAndEquipmentGross>
  <!--Property, Plant and Equipment, Gross-Buildings, building improvements and leasehold improvements [Member]-->
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="c20141231_PropertyPlantAndEquipmentByTypeAxis_BuildingAndBuildingImprovementsMember" unitRef="U001" decimals="-3">107202000</us-gaap:PropertyPlantAndEquipmentGross>
  <!--Property, plant and equipment, net-->
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="c20131231" unitRef="U001" decimals="-3">264240000</us-gaap:PropertyPlantAndEquipmentNet>
  <!--Property, plant and equipment, net-->
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="c20141231" unitRef="U001" decimals="-3">313979000</us-gaap:PropertyPlantAndEquipmentNet>
  <!--Property, Plant and Equipment, Estimated Useful Lives-Leasehold Improvements [Member]-->
  <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives contextRef="c20140101to20141231_PropertyPlantAndEquipmentByTypeAxis_LeaseholdsAndLeaseholdImprovementsMember">Lesser of the asset life or lease term</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
  <!--Property, Plant and Equipment, Estimated Useful Lives-Software [Member]-->
  <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives contextRef="c20140101to20141231_PropertyPlantAndEquipmentByTypeAxis_ComputerSoftwareIntangibleAssetMember">Lesser of 3-5 years or product life</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
  <!--Property, Plant and Equipment [Table Text Block]-->
  <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c20140101to20141231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Property, plant and equipment consist of the following:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt; font-weight: bold;"&gt;(in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;2014&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;2013&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Land and improvements&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;12,838&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;10,605&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Buildings, building improvements and leasehold improvements&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;107,202&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;83,823&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Furniture and equipment&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;130,131&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;107,006&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Software&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;25,354&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;21,832&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Construction-in-progress&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;117,884&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;98,345&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 76%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;393,409&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;321,611&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Less: Accumulated depreciation and amortization&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(79,430&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(57,371&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Total property, plant and equipment, net&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;313,979&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;264,240&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
  <!--Property, Plant and Equipment Disclosure [Text Block]-->
  <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c20140101to20141231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;&lt;font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;8.&lt;/font&gt;&lt;font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Property, plant and equipment&lt;/font&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Property, plant and equipment consist of the following:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt; font-weight: bold;"&gt;(in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;2014&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;2013&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Land and improvements&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;12,838&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;10,605&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Buildings, building improvements and leasehold improvements&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;107,202&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;83,823&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Furniture and equipment&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;130,131&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;107,006&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Software&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;25,354&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;21,832&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Construction-in-progress&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;117,884&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;98,345&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 76%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;393,409&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;321,611&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Less: Accumulated depreciation and amortization&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(79,430&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(57,371&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Total property, plant and equipment, net&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;313,979&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;264,240&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;For the years ended December 31, 2014 and 2013, construction-in-progress included costs related to Building 55, the Company's large-scale manufacturing facility, for which the Company is in the process of receiving regulatory approval.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;During the year ended December 31, 2013, the Company recorded an impairment related to idle equipment of $1.2 million. The fair value of the asset group was determined via observable prices for similar equipment along with the estimated prices for scrap (salvage value). The impairment is classified in the Company's statements of operations as selling, general and administrative expense with in the Company's Biodefense segment. The impairment reflects management's assessment of the estimated recoverability of the equipment.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Depreciation and amortization expense was $23.0 million, $17.0 million and $11.2 million for the years ended December 31, 2014, 2013 and 2012, respectively. The increase in depreciation expense as compared to December 31, 2013 was primarily due to the Company's Baltimore facility being placed-in-service in December 2013. As of December 31, 2014, 2013 and 2012 there was no unamortized internal use software-cost.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;For the year ended December 31, 2014, the Company had $2.4 million of capitalized software development costs.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
  <!--Total purchase commitment to Norwood Laboratories Inc.-->
  <us-gaap:PurchaseObligation contextRef="c20141231" unitRef="U001" decimals="0">15200000</us-gaap:PurchaseObligation>
  <!--Quarterly Financial Information [Text Block]-->
  <us-gaap:QuarterlyFinancialInformationTextBlock contextRef="c20140101to20141231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;&lt;font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;22.&lt;/font&gt;&lt;font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Quarterly financial data (unaudited)&lt;/font&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Quarterly financial information for the years ended December 31, 2013 and 2014 is presented in the following tables:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="14" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Three months ended&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt; font-weight: bold;"&gt;(in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;March 31,&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;June 30,&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;September 30,&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Fiscal year 2014&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 14.4pt; font-size: 10pt;"&gt;Revenue&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;53,884&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;110,325&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;137,954&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;147,975&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 14.4pt; font-size: 10pt;"&gt;Income (loss) from operations&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(25,458&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;7,862&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;31,032&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;44,620&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 14.4pt; font-size: 10pt;"&gt;Net income (loss)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(20,236&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;5,029&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;21,832&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;30,116&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 14.4pt; font-size: 10pt;"&gt;Net income (loss) per share, basic&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(0.55&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;0.13&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;0.58&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;0.80&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 14.4pt; font-size: 10pt;"&gt;Net income (loss) per share, diluted&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(0.55&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;0.13&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;0.49&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;0.66&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Fiscal year 2013&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 14.4pt; font-size: 10pt;"&gt;Revenue&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;43,100&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;82,436&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;89,102&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;98,107&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 14.4pt; font-size: 10pt;"&gt;Income (loss) from operations&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(13,350&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;14,712&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;18,147&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;23,293&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 14.4pt; font-size: 10pt;"&gt;Net income (loss)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(8,062&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;10,484&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;13,491&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;15,222&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 14.4pt; font-size: 10pt;"&gt;Net income (loss) per share, basic&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(0.22&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;0.29&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;0.37&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;0.42&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 14.4pt; font-size: 10pt;"&gt;Net income (loss) per share, diluted&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(0.22&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;0.29&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;0.36&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;0.41&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:QuarterlyFinancialInformationTextBlock>
  <!--Related Party Transactions Disclosure [Text Block]-->
  <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c20140101to20141231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;&lt;font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;19.&lt;/font&gt;&lt;font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Related party transactions&lt;/font&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;The Company entered into an agreement in February 2009 with an entity controlled by family members of the Company's Executive Chairman to market and sell BioThrax. The agreement was effective as of November 2008 and requires payment based on a percentage of net sales of biodefense products of 17.5% in Saudi Arabia and 15% in Qatar and United Arab Emirates, and reimbursement of certain expenses. No expenses were incurred under this agreement during 2014, 2013 and 2012.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
  <!--Percentage of net sales of biodefense products subject to payment to related party (in hundredths)-United Arab Emirates [Member]-->
  <us-gaap:RelatedPartyTransactionRate contextRef="c20140101to20141231_StatementGeographicalAxis_AE" unitRef="U005" decimals="2">0.15</us-gaap:RelatedPartyTransactionRate>
  <!--Percentage of net sales of biodefense products subject to payment to related party (in hundredths)-Qatar [Member]-->
  <us-gaap:RelatedPartyTransactionRate contextRef="c20140101to20141231_StatementGeographicalAxis_QA" unitRef="U005" decimals="2">0.15</us-gaap:RelatedPartyTransactionRate>
  <!--Percentage of net sales of biodefense products subject to payment to related party (in hundredths)-Saudi Arabia [Member]-->
  <us-gaap:RelatedPartyTransactionRate contextRef="c20140101to20141231_StatementGeographicalAxis_SA" unitRef="U005" decimals="3">0.175</us-gaap:RelatedPartyTransactionRate>
  <!--Repayments of Long-term Debt-->
  <us-gaap:RepaymentsOfLongTermDebt contextRef="c20130101to20131231" unitRef="U001" decimals="-3">62774000</us-gaap:RepaymentsOfLongTermDebt>
  <!--Repayments of Long-term Debt-->
  <us-gaap:RepaymentsOfLongTermDebt contextRef="c20120101to20121231" unitRef="U001" decimals="-3">10227000</us-gaap:RepaymentsOfLongTermDebt>
  <!--Repayments of Long-term Debt-->
  <us-gaap:RepaymentsOfLongTermDebt contextRef="c20140101to20141231" unitRef="U001" decimals="-3">62000000</us-gaap:RepaymentsOfLongTermDebt>
  <!--Repayments of Long-term Debt-Revolving Credit Loan dated December 2013, due in December 2018 [Member]-->
  <us-gaap:RepaymentsOfLongTermDebt contextRef="c20140101to20141231_LongtermDebtTypeAxis_RevolvingCreditLoanDatedDecember2013DueInDecember2018Member" unitRef="U001" decimals="-5">62000000</us-gaap:RepaymentsOfLongTermDebt>
  <!--Research and development-->
  <us-gaap:ResearchAndDevelopmentExpense contextRef="c20140101to20141231" unitRef="U001" decimals="-3">150829000</us-gaap:ResearchAndDevelopmentExpense>
  <!--Research and development-->
  <us-gaap:ResearchAndDevelopmentExpense contextRef="c20130101to20131231" unitRef="U001" decimals="-3">119933000</us-gaap:ResearchAndDevelopmentExpense>
  <!--Research and development-->
  <us-gaap:ResearchAndDevelopmentExpense contextRef="c20120101to20121231" unitRef="U001" decimals="-3">120226000</us-gaap:ResearchAndDevelopmentExpense>
  <!--Research and development-Biodefense [Member]-->
  <us-gaap:ResearchAndDevelopmentExpense contextRef="c20120101to20121231_StatementBusinessSegmentsAxis_BiodefenseMember" unitRef="U001" decimals="-3">68579000</us-gaap:ResearchAndDevelopmentExpense>
  <!--Research and development-All Other [Member]-->
  <us-gaap:ResearchAndDevelopmentExpense contextRef="c20120101to20121231_StatementBusinessSegmentsAxis_AllOtherSegmentsMember" unitRef="U001" decimals="-3">7059000</us-gaap:ResearchAndDevelopmentExpense>
  <!--Research and development-Biosciences [Member]-->
  <us-gaap:ResearchAndDevelopmentExpense contextRef="c20120101to20121231_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U001" decimals="-3">44588000</us-gaap:ResearchAndDevelopmentExpense>
  <!--Research and development-Biosciences [Member]-->
  <us-gaap:ResearchAndDevelopmentExpense contextRef="c20130101to20131231_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U001" decimals="-3">50652000</us-gaap:ResearchAndDevelopmentExpense>
  <!--Research and development-All Other [Member]-->
  <us-gaap:ResearchAndDevelopmentExpense contextRef="c20130101to20131231_StatementBusinessSegmentsAxis_AllOtherSegmentsMember" unitRef="U001" decimals="-3">6618000</us-gaap:ResearchAndDevelopmentExpense>
  <!--Research and development-Biosciences [Member]-->
  <us-gaap:ResearchAndDevelopmentExpense contextRef="c20140101to20141231_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U001" decimals="-3">60821000</us-gaap:ResearchAndDevelopmentExpense>
  <!--Research and development-All Other [Member]-->
  <us-gaap:ResearchAndDevelopmentExpense contextRef="c20140101to20141231_StatementBusinessSegmentsAxis_AllOtherSegmentsMember" unitRef="U001" decimals="-3">8033000</us-gaap:ResearchAndDevelopmentExpense>
  <!--Research and development-Biodefense [Member]-->
  <us-gaap:ResearchAndDevelopmentExpense contextRef="c20140101to20141231_StatementBusinessSegmentsAxis_BiodefenseMember" unitRef="U001" decimals="-3">81975000</us-gaap:ResearchAndDevelopmentExpense>
  <!--Research and development-Biodefense [Member]-->
  <us-gaap:ResearchAndDevelopmentExpense contextRef="c20130101to20131231_StatementBusinessSegmentsAxis_BiodefenseMember" unitRef="U001" decimals="-3">62663000</us-gaap:ResearchAndDevelopmentExpense>
  <!--Research and Development Expense, Policy [Policy Text Block]-->
  <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c20140101to20141231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Research and development&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Research and development costs are expensed as incurred. Research and development costs primarily consist of salaries and fees paid to outside service providers and the costs of materials used in clinical trials and research and development. Other research and development expenses include fees paid to consultants, materials and related expenses for personnel and facility expenses.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
  <!--Restructuring and Related Cost, Cost Incurred to Date-->
  <us-gaap:RestructuringAndRelatedCostCostIncurredToDate1 contextRef="c20141231" unitRef="U001" decimals="-3">2806000</us-gaap:RestructuringAndRelatedCostCostIncurredToDate1>
  <!--Restructuring and Related Cost, Cost Incurred to Date-Termination benefits [Member]-->
  <us-gaap:RestructuringAndRelatedCostCostIncurredToDate1 contextRef="c20141231_RestructuringCostAndReserveAxis_SpecialTerminationBenefitsMember" unitRef="U001" decimals="-3">2114000</us-gaap:RestructuringAndRelatedCostCostIncurredToDate1>
  <!--Restructuring and Related Cost, Cost Incurred to Date-Contract termination costs [Member]-->
  <us-gaap:RestructuringAndRelatedCostCostIncurredToDate1 contextRef="c20141231_RestructuringCostAndReserveAxis_ContractTerminationMember" unitRef="U001" decimals="-3">431000</us-gaap:RestructuringAndRelatedCostCostIncurredToDate1>
  <!--Restructuring and Related Cost, Cost Incurred to Date-Other costs [Member]-->
  <us-gaap:RestructuringAndRelatedCostCostIncurredToDate1 contextRef="c20141231_RestructuringCostAndReserveAxis_OtherRestructuringMember" unitRef="U001" decimals="-3">261000</us-gaap:RestructuringAndRelatedCostCostIncurredToDate1>
  <!--Restructuring expenses-EPDU Restructuring Plan [Member]-->
  <us-gaap:RestructuringCharges contextRef="c20140101to20141231_RestructuringPlanAxis_EpduRestructuringPlanMember" unitRef="U001" decimals="-3">0</us-gaap:RestructuringCharges>
  <!--Restructuring expenses-->
  <us-gaap:RestructuringCharges contextRef="c20140101to20141231" unitRef="U001" decimals="-3">0</us-gaap:RestructuringCharges>
  <!--Restructuring expenses-Termination benefits [Member]-EPDU Restructuring Plan [Member]-->
  <us-gaap:RestructuringCharges contextRef="c20130101to20131231_RestructuringCostAndReserveAxis_SpecialTerminationBenefitsMember_RestructuringPlanAxis_EpduRestructuringPlanMember" unitRef="U001" decimals="-3">2114000</us-gaap:RestructuringCharges>
  <!--Restructuring expenses-Contract termination costs [Member]-EPDU Restructuring Plan [Member]-->
  <us-gaap:RestructuringCharges contextRef="c20130101to20131231_RestructuringCostAndReserveAxis_ContractTerminationMember_RestructuringPlanAxis_EpduRestructuringPlanMember" unitRef="U001" decimals="-3">431000</us-gaap:RestructuringCharges>
  <!--Restructuring expenses-Termination benefits [Member]-EPDU Restructuring Plan [Member]-->
  <us-gaap:RestructuringCharges contextRef="c20140101to20141231_RestructuringCostAndReserveAxis_SpecialTerminationBenefitsMember_RestructuringPlanAxis_EpduRestructuringPlanMember" unitRef="U001" decimals="-3">0</us-gaap:RestructuringCharges>
  <!--Restructuring expenses-Contract termination costs [Member]-EPDU Restructuring Plan [Member]-->
  <us-gaap:RestructuringCharges contextRef="c20140101to20141231_RestructuringCostAndReserveAxis_ContractTerminationMember_RestructuringPlanAxis_EpduRestructuringPlanMember" unitRef="U001" decimals="-3">0</us-gaap:RestructuringCharges>
  <!--Restructuring expenses-->
  <us-gaap:RestructuringCharges contextRef="c20130101to20131231" unitRef="U001" decimals="-3">2679000</us-gaap:RestructuringCharges>
  <!--Restructuring expenses-EPDU Restructuring Plan [Member]-->
  <us-gaap:RestructuringCharges contextRef="c20130101to20131231_RestructuringPlanAxis_EpduRestructuringPlanMember" unitRef="U001" decimals="-3">134000</us-gaap:RestructuringCharges>
  <!--Headcount reduction-->
  <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated contextRef="c20140101to20141231" unitRef="U009" decimals="INF">14</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated>
  <!--Restructuring Reserve-->
  <us-gaap:RestructuringReserve contextRef="c20121231" unitRef="U001" decimals="-3">0</us-gaap:RestructuringReserve>
  <!--Restructuring Reserve-Contract termination costs [Member]-EPDU Restructuring Plan [Member]-->
  <us-gaap:RestructuringReserve contextRef="c20121231_RestructuringCostAndReserveAxis_ContractTerminationMember_RestructuringPlanAxis_EpduRestructuringPlanMember" unitRef="U001" decimals="-3">0</us-gaap:RestructuringReserve>
  <!--Restructuring Reserve-EPDU Restructuring Plan [Member]-->
  <us-gaap:RestructuringReserve contextRef="c20121231_RestructuringPlanAxis_EpduRestructuringPlanMember" unitRef="U001" decimals="-3">0</us-gaap:RestructuringReserve>
  <!--Restructuring Reserve-Termination benefits [Member]-EPDU Restructuring Plan [Member]-->
  <us-gaap:RestructuringReserve contextRef="c20121231_RestructuringCostAndReserveAxis_SpecialTerminationBenefitsMember_RestructuringPlanAxis_EpduRestructuringPlanMember" unitRef="U001" decimals="-3">0</us-gaap:RestructuringReserve>
  <!--Restructuring Reserve-EPDU Restructuring Plan [Member]-Termination benefits [Member]-->
  <us-gaap:RestructuringReserve contextRef="c20141231_RestructuringCostAndReserveAxis_SpecialTerminationBenefitsMember_RestructuringPlanAxis_EpduRestructuringPlanMember" unitRef="U001" decimals="-3">454000</us-gaap:RestructuringReserve>
  <!--Restructuring Reserve-EPDU Restructuring Plan [Member]-->
  <us-gaap:RestructuringReserve contextRef="c20141231_RestructuringPlanAxis_EpduRestructuringPlanMember" unitRef="U001" decimals="-3">0</us-gaap:RestructuringReserve>
  <!--Restructuring Reserve-EPDU Restructuring Plan [Member]-Contract termination costs [Member]-->
  <us-gaap:RestructuringReserve contextRef="c20141231_RestructuringCostAndReserveAxis_ContractTerminationMember_RestructuringPlanAxis_EpduRestructuringPlanMember" unitRef="U001" decimals="-3">0</us-gaap:RestructuringReserve>
  <!--Restructuring Reserve-->
  <us-gaap:RestructuringReserve contextRef="c20131231" unitRef="U001" decimals="-3">454000</us-gaap:RestructuringReserve>
  <!--Restructuring and Related Activities Disclosure [Text Block]-->
  <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock contextRef="c20140101to20141231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;13. Restructuring&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 27pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;In February 2013, the Company adopted a plan to restructure the operations of Emergent Product Development UK Limited ("EPDU") and OETC due to the results of the Phase 2b clinical trial for the Company's tuberculosis vaccine product candidate. The Company completed this restructuring in 2013.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 27pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;The restructuring plan included a headcount reduction of 14 employees at EPDU, the termination of a facility lease, and the impairment of leasehold improvements and equipment. These costs, which are included in selling, general and administrative expense in the Company's statement of operations and are included within the Biosciences segment, are detailed below:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Incurred during&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;the year ended&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;(in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;December 31, 2013&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Termination benefits&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;2,114&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Contract termination costs&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;431&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Other costs&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;261&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Total&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;2,806&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;The following is a summary of the activity for the liabilities related to the EPDU restructuring:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Contract&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Termination&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Termination &lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Other&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;&lt;font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;(in thousands)&lt;/font&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Benefits&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Costs&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Costs&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Total&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Balance at December 31, 2012&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Expenses incurred&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;2,114&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;431&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;134&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;2,679&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Amount paid&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(1,660&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(431&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(134&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(2,225&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Other adjustments&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Balance at December 31, 2013&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;454&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;454&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Expenses incurred&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Amount paid&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(454&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(454&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Other adjustments&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Balance at December 31, 2014&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
  <!--Other adjustments-Contract termination costs [Member]-EPDU Restructuring Plan [Member]-->
  <us-gaap:RestructuringReserveTranslationAndOtherAdjustment contextRef="c20130101to20131231_RestructuringCostAndReserveAxis_ContractTerminationMember_RestructuringPlanAxis_EpduRestructuringPlanMember" unitRef="U001" decimals="-3">0</us-gaap:RestructuringReserveTranslationAndOtherAdjustment>
  <!--Other adjustments-Termination benefits [Member]-EPDU Restructuring Plan [Member]-->
  <us-gaap:RestructuringReserveTranslationAndOtherAdjustment contextRef="c20130101to20131231_RestructuringCostAndReserveAxis_SpecialTerminationBenefitsMember_RestructuringPlanAxis_EpduRestructuringPlanMember" unitRef="U001" decimals="-3">0</us-gaap:RestructuringReserveTranslationAndOtherAdjustment>
  <!--Other adjustments-Termination benefits [Member]-EPDU Restructuring Plan [Member]-->
  <us-gaap:RestructuringReserveTranslationAndOtherAdjustment contextRef="c20140101to20141231_RestructuringCostAndReserveAxis_SpecialTerminationBenefitsMember_RestructuringPlanAxis_EpduRestructuringPlanMember" unitRef="U001" decimals="-3">0</us-gaap:RestructuringReserveTranslationAndOtherAdjustment>
  <!--Other adjustments-->
  <us-gaap:RestructuringReserveTranslationAndOtherAdjustment contextRef="c20130101to20131231" unitRef="U001" decimals="-3">0</us-gaap:RestructuringReserveTranslationAndOtherAdjustment>
  <!--Other adjustments-Contract termination costs [Member]-EPDU Restructuring Plan [Member]-->
  <us-gaap:RestructuringReserveTranslationAndOtherAdjustment contextRef="c20140101to20141231_RestructuringCostAndReserveAxis_ContractTerminationMember_RestructuringPlanAxis_EpduRestructuringPlanMember" unitRef="U001" decimals="-3">0</us-gaap:RestructuringReserveTranslationAndOtherAdjustment>
  <!--Other adjustments-EPDU Restructuring Plan [Member]-->
  <us-gaap:RestructuringReserveTranslationAndOtherAdjustment contextRef="c20140101to20141231_RestructuringPlanAxis_EpduRestructuringPlanMember" unitRef="U001" decimals="-3">0</us-gaap:RestructuringReserveTranslationAndOtherAdjustment>
  <!--Other adjustments-->
  <us-gaap:RestructuringReserveTranslationAndOtherAdjustment contextRef="c20140101to20141231" unitRef="U001" decimals="-3">0</us-gaap:RestructuringReserveTranslationAndOtherAdjustment>
  <!--Other adjustments-EPDU Restructuring Plan [Member]-->
  <us-gaap:RestructuringReserveTranslationAndOtherAdjustment contextRef="c20130101to20131231_RestructuringPlanAxis_EpduRestructuringPlanMember" unitRef="U001" decimals="-3">0</us-gaap:RestructuringReserveTranslationAndOtherAdjustment>
  <!--Retained earnings-->
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c20141231" unitRef="U001" decimals="-3">288269000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <!--Retained earnings-->
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c20131231" unitRef="U001" decimals="-3">251528000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <!--Revenue recognition-->
  <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="c20140101to20141231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Revenue recognition&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;The Company recognizes revenues from product sales if four basic criteria have been met:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify;"&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td style="width: 36pt;"&gt;&lt;/td&gt;&lt;td style="width: 18pt; font-family: Wingdings; font-size: 10pt; vertical-align: top; align: right;"&gt;&amp;#61607;&lt;/td&gt;&lt;td style="text-align: justify; width: auto; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; vertical-align: top;"&gt;there is persuasive evidence of an arrangement;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align: justify;"&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td style="width: 36pt;"&gt;&lt;/td&gt;&lt;td style="width: 18pt; font-family: Wingdings; font-size: 10pt; vertical-align: top; align: right;"&gt;&amp;#61607;&lt;/td&gt;&lt;td style="text-align: justify; width: auto; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; vertical-align: top;"&gt;delivery has occurred or title has passed to the Company's customer;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align: justify;"&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td style="width: 36pt;"&gt;&lt;/td&gt;&lt;td style="width: 18pt; font-family: Wingdings; font-size: 10pt; vertical-align: top; align: right;"&gt;&amp;#61607;&lt;/td&gt;&lt;td style="text-align: justify; width: auto; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; vertical-align: top;"&gt;the fee is fixed or determinable; and&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align: justify;"&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td style="width: 36pt;"&gt;&lt;/td&gt;&lt;td style="width: 18pt; font-family: Wingdings; font-size: 10pt; vertical-align: top; align: right;"&gt;&amp;#61607;&lt;/td&gt;&lt;td style="text-align: justify; width: auto; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; vertical-align: top;"&gt;collectibility is reasonably assured.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; margin-top: 3pt; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; margin-bottom: 3pt; color: #000000; font-size: 10pt;"&gt;All revenues from product sales are recorded net of applicable allowances for sales rebates, special promotional programs, and discounts. The Company estimates allowances for revenue reducing obligations using a combination of information received from third parties including market data, inventory reports from major wholesalers, historical information and analysis. These estimates are subject to the inherent limitations of estimates that rely on third-party data, as certain third-party information may itself rely on estimates and reflect other limitations. Provisions for estimated rebates and other allowances, such as discounts and promotional and other credits, are estimated based on historical payment experience, historical relationship to revenues, estimated customer inventory levels and contract terms, and actual discounts offered.&lt;/div&gt;&lt;div style="margin-top: 3pt; margin-bottom: 3pt;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; margin-top: 3pt; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; margin-bottom: 3pt; color: #000000; font-size: 10pt;"&gt;The Company markets and sells its Biosciences products through commercial wholesalers (direct customers) who purchase the products at a price referred to as the wholesale acquisition cost ("WAC"). Additionally, the Company enters into agreements with indirect customers for a contracted price that is less than the WAC. The indirect customers, such as group-purchasing organizations, physician practice-management groups and hospitals, purchase the Company's products from the wholesalers. Under these agreements with wholesalers, the Company guarantees to credit the wholeseller for the difference between the WAC and the indirect customers' contracted price. This credit is referred to as a chargeback. Adjustments to the Company's chargeback provisions are made periodically to reflect new facts and circumstances that may indicate that historical experience may not be indicative of current and/or future results. The Company makes subjective judgments primarily based on its evaluation of current market conditions and trade inventory levels related to the Company's products. This evaluation may result in an increase or decrease in the experience rate that is applied to current and future sales, or as an adjustment to past sales, or both&lt;font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Under previous contracts with HHS, the Company invoiced HHS and recognized the related revenues upon delivery of the product to the government carrier, at which time title to the product passed to HHS. Effective September 30, 2011, the Company has a contract from the Centers for Disease Control and Prevention ("CDC"), an operating division of HHS, to supply up to 44.75 million doses of BioThrax over a five year period. Under the Company's contract from the CDC, the Company invoices the CDC and recognizes the related revenue upon acceptance by the government at delivery site, at which time title to the product passes to the CDC. In addition, the Company has generated RSDL sales under its indefinite delivery, indefinite quantity contract with the U.S. government and recognizes revenue upon delivery.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Collaborative research and development agreements can provide for one or more of upfront license fees, research payments, and milestone payments. The Company analyzes its multiple element revenue-generating arrangements to determine whether the elements can be separated and accounted for individually as separate units of accounting. An item can generally be considered a separate unit of accounting if both of the following criteria are met: the delivered item(s) has value to the customer on a stand-alone basis and if the arrangement includes a general right of return and delivery or performance of the undelivered item(s) is considered probable and substantially in the control of the Company. Items that cannot be divided into separate units are combined with other units of accounting, as appropriate. Consideration received is allocated among the separate units based on the unit's relative selling price and is recognized when the appropriate revenue recognition criteria are met. The Company deems services to be rendered if no continuing obligation exists on the part of the Company.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Revenue associated with non-refundable upfront license fees under arrangements where the license fees and research and development activities cannot be accounted for as separate units of accounting is deferred and recognized as revenue either on a straight-line basis over the Company's continued involvement in the research and development process or based on the proportional performance of the Company's expected future obligation under the contract. Revenues from the achievement of research and development milestones, if deemed substantive, are recognized as revenue when the milestones are achieved, and the milestone payments are due and collectible. If not deemed substantive, the Company recognizes such milestone as revenue on a straight-line basis over the remaining expected term of continued involvement in the research and development process.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Milestones are considered substantive if all of the following conditions are met; (1) the milestone is non-refundable; (2) achievement of the milestone was not reasonably assured at the inception of the arrangement; (3) substantive effort is involved to achieve the milestone; and (4) the amount of the milestone appears reasonable in relation to the effort expended. Payments received in advance of work performed are recorded as deferred revenue.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;The Company generates contract and grant revenue from cost-plus-fee contracts. Revenues on reimbursable contracts are recognized as costs are incurred, generally based on allowable costs incurred during the period, plus any recognizable earned fee. The Company considers fixed fees under cost-plus-fee contracts to be earned in proportion to the allowable costs incurred in performance of the contract. The Company analyzes costs for contracts and reimbursable grants to ensure reporting of revenues gross versus net is appropriate. For each of the three years in the period ended December 31, 2014, the costs incurred under the contracts and grants approximated the revenue earned.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Revenue associated with non-refundable upfront license fees that can be treated as a single unit of accounting are recognized when all ongoing obligations have been delivered. Revenue associated with non-refundable upfront license fees under arrangements where the license fees and research and development activities cannot be accounted for as separate units of accounting are deferred and recognized as revenue either on a straight-line basis over the Company's continued involvement in the research and development process or based on the proportional performance of the Company's expected future obligations under the contract. Revenues from the achievement of research and development milestones, if deemed substantive, are recognized as revenue when the milestones are achieved, and the milestone payments are due and collectible. If not deemed substantive, the Company recognizes such milestone as revenue on a straight-line basis over the remaining expected term of continued involvement in the research and development process or based on the proportional performance of the Company's expected future obligations under the contract.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;The Company's contract with the Biomedical Advanced Research and Development Authority ("BARDA") to establish a Center for Innovation in Advanced Development and Manufacturing ("CIADM") is a service arrangement that includes multiple elements. The CIADM contract requires the Company to provide a flexible infrastructure to supply medical countermeasures to the U.S. government over the contract period and includes such items as construction and facility design, workforce development and licensure of a pandemic flu vaccine. Since none of the individual elements by themselves satisfy the purpose of the contract, the Company has concluded that the CIADM contract elements cannot be separated as they do not have stand-alone value to the U.S. government. Therefore, the Company has concluded that there is a single unit of accounting associated with the CIADM contract. The Company recognizes revenue under the CIADM contract on a straight-line basis, based upon its estimate of the total payments to be received under the contract. The Company analyzes the estimated payments to be received on a quarterly basis to determine if an adjustment to revenue is required. Changes in estimates attributed to modifications in the estimate of total payments to be received are recorded prospectively.&lt;/div&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
  <!--Revenues-Biosciences [Member]-->
  <us-gaap:Revenues contextRef="c20120101to20121231_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U001" decimals="-3">5419000</us-gaap:Revenues>
  <!--Revenues-Biosciences [Member]-->
  <us-gaap:Revenues contextRef="c20140101to20141231_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U001" decimals="-3">79591000</us-gaap:Revenues>
  <!--Revenues-Biodefense [Member]-->
  <us-gaap:Revenues contextRef="c20120101to20121231_StatementBusinessSegmentsAxis_BiodefenseMember" unitRef="U001" decimals="-3">276469000</us-gaap:Revenues>
  <!--Revenues-Intersegment Eliminations [Member]-All Other [Member]-->
  <us-gaap:Revenues contextRef="c20130101to20131231_ConsolidationItemsAxis_IntersegmentEliminationMember_StatementBusinessSegmentsAxis_AllOtherSegmentsMember" unitRef="U001" decimals="-3">0</us-gaap:Revenues>
  <!--Revenues-Intersegment Eliminations [Member]-Biodefense [Member]-->
  <us-gaap:Revenues contextRef="c20120101to20121231_ConsolidationItemsAxis_IntersegmentEliminationMember_StatementBusinessSegmentsAxis_BiodefenseMember" unitRef="U001" decimals="-3">0</us-gaap:Revenues>
  <!--Revenues-Intersegment Eliminations [Member]-->
  <us-gaap:Revenues contextRef="c20140101to20141231_ConsolidationItemsAxis_IntersegmentEliminationMember" unitRef="U001" decimals="-3">0</us-gaap:Revenues>
  <!--Revenues-Intersegment Eliminations [Member]-->
  <us-gaap:Revenues contextRef="c20130101to20131231_ConsolidationItemsAxis_IntersegmentEliminationMember" unitRef="U001" decimals="-3">0</us-gaap:Revenues>
  <!--Revenues-All Other [Member]-->
  <us-gaap:Revenues contextRef="c20120101to20121231_StatementBusinessSegmentsAxis_AllOtherSegmentsMember" unitRef="U001" decimals="-3">0</us-gaap:Revenues>
  <!--Revenues-All Other [Member]-->
  <us-gaap:Revenues contextRef="c20140101to20141231_StatementBusinessSegmentsAxis_AllOtherSegmentsMember" unitRef="U001" decimals="-3">0</us-gaap:Revenues>
  <!--Revenues-Intersegment Eliminations [Member]-Biosciences [Member]-->
  <us-gaap:Revenues contextRef="c20140101to20141231_ConsolidationItemsAxis_IntersegmentEliminationMember_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U001" decimals="-3">0</us-gaap:Revenues>
  <!--Revenues-Biosciences [Member]-->
  <us-gaap:Revenues contextRef="c20130101to20131231_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U001" decimals="-3">1181000</us-gaap:Revenues>
  <!--Revenues-Biosciences [Member]-Intersegment Eliminations [Member]-->
  <us-gaap:Revenues contextRef="c20130101to20131231_ConsolidationItemsAxis_IntersegmentEliminationMember_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U001" decimals="-3">0</us-gaap:Revenues>
  <!--Revenues-Intersegment Eliminations [Member]-->
  <us-gaap:Revenues contextRef="c20120101to20121231_ConsolidationItemsAxis_IntersegmentEliminationMember" unitRef="U001" decimals="-3">0</us-gaap:Revenues>
  <!--Revenues-Biodefense [Member]-->
  <us-gaap:Revenues contextRef="c20130101to20131231_StatementBusinessSegmentsAxis_BiodefenseMember" unitRef="U001" decimals="-3">311564000</us-gaap:Revenues>
  <!--Revenues-Biosciences [Member]-Intersegment Eliminations [Member]-->
  <us-gaap:Revenues contextRef="c20120101to20121231_ConsolidationItemsAxis_IntersegmentEliminationMember_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U001" decimals="-3">0</us-gaap:Revenues>
  <!--Revenues-->
  <us-gaap:Revenues contextRef="c20120101to20121231" unitRef="U001" decimals="-3">281888000</us-gaap:Revenues>
  <!--Revenues-->
  <us-gaap:Revenues contextRef="c20130101to20131231" unitRef="U001" decimals="-3">312745000</us-gaap:Revenues>
  <!--Revenues-Intersegment Eliminations [Member]-All Other [Member]-->
  <us-gaap:Revenues contextRef="c20120101to20121231_ConsolidationItemsAxis_IntersegmentEliminationMember_StatementBusinessSegmentsAxis_AllOtherSegmentsMember" unitRef="U001" decimals="-3">0</us-gaap:Revenues>
  <!--Revenues-All Other [Member]-->
  <us-gaap:Revenues contextRef="c20130101to20131231_StatementBusinessSegmentsAxis_AllOtherSegmentsMember" unitRef="U001" decimals="-3">0</us-gaap:Revenues>
  <!--Revenues-->
  <us-gaap:Revenues contextRef="c20140101to20141231" unitRef="U001" decimals="-3">450138000</us-gaap:Revenues>
  <!--Revenues-Intersegment Eliminations [Member]-All Other [Member]-->
  <us-gaap:Revenues contextRef="c20140101to20141231_ConsolidationItemsAxis_IntersegmentEliminationMember_StatementBusinessSegmentsAxis_AllOtherSegmentsMember" unitRef="U001" decimals="-3">0</us-gaap:Revenues>
  <!--Revenues-Biodefense [Member]-Intersegment Eliminations [Member]-->
  <us-gaap:Revenues contextRef="c20140101to20141231_ConsolidationItemsAxis_IntersegmentEliminationMember_StatementBusinessSegmentsAxis_BiodefenseMember" unitRef="U001" decimals="-3">0</us-gaap:Revenues>
  <!--Revenues-Biodefense [Member]-->
  <us-gaap:Revenues contextRef="c20140101to20141231_StatementBusinessSegmentsAxis_BiodefenseMember" unitRef="U001" decimals="-3">370547000</us-gaap:Revenues>
  <!--Revenues-Biodefense [Member]-Intersegment Eliminations [Member]-->
  <us-gaap:Revenues contextRef="c20130101to20131231_ConsolidationItemsAxis_IntersegmentEliminationMember_StatementBusinessSegmentsAxis_BiodefenseMember" unitRef="U001" decimals="-3">0</us-gaap:Revenues>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value-Stock Options [Member]-->
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c20141231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U001" decimals="0">19499871</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
  <!--Expected average life of options-Emergent BioSolutions Inc. 2006 Stock Incentive Plan [Member]-Stock Options [Member]-->
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c20140101to20141231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember">P4Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <!--Expected average life of options-Stock Options [Member]-Emergent BioSolutions Inc. 2006 Stock Incentive Plan [Member]-->
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c20120101to20121231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember">P3Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <!--Expected average life of options-Emergent BioSolutions Inc. 2006 Stock Incentive Plan [Member]-Stock Options [Member]-->
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c20130101to20131231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember">P4Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term-Stock Options [Member]-->
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c20120101to20121231_AwardTypeAxis_EmployeeStockOptionMember">P5Y1M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term-Stock Options [Member]-->
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c20140101to20141231_AwardTypeAxis_EmployeeStockOptionMember">P3Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term-Stock Options [Member]-->
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c20130101to20131231_AwardTypeAxis_EmployeeStockOptionMember">P3Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term-Stock Options [Member]-->
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c20140101to20141231_AwardTypeAxis_EmployeeStockOptionMember">P4Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term-Stock Options [Member]-->
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c20130101to20131231_AwardTypeAxis_EmployeeStockOptionMember">P4Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <!--Product sales-->
  <us-gaap:SalesRevenueGoodsNet contextRef="c20140101to20141231" unitRef="U001" decimals="-3">308345000</us-gaap:SalesRevenueGoodsNet>
  <!--Product sales-->
  <us-gaap:SalesRevenueGoodsNet contextRef="c20130101to20131231" unitRef="U001" decimals="-3">257922000</us-gaap:SalesRevenueGoodsNet>
  <!--Product sales-->
  <us-gaap:SalesRevenueGoodsNet contextRef="c20120101to20121231" unitRef="U001" decimals="-3">215879000</us-gaap:SalesRevenueGoodsNet>
  <!--Revenue-->
  <us-gaap:SalesRevenueNet contextRef="c20130101to20131231" unitRef="U001" decimals="-3">312745000</us-gaap:SalesRevenueNet>
  <!--Revenue-->
  <us-gaap:SalesRevenueNet contextRef="c20140101to20141231" unitRef="U001" decimals="-3">450138000</us-gaap:SalesRevenueNet>
  <!--Revenue-->
  <us-gaap:SalesRevenueNet contextRef="c20120101to20121231" unitRef="U001" decimals="-3">281888000</us-gaap:SalesRevenueNet>
  <!--Revenue-->
  <us-gaap:SalesRevenueNet contextRef="c20141001to20141231" unitRef="U001" decimals="-3">147975000</us-gaap:SalesRevenueNet>
  <!--Revenue-->
  <us-gaap:SalesRevenueNet contextRef="c20130701to20130930" unitRef="U001" decimals="-3">89102000</us-gaap:SalesRevenueNet>
  <!--Revenue-->
  <us-gaap:SalesRevenueNet contextRef="c20130101to20130331" unitRef="U001" decimals="-3">43100000</us-gaap:SalesRevenueNet>
  <!--Revenue-->
  <us-gaap:SalesRevenueNet contextRef="c20140701to20140930" unitRef="U001" decimals="-3">137954000</us-gaap:SalesRevenueNet>
  <!--Revenue-->
  <us-gaap:SalesRevenueNet contextRef="c20140101to20140331" unitRef="U001" decimals="-3">53884000</us-gaap:SalesRevenueNet>
  <!--Revenue-->
  <us-gaap:SalesRevenueNet contextRef="c20140401to20140630" unitRef="U001" decimals="-3">110325000</us-gaap:SalesRevenueNet>
  <!--Revenue-->
  <us-gaap:SalesRevenueNet contextRef="c20131001to20131231" unitRef="U001" decimals="-3">98107000</us-gaap:SalesRevenueNet>
  <!--Revenue-->
  <us-gaap:SalesRevenueNet contextRef="c20130401to20130630" unitRef="U001" decimals="-3">82436000</us-gaap:SalesRevenueNet>
  <!--Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]-Evolva Holding SA 035 [Member]-->
  <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock contextRef="c20140101to20141231_BusinessAcquisitionAxis_EvolvaHoldingSA035Member">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: left; text-indent: 18pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;The table below summarizes the preliminary allocation of the purchase price based upon fair values of assets acquired. As of the date of this filing, the valuation of acquired intangible assets and other fair value adjustments are not complete as the Company is obtaining and analyzing additional information related to the aforementioned items.&amp;#160; As such, the purchase price allocation is subject to change.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;(in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Acquired intangible assets&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;27,700&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Goodwill&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;2,000&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Total purchase price&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;29,700&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
  <!--Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]-Cangene [Member]-->
  <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock contextRef="c20140101to20141231_BusinessAcquisitionAxis_CangeneMember">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; margin-top: 3pt; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; margin-bottom: 3pt; color: #000000; font-size: 10pt;"&gt;The table below summarizes the allocation of the purchase price based upon estimated fair values of assets acquired and liabilities assumed at February 21, 2014.&lt;/div&gt;&lt;div style="margin-top: 3pt; margin-bottom: 3pt;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;(in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Fair value of tangible assets acquired and liabilities assumed:&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Cash&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;43,631&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Accounts receivable&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;19,652&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Inventory (i)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;55,259&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Prepaid expenses and other assets&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;2,375&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Property, plant and equipment&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;40,264&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Deferred taxes, net&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;21,337&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Income tax receivable&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;2,452&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Accounts payable and accrued liabilities&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(22,918&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Provision for chargebacks&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(1,946&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Contingent purchase consideration&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(1,284&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Deferred revenue&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(6,378&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Total fair value of tangible assets acquired and liabilities assumed&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;152,444&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Acquired in-process research and development&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;8,300&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Acquired intangible assets&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;36,200&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Goodwill&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;24,566&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Total purchase price&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;221,510&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top: 3pt; margin-bottom: 3pt;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; margin-top: 3pt; font-family: 'Times New Roman', Times, serif; margin-bottom: 3pt; color: #000000; font-size: 10pt;"&gt;(i) Acquired inventory reflects a $8.8 million adjustment to record inventory at fair value, referred to as a step-up adjustment. The $8.8 million step-up is estimated to be amortized through cost of product sales and contract manufacturing over the next five years based on expected inventory turnover, which will increase cost of product sales and contract manufacturing during such period.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
  <!--Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]-HPPD [Member]-->
  <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock contextRef="c20140101to20141231_BusinessAcquisitionAxis_HppdMember">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;The table below summarizes the allocation of the purchase price based upon fair values of assets acquired and liabilities assumed at August 1, 2013.&amp;#160;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;(in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Acquired intangible assets&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;32,099&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Goodwill&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;9,916&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Acquired equipment&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;1,543&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Other&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;11&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Assumed liabilities&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(1,464&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Total purchase price&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;42,105&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
  <!--Fair Value Hierarchy for Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis-->
  <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="c20140101to20141231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;&amp;#160;&amp;#160;The following table represents the Company's fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="15" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;At December 31, 2014&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;(in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Level 1&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Level 2&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Level 3&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Total&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Assets:&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Investment in money market funds (1)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;111,912&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;111,912&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Total assets&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;111,912&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;111,912&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Liabilities:&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Contingent consideration&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;47,657&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;47,657&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Total liabilities&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;47,657&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;47,657&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="15" valign="bottom" style="border-bottom: #000000 2px solid; background-color: #ffffff; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;At December 31, 2013&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #ffffff; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;(in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; background-color: #cceeff; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Level 1&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #cceeff; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; background-color: #cceeff; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Level 2&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #cceeff; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; background-color: #cceeff; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Level 3&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #cceeff; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; background-color: #cceeff; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Total&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #cceeff; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Assets:&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Investment in money market funds (1)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;37,701&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;37,701&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Total assets&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;37,701&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;37,701&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Liabilities:&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Contingent price consideration&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;16,619&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;16,619&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Total liabilities&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;16,619&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;16,619&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(1) Included in cash and cash equivalents in accompanying consolidated balance sheets.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
  <!--Schedule of Business Acquisitions, by Acquisition [Table Text Block]-HPPD [Member]-->
  <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock contextRef="c20140101to20141231_BusinessAcquisitionAxis_HppdMember">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="background-color: #ffffff;"&gt;&lt;div style="text-align: left; text-indent: 18pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;The total purchase price is summarized below:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;(in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Amount of cash paid to Bracco Diagnostics Inc.&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;25,873&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Fair value of contingent purchase consideration&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;16,232&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Total purchase price&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;42,105&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock>
  <!--Schedule of Business Acquisitions, by Acquisition [Table Text Block]-Evolva Holding SA 035 [Member]-->
  <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock contextRef="c20140101to20141231_BusinessAcquisitionAxis_EvolvaHoldingSA035Member">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="background-color: #ffffff;"&gt;&lt;div style="text-align: left; text-indent: 18pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;The total preliminary purchase price is summarized below:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;(in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Amount of cash paid to Evolva Holdings SA&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;1,500&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Fair value of contingent consideration&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;28,200&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Total purchase price&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;29,700&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock>
  <!--Option award activity-->
  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c20140101to20141231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;The following is a summary of option award activity under the Emergent Plans:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;2006 Plan&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;2004 Plan&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Number of Shares&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Weighted-Average Exercise Price&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Number of Shares&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Weighted-Average Exercise Price&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Aggregate Intrinsic Value&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 40%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -9pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 9pt; font-size: 10pt;"&gt;Outstanding at December 31, 2013&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;3,633,146&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;17.01&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;53,156&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;8.86&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;23,148,738&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 40%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -9.35pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 16.55pt; font-size: 10pt;"&gt;Granted&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;1,125,321&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;27.46&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 40%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -9.35pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 16.55pt; font-size: 10pt;"&gt;Exercised&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(784,811&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;16.72&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(10,000&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;2.74&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 40%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -9.35pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 16.55pt; font-size: 10pt;"&gt;Forfeited&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(135,663&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;19.96&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 40%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -9pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 9pt; font-size: 10pt;"&gt;Outstanding at December 31, 2014&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;3,837,993&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;20.04&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;43,156&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;10.28&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;29,181,534&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 40%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -9pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 9pt; font-size: 10pt;"&gt;Exercisable at December 31, 2014&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;1,993,261&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;17.81&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;43,156&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;10.28&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;19,499,871&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 40%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -9pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 9pt; font-size: 10pt;"&gt;Options expected to vest at December 31, 2014&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;1,158,434&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;21.41&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;7,193,136&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
  <!--Intangible Assets-->
  <us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock contextRef="c20140101to20141231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; margin-top: 3pt; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; margin-bottom: 3pt; color: #000000; font-size: 10pt;"&gt;Intangible assets consist of the following:&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Manufacturing&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Corporate&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Marketed&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Licensed&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Biodefense&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Contract&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;&lt;font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;(in thousands)&lt;/font&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;RSDL&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Agreement&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Tradename&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Products&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Products&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Products&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Manufacturing&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Total&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Cost basis&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 20%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Balance at December 31, 2013&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;28,621&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;3,478&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;32,099&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 20%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Additions&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;2,800&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;8,100&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;3,100&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;16,700&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;5,500&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;36,200&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 20%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Balance at December 31, 2014&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;28,621&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;3,478&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;2,800&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;8,100&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;3,100&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;16,700&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;5,500&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;68,299&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 20%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 20%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Accumulated amortization&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 20%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Balance at December 31, 2013&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(1,468&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(483&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(1,951&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 20%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Amortization&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(3,519&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(1,159&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(478&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(692&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(378&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(1,191&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(587&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(8,004&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 20%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Balance at December 31, 2014&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(4,987&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(1,642&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(478&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(692&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(378&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(1,191&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(587&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(9,955&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 20%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 20%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Net book value at December 31, 2014&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;23,634&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;1,836&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;2,322&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;7,408&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;2,722&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;15,509&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;4,913&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;58,344&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock>
  <!--Assumptions used in valuing stock options granted-->
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c20140101to20141231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;The Company determines the fair value of restricted stock units and stock options using the closing market price of the Company's common stock on the day prior to the date of grant. The Company utilizes the Black-Scholes valuation model for estimating the fair value of all stock options granted. Set forth below are the assumptions used in valuing the stock options granted and a discussion of the Company's methodology for developing each of the assumptions used:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td style="width: 33.85%; vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" style="width: 66.15%; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Year Ended December 31,&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width: 33.85%; vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: #000000 2px solid; width: 5.59%; vertical-align: top;"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: #000000 2px solid; width: 16.46%; vertical-align: top;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;2014&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: #000000 2px solid; width: 5.59%; vertical-align: top;"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: #000000 2px solid; width: 16.46%; vertical-align: top;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;2013&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: #000000 2px solid; width: 5.59%; vertical-align: top;"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: #000000 2px solid; width: 16.46%; vertical-align: top;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;2012&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width: 33.85%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Expected dividend yield&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 5.59%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16.46%; vertical-align: bottom;"&gt;&lt;div style="text-align: right; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;0%&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 5.59%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16.46%; vertical-align: bottom;"&gt;&lt;div style="text-align: right; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;0%&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 5.59%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16.46%; vertical-align: bottom;"&gt;&lt;div style="text-align: right; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;0%&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width: 33.85%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Expected volatility&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 5.59%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16.46%; vertical-align: bottom;"&gt;&lt;div style="text-align: right; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;35-38%&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 5.59%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16.46%; vertical-align: bottom;"&gt;&lt;div style="text-align: right; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;39-49%&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 5.59%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16.46%; vertical-align: bottom;"&gt;&lt;div style="text-align: right; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;41-52%&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width: 33.85%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Risk-free interest rate&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 5.59%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16.46%; vertical-align: bottom;"&gt;&lt;div style="text-align: right; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;1.14-1.65%&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 5.59%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16.46%; vertical-align: bottom;"&gt;&lt;div style="text-align: right; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;0.32-0.70%&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 5.59%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16.46%; vertical-align: bottom;"&gt;&lt;div style="text-align: right; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;0.36-0.54%&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width: 33.85%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Expected average life of options&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 5.59%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16.46%; vertical-align: bottom;"&gt;&lt;div style="text-align: right; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;4.5 years&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 5.59%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16.46%; vertical-align: bottom;"&gt;&lt;div style="text-align: right; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;4.4 years&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 5.59%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16.46%; vertical-align: bottom;"&gt;&lt;div style="text-align: right; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;3.4 years&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <!--Components of the provision for income taxes attributable to operations-->
  <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="c20140101to20141231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Significant components of the provisions for income taxes attributable to operations consist of the following:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="10" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Year ended December 31,&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;(in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;2014&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;2013&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;2012&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Current&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Federal&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;10,412&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(878&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;11,481&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;State&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;479&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(173&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(1,045&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;International&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;112&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;300&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;103&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Total current&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;11,003&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(751&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;10,539&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Deferred&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Federal&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;7,693&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;12,679&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;3,758&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;State&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;128&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;1,028&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(375&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;International&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(2,503&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;152&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Total deferred&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;5,318&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;13,859&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;3,383&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Total provision for income taxes&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;16,321&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;13,108&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;13,922&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
  <!--Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]-->
  <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c20140101to20141231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;The provision for income taxes differs from the amount of taxes determined by applying the U.S. federal statutory rate to loss before provision for income taxes as a result of the following:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="10" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Year ended December 31,&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt; font-weight: bold;"&gt;(in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;2014&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;2013&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;2012&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;US&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;59,764&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;52,749&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;52,391&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;International&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(6,702&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(8,506&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(14,945&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Earnings before taxes on income&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;53,062&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;44,243&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;37,446&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 64%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Federal tax at statutory rates&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;18,572&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;15,485&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;13,106&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;State taxes, net of federal benefit&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;257&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;538&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(2,079&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Impact of foreign operations&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;186&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(1,116&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(3,604&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Change in valuation allowance&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;1,808&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;1,434&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;4,629&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Effect of foreign rates&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(22&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Tax credits&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(7,137&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(5,918&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(2,904&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Other differences&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;124&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(227&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;139&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Permanent differences&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;2,511&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;2,912&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;4,657&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Provision for income taxes&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;16,321&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;13,108&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;13,922&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
  <!--Net deferred tax asset-->
  <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c20140101to20141231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: justify; text-indent: 18pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;The Company's net deferred tax asset (liability) consists of the following:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt; font-weight: bold;"&gt;(in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;2014&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;2013&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Net operating loss carryforward&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;20,530&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;23,256&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Research and development carryforward&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;8,049&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;7,395&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Scientific research and experimental development credit carryforward&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;29,556&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Intangible assets&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;5,689&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;3,300&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Stock compensation&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;8,196&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;6,378&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Foreign deferrals&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;75,511&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;64,090&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Inventory reserves&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;4,122&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Deferred revenue&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;244&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Other&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;7,219&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;1,222&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Deferred tax asset&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;159,116&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;105,641&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Fixed assets&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(34,839&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(32,588&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Intangible assets&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(6,538&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Other&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(10,891&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(5,714&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Deferred tax liability&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(52,268&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(38,302&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Valuation allowance&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(92,374&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(68,846&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Net deferred tax (liabilities)/ asset&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;14,474&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(1,507&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
  <!--Gross unrecognized tax benefits activity-->
  <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock contextRef="c20140101to20141231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;The table below presents the gross unrecognized tax benefits activity for 2014, 2013 and 2012:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt; font-weight: bold;"&gt;(in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Gross unrecognized tax benefits at December 31, 2011&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;1,056&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Increases for tax positions for prior years&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;25&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Decreases for tax positions for prior years&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(65&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Increases for tax positions for current year&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Settlements&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Lapse of statute of limitations&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Gross unrecognized tax benefits at December 31, 2012&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;1,016&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Increases for tax positions for prior years&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;165&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Decreases for tax positions for prior years&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Increases for tax positions for current year&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;15&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Settlements&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Lapse of statute of limitations&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(75&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Gross unrecognized tax benefits at December 31, 2013&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;1,121&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Increases for tax positions for prior years&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;150&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Decreases for tax positions for prior years&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Increases for tax positions for current year&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;102&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Settlements&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Lapse of statute of limitations&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(125&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Gross unrecognized tax benefits at December 31, 2014&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;1,248&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
  <!--Restricted stock units activity-->
  <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock contextRef="c20140101to20141231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;The following is a summary of restricted stock unit award activity under the 2006 Plan:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Number of Shares&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Weighted-Average Grant Price&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Aggregate Intrinsic Value&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Outstanding at December 31, 2013&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;789,951&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;16.53&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;18,246,611&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Granted&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;562,662&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;27.46&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Vested&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(361,010&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;17.79&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Forfeited&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(64,247&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;19.84&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Outstanding at December 31, 2014&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;927,356&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;22.44&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;25,251,904&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
  <!--Future Minimum Lease Payments under Operating Lease Obligations-->
  <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="c20140101to20141231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Future minimum lease payments under operating lease obligations as of December 31, 2014 were as follows:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;(in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;2015&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;2,558&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;2016&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;2,204&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;2017&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;1,950&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;2018&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;1,813&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;2019&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;1,697&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;2020 and beyond&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;904&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Total minimum lease payments&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;11,126&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Minimum lease receipts&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(1,388&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Total minimum lease payments&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$9,738&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
  <!--Quarterly financial information-->
  <us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock contextRef="c20140101to20141231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Quarterly financial information for the years ended December 31, 2013 and 2014 is presented in the following tables:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="14" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Three months ended&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt; font-weight: bold;"&gt;(in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;March 31,&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;June 30,&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;September 30,&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Fiscal year 2014&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 14.4pt; font-size: 10pt;"&gt;Revenue&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;53,884&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;110,325&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;137,954&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;147,975&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 14.4pt; font-size: 10pt;"&gt;Income (loss) from operations&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(25,458&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;7,862&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;31,032&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;44,620&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 14.4pt; font-size: 10pt;"&gt;Net income (loss)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(20,236&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;5,029&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;21,832&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;30,116&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 14.4pt; font-size: 10pt;"&gt;Net income (loss) per share, basic&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(0.55&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;0.13&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;0.58&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;0.80&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 14.4pt; font-size: 10pt;"&gt;Net income (loss) per share, diluted&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(0.55&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;0.13&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;0.49&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;0.66&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Fiscal year 2013&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 14.4pt; font-size: 10pt;"&gt;Revenue&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;43,100&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;82,436&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;89,102&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;98,107&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 14.4pt; font-size: 10pt;"&gt;Income (loss) from operations&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(13,350&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;14,712&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;18,147&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;23,293&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 14.4pt; font-size: 10pt;"&gt;Net income (loss)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(8,062&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;10,484&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;13,491&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;15,222&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 14.4pt; font-size: 10pt;"&gt;Net income (loss) per share, basic&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(0.22&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;0.29&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;0.37&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;0.42&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 14.4pt; font-size: 10pt;"&gt;Net income (loss) per share, diluted&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(0.22&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;0.29&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;0.36&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;0.41&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock>
  <!--Summary of basic and diluted net income per share-->
  <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c20140101to20141231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;The following table presents the calculation of basic and diluted net income per share:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="10" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt; font-weight: bold;"&gt;(in thousands, except share and per share data)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;2014&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;2013&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;2012&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Numerator:&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Net income&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;36,741&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;31,135&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;23,524&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Interest expense applicable to convertible debt, net of tax&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;2,879&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Amortization of debt issuance costs, net of tax&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;735&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Adjusted net income&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;40,355&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;31,135&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;23,524&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 64%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Denominator:&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Weighted-average number of shares&amp;#8212;basic&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;37,344,891&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;36,201,283&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;36,080,495&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Dilutive securities&amp;#8212;equity awards&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;737,391&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;546,273&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;340,167&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Dilutive securities&amp;#8212;convertible debt&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;7,720,525&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Weighted-average number of shares&amp;#8212;diluted&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;45,802,807&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;36,747,556&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;36,420,662&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 64%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Earnings per share-basic&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;0.98&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;0.86&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;0.65&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Earnings per share-diluted&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;0.88&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;0.85&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;0.65&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
  <!--Schedule of Inventory, Current [Table Text Block]-->
  <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="c20140101to20141231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Inventories consist of the following:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt; font-weight: bold;"&gt;(in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;2014&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;2013&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Raw materials and supplies&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;17,375&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;2,656&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Work-in-process&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;33,477&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;9,819&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Finished goods&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;14,822&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;2,168&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Total inventories&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;65,674&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;14,643&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
  <!--Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]-->
  <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c20140101to20141231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Stock-based compensation expense was recorded in the following financial statement line items:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="11" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Years Ended&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="11" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;(in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: top;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;2014&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="3" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: top;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;2013&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="3" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: top;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;2012&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Cost of product sales&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;1,145&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;575&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;513&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Research and development&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;3,606&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;3,283&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;3,451&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;General and administrative&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;8,078&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;7,380&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;7,151&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Total stock-based compensation expense&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;12,829&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;11,238&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;11,115&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
  <!--Schedule of Goodwill [Table Text Block]-->
  <us-gaap:ScheduleOfGoodwillTextBlock contextRef="c20140101to20141231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="margin-top: 3pt; margin-bottom: 3pt;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; margin-top: 3pt; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; margin-bottom: 3pt; color: #000000; font-size: 10pt;"&gt;The following table is a summary of changes in goodwill by reporting unit:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;(in thousands)&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Biosciences therapeutics&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Biosciences contracts manufacturing&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Biodefense therapeutics&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Biodefense medical device(s)&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Total&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Cost Basis&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 40%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Balance at December 31, 2013&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;5,502&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;8,452&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;13,954&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 40%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Additions&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;8,400&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;6,736&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;11,430&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;1,464&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;28,030&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 40%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Balance at December 31, 2014&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;13,902&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;6,736&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;11,430&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;9,916&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;41,984&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 40%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
  <!--Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]-Cangene [Member]-->
  <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock contextRef="c20140101to20141231_BusinessAcquisitionAxis_CangeneMember">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; margin-top: 3pt; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; margin-bottom: 3pt; color: #000000; font-size: 10pt;"&gt;The table below summarizes the preliminary estimated fair value of intangible assets acquired and the estimated amortization periods:&lt;/div&gt;&lt;div style="margin-top: 3pt; margin-bottom: 3pt;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: middle;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="3" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Amortization&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: middle;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" valign="bottom" style="vertical-align: middle;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="3" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Period&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;( in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Amount&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="3" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;in years&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="3" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Corporate Trade Name&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;2,800&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;5.0&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Marketed Products&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;8,100&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;10.0&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Licensed Products&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;3,100&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;7.0&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Biodefense Products&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;16,700&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;12.0&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Contract Manufacturing&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;5,500&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;8.0&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Total identified intangible assets&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;36,200&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; padding-bottom: 4px; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock>
  <!--Segment information-->
  <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="c20140101to20141231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;21. Segment information&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;For financial reporting purposes, the Company reports financial information for two business segments: Biodefense and Biosciences. The Company's two business segments, or divisions, engage in business activities for which discrete financial information is provided to and resources are allocated by the chief operating decision maker. The accounting policies of the reportable segments are the same as those described in the summary of significant accounting policies. The Company's reportable segments are business units that offer different products and product candidates and are managed separately because they manufacture and develop distinct products with different manufacturing and development processes, along with having separate and distinct sales and marketing processes.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;The Biodefense division is a specialty biopharmaceutical business focused on countermeasures that address Chemical, Biological, Radiological, Nuclear and Explosive threats and consists of two business units: vaccines and therapeutics, and medical devices. Revenues in this segment are primarily from sales of the Company's FDA-licensed product, BioThrax&amp;#174; (Anthrax Vaccine Adsorbed), to the U.S. government. The Biosciences division is directed to commercial opportunities and primarily targets hematology/oncology, transplantation and infectious diseases, and consists of three business units: therapeutics, vaccines and contract manufacturing. The "All Other" segment relates to the general operating costs of the Company and includes costs of the centralized services departments, which are not allocated to the other segments, as well as spending on activities that are not classified as Biodefense or Biosciences. The assets in this segment consist primarily of cash. For the years ended December 31, 2014, 2013 and 2012, respectively, the Company had total assets of $242.5 million, $56.7 million and $5.5 million located in foreign jurisdictions.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="margin-top: 8pt; margin-bottom: 10pt;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="14" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Reportable Segments&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;(in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Biodefense&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Biosciences&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;All Other&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Total&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Year Ended December 31, 2014&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;External revenue&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;370,547&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;79,591&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;450,138&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Intersegment revenue (expense)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Research and development&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;81,975&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;60,821&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;8,033&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;150,829&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Interest income&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;62&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;258&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;320&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Interest expense&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(8,240&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(8,240&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Depreciation and amortization&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;17,669&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;5,070&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;267&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;23,006&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Net income (loss)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;96,966&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(51,300&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(8,925&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;36,741&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Intangible assets&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;40,979&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;17,365&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;58,344&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;In-process research and development assets&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;27,700&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;50,100&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;77,800&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Goodwill&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;20,638&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;21,346&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;41,984&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Total assets&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;439,797&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;344,420&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;161,045&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;945,262&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Expenditures for long-lived assets&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;26,736&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;2,444&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;1,493&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;30,673&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Year Ended December 31, 2013&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;External revenue&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;311,564&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;1,181&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;312,745&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Intersegment revenue (expense)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Research and development&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;62,663&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;50,652&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;6,618&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;119,933&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Interest income&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;139&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;139&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Interest expense&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Depreciation and amortization&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;15,584&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;1,238&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;186&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;17,008&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Net income (loss)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;87,289&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(50,925&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(5,229&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;31,135&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Intangible assets&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;30,148&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;30,148&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;In-process research and development assets&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;41,800&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;41,800&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Goodwill&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;8,452&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;5,502&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;13,954&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Total assets&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;331,827&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;98,510&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;196,293&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;626,630&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Expenditures for long-lived assets&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;30,700&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;1,343&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;9,978&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;42,021&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Year Ended December 31, 2012&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;External revenue&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;276,469&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;5,419&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;281,888&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Intersegment revenue (expense)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Research and development&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;68,579&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;44,588&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;7,059&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;120,226&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Interest income&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;134&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;134&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Interest expense&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(6&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(6&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Depreciation and amortization&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;8,951&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;2,147&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;99&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;11,197&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Net income (loss)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;94,865&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(63,928&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(7,413&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;23,524&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;In-process research and development assets&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;41,800&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;41,800&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Goodwill&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;5,502&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;5,502&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Total assets&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;354,010&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;56,148&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;154,072&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;564,230&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Expenditures for long-lived assets&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;52,957&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;810&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;78&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;53,845&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
  <!--Costs of the restructuring-->
  <us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock contextRef="c20140101to20141231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: justify; text-indent: 27pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;The restructuring plan included a headcount reduction of 14 employees at EPDU, the termination of a facility lease, and the impairment of leasehold improvements and equipment. These costs, which are included in selling, general and administrative expense in the Company's statement of operations and are included within the Biosciences segment, are detailed below:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Incurred during&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;the year ended&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;(in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;December 31, 2013&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Termination benefits&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;2,114&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Contract termination costs&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;431&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Other costs&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;261&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Total&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;2,806&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock>
  <!--Summary of the activity for liabilities related to EPDU restructuring-->
  <us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock contextRef="c20140101to20141231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;The following is a summary of the activity for the liabilities related to the EPDU restructuring:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Contract&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Termination&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Termination &lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Other&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;&lt;font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;(in thousands)&lt;/font&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Benefits&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Costs&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Costs&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Total&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Balance at December 31, 2012&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Expenses incurred&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;2,114&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;431&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;134&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;2,679&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Amount paid&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(1,660&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(431&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(134&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(2,225&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Other adjustments&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Balance at December 31, 2013&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;454&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;454&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Expenses incurred&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Amount paid&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(454&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(454&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Other adjustments&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Balance at December 31, 2014&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock>
  <!--Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]-->
  <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock contextRef="c20140101to20141231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Accounts receivable consist of the following:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="7" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt; font-weight: bold;"&gt;(in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;2014&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="3" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;2013&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Billed&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;39,948&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;45,757&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Unbilled&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;18,886&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;14,830&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -7.2pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 7.2pt; font-size: 10pt;"&gt;Total&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;58,834&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;60,587&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
  <!--Segment Reporting Disclosure [Text Block]-->
  <us-gaap:SegmentReportingDisclosureTextBlock contextRef="c20140101to20141231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;21. Segment information&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;For financial reporting purposes, the Company reports financial information for two business segments: Biodefense and Biosciences. The Company's two business segments, or divisions, engage in business activities for which discrete financial information is provided to and resources are allocated by the chief operating decision maker. The accounting policies of the reportable segments are the same as those described in the summary of significant accounting policies. The Company's reportable segments are business units that offer different products and product candidates and are managed separately because they manufacture and develop distinct products with different manufacturing and development processes, along with having separate and distinct sales and marketing processes.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;The Biodefense division is a specialty biopharmaceutical business focused on countermeasures that address Chemical, Biological, Radiological, Nuclear and Explosive threats and consists of two business units: vaccines and therapeutics, and medical devices. Revenues in this segment are primarily from sales of the Company's FDA-licensed product, BioThrax&amp;#174; (Anthrax Vaccine Adsorbed), to the U.S. government. The Biosciences division is directed to commercial opportunities and primarily targets hematology/oncology, transplantation and infectious diseases, and consists of three business units: therapeutics, vaccines and contract manufacturing. The "All Other" segment relates to the general operating costs of the Company and includes costs of the centralized services departments, which are not allocated to the other segments, as well as spending on activities that are not classified as Biodefense or Biosciences. The assets in this segment consist primarily of cash. For the years ended December 31, 2014, 2013 and 2012, respectively, the Company had total assets of $242.5 million, $56.7 million and $5.5 million located in foreign jurisdictions.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="margin-top: 8pt; margin-bottom: 10pt;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="14" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Reportable Segments&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;(in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Biodefense&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Biosciences&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;All Other&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Total&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Year Ended December 31, 2014&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;External revenue&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;370,547&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;79,591&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;450,138&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Intersegment revenue (expense)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Research and development&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;81,975&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;60,821&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;8,033&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;150,829&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Interest income&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;62&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;258&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;320&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Interest expense&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(8,240&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(8,240&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Depreciation and amortization&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;17,669&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;5,070&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;267&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;23,006&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Net income (loss)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;96,966&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(51,300&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(8,925&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;36,741&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Intangible assets&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;40,979&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;17,365&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;58,344&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;In-process research and development assets&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;27,700&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;50,100&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;77,800&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Goodwill&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;20,638&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;21,346&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;41,984&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Total assets&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;439,797&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;344,420&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;161,045&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;945,262&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Expenditures for long-lived assets&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;26,736&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;2,444&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;1,493&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;30,673&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Year Ended December 31, 2013&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;External revenue&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;311,564&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;1,181&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;312,745&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Intersegment revenue (expense)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Research and development&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;62,663&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;50,652&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;6,618&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;119,933&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Interest income&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;139&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;139&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Interest expense&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Depreciation and amortization&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;15,584&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;1,238&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;186&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;17,008&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Net income (loss)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;87,289&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(50,925&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(5,229&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;31,135&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Intangible assets&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;30,148&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;30,148&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;In-process research and development assets&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;41,800&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;41,800&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Goodwill&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;8,452&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;5,502&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;13,954&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Total assets&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;331,827&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;98,510&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;196,293&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;626,630&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Expenditures for long-lived assets&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;30,700&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;1,343&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;9,978&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;42,021&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Year Ended December 31, 2012&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;External revenue&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;276,469&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;5,419&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;281,888&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Intersegment revenue (expense)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Research and development&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;68,579&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;44,588&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;7,059&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;120,226&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Interest income&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;134&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;134&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Interest expense&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(6&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(6&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Depreciation and amortization&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;8,951&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;2,147&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;99&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;11,197&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Net income (loss)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;94,865&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(63,928&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(7,413&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;23,524&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;In-process research and development assets&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;41,800&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;41,800&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Goodwill&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;5,502&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;5,502&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Total assets&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;354,010&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;56,148&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;154,072&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;564,230&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Expenditures for long-lived assets&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;52,957&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;810&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;78&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;53,845&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
  <!--Selling, General and Administrative Expense-->
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c20120101to20121231" unitRef="U001" decimals="-3">76018000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <!--Selling, General and Administrative Expense-->
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c20140101to20141231" unitRef="U001" decimals="-3">122841000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <!--Selling, General and Administrative Expense-->
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c20130101to20131231" unitRef="U001" decimals="-3">87883000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <!--Granted (in shares)-Restricted Stock Units (RSUs) [Member]-Emergent BioSolutions Inc. 2006 Stock Incentive Plan [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="c20140101to20141231_AwardTypeAxis_RestrictedStockUnitsRSUMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember" unitRef="U002" decimals="0">562662</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value-Restricted Stock Units (RSUs) [Member]-Emergent BioSolutions Inc. 2006 Stock Incentive Plan [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="c20140101to20141231_AwardTypeAxis_RestrictedStockUnitsRSUMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember" unitRef="U003" decimals="2">27.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <!--Granted (in dollars per share)-Emergent BioSolutions Inc. 2006 Stock Incentive Plan [Member]-Stock Options [Member]-->
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="c20140101to20141231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember" unitRef="U003" decimals="2">27.46</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <!--Granted (in dollars per share)-Emergent BioSolutions Employee Stock Option Plan [Member]-Stock Options [Member]-->
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="c20140101to20141231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EmergentBiosolutionsEmployeeStockOptionPlanMember" unitRef="U003" decimals="0">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number-Emergent BioSolutions Inc. 2006 Stock Incentive Plan [Member]-Restricted Stock Units (RSUs) [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="c20131231_AwardTypeAxis_RestrictedStockUnitsRSUMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember" unitRef="U002" decimals="0">789951</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number-Emergent BioSolutions Inc. 2006 Stock Incentive Plan [Member]-Restricted Stock Units (RSUs) [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="c20141231_AwardTypeAxis_RestrictedStockUnitsRSUMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember" unitRef="U002" decimals="0">927356</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <!--Stock-based compensation expense-->
  <us-gaap:ShareBasedCompensation contextRef="c20140101to20141231" unitRef="U001" decimals="-3">12829000</us-gaap:ShareBasedCompensation>
  <!--Stock-based compensation expense-->
  <us-gaap:ShareBasedCompensation contextRef="c20120101to20121231" unitRef="U001" decimals="-3">11115000</us-gaap:ShareBasedCompensation>
  <!--Stock-based compensation expense-->
  <us-gaap:ShareBasedCompensation contextRef="c20130101to20131231" unitRef="U001" decimals="-3">11238000</us-gaap:ShareBasedCompensation>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized-Emergent BioSolutions Inc. 2006 Stock Incentive Plan [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized contextRef="c20140101to20141231_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember" unitRef="U002" decimals="0">4000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period-Restricted Stock Units (RSUs) [Member]-Emergent BioSolutions Inc. 2006 Stock Incentive Plan [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="c20140101to20141231_AwardTypeAxis_RestrictedStockUnitsRSUMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember" unitRef="U002" decimals="0">361010</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
  <!--Maximum number of shares that may be granted per year to a single participant (in shares)-Stock Options [Member]-Emergent BioSolutions Inc. 2006 Stock Incentive Plan [Member]-Maximum [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee contextRef="c20140101to20141231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember_RangeAxis_MaximumMember" unitRef="U002" decimals="0">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee>
  <!--Maximum number of shares that may be granted per year to a single participant (in shares)-Employee Stock Purchase Plan [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee contextRef="c20140101to20141231_PlanNameAxis_EmployeeStockPurchasePlanMember" unitRef="U002" decimals="0">800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum-Stock Options [Member]-Emergent BioSolutions Inc. 2006 Stock Incentive Plan [Member]-Maximum [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="c20120101to20121231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember_RangeAxis_MaximumMember" unitRef="U005" decimals="4">0.0054</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum-Stock Options [Member]-Emergent BioSolutions Inc. 2006 Stock Incentive Plan [Member]-Maximum [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="c20140101to20141231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember_RangeAxis_MaximumMember" unitRef="U005" decimals="4">0.0165</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum-Emergent BioSolutions Inc. 2006 Stock Incentive Plan [Member]-Maximum [Member]-Stock Options [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="c20130101to20131231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember_RangeAxis_MaximumMember" unitRef="U005" decimals="3">0.007</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value-Emergent BioSolutions Inc. 2006 Stock Incentive Plan [Member]-Restricted Stock Units (RSUs) [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="c20131231_AwardTypeAxis_RestrictedStockUnitsRSUMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember" unitRef="U003" decimals="2">16.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value-Emergent BioSolutions Inc. 2006 Stock Incentive Plan [Member]-Restricted Stock Units (RSUs) [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="c20141231_AwardTypeAxis_RestrictedStockUnitsRSUMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember" unitRef="U003" decimals="2">22.44</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value-Restricted Stock Units (RSUs) [Member]-Emergent BioSolutions Inc. 2006 Stock Incentive Plan [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue contextRef="c20140101to20141231_AwardTypeAxis_RestrictedStockUnitsRSUMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember" unitRef="U003" decimals="2">19.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period-Restricted Stock Units (RSUs) [Member]-Emergent BioSolutions Inc. 2006 Stock Incentive Plan [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="c20140101to20141231_AwardTypeAxis_RestrictedStockUnitsRSUMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember" unitRef="U002" decimals="0">64247</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Offering Date-Employee Stock Purchase Plan [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate contextRef="c20140101to20141231_PlanNameAxis_EmployeeStockPurchasePlanMember" unitRef="U005" decimals="2">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum-Stock Options [Member]-Emergent BioSolutions Inc. 2006 Stock Incentive Plan [Member]-Minimum [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="c20140101to20141231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember_RangeAxis_MinimumMember" unitRef="U005" decimals="4">0.0114</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum-Stock Options [Member]-Minimum [Member]-Emergent BioSolutions Inc. 2006 Stock Incentive Plan [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="c20130101to20131231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember_RangeAxis_MinimumMember" unitRef="U005" decimals="4">0.0032</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum-Minimum [Member]-Stock Options [Member]-Emergent BioSolutions Inc. 2006 Stock Incentive Plan [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="c20120101to20121231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember_RangeAxis_MinimumMember" unitRef="U005" decimals="4">0.0036</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
  <!--Exercised (in dollars per share)-Emergent BioSolutions Employee Stock Option Plan [Member]-Stock Options [Member]-->
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="c20140101to20141231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EmergentBiosolutionsEmployeeStockOptionPlanMember" unitRef="U003" decimals="2">2.74</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <!--Exercised (in dollars per share)-Emergent BioSolutions Inc. 2006 Stock Incentive Plan [Member]-Stock Options [Member]-->
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="c20140101to20141231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember" unitRef="U003" decimals="2">16.72</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures-Emergent BioSolutions Employee Stock Option Plan [Member]-Stock Options [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="c20140101to20141231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EmergentBiosolutionsEmployeeStockOptionPlanMember" unitRef="U002" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures-Emergent BioSolutions Inc. 2006 Stock Incentive Plan [Member]-Stock Options [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="c20140101to20141231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember" unitRef="U002" decimals="0">1125321</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price-Stock Options [Member]-Emergent BioSolutions Employee Stock Option Plan [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="c20141231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EmergentBiosolutionsEmployeeStockOptionPlanMember" unitRef="U003" decimals="2">10.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price-Emergent BioSolutions Inc. 2006 Stock Incentive Plan [Member]-Stock Options [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="c20141231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember" unitRef="U003" decimals="2">17.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate-Emergent BioSolutions Inc. 2006 Stock Incentive Plan [Member]-Stock Options [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c20140101to20141231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember" unitRef="U005" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate-Stock Options [Member]-Emergent BioSolutions Inc. 2006 Stock Incentive Plan [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c20120101to20121231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember" unitRef="U005" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate-Emergent BioSolutions Inc. 2006 Stock Incentive Plan [Member]-Stock Options [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c20130101to20131231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember" unitRef="U005" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value-Restricted Stock Units (RSUs) [Member]-Emergent BioSolutions Inc. 2006 Stock Incentive Plan [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue contextRef="c20140101to20141231_AwardTypeAxis_RestrictedStockUnitsRSUMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember" unitRef="U003" decimals="2">17.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number-Emergent BioSolutions Employee Stock Option Plan [Member]-Stock Options [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="c20141231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EmergentBiosolutionsEmployeeStockOptionPlanMember" unitRef="U002" decimals="0">43156</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number-Stock Options [Member]-Emergent BioSolutions Inc. 2006 Stock Incentive Plan [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="c20141231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember" unitRef="U002" decimals="0">1993261</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <!--Employee subscription rate (in hundredths)-Employee Stock Purchase Plan [Member]-Maximum [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate contextRef="c20141231_PlanNameAxis_EmployeeStockPurchasePlanMember_RangeAxis_MaximumMember" unitRef="U005" decimals="INF">0.1</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
  <!--Employee subscription rate (in hundredths)-Minimum [Member]-Employee Stock Purchase Plan [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate contextRef="c20141231_PlanNameAxis_EmployeeStockPurchasePlanMember_RangeAxis_MinimumMember" unitRef="U005" decimals="INF">0.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
  <!--Common stock available for future awards (in shares)-Emergent BioSolutions Inc. 2006 Stock Incentive Plan [Member]-Stock Options [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="c20141231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember" unitRef="U002" decimals="0">4461925</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <!--Total intrinsic value of options exercised-Stock Options [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c20130101to20131231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U001" decimals="-5">6900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <!--Total intrinsic value of options exercised-Stock Options [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c20140101to20141231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U001" decimals="-5">7500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <!--Total intrinsic value of options exercised-Stock Options [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c20120101to20121231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U001" decimals="0">589000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <!--Expected volatility (in hundredths)-Minimum [Member]-Stock Options [Member]-Emergent BioSolutions Inc. 2006 Stock Incentive Plan [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c20120101to20121231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember_RangeAxis_MinimumMember" unitRef="U005" decimals="2">0.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <!--Expected volatility (in hundredths)-Stock Options [Member]-Minimum [Member]-Emergent BioSolutions Inc. 2006 Stock Incentive Plan [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c20130101to20131231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember_RangeAxis_MinimumMember" unitRef="U005" decimals="2">0.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <!--Expected volatility (in hundredths)-Stock Options [Member]-Emergent BioSolutions Inc. 2006 Stock Incentive Plan [Member]-Maximum [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c20120101to20121231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember_RangeAxis_MaximumMember" unitRef="U005" decimals="2">0.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <!--Expected volatility (in hundredths)-Emergent BioSolutions Inc. 2006 Stock Incentive Plan [Member]-Maximum [Member]-Stock Options [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c20130101to20131231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember_RangeAxis_MaximumMember" unitRef="U005" decimals="2">0.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <!--Expected volatility (in hundredths)-Stock Options [Member]-Emergent BioSolutions Inc. 2006 Stock Incentive Plan [Member]-Maximum [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c20140101to20141231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember_RangeAxis_MaximumMember" unitRef="U005" decimals="2">0.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <!--Expected volatility (in hundredths)-Stock Options [Member]-Emergent BioSolutions Inc. 2006 Stock Incentive Plan [Member]-Minimum [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c20140101to20141231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember_RangeAxis_MinimumMember" unitRef="U005" decimals="2">0.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <!--Common stock authorized for issuance under the plan (in shares)-Emergent BioSolutions Inc. 2006 Stock Incentive Plan [Member]-Stock Options [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="c20141231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember" unitRef="U002" decimals="0">15178826</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <!--Common stock authorized for issuance under the plan (in shares)-Employee Stock Purchase Plan [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="c20141231_PlanNameAxis_EmployeeStockPurchasePlanMember" unitRef="U002" decimals="-5">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <!--Weighted average grant date fair value of options granted (in dollars per share)-Stock Options [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="c20120101to20121231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U003" decimals="2">5.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <!--Weighted average grant date fair value of options granted (in dollars per share)-Stock Options [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="c20140101to20141231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U003" decimals="2">8.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <!--Forfeited (in dollars per share)-Emergent BioSolutions Inc. 2006 Stock Incentive Plan [Member]-Stock Options [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="c20140101to20141231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember" unitRef="U003" decimals="2">19.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
  <!--Forfeited (in dollars per share)-Emergent BioSolutions Employee Stock Option Plan [Member]-Stock Options [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="c20140101to20141231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EmergentBiosolutionsEmployeeStockOptionPlanMember" unitRef="U003" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period-Emergent BioSolutions Inc. 2006 Stock Incentive Plan [Member]-Stock Options [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="c20140101to20141231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember" unitRef="U002" decimals="0">135663</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period-Emergent BioSolutions Employee Stock Option Plan [Member]-Stock Options [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="c20140101to20141231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EmergentBiosolutionsEmployeeStockOptionPlanMember" unitRef="U002" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price-Emergent BioSolutions Inc. 2006 Stock Incentive Plan [Member]-Stock Options [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c20131231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember" unitRef="U003" decimals="2">17.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price-Emergent BioSolutions Employee Stock Option Plan [Member]-Stock Options [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c20131231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EmergentBiosolutionsEmployeeStockOptionPlanMember" unitRef="U003" decimals="2">8.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price-Stock Options [Member]-Emergent BioSolutions Inc. 2006 Stock Incentive Plan [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c20141231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember" unitRef="U003" decimals="2">20.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price-Emergent BioSolutions Employee Stock Option Plan [Member]-Stock Options [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c20141231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EmergentBiosolutionsEmployeeStockOptionPlanMember" unitRef="U003" decimals="2">10.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <!--Accounting for stock-based compensation-->
  <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c20140101to20141231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Accounting for stock-based compensation&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;The Company has two stock-based employee compensation plans, the Third Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan (the "2006 Plan") and the Emergent BioSolutions Employee Stock Option Plan (the "2004 Plan" and together with the 2006 Plan, the "Emergent Plans"). The Company has granted options to purchase shares of common stock under the Emergent Plans and has granted restricted stock units under the 2006 Plan. The Emergent Plans have both incentive and non-qualified stock option features. The Company no longer grants equity awards under the 2004 Plan.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; margin-top: 3pt; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; margin-bottom: 3pt; color: #000000; font-size: 10pt;"&gt;On May 22, 2014, the Company's shareholders approved an amendment to the 2006 Plan, which increased the number of shares of common stock available for issuance under plan awards by 4,000,000. As part of this amendment, awards of restricted stock units granted after May 22, 2014 are counted against the maximum aggregate number of shares of common stock available for issuance under the 2006 Plan as 2.3 shares of common stock for every one restricted stock unit granted. The maximum number of shares subject to awards that may be granted per year under the 2006 Plan to a single participant is 1,000,000.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;As of December 31, 2014, an aggregate of 15,178,826 shares of common stock were authorized for issuance under the 2006 Plan, of which a total of 4,461,925 shares of common stock remain available for future awards to be made to plan participants. The exercise price of each option must be not less than 100% of the fair market value of the shares underlying such option on the date of grant. Awards granted under the 2006 Plan have a contractual life of no more than 10 years. The terms and conditions of equity awards (such as price, vesting schedule, term and number of shares) under the Emergent Plans are determined by the compensation committee of the Company's board of directors, which administers the Emergent Plans. Each equity award granted under the Emergent Plans vests as specified in the relevant agreement with the award recipient and no option can be exercised after ten years from the date of grant.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;On May 17, 2012, the Company's shareholders approved the 2012 Employee Stock Purchase Plan ("ESPP"), as defined in Section 423 of the Internal Revenue Code of 1986. All employees of the Company are eligible to participate in the ESPP, except those owning 5% or more of the Company's stock. One million shares of common stock have been authorized for issuance under the ESPP. The ESPP has two plan periods: December 1&lt;sup&gt;st&lt;/sup&gt; to May 31&lt;sup&gt;st&lt;/sup&gt; and June 1&lt;sup&gt;st&lt;/sup&gt; to November 30&lt;sup&gt;th&lt;/sup&gt;. Employees are permitted to contribute between 1 % and 10 % of compensation during a plan period. The ESPP allows for employees to purchase shares of the Company's stock at a 15% discount at the end of each plan period based on the share price at that time. The maximum number of shares an employee may purchase during any plan period is 800 shares. The Company utilizes the Black-Scholes valuation model for estimating the fair value of all shares under its ESPP.&lt;font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;The fair value of each ESPP share is estimated at the beginning of each plan period.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;The Company determines the fair value of restricted stock units and stock options using the closing market price of the Company's common stock on the day prior to the date of grant. The Company utilizes the Black-Scholes valuation model for estimating the fair value of all stock options granted. Set forth below are the assumptions used in valuing the stock options granted and a discussion of the Company's methodology for developing each of the assumptions used:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td style="width: 33.85%; vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" style="width: 66.15%; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Year Ended December 31,&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width: 33.85%; vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: #000000 2px solid; width: 5.59%; vertical-align: top;"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: #000000 2px solid; width: 16.46%; vertical-align: top;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;2014&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: #000000 2px solid; width: 5.59%; vertical-align: top;"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: #000000 2px solid; width: 16.46%; vertical-align: top;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;2013&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: #000000 2px solid; width: 5.59%; vertical-align: top;"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: #000000 2px solid; width: 16.46%; vertical-align: top;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;2012&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width: 33.85%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Expected dividend yield&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 5.59%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16.46%; vertical-align: bottom;"&gt;&lt;div style="text-align: right; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;0%&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 5.59%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16.46%; vertical-align: bottom;"&gt;&lt;div style="text-align: right; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;0%&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 5.59%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16.46%; vertical-align: bottom;"&gt;&lt;div style="text-align: right; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;0%&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width: 33.85%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Expected volatility&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 5.59%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16.46%; vertical-align: bottom;"&gt;&lt;div style="text-align: right; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;35-38%&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 5.59%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16.46%; vertical-align: bottom;"&gt;&lt;div style="text-align: right; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;39-49%&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 5.59%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16.46%; vertical-align: bottom;"&gt;&lt;div style="text-align: right; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;41-52%&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width: 33.85%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Risk-free interest rate&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 5.59%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16.46%; vertical-align: bottom;"&gt;&lt;div style="text-align: right; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;1.14-1.65%&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 5.59%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16.46%; vertical-align: bottom;"&gt;&lt;div style="text-align: right; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;0.32-0.70%&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 5.59%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16.46%; vertical-align: bottom;"&gt;&lt;div style="text-align: right; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;0.36-0.54%&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width: 33.85%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Expected average life of options&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 5.59%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16.46%; vertical-align: bottom;"&gt;&lt;div style="text-align: right; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;4.5 years&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 5.59%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16.46%; vertical-align: bottom;"&gt;&lt;div style="text-align: right; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;4.4 years&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 5.59%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16.46%; vertical-align: bottom;"&gt;&lt;div style="text-align: right; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;3.4 years&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify;"&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td style="width: 36pt;"&gt;&lt;/td&gt;&lt;td style="width: 18pt; font-family: Wingdings; font-size: 10pt; vertical-align: top; align: right;"&gt;&amp;#61607;&lt;/td&gt;&lt;td style="text-align: justify; width: auto; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; vertical-align: top;"&gt;Expected dividend yield &amp;#8212; the Company does not pay regular dividends on its common stock and does not anticipate paying any dividends in the foreseeable future.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align: justify;"&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td style="width: 36pt;"&gt;&lt;/td&gt;&lt;td style="width: 18pt; font-family: Wingdings; font-size: 10pt; vertical-align: top; align: right;"&gt;&amp;#61607;&lt;/td&gt;&lt;td style="text-align: justify; width: auto; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; vertical-align: top;"&gt;Expected volatility &amp;#8212; a measure of the amount by which a financial variable, such as share price, has fluctuated (historical volatility) or is expected to fluctuate (implied volatility) during a period. The Company analyzed its own historical volatility to estimate expected volatility over the same period as the expected average life of the options.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align: justify;"&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td style="width: 36pt;"&gt;&lt;/td&gt;&lt;td style="width: 18pt; font-family: Wingdings; font-size: 10pt; vertical-align: top; align: right;"&gt;&amp;#61607;&lt;/td&gt;&lt;td style="text-align: justify; width: auto; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; vertical-align: top;"&gt;Risk-free interest rate &amp;#8212; the range of U.S. Treasury rates with a term that most closely resembles the expected life of the option as of the date on which the option is granted.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align: justify;"&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td style="width: 36pt;"&gt;&lt;/td&gt;&lt;td style="width: 18pt; font-family: Wingdings; font-size: 10pt; vertical-align: top; align: right;"&gt;&amp;#61607;&lt;/td&gt;&lt;td style="text-align: justify; width: auto; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; vertical-align: top;"&gt;Expected average life of options &amp;#8212; the period of time that options granted are expected to remain outstanding, based primarily on the Company's expectation of optionee exercise behavior subsequent to vesting of options.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number-Stock Options [Member]-Emergent BioSolutions Employee Stock Option Plan [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c20131231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EmergentBiosolutionsEmployeeStockOptionPlanMember" unitRef="U002" decimals="0">53156</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number-Emergent BioSolutions Inc. 2006 Stock Incentive Plan [Member]-Stock Options [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c20131231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember" unitRef="U002" decimals="0">3633146</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number-Stock Options [Member]-Emergent BioSolutions Employee Stock Option Plan [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c20141231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EmergentBiosolutionsEmployeeStockOptionPlanMember" unitRef="U002" decimals="0">43156</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number-Emergent BioSolutions Inc. 2006 Stock Incentive Plan [Member]-Stock Options [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c20141231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember" unitRef="U002" decimals="0">3837993</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number-Emergent BioSolutions Employee Stock Option Plan [Member]-Stock Options [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="c20141231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EmergentBiosolutionsEmployeeStockOptionPlanMember" unitRef="U002" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number-Emergent BioSolutions Inc. 2006 Stock Incentive Plan [Member]-Stock Options [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="c20141231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember" unitRef="U002" decimals="0">1158434</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value-Stock Options [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c20131231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U001" decimals="0">23148738</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value-Stock Options [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c20141231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U001" decimals="0">29181534</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price-Stock Options [Member]-Emergent BioSolutions Employee Stock Option Plan [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="c20141231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EmergentBiosolutionsEmployeeStockOptionPlanMember" unitRef="U003" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price-Emergent BioSolutions Inc. 2006 Stock Incentive Plan [Member]-Stock Options [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="c20141231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember" unitRef="U003" decimals="2">21.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value-Stock Options [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="c20141231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U001" decimals="0">7193136</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
  <!--Significant Accounting Policies [Text Block]-->
  <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c20140101to20141231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;&lt;font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2.&lt;/font&gt;&amp;#160;&lt;font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Summary of significant accounting policies&lt;/font&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Basis of presentation and consolidation&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;The accompanying consolidated financial statements include the accounts of Emergent and its wholly-owned and majority-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. For investments in variable interest entities, the Company consolidates when it is determined to be the primary beneficiary.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Use of estimates&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Cash and cash equivalents&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Cash equivalents are highly liquid investments with a maturity of 90 days or less at the date of purchase and consist of time deposits and investments in money market funds with commercial banks and financial institutions. Also, the Company maintains cash balances with financial institutions in excess of insured limits. The Company does not anticipate any losses with such cash balances.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Fair value of measurements&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;The Company measures and records cash equivalents and investment securities considered available-for-sale at fair value in the accompanying financial statements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability, an exit price, in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value include:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify;"&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td style="width: 36pt;"&gt;&lt;/td&gt;&lt;td style="width: 72pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; vertical-align: top; align: right;"&gt;Level 1 &amp;#8212;&lt;/td&gt;&lt;td style="text-align: justify; width: auto; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; vertical-align: top;"&gt;Observable inputs for identical assets or liabilities such as quoted prices in active markets;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align: justify;"&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td style="width: 36pt;"&gt;&lt;/td&gt;&lt;td style="width: 72pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; vertical-align: top; align: right;"&gt;Level 2 &amp;#8212;&lt;/td&gt;&lt;td style="text-align: justify; width: auto; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; vertical-align: top;"&gt;Inputs other than quoted prices in active markets that are either directly or indirectly observable; and&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align: justify;"&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td style="width: 36pt;"&gt;&lt;/td&gt;&lt;td style="width: 72pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; vertical-align: top; align: right;"&gt;Level 3 &amp;#8212;&lt;/td&gt;&lt;td style="text-align: justify; width: auto; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; vertical-align: top;"&gt;Unobservable inputs in which little or no market data exists, which are therefore developed by the Company using estimates and assumptions that reflect those that a market participant would use.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;The carrying amounts of the Company's short-term financial instruments, which include cash and cash equivalents, accounts receivable and accounts payable, approximate their fair values due to their short maturities.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Significant customers and accounts receivable&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;For the years ended December 31, 2014, 2013 and 2012, the Company's primary customer was the U.S. Department of Health and Human Services ("HHS"). For the years ended December 31, 2014, 2013 and 2012, revenues from HHS and HHS agencies comprised 74.3%, 95.5% and 97.9%, respectively, of total revenues and are included in the Company's Biodefense segment. As of December 31, 2014 and 2013, the Company's receivable balances were comprised of 40.4% and 96.2%, respectively, from this customer. The overall decrease in the percentage of receivables attributed to HHS was due to the additional non-U.S. government revenue generating products from the Company's acquisition of Cangene in February 2014. Unbilled accounts receivable, included in accounts receivable, as of December 31, 2014 and 2013 were $18.9 million and $14.8 million, respectively, relates to various service contracts for which work has been performed, though invoicing has not yet occurred. Accounts receivable are stated at invoice amounts and consist primarily of amounts due from the U.S. government and collaborative partners as well as amounts due under reimbursement contracts with other government entities and non-government and philanthropic organizations. If necessary, the Company records a provision for doubtful receivables to allow for any amounts which may be unrecoverable. This provision is based upon an analysis of the Company's prior collection experience, customer creditworthiness and current economic trends. As of December 31, 2014 and 2013, an allowance for doubtful accounts was not recorded as the collection history from the Company's customers indicated that collection was probable.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Concentrations of credit risk&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. The Company places its cash and cash equivalents with high quality financial institutions. Management believes that the financial risks associated with its cash and cash equivalents are minimal. Because accounts receivable consist primarily of amounts due from the U.S. government for product sales and from government agencies under government grants and development contracts, management deems there to be minimal credit risk.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Inventories&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Inventories are stated at the lower of cost or market with cost being determined using a standard cost method, which approximates average cost. Average cost consists primarily of material, labor and manufacturing overhead expenses (including fixed production-overhead costs) and includes the services and products of third party suppliers. The Company analyzes its inventory levels quarterly and writes down, in the applicable period, inventory that has become obsolete, inventory that has a cost basis in excess of its expected net realizable value and inventory in excess of expected customer demand. The Company also writes off, in the applicable period, the costs related to expired inventory.&amp;#160;Costs of purchased inventories are recorded using weighted-average costing. The Company determines normal capacity for each production facility and allocates fixed production-overhead costs on that basis.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Property, plant and equipment&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Property, plant and equipment are stated at cost. Depreciation is computed using the straight-line method over the following estimated useful lives:&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td style="width: 50.01%; vertical-align: top;"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Buildings&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 49.99%; vertical-align: top;"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;31-39 years&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width: 50.01%; vertical-align: top;"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Building improvements&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 49.99%; vertical-align: top;"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;10-39 years&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width: 50.01%; vertical-align: top;"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Furniture and equipment&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 49.99%; vertical-align: top;"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;3-15 years&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width: 50.01%; vertical-align: top;"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Software&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 49.99%; vertical-align: top;"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Lesser of 3-5 years or product life&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width: 50.01%; vertical-align: top;"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Leasehold improvements&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 49.99%; vertical-align: top;"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Lesser of the asset life or lease term&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is credited or charged to operations. Repairs and maintenance costs are expensed as incurred.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Income taxes&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Income taxes are accounted for using the liability method. Deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between financial statement carrying amounts of existing assets and liabilities and their respective tax bases and net operating loss and research and development tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which those temporary differences are expected to be recovered or settled.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;The Company's ability to realize deferred tax assets depends upon future taxable income as well as the limitations discussed below. For financial reporting purposes, a deferred tax asset must be reduced by a valuation allowance if it is more likely than not that some portion or all of the deferred tax assets will not be realized prior to expiration. The Company considers future taxable income and ongoing tax planning strategies in assessing the need for valuation allowances. In general, if the Company determines that it is more likely than not to realize more than the recorded amounts of net deferred tax assets in the future, the Company will reverse all or a portion of the valuation allowance established against its deferred tax assets, resulting in a decrease to the provision for income taxes in the period in which the determination is made. Likewise, if the Company determines that it is not more likely than not to realize all or part of the net deferred tax asset in the future, the Company will establish a valuation allowance against deferred tax assets, with an offsetting increase to the provision for income taxes, in the period in which the determination is made.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Under sections 382 and 383 of the Internal Revenue Code, if an ownership change occurs with respect to a "loss corporation", as defined, there are annual limitations on the amount of net operating losses and deductions that are available. The Company believes the use of net operating losses and research and development tax credits acquired in the Trubion acquisition will not be significantly limited. Due to the acquisition of Microscience in 2005 and the Company's initial public offering, the Company believes the use of the operating losses incurred prior to 2005 will be significantly limited.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Revenue recognition&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;The Company recognizes revenues from product sales if four basic criteria have been met:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify;"&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td style="width: 36pt;"&gt;&lt;/td&gt;&lt;td style="width: 18pt; font-family: Wingdings; font-size: 10pt; vertical-align: top; align: right;"&gt;&amp;#61607;&lt;/td&gt;&lt;td style="text-align: justify; width: auto; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; vertical-align: top;"&gt;there is persuasive evidence of an arrangement;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align: justify;"&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td style="width: 36pt;"&gt;&lt;/td&gt;&lt;td style="width: 18pt; font-family: Wingdings; font-size: 10pt; vertical-align: top; align: right;"&gt;&amp;#61607;&lt;/td&gt;&lt;td style="text-align: justify; width: auto; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; vertical-align: top;"&gt;delivery has occurred or title has passed to the Company's customer;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align: justify;"&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td style="width: 36pt;"&gt;&lt;/td&gt;&lt;td style="width: 18pt; font-family: Wingdings; font-size: 10pt; vertical-align: top; align: right;"&gt;&amp;#61607;&lt;/td&gt;&lt;td style="text-align: justify; width: auto; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; vertical-align: top;"&gt;the fee is fixed or determinable; and&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align: justify;"&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td style="width: 36pt;"&gt;&lt;/td&gt;&lt;td style="width: 18pt; font-family: Wingdings; font-size: 10pt; vertical-align: top; align: right;"&gt;&amp;#61607;&lt;/td&gt;&lt;td style="text-align: justify; width: auto; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; vertical-align: top;"&gt;collectibility is reasonably assured.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; margin-top: 3pt; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; margin-bottom: 3pt; color: #000000; font-size: 10pt;"&gt;All revenues from product sales are recorded net of applicable allowances for sales rebates, special promotional programs, and discounts. The Company estimates allowances for revenue reducing obligations using a combination of information received from third parties including market data, inventory reports from major wholesalers, historical information and analysis. These estimates are subject to the inherent limitations of estimates that rely on third-party data, as certain third-party information may itself rely on estimates and reflect other limitations. Provisions for estimated rebates and other allowances, such as discounts and promotional and other credits, are estimated based on historical payment experience, historical relationship to revenues, estimated customer inventory levels and contract terms, and actual discounts offered.&lt;/div&gt;&lt;div style="margin-top: 3pt; margin-bottom: 3pt;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; margin-top: 3pt; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; margin-bottom: 3pt; color: #000000; font-size: 10pt;"&gt;The Company markets and sells its Biosciences products through commercial wholesalers (direct customers) who purchase the products at a price referred to as the wholesale acquisition cost ("WAC"). Additionally, the Company enters into agreements with indirect customers for a contracted price that is less than the WAC. The indirect customers, such as group-purchasing organizations, physician practice-management groups and hospitals, purchase the Company's products from the wholesalers. Under these agreements with wholesalers, the Company guarantees to credit the wholeseller for the difference between the WAC and the indirect customers' contracted price. This credit is referred to as a chargeback. Adjustments to the Company's chargeback provisions are made periodically to reflect new facts and circumstances that may indicate that historical experience may not be indicative of current and/or future results. The Company makes subjective judgments primarily based on its evaluation of current market conditions and trade inventory levels related to the Company's products. This evaluation may result in an increase or decrease in the experience rate that is applied to current and future sales, or as an adjustment to past sales, or both&lt;font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Under previous contracts with HHS, the Company invoiced HHS and recognized the related revenues upon delivery of the product to the government carrier, at which time title to the product passed to HHS. Effective September 30, 2011, the Company has a contract from the Centers for Disease Control and Prevention ("CDC"), an operating division of HHS, to supply up to 44.75 million doses of BioThrax over a five year period. Under the Company's contract from the CDC, the Company invoices the CDC and recognizes the related revenue upon acceptance by the government at delivery site, at which time title to the product passes to the CDC. In addition, the Company has generated RSDL sales under its indefinite delivery, indefinite quantity contract with the U.S. government and recognizes revenue upon delivery.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Collaborative research and development agreements can provide for one or more of upfront license fees, research payments, and milestone payments. The Company analyzes its multiple element revenue-generating arrangements to determine whether the elements can be separated and accounted for individually as separate units of accounting. An item can generally be considered a separate unit of accounting if both of the following criteria are met: the delivered item(s) has value to the customer on a stand-alone basis and if the arrangement includes a general right of return and delivery or performance of the undelivered item(s) is considered probable and substantially in the control of the Company. Items that cannot be divided into separate units are combined with other units of accounting, as appropriate. Consideration received is allocated among the separate units based on the unit's relative selling price and is recognized when the appropriate revenue recognition criteria are met. The Company deems services to be rendered if no continuing obligation exists on the part of the Company.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Revenue associated with non-refundable upfront license fees under arrangements where the license fees and research and development activities cannot be accounted for as separate units of accounting is deferred and recognized as revenue either on a straight-line basis over the Company's continued involvement in the research and development process or based on the proportional performance of the Company's expected future obligation under the contract. Revenues from the achievement of research and development milestones, if deemed substantive, are recognized as revenue when the milestones are achieved, and the milestone payments are due and collectible. If not deemed substantive, the Company recognizes such milestone as revenue on a straight-line basis over the remaining expected term of continued involvement in the research and development process.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Milestones are considered substantive if all of the following conditions are met; (1) the milestone is non-refundable; (2) achievement of the milestone was not reasonably assured at the inception of the arrangement; (3) substantive effort is involved to achieve the milestone; and (4) the amount of the milestone appears reasonable in relation to the effort expended. Payments received in advance of work performed are recorded as deferred revenue.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;The Company generates contract and grant revenue from cost-plus-fee contracts. Revenues on reimbursable contracts are recognized as costs are incurred, generally based on allowable costs incurred during the period, plus any recognizable earned fee. The Company considers fixed fees under cost-plus-fee contracts to be earned in proportion to the allowable costs incurred in performance of the contract. The Company analyzes costs for contracts and reimbursable grants to ensure reporting of revenues gross versus net is appropriate. For each of the three years in the period ended December 31, 2014, the costs incurred under the contracts and grants approximated the revenue earned.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Revenue associated with non-refundable upfront license fees that can be treated as a single unit of accounting are recognized when all ongoing obligations have been delivered. Revenue associated with non-refundable upfront license fees under arrangements where the license fees and research and development activities cannot be accounted for as separate units of accounting are deferred and recognized as revenue either on a straight-line basis over the Company's continued involvement in the research and development process or based on the proportional performance of the Company's expected future obligations under the contract. Revenues from the achievement of research and development milestones, if deemed substantive, are recognized as revenue when the milestones are achieved, and the milestone payments are due and collectible. If not deemed substantive, the Company recognizes such milestone as revenue on a straight-line basis over the remaining expected term of continued involvement in the research and development process or based on the proportional performance of the Company's expected future obligations under the contract.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;The Company's contract with the Biomedical Advanced Research and Development Authority ("BARDA") to establish a Center for Innovation in Advanced Development and Manufacturing ("CIADM") is a service arrangement that includes multiple elements. The CIADM contract requires the Company to provide a flexible infrastructure to supply medical countermeasures to the U.S. government over the contract period and includes such items as construction and facility design, workforce development and licensure of a pandemic flu vaccine. Since none of the individual elements by themselves satisfy the purpose of the contract, the Company has concluded that the CIADM contract elements cannot be separated as they do not have stand-alone value to the U.S. government. Therefore, the Company has concluded that there is a single unit of accounting associated with the CIADM contract. The Company recognizes revenue under the CIADM contract on a straight-line basis, based upon its estimate of the total payments to be received under the contract. The Company analyzes the estimated payments to be received on a quarterly basis to determine if an adjustment to revenue is required. Changes in estimates attributed to modifications in the estimate of total payments to be received are recorded prospectively.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Mergers and Acquisitions&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;In a business combination, the acquisition method of accounting requires that the assets acquired and liabilities assumed be recorded as of the date of the merger or acquisition at their respective fair values with limited exceptions. Assets acquired and liabilities assumed in a business combination that arise from contingencies are recognized at fair value if fair value can reasonably be estimated. If the acquisition date fair value of an asset acquired or liability assumed that arises from a contingency cannot be determined, the asset or liability is recognized if probable and reasonably estimable; if these criteria are not met, no asset or liability is recognized. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Accordingly, the Company may be required to value assets at fair value measures that do not reflect our intended use of those assets. Any excess of the purchase price (consideration transferred) over the estimated fair values of net assets acquired is recorded as goodwill. Transaction costs and costs to restructure the acquired company are expensed as incurred. The operating results of the acquired business are reflected in our consolidated financial statements after the date of the merger or acquisition. If the Company determines the assets acquired do not meet the definition of a business under the acquisition method of accounting, the transaction will be accounted for as an acquisition of assets rather than a business combination and, therefore, no goodwill will be recorded. The fair values of intangible assets, including acquired in-process research and development, or IPR&amp;amp;D, are determined utilizing information available near the merger or acquisition date based on expectations and assumptions that are deemed reasonable by management. Given the considerable judgment involved in determining fair values, the Company typically obtains assistance from third-party valuation specialists for significant items. Amounts allocated to acquired IPR&amp;amp;D are capitalized and accounted for as indefinite-lived intangible assets. Upon successful completion of each project, the Company will make a separate determination as to the then useful life of the asset and begin amortization. The judgments made in determining estimated fair values assigned to assets acquired and liabilities assumed in a business combination, as well as asset lives, can materially affect the Company's results of operations.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;The fair values of identifiable intangible assets related to currently marketed products and product rights are primarily determined by using an "income approach" through which fair value is estimated based on each asset's discounted projected net cash flows. Our estimates of market participant net cash flows consider historical and projected pricing, margins and expense levels; the performance of competing products where applicable; relevant industry and therapeutic area growth drivers and factors; current and expected trends in technology and product life cycles; the time and investment that will be required to develop products and technologies; the ability to obtain marketing and regulatory approvals; the ability to manufacture and commercialize the products; the extent and timing of potential new product introductions by the Company's competitors; and the life of each asset's underlying patent, if any. The net cash flows are then probability-adjusted where appropriate to consider the uncertainties associated with the underlying assumptions, as well as the risk profile of the net cash flows utilized in the valuation. The probability-adjusted future net cash flows of each product are then discounted to present value utilizing an appropriate discount rate.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;The fair values of identifiable intangible assets related to IPR&amp;amp;D are determined using an income approach, through which fair value is estimated based on each asset's probability-adjusted future net cash flows, which reflect the different stages of development of each product and the associated probability of successful completion. The net cash flows are then discounted to present value using an appropriate discount rate. Indefinite-lived intangible assets are tested for impairment annually or whenever events or changes in circumstances indicate that its carrying amount may not be recoverable.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Goodwill&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;The Company assesses the carrying value of goodwill on an annual basis, or whenever events or changes in circumstances indicate the carrying value of goodwill may not be recoverable,&lt;font style="font-style: italic; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;to determine whether any impairment in this asset may exist and, if so, the extent of such impairment. The provisions of the relevant accounting guidance require that the Company perform a two-step impairment test. In the first step, the Company compares the fair value of its reporting unit to the carrying value of the reporting unit. If the carrying value of the reporting unit exceeds the fair value of the reporting unit, then the second step of the impairment test is performed in order to determine the implied fair value of the reporting unit's goodwill. If the carrying value of the reporting unit's goodwill exceeds its implied fair value, an impairment loss equal to the difference is recognized. The Company calculates the fair value of the reporting unit utilizing the income approach. The income approach utilizes a discounted cash flow model, using a discount rate based on the Company's estimated weighted average cost of capital. The Company also evaluates goodwill for certain reporting units using the qualitative assessment method, which permits companies to qualitatively assess whether it is more-likely-than-not that the fair value of a reporting unit is less than its carrying amount. The Company considers developments in its operations, the industry in which it operates and overall macroeconomic factors that could have affected the fair value of the reporting unit since the date of the most recent quantitative analysis of a reporting unit's fair value.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;The determination of the fair value of a reporting unit is judgmental in nature and involves the use of significant estimates and assumptions. The estimates and assumptions used in calculating fair value include identifying future cash flows, which requires that the Company makes a number of critical legal, economic, market and business assumptions that reflect best estimates as of the testing date. The Company's assumptions and estimates may differ significantly from actual results, or circumstances could change that would cause the Company to conclude that an impairment now exists or that it previously understated the extent of impairment. The Company selected October 1&lt;sup&gt;st&lt;/sup&gt; as its annual impairment test date.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Contingent purchase consideration obligations&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;The Company records contingent purchase obligations at fair value. Obligations are based on sales royalties, primarily for RSDL. The fair value model used to calculate this obligation is based on the income approach (a discounted cash flow model) that has been risk adjusted based on the probability of achievement of net sales.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;The inputs the Company uses for determining the fair value of the contingent purchase consideration are Level 3 fair value measurements. The Company re-evaluates the fair value of the contingent purchase consideration obligation on a quarterly basis. Changes in the fair value can result from adjustments to the discount rates and updates in the assumed timing of or achievement of net sales. Any future increase in the fair value of the contingent purchase consideration obligation is based on an increased likelihood that the underlying net sales will be achieved and the associated payment or payments which will therefore become due and payable. These increases in the fair value of the contingent purchase consideration obligation will result in a charge to cost of product sales in the period in which the increase is determined. Similarly, any future decrease in the fair value of the contingent purchase consideration obligation will result in a reduction in cost of product sales.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Contingent value rights&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;The Company records contingent value right ("CVR") obligations at fair value. Obligations generally become due and payable only upon achievement of certain developmental, regulatory or commercial milestones. The fair value model used for the CVR obligations are based on a discounted cash flow model that has been risk adjusted based on the probability of achievement of the milestones.&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;The Company believes that the inputs it uses for determining the fair value of the CVR obligations are Level 3 fair value measurements. The Company re-evaluates the fair value on a quarterly basis. Changes in the fair value of the CVR obligations can result from adjustments to the discount rates, updates in the assumed timing of achievement of any development milestones or changes in the probability of certain events and changes in the assumed probability associated with approval. Any future increase in the fair value of the CVR obligations, based on an increased likelihood that the underlying milestones will be achieved and the associated payment or payments will therefore become due and payable, will result in a charge to research and development expense in the period in which the increase is determined. Similarly, any future decrease in the fair value of the CVR obligations will result in a reduction in research and development expense.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Impairment of in process research and development and long-lived assets&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;The Company assesses IPR&amp;amp;D assets for impairment on an annual basis or more frequently if indicators of impairment are present. The Company's annual assessment includes a comparison of the fair value of IPR&amp;amp;D assets to existing carrying value, and recognizes an impairment when the carrying value is greater than the determined fair value. The Company believes that the assumptions used in valuing the intangible and IPR&amp;amp;D assets are reasonable and are based upon its best estimate of likely outcomes of sales and clinical development. The underlying assumptions and estimates used to value these assets are subject to change in the future, and actual results may differ significantly from the assumptions and estimates. The Company has selected October 1&lt;sup&gt;st&lt;/sup&gt; as its annual impairment test date for indefinite-lived intangible assets.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;The Company assesses the recoverability of its long-lived assets or asset groups for which an indicator of impairment exists by determining whether the carrying value of such assets can be recovered through undiscounted future operating cash flows. If the Company concludes that the carrying value will not be recovered, the Company measures the amount of such impairment by comparing the fair value to the carrying value of the assets or asset groups.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Research and development&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Research and development costs are expensed as incurred. Research and development costs primarily consist of salaries and fees paid to outside service providers and the costs of materials used in clinical trials and research and development. Other research and development expenses include fees paid to consultants, materials and related expenses for personnel and facility expenses.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Comprehensive income&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Comprehensive income is comprised of net income and other changes in equity that are excluded from net income. The Company includes translation gains and losses incurred when converting its subsidiaries' financial statements from their functional currency to the U.S. dollar in accumulated other comprehensive income.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Foreign currencies&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Except for the Company's Canadian subsidiaries, the local currency is the functional currency for the Company's foreign subsidiaries and, as such, assets and liabilities are translated into U.S. dollars at year-end exchange rates. Income and expense items are translated at average exchange rates during the year. Translation adjustments resulting from this process are charged or credited to other comprehensive income. The Company's Canadian subsidiaries local currency is U.S. dollars due to substantially all the transactions of the subsidiaries being denominated in U.S. dollars.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Capitalized interest&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;The Company capitalizes interest based on the cost of major ongoing capital projects which have not yet been placed in service. For the years ended December 31, 2014, 2013 and 2012, the Company incurred interest of $7.5 million, $2.0 million and $2.2 million, respectively. Of these amounts, the Company capitalized $2.5 million, $2.0 million and $2.2 million, respectively.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Certain risks and uncertainties&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;The Company has derived a majority of all of its revenue from sales of BioThrax under contracts with the U.S. government. The Company's CDC contract does not necessarily increase the likelihood that it will secure future comparable contracts with the U.S. government. The Company expects that a significant portion of the business that it will seek in the near future, in particular for BioThrax, will be under government contracts that present a number of risks that are not typically present in the commercial contracting process. U.S. government contracts for BioThrax are subject to unilateral termination or modification by the government. The Company may fail to achieve significant sales of BioThrax to customers in addition to the U.S. government, which would harm its growth opportunities. The Company may not be able to sustain or increase profitability. The Company may not be able to manufacture BioThrax consistently in accordance with FDA specifications.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Earnings per share&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;The Company calculates basic earnings per share by dividing net income by the weighted average number of shares of common stock outstanding during the period.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;During the year ended December 31, 2014, the Company issued 2.875% Convertible Senior Notes due 2021 (the "Notes"). Due to the issuance, the Company calculates diluted earnings per share using the if-converted method by dividing the adjusted net income by the weighted average number of shares of common stock outstanding during the period. The adjusted net income is adjusted for interest expense and amortization of debt issuance cost, both net of tax, associated with the Notes. The weighted average number of shares-diluted is adjusted for the potential dilutive effect of the exercise of stock options and the vesting of restricted stock units along with the assumption of the conversion of the Notes, at the beginning of the period.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;For the years ended December 31, 2013 and 2012, diluted earnings per share is computed using the treasury method by dividing net income by the weighted average number of shares of common stock outstanding during the period, adjusted for the potential dilutive effect of other securities if such securities were converted or exercised.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Accounting for stock-based compensation&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;The Company has two stock-based employee compensation plans, the Third Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan (the "2006 Plan") and the Emergent BioSolutions Employee Stock Option Plan (the "2004 Plan" and together with the 2006 Plan, the "Emergent Plans"). The Company has granted options to purchase shares of common stock under the Emergent Plans and has granted restricted stock units under the 2006 Plan. The Emergent Plans have both incentive and non-qualified stock option features. The Company no longer grants equity awards under the 2004 Plan.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; margin-top: 3pt; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; margin-bottom: 3pt; color: #000000; font-size: 10pt;"&gt;On May 22, 2014, the Company's shareholders approved an amendment to the 2006 Plan, which increased the number of shares of common stock available for issuance under plan awards by 4,000,000. As part of this amendment, awards of restricted stock units granted after May 22, 2014 are counted against the maximum aggregate number of shares of common stock available for issuance under the 2006 Plan as 2.3 shares of common stock for every one restricted stock unit granted. The maximum number of shares subject to awards that may be granted per year under the 2006 Plan to a single participant is 1,000,000.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;As of December 31, 2014, an aggregate of 15,178,826 shares of common stock were authorized for issuance under the 2006 Plan, of which a total of 4,461,925 shares of common stock remain available for future awards to be made to plan participants. The exercise price of each option must be not less than 100% of the fair market value of the shares underlying such option on the date of grant. Awards granted under the 2006 Plan have a contractual life of no more than 10 years. The terms and conditions of equity awards (such as price, vesting schedule, term and number of shares) under the Emergent Plans are determined by the compensation committee of the Company's board of directors, which administers the Emergent Plans. Each equity award granted under the Emergent Plans vests as specified in the relevant agreement with the award recipient and no option can be exercised after ten years from the date of grant.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;On May 17, 2012, the Company's shareholders approved the 2012 Employee Stock Purchase Plan ("ESPP"), as defined in Section 423 of the Internal Revenue Code of 1986. All employees of the Company are eligible to participate in the ESPP, except those owning 5% or more of the Company's stock. One million shares of common stock have been authorized for issuance under the ESPP. The ESPP has two plan periods: December 1&lt;sup&gt;st&lt;/sup&gt; to May 31&lt;sup&gt;st&lt;/sup&gt; and June 1&lt;sup&gt;st&lt;/sup&gt; to November 30&lt;sup&gt;th&lt;/sup&gt;. Employees are permitted to contribute between 1 % and 10 % of compensation during a plan period. The ESPP allows for employees to purchase shares of the Company's stock at a 15% discount at the end of each plan period based on the share price at that time. The maximum number of shares an employee may purchase during any plan period is 800 shares. The Company utilizes the Black-Scholes valuation model for estimating the fair value of all shares under its ESPP.&lt;font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;The fair value of each ESPP share is estimated at the beginning of each plan period.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;The Company determines the fair value of restricted stock units and stock options using the closing market price of the Company's common stock on the day prior to the date of grant. The Company utilizes the Black-Scholes valuation model for estimating the fair value of all stock options granted. Set forth below are the assumptions used in valuing the stock options granted and a discussion of the Company's methodology for developing each of the assumptions used:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td style="width: 33.85%; vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" style="width: 66.15%; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Year Ended December 31,&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width: 33.85%; vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: #000000 2px solid; width: 5.59%; vertical-align: top;"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: #000000 2px solid; width: 16.46%; vertical-align: top;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;2014&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: #000000 2px solid; width: 5.59%; vertical-align: top;"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: #000000 2px solid; width: 16.46%; vertical-align: top;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;2013&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: #000000 2px solid; width: 5.59%; vertical-align: top;"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: #000000 2px solid; width: 16.46%; vertical-align: top;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;2012&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width: 33.85%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Expected dividend yield&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 5.59%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16.46%; vertical-align: bottom;"&gt;&lt;div style="text-align: right; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;0%&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 5.59%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16.46%; vertical-align: bottom;"&gt;&lt;div style="text-align: right; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;0%&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 5.59%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16.46%; vertical-align: bottom;"&gt;&lt;div style="text-align: right; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;0%&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width: 33.85%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Expected volatility&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 5.59%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16.46%; vertical-align: bottom;"&gt;&lt;div style="text-align: right; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;35-38%&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 5.59%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16.46%; vertical-align: bottom;"&gt;&lt;div style="text-align: right; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;39-49%&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 5.59%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16.46%; vertical-align: bottom;"&gt;&lt;div style="text-align: right; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;41-52%&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width: 33.85%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Risk-free interest rate&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 5.59%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16.46%; vertical-align: bottom;"&gt;&lt;div style="text-align: right; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;1.14-1.65%&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 5.59%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16.46%; vertical-align: bottom;"&gt;&lt;div style="text-align: right; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;0.32-0.70%&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 5.59%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16.46%; vertical-align: bottom;"&gt;&lt;div style="text-align: right; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;0.36-0.54%&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width: 33.85%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Expected average life of options&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 5.59%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16.46%; vertical-align: bottom;"&gt;&lt;div style="text-align: right; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;4.5 years&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 5.59%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16.46%; vertical-align: bottom;"&gt;&lt;div style="text-align: right; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;4.4 years&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 5.59%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16.46%; vertical-align: bottom;"&gt;&lt;div style="text-align: right; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;3.4 years&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify;"&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td style="width: 36pt;"&gt;&lt;/td&gt;&lt;td style="width: 18pt; font-family: Wingdings; font-size: 10pt; vertical-align: top; align: right;"&gt;&amp;#61607;&lt;/td&gt;&lt;td style="text-align: justify; width: auto; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; vertical-align: top;"&gt;Expected dividend yield &amp;#8212; the Company does not pay regular dividends on its common stock and does not anticipate paying any dividends in the foreseeable future.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align: justify;"&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td style="width: 36pt;"&gt;&lt;/td&gt;&lt;td style="width: 18pt; font-family: Wingdings; font-size: 10pt; vertical-align: top; align: right;"&gt;&amp;#61607;&lt;/td&gt;&lt;td style="text-align: justify; width: auto; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; vertical-align: top;"&gt;Expected volatility &amp;#8212; a measure of the amount by which a financial variable, such as share price, has fluctuated (historical volatility) or is expected to fluctuate (implied volatility) during a period. The Company analyzed its own historical volatility to estimate expected volatility over the same period as the expected average life of the options.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align: justify;"&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td style="width: 36pt;"&gt;&lt;/td&gt;&lt;td style="width: 18pt; font-family: Wingdings; font-size: 10pt; vertical-align: top; align: right;"&gt;&amp;#61607;&lt;/td&gt;&lt;td style="text-align: justify; width: auto; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; vertical-align: top;"&gt;Risk-free interest rate &amp;#8212; the range of U.S. Treasury rates with a term that most closely resembles the expected life of the option as of the date on which the option is granted.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align: justify;"&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td style="width: 36pt;"&gt;&lt;/td&gt;&lt;td style="width: 18pt; font-family: Wingdings; font-size: 10pt; vertical-align: top; align: right;"&gt;&amp;#61607;&lt;/td&gt;&lt;td style="text-align: justify; width: auto; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; vertical-align: top;"&gt;Expected average life of options &amp;#8212; the period of time that options granted are expected to remain outstanding, based primarily on the Company's expectation of optionee exercise behavior subsequent to vesting of options.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <!--Stock Repurchase Program, Authorized Amount-Stock Repurchase Plan of 2012 [Member]-->
  <us-gaap:StockRepurchaseProgramAuthorizedAmount1 contextRef="c20141231_ShareRepurchaseProgramAxis_StockRepurchasePlanOf2012Member" unitRef="U001" decimals="-5">35000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
  <!--Stock repurchased as part of stock swap (in shares)-Senior Managment [Member]-->
  <us-gaap:StockRedeemedOrCalledDuringPeriodShares contextRef="c20140101to20141231_RelatedPartyTransactionsByRelatedPartyAxis_ChiefExecutiveOfficerMember" unitRef="U002" xsi:nil="true" />
  <!--Stock repurchased during period, value-Accumulated Other Comprehensive Loss [Member]-->
  <us-gaap:StockRepurchasedDuringPeriodValue contextRef="c20130101to20131231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3">0</us-gaap:StockRepurchasedDuringPeriodValue>
  <!--Stock repurchased during period, value-->
  <us-gaap:StockRepurchasedDuringPeriodValue contextRef="c20120101to20121231" unitRef="U001" decimals="-3">5906000</us-gaap:StockRepurchasedDuringPeriodValue>
  <!--Stock repurchased during period, value-Noncontrolling Interest in Subsidiary [Member]-->
  <us-gaap:StockRepurchasedDuringPeriodValue contextRef="c20140101to20141231_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U001" decimals="-3">0</us-gaap:StockRepurchasedDuringPeriodValue>
  <!--Stock repurchased during period, value-Noncontrolling Interest in Subsidiary [Member]-->
  <us-gaap:StockRepurchasedDuringPeriodValue contextRef="c20120101to20121231_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U001" decimals="-3">0</us-gaap:StockRepurchasedDuringPeriodValue>
  <!--Stock repurchased during period, value-Treasury Stock [Member]-->
  <us-gaap:StockRepurchasedDuringPeriodValue contextRef="c20130101to20131231_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="U001" decimals="-3">213000</us-gaap:StockRepurchasedDuringPeriodValue>
  <!--Stock repurchased during period, value-Accumulated Other Comprehensive Loss [Member]-->
  <us-gaap:StockRepurchasedDuringPeriodValue contextRef="c20120101to20121231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3">0</us-gaap:StockRepurchasedDuringPeriodValue>
  <!--Stock repurchased during period, value-Treasury Stock [Member]-->
  <us-gaap:StockRepurchasedDuringPeriodValue contextRef="c20140101to20141231_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="U001" decimals="-3">201000</us-gaap:StockRepurchasedDuringPeriodValue>
  <!--Stock repurchased during period, value-->
  <us-gaap:StockRepurchasedDuringPeriodValue contextRef="c20140101to20141231" unitRef="U001" decimals="-3">201000</us-gaap:StockRepurchasedDuringPeriodValue>
  <!--Stock repurchased during period, value-Accumulated Other Comprehensive Loss [Member]-->
  <us-gaap:StockRepurchasedDuringPeriodValue contextRef="c20140101to20141231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3">0</us-gaap:StockRepurchasedDuringPeriodValue>
  <!--Stock repurchased during period, value-->
  <us-gaap:StockRepurchasedDuringPeriodValue contextRef="c20130101to20131231" unitRef="U001" decimals="-3">213000</us-gaap:StockRepurchasedDuringPeriodValue>
  <!--Stock repurchased during period, value-Treasury Stock [Member]-->
  <us-gaap:StockRepurchasedDuringPeriodValue contextRef="c20120101to20121231_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="U001" decimals="-3">5906000</us-gaap:StockRepurchasedDuringPeriodValue>
  <!--Stock repurchased during period, value-Noncontrolling Interest in Subsidiary [Member]-->
  <us-gaap:StockRepurchasedDuringPeriodValue contextRef="c20130101to20131231_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U001" decimals="-3">0</us-gaap:StockRepurchasedDuringPeriodValue>
  <!--Stock repurchased during period, value-Stock Repurchase Plan of 2012 [Member]-->
  <us-gaap:StockRepurchasedDuringPeriodValue contextRef="c20140101to20141231_ShareRepurchaseProgramAxis_StockRepurchasePlanOf2012Member" unitRef="U001" decimals="-5">5800000</us-gaap:StockRepurchasedDuringPeriodValue>
  <!--Employee equity award plans activity (in shares)-Common Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="c20140101to20141231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0">1092876</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
  <!--Employee equity award plans activity (in shares)-Common Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="c20130101to20131231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0">764446</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
  <!--Employee equity award plans activity (in shares)-Common Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="c20120101to20121231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0">269852</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period-Emergent BioSolutions Employee Stock Option Plan [Member]-Stock Options [Member]-->
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c20140101to20141231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EmergentBiosolutionsEmployeeStockOptionPlanMember" unitRef="U002" decimals="0">10000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period-Emergent BioSolutions Inc. 2006 Stock Incentive Plan [Member]-Stock Options [Member]-->
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c20140101to20141231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember" unitRef="U002" decimals="0">784811</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <!--Employee equity award plans activity-Retained Earnings [Member]-->
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c20130101to20131231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <!--Employee equity award plans activity-Noncontrolling Interest in Subsidiary [Member]-->
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c20140101to20141231_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U001" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <!--Employee equity award plans activity-Retained Earnings [Member]-->
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c20120101to20121231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <!--Employee equity award plans activity-->
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c20120101to20121231" unitRef="U001" decimals="-3">10310000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <!--Employee equity award plans activity-Additional Paid-in Capital [Member]-->
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c20140101to20141231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3">26585000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <!--Employee equity award plans activity-Additional Paid-in Capital [Member]-->
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c20120101to20121231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3">10310000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <!--Employee equity award plans activity-Accumulated Other Comprehensive Loss [Member]-->
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c20120101to20121231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <!--Employee equity award plans activity-->
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c20130101to20131231" unitRef="U001" decimals="-3">16674000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <!--Employee equity award plans activity-Additional Paid-in Capital [Member]-->
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c20130101to20131231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3">16673000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <!--Employee equity award plans activity-Common Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c20120101to20121231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <!--Employee equity award plans activity-Accumulated Other Comprehensive Loss [Member]-->
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c20140101to20141231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <!--Employee equity award plans activity-Accumulated Other Comprehensive Loss [Member]-->
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c20130101to20131231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <!--Employee equity award plans activity-Common Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c20140101to20141231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3">1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <!--Employee equity award plans activity-Noncontrolling Interest in Subsidiary [Member]-->
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c20120101to20121231_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U001" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <!--Employee equity award plans activity-Retained Earnings [Member]-->
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c20140101to20141231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <!--Employee equity award plans activity-Noncontrolling Interest in Subsidiary [Member]-->
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c20130101to20131231_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U001" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <!--Employee equity award plans activity-->
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c20140101to20141231" unitRef="U001" decimals="-3">26586000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <!--Employee equity award plans activity-Common Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c20130101to20131231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3">1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <!--Stock repurchased during period (in shares)-Treasury Stock [Member]-->
  <us-gaap:StockRepurchasedDuringPeriodShares contextRef="c20140101to20141231_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="U002" decimals="0">7236</us-gaap:StockRepurchasedDuringPeriodShares>
  <!--Stock repurchased during period (in shares)-Treasury Stock [Member]-->
  <us-gaap:StockRepurchasedDuringPeriodShares contextRef="c20120101to20121231_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="U002" decimals="0">403158</us-gaap:StockRepurchasedDuringPeriodShares>
  <!--Stock repurchased during period (in shares)-Treasury Stock [Member]-->
  <us-gaap:StockRepurchasedDuringPeriodShares contextRef="c20130101to20131231_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="U002" decimals="0">9795</us-gaap:StockRepurchasedDuringPeriodShares>
  <!--Stock repurchased during period (in shares)-Stock Repurchase Plan of 2012 [Member]-->
  <us-gaap:StockRepurchasedDuringPeriodShares contextRef="c20140101to20141231_ShareRepurchaseProgramAxis_StockRepurchasePlanOf2012Member" unitRef="U002" decimals="0">398481</us-gaap:StockRepurchasedDuringPeriodShares>
  <!--Stockholders' Equity Attributable to Parent-->
  <us-gaap:StockholdersEquity contextRef="c20141231" unitRef="U001" decimals="-3">553201000</us-gaap:StockholdersEquity>
  <!--Stockholders' Equity Attributable to Parent-->
  <us-gaap:StockholdersEquity contextRef="c20131231" unitRef="U001" decimals="-3">489618000</us-gaap:StockholdersEquity>
  <!--Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest-->
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c20141231" unitRef="U001" decimals="-3">553201000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <!--Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest-->
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c20131231" unitRef="U001" decimals="-3">489165000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <!--Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest-->
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c20111231" unitRef="U001" decimals="-3">416727000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <!--Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest-Noncontrolling Interest in Subsidiary [Member]-->
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c20111231_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U001" decimals="-3">2481000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <!--Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest-Retained Earnings [Member]-->
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c20111231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3">196869000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <!--Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest-Accumulated Other Comprehensive Loss [Member]-->
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c20111231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3">-3313000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <!--Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest-Additional Paid-in Capital [Member]-->
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c20111231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3">220654000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <!--Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest-Treasury Stock [Member]-->
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c20111231_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="U001" decimals="-3">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <!--Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest-Common Stock [Member]-->
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c20111231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3">36000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <!--Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest-Accumulated Other Comprehensive Loss [Member]-->
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c20131231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3">-3465000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <!--Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest-Additional Paid-in Capital [Member]-->
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c20141231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3">274222000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <!--Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest-->
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c20121231" unitRef="U001" decimals="-3">442128000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <!--Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest-Common Stock [Member]-->
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c20131231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3">37000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <!--Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest-Treasury Stock [Member]-->
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c20121231_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="U001" decimals="-3">-5906000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <!--Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest-Retained Earnings [Member]-->
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c20141231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3">288269000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <!--Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest-Additional Paid-in Capital [Member]-->
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c20131231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3">247637000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <!--Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest-Retained Earnings [Member]-->
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c20131231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3">251528000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <!--Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest-Accumulated Other Comprehensive Loss [Member]-->
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c20141231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3">-3008000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <!--Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest-Treasury Stock [Member]-->
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c20131231_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="U001" decimals="-3">-6119000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <!--Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest-Common Stock [Member]-->
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c20141231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3">38000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <!--Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest-Treasury Stock [Member]-->
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c20141231_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="U001" decimals="-3">-6320000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <!--Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest-Additional Paid-in Capital [Member]-->
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c20121231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3">230964000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <!--Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest-Retained Earnings [Member]-->
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c20121231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3">220393000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <!--Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest-Noncontrolling Interest in Subsidiary [Member]-->
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c20131231_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U001" decimals="-3">-453000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <!--Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest-Noncontrolling Interest in Subsidiary [Member]-->
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c20121231_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U001" decimals="-3">770000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <!--Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest-Accumulated Other Comprehensive Loss [Member]-->
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c20121231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3">-4129000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <!--Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest-Noncontrolling Interest in Subsidiary [Member]-->
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c20141231_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U001" decimals="-3">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <!--Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest-Common Stock [Member]-->
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c20121231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3">36000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <!--Stockholders' equity-->
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c20140101to20141231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;&lt;font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;11.&lt;/font&gt;&lt;font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Stockholders' equity&lt;/font&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Preferred stock&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;The Company is authorized to issue up to 15,000,000 shares of preferred stock, $0.001 par value per share ("Preferred Stock"). Any Preferred Stock issued may have dividend rights, voting rights, conversion privileges, redemption characteristics, and sinking fund requirements as approved by the Company's board of directors.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Common stock&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;The Company currently has one class of common stock, $0.001 par value per share common stock ("Common Stock"), authorized and outstanding. The Company is authorized to issue up to 100,000,000 shares of Common Stock. Holders of Common Stock are entitled to one vote for each share of Common Stock held on all matters, except as may be provided by law.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Treasury stock&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;On May 17, 2012, the Company's Board of Directors authorized the repurchase of up to $35.0 million of its common stock through a share repurchase program. The Company repurchased 398,481 shares for $5.8 million during the year ended December 31, 2012. There were no repurchases under the plan during the year ended December 31, 2013. The repurchase program was terminated on December 31, 2013.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Stock options and restricted stock units&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;The following is a summary of option award activity under the Emergent Plans:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;2006 Plan&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;2004 Plan&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Number of Shares&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Weighted-Average Exercise Price&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Number of Shares&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Weighted-Average Exercise Price&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Aggregate Intrinsic Value&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 40%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -9pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 9pt; font-size: 10pt;"&gt;Outstanding at December 31, 2013&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;3,633,146&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;17.01&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;53,156&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;8.86&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;23,148,738&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 40%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -9.35pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 16.55pt; font-size: 10pt;"&gt;Granted&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;1,125,321&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;27.46&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 40%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -9.35pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 16.55pt; font-size: 10pt;"&gt;Exercised&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(784,811&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;16.72&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(10,000&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;2.74&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 40%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -9.35pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 16.55pt; font-size: 10pt;"&gt;Forfeited&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(135,663&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;19.96&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 40%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -9pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 9pt; font-size: 10pt;"&gt;Outstanding at December 31, 2014&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;3,837,993&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;20.04&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;43,156&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;10.28&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;29,181,534&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 40%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -9pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 9pt; font-size: 10pt;"&gt;Exercisable at December 31, 2014&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;1,993,261&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;17.81&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;43,156&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;10.28&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;19,499,871&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 40%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -9pt; font-family: 'Times New Roman', Times, serif; color: #000000; margin-left: 9pt; font-size: 10pt;"&gt;Options expected to vest at December 31, 2014&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;1,158,434&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;21.41&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;7,193,136&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;The following is a summary of restricted stock unit award activity under the 2006 Plan:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Number of Shares&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Weighted-Average Grant Price&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Aggregate Intrinsic Value&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Outstanding at December 31, 2013&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;789,951&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;16.53&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;18,246,611&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Granted&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;562,662&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;27.46&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Vested&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(361,010&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;17.79&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Forfeited&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;(64,247&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;19.84&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Outstanding at December 31, 2014&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;927,356&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;22.44&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;25,251,904&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;The weighted average remaining contractual term of options outstanding as of December 31, 2014 and 2013 was 4.0 and 4.1 years, respectively. The weighted average remaining contractual term of options exercisable as of December 31, 2014 and 2013 was 3.2 and 3.4&amp;#160; years, respectively.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 27pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;The weighted average grant date fair value of options granted during the years ended December 31, 2014, 2013 and 2012 was $8.84, $5.38 and $5.16 respectively. The total intrinsic value of options exercised during the years ended December 31, 2014, 2013 and 2012 was $7.5 million, $6.9 million and $589,000, respectively. The total fair value of awards vested during 2014, 2013 and 2012 was $12.3 million, $9.1 million and $10.3 million, respectively.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Stock-based compensation expense was recorded in the following financial statement line items:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="11" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Years Ended&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="11" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;(in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: top;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;2014&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="3" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: top;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;2013&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="3" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: top;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;2012&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Cost of product sales&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;1,145&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;575&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;513&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Research and development&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;3,606&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;3,283&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;3,451&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;General and administrative&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;8,078&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;7,380&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;7,151&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Total stock-based compensation expense&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;12,829&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;11,238&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;11,115&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <!--Subsequent events [Text Block]-->
  <us-gaap:SubsequentEventsTextBlock contextRef="c20140101to20141231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;&lt;font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;23.&lt;/font&gt;&lt;font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Subsequent events&lt;/font&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Beginning on January 28, 2015, during standard quality inspections performed in accordance with customary procedures, the Company discovered foreign particles in a limited number of vials in two manufactured lots of BioThrax. In order to determine the source of the foreign particles, the Company has been investigating its operations as well as those of its suppliers and contract manufacturers. Under the Company's quality standards, these two BioThrax lots will be rejected. Currently, there is no evidence that any other BioThrax lots have been affected, but as a precautionary measure, the Company has quarantined 13 additional lots in inventory pending the findings of its investigation. It is the Company's goal to complete this investigation within the next 60 days. Consequently, no BioThrax deliveries will be made in the first quarter. Based upon current information and depending on the disposition of the quarantined lots, the impact on previously forecasted 2015 BioThrax revenues is anticipated to be between $0 and $65 million. Additionally, the cost of inventory for which there is a reasonable possibility of loss is estimated to be approximately $2 million to $15 million. Since the investigation is ongoing and the full scope of the issue has not been determined with certainty, the actual impact may be greater than anticipated.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
  <!--Tax Credit Carryforward, Expiration Date-EBS_CanadianFederalScientificResearchAndExperimentalDevelopment [Member]-->
  <us-gaap:TaxCreditCarryforwardExpirationDate contextRef="c20140101to20141231_TaxCreditCarryforwardAxis_EBSCanadianFederalScientificResearchAndDevelopmentMember">2032-12-31</us-gaap:TaxCreditCarryforwardExpirationDate>
  <!--Tax Credit Carryforward, Expiration Date-Research and Development Tax Credit [Member]-->
  <us-gaap:TaxCreditCarryforwardExpirationDate contextRef="c20140101to20141231_TaxCreditCarryforwardAxis_ResearchMember">2023-12-31</us-gaap:TaxCreditCarryforwardExpirationDate>
  <!--Tax Credit Carryforward, Expiration Date-EBS_ManitobaScientificResearchAndExperimentalDevelopment [Member]-->
  <us-gaap:TaxCreditCarryforwardExpirationDate contextRef="c20140101to20141231_TaxCreditCarryforwardAxis_EBSManitobaScientificResearchAndExperimentalDevelopmentMember">2019-12-31</us-gaap:TaxCreditCarryforwardExpirationDate>
  <!--Tax credit carryforward, amount-EBS_ManitobaScientificResearchAndExperimentalDevelopment [Member]-->
  <us-gaap:TaxCreditCarryforwardAmount contextRef="c20141231_TaxCreditCarryforwardAxis_EBSManitobaScientificResearchAndExperimentalDevelopmentMember" unitRef="U001" decimals="-5">22900000</us-gaap:TaxCreditCarryforwardAmount>
  <!--Tax credit carryforward, amount-EBS_CanadianFederalScientificResearchAndExperimentalDevelopment [Member]-->
  <us-gaap:TaxCreditCarryforwardAmount contextRef="c20141231_TaxCreditCarryforwardAxis_EBSCanadianFederalScientificResearchAndDevelopmentMember" unitRef="U001" decimals="-5">9300000</us-gaap:TaxCreditCarryforwardAmount>
  <!--Tax credit carryforward, amount-Research and Development Tax Credit [Member]-->
  <us-gaap:TaxCreditCarryforwardAmount contextRef="c20141231_TaxCreditCarryforwardAxis_ResearchMember" unitRef="U001" decimals="-5">8100000</us-gaap:TaxCreditCarryforwardAmount>
  <!--Treasury stock ( in shares)-->
  <us-gaap:TreasuryStockShares contextRef="c20131231" unitRef="U002" decimals="0">412953</us-gaap:TreasuryStockShares>
  <!--Treasury stock ( in shares)-->
  <us-gaap:TreasuryStockShares contextRef="c20141231" unitRef="U002" decimals="0">420189</us-gaap:TreasuryStockShares>
  <!--Treasury Stock, Value-->
  <us-gaap:TreasuryStockValue contextRef="c20131231" unitRef="U001" decimals="-3">6119000</us-gaap:TreasuryStockValue>
  <!--Treasury Stock, Value-->
  <us-gaap:TreasuryStockValue contextRef="c20141231" unitRef="U001" decimals="-3">6320000</us-gaap:TreasuryStockValue>
  <!--Increases for tax positions for current year-->
  <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c20140101to20141231" unitRef="U001" decimals="-3">102000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
  <!--Increases for tax positions for current year-->
  <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c20120101to20121231" unitRef="U001" decimals="-3">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
  <!--Increases for tax positions for current year-->
  <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c20130101to20131231" unitRef="U001" decimals="-3">15000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
  <!--Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions-->
  <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="c20120101to20121231" unitRef="U001" decimals="-3">65000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
  <!--Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions-->
  <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="c20140101to20141231" unitRef="U001" decimals="-3">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
  <!--Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions-->
  <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="c20130101to20131231" unitRef="U001" decimals="-3">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
  <!--Lapse of statute of limitations-->
  <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations contextRef="c20130101to20131231" unitRef="U001" decimals="-3">-75000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
  <!--Lapse of statute of limitations-->
  <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations contextRef="c20140101to20141231" unitRef="U001" decimals="-3">-125000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
  <!--Lapse of statute of limitations-->
  <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations contextRef="c20120101to20121231" unitRef="U001" decimals="-3">0</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
  <!--Unrecognized Tax Benefits-->
  <us-gaap:UnrecognizedTaxBenefits contextRef="c20111231" unitRef="U001" decimals="-3">1056000</us-gaap:UnrecognizedTaxBenefits>
  <!--Unrecognized Tax Benefits-->
  <us-gaap:UnrecognizedTaxBenefits contextRef="c20121231" unitRef="U001" decimals="-3">1016000</us-gaap:UnrecognizedTaxBenefits>
  <!--Unrecognized Tax Benefits-->
  <us-gaap:UnrecognizedTaxBenefits contextRef="c20141231" unitRef="U001" decimals="-3">1248000</us-gaap:UnrecognizedTaxBenefits>
  <!--Unrecognized Tax Benefits-->
  <us-gaap:UnrecognizedTaxBenefits contextRef="c20131231" unitRef="U001" decimals="-3">1121000</us-gaap:UnrecognizedTaxBenefits>
  <!--Unrecognized Tax Benefits, Increase Resulting from Settlements with Taxing Authorities-->
  <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities contextRef="c20130101to20131231" unitRef="U001" decimals="-3">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities>
  <!--Unrecognized Tax Benefits, Increase Resulting from Settlements with Taxing Authorities-->
  <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities contextRef="c20120101to20121231" unitRef="U001" decimals="-3">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities>
  <!--Unrecognized Tax Benefits, Increase Resulting from Settlements with Taxing Authorities-->
  <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities contextRef="c20140101to20141231" unitRef="U001" decimals="-3">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities>
  <!--Increases for tax positions for prior years-->
  <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="c20130101to20131231" unitRef="U001" decimals="-3">165000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
  <!--Increases for tax positions for prior years-->
  <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="c20140101to20141231" unitRef="U001" decimals="-3">150000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
  <!--Increases for tax positions for prior years-->
  <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="c20120101to20121231" unitRef="U001" decimals="-3">25000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
  <!--Accrued interest and penalties related to unrecognized tax benefits-->
  <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued contextRef="c20131231" unitRef="U001" decimals="0">15000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
  <!--Accrued interest and penalties related to unrecognized tax benefits-->
  <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued contextRef="c20141231" unitRef="U001" decimals="0">26000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
  <!--Use of estimates-->
  <us-gaap:UseOfEstimates contextRef="c20140101to20141231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Use of estimates&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
  <!--Weighted-average number of shares - basic (in shares)-->
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c20120101to20121231" unitRef="U002" decimals="0">36080495</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <!--Weighted-average number of shares - basic (in shares)-->
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c20130101to20131231" unitRef="U002" decimals="0">36201283</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <!--Weighted-average number of shares - basic (in shares)-->
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c20140101to20141231" unitRef="U002" decimals="0">37344891</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <!--Weighted-average number of shares - diluted (in shares)-->
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c20130101to20131231" unitRef="U002" decimals="0">36747556</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <!--Weighted-average number of shares - diluted (in shares)-->
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c20120101to20121231" unitRef="U002" decimals="0">36420662</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <!--Weighted-average number of shares - diluted (in shares)-->
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c20140101to20141231" unitRef="U002" decimals="0">45802807</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <!--EBS_NorwoodLaboratoriesPurchase-->
  <ebs:EBSNorwoodLaboratoriesPurchaseCommitment contextRef="c20140101to20141231" unitRef="U001" decimals="-5">1500000</ebs:EBSNorwoodLaboratoriesPurchaseCommitment>
  <!--Second contingent payment received based upon development and regulatory milestones-Morphosys [Member]-->
  <ebs:SecondContingentPaymentReceivedBasedUponDevelopmentAndRegulatoryMilestones contextRef="c20140101to20141231_TypeOfArrangementAxis_MorphosysMember" unitRef="U001" decimals="-5">83000000</ebs:SecondContingentPaymentReceivedBasedUponDevelopmentAndRegulatoryMilestones>
  <!--Allocation of non refundable proceeds to undelivered items unit-Morphosys [Member]-->
  <ebs:AllocationOfNonRefundableProceedsToUndeliveredItemsUnit contextRef="c20140101to20141231_TypeOfArrangementAxis_MorphosysMember" unitRef="U001" decimals="-5">4700000</ebs:AllocationOfNonRefundableProceedsToUndeliveredItemsUnit>
  <!--First contingent payment received based upon development and regulatory milestones-Morphosys [Member]-->
  <ebs:FirstContingentPaymentBasedUponDevelopmentAndRegulatoryMilestones contextRef="c20140101to20141231_TypeOfArrangementAxis_MorphosysMember" unitRef="U001" decimals="-5">80000000</ebs:FirstContingentPaymentBasedUponDevelopmentAndRegulatoryMilestones>
  <!--Maximum funding requirement cap-Morphosys [Member]-->
  <ebs:MaximumFundingRequirementCap contextRef="c20140101to20141231_TypeOfArrangementAxis_MorphosysMember" unitRef="U001" decimals="-6">186000000</ebs:MaximumFundingRequirementCap>
  <!--Reduction of research and development expense-Morphosys [Member]-->
  <ebs:ReductionOfResearchAndDevelopmentExpense contextRef="c20140101to20141231_TypeOfArrangementAxis_MorphosysMember" unitRef="U001" decimals="-3">1509000</ebs:ReductionOfResearchAndDevelopmentExpense>
  <!--Present value factor used for estimating selling price of License-Morphosys [Member]-->
  <ebs:PresentValueFactorUsedForEstimatingSellingPriceOfLicense contextRef="c20140101to20141231_TypeOfArrangementAxis_MorphosysMember" unitRef="U005" decimals="INF">0.12</ebs:PresentValueFactorUsedForEstimatingSellingPriceOfLicense>
  <!--Number of units of accounting-Morphosys [Member]-->
  <ebs:NumberOfUnitsOfAccounting contextRef="c20140101to20141231_TypeOfArrangementAxis_MorphosysMember" unitRef="U008" decimals="INF">2</ebs:NumberOfUnitsOfAccounting>
  <!--Non refundable receipt-Morphosys [Member]-->
  <ebs:NonRefundableReceipt contextRef="c20140101to20141231_TypeOfArrangementAxis_MorphosysMember" unitRef="U001" decimals="-6">20000000</ebs:NonRefundableReceipt>
  <!--Allocation of non refundable proceeds to units of accounting-Morphosys [Member]-->
  <ebs:AllocationOfNonRefundableProceedsToUnitsOfAccounting contextRef="c20140101to20141231_TypeOfArrangementAxis_MorphosysMember" unitRef="U001" decimals="-5">20000000</ebs:AllocationOfNonRefundableProceedsToUnitsOfAccounting>
  <!--Additional contingent payment-Morphosys [Member]-->
  <ebs:AdditionalContingentPayment contextRef="c20140101to20141231_TypeOfArrangementAxis_MorphosysMember" unitRef="U001" decimals="-6">163000000</ebs:AdditionalContingentPayment>
  <!--Tiered royalty obligation specified as percentage-Morphosys [Member]-->
  <ebs:TieredRoyaltyObligationSpecifiedAsPercentage contextRef="c20140101to20141231_TypeOfArrangementAxis_MorphosysMember" unitRef="U005" decimals="1">0.2</ebs:TieredRoyaltyObligationSpecifiedAsPercentage>
  <!--Allocation of non refundable proceeds to License unit-Morphosys [Member]-->
  <ebs:AllocationOfNonRefundableProceedsToLicenseUnit contextRef="c20140101to20141231_TypeOfArrangementAxis_MorphosysMember" unitRef="U001" decimals="-5">15300000</ebs:AllocationOfNonRefundableProceedsToLicenseUnit>
  <!--Contingent value rights based on the regulatory filing milestones-Evolva Holding SA 035 [Member]-->
  <ebs:ContingentValueRightsBasedOnTheRegulatoryFilingMilestones contextRef="c20141217_BusinessAcquisitionAxis_EvolvaHoldingSA035Member" unitRef="U001" decimals="-5">50000000</ebs:ContingentValueRightsBasedOnTheRegulatoryFilingMilestones>
  <!--Contingent value rights based on the achievement of certain development-Evolva Holding SA 035 [Member]-->
  <ebs:ContingentValueRightsBasedOnTheAchievementOfCertainDevelopment contextRef="c20141217_BusinessAcquisitionAxis_EvolvaHoldingSA035Member" unitRef="U001" decimals="-5">15000000</ebs:ContingentValueRightsBasedOnTheAchievementOfCertainDevelopment>
  <!--Contingent value rights based on the novation of the contract-Evolva Holding SA 035 [Member]-->
  <ebs:ContingentValueRightsBasedOnTheNovationOfTheContract contextRef="c20141217_BusinessAcquisitionAxis_EvolvaHoldingSA035Member" unitRef="U001" decimals="-5">4000000</ebs:ContingentValueRightsBasedOnTheNovationOfTheContract>
  <!--Research and Development Contract Costs-Evolva Holding SA 035 [Member]-->
  <ebs:ResearchAndDevelopmentContractCosts contextRef="c20141217_BusinessAcquisitionAxis_EvolvaHoldingSA035Member" unitRef="U001" decimals="-6">15000000</ebs:ResearchAndDevelopmentContractCosts>
  <!--Amortization period of step up adjustment-Cangene [Member]-->
  <ebs:AmortizationPeriodOfStepUpAdjustment contextRef="c20140101to20141231_BusinessAcquisitionAxis_CangeneMember">P5Y</ebs:AmortizationPeriodOfStepUpAdjustment>
  <!--Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, In-process research and development-Cangene [Member]-->
  <ebs:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment contextRef="c20140221_BusinessAcquisitionAxis_CangeneMember" unitRef="U001" decimals="-3">8300000</ebs:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment>
  <!--Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Income tax receivable-Cangene [Member]-->
  <ebs:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncomeTaxReceivable contextRef="c20140221_BusinessAcquisitionAxis_CangeneMember" unitRef="U001" decimals="-3">2452000</ebs:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncomeTaxReceivable>
  <!--Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Provision for Chargebacks-Cangene [Member]-->
  <ebs:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesProvisionForChargebacks contextRef="c20140221_BusinessAcquisitionAxis_CangeneMember" unitRef="U001" decimals="-3">1946000</ebs:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesProvisionForChargebacks>
  <!--Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Royalty Provision-Cangene [Member]-->
  <ebs:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesRoyaltyProvision contextRef="c20140221_BusinessAcquisitionAxis_CangeneMember" unitRef="U001" decimals="-3">1284000</ebs:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesRoyaltyProvision>
  <!--us-gaap_ Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Accrued Liabilities-Cangene [Member]-->
  <ebs:UsGaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAccruedLiabilities contextRef="c20140221_BusinessAcquisitionAxis_CangeneMember" unitRef="U001" decimals="-3">22918000</ebs:UsGaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAccruedLiabilities>
  <!--Contingent Consideration Percentage Of Net Sales-HPPD [Member]-Maximum [Member]-->
  <ebs:ContingentConsiderationPercentageOfNetSales contextRef="c20130801_BusinessAcquisitionAxis_HppdMember_RangeAxis_MaximumMember" unitRef="U005" decimals="INF">0.1</ebs:ContingentConsiderationPercentageOfNetSales>
  <!--Contingent Consideration Percentage Of Net Sales-Minimum [Member]-HPPD [Member]-->
  <ebs:ContingentConsiderationPercentageOfNetSales contextRef="c20130801_BusinessAcquisitionAxis_HppdMember_RangeAxis_MinimumMember" unitRef="U005" decimals="INF">0.05</ebs:ContingentConsiderationPercentageOfNetSales>
  <!--EBS_SalesBasedRoyaltyPayments-Evolva Holding SA 035 [Member]-Minimum [Member]-->
  <ebs:EBSSalesBasedRoyaltyPayments contextRef="c20141217_BusinessAcquisitionAxis_EvolvaHoldingSA035Member_RangeAxis_MinimumMember" unitRef="U005" decimals="INF">0.05</ebs:EBSSalesBasedRoyaltyPayments>
  <!--EBS_SalesBasedRoyaltyPayments-Evolva Holding SA 035 [Member]-Maximum [Member]-->
  <ebs:EBSSalesBasedRoyaltyPayments contextRef="c20141217_BusinessAcquisitionAxis_EvolvaHoldingSA035Member_RangeAxis_MaximumMember" unitRef="U005" decimals="INF">0.1</ebs:EBSSalesBasedRoyaltyPayments>
  <!--Share based Compensation Arrangement Share based Payment Award, Awards Vested in Period, Fair Value-Stock Options [Member]-->
  <ebs:ShareBasedCompensationArrangementShareBasedPaymentAwardAwardsVestedInPeriodFairValue contextRef="c20140101to20141231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U001" decimals="-5">12300000</ebs:ShareBasedCompensationArrangementShareBasedPaymentAwardAwardsVestedInPeriodFairValue>
  <!--Share based Compensation Arrangement Share based Payment Award, Awards Vested in Period, Fair Value-Stock Options [Member]-->
  <ebs:ShareBasedCompensationArrangementShareBasedPaymentAwardAwardsVestedInPeriodFairValue contextRef="c20120101to20121231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U001" decimals="-5">10300000</ebs:ShareBasedCompensationArrangementShareBasedPaymentAwardAwardsVestedInPeriodFairValue>
  <!--Share based Compensation Arrangement Share based Payment Award, Awards Vested in Period, Fair Value-Stock Options [Member]-->
  <ebs:ShareBasedCompensationArrangementShareBasedPaymentAwardAwardsVestedInPeriodFairValue contextRef="c20130101to20131231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U001" decimals="-5">9100000</ebs:ShareBasedCompensationArrangementShareBasedPaymentAwardAwardsVestedInPeriodFairValue>
  <!--Employee Stock Purchase Plan, Number of plan periods-Employee Stock Purchase Plan [Member]-->
  <ebs:EmployeeStockPurchasePlanNumberOfPlanPeriods contextRef="c20140101to20141231_PlanNameAxis_EmployeeStockPurchasePlanMember" unitRef="U007" decimals="INF">2</ebs:EmployeeStockPurchasePlanNumberOfPlanPeriods>
  <!--Employee Stock Purchase Plan, Threshold limit for common stock ownership to be ineligible to participate in ESPP, Percentage-Employee Stock Purchase Plan [Member]-->
  <ebs:EmployeeStockPurchasePlanThresholdLimitForCommonStockOwnershipToBeIneligibleToParticipateInEsppPercentage contextRef="c20140101to20141231_PlanNameAxis_EmployeeStockPurchasePlanMember" unitRef="U005" decimals="INF">0.05</ebs:EmployeeStockPurchasePlanThresholdLimitForCommonStockOwnershipToBeIneligibleToParticipateInEsppPercentage>
  <!--Share Based Compensation Arrangement, Equity Instruments other than Options, Outstanding, Aggregate Intrinsic value-Emergent BioSolutions Inc. 2006 Stock Incentive Plan [Member]-Restricted Stock Units (RSUs) [Member]-->
  <ebs:ShareBasedCompensationArrangementEquityInstrumentsOtherThanOptionsOutstandingAggregateIntrinsicValue contextRef="c20131231_AwardTypeAxis_RestrictedStockUnitsRSUMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember" unitRef="U001" decimals="0">18246611</ebs:ShareBasedCompensationArrangementEquityInstrumentsOtherThanOptionsOutstandingAggregateIntrinsicValue>
  <!--Share Based Compensation Arrangement, Equity Instruments other than Options, Outstanding, Aggregate Intrinsic value-Restricted Stock Units (RSUs) [Member]-Emergent BioSolutions Inc. 2006 Stock Incentive Plan [Member]-->
  <ebs:ShareBasedCompensationArrangementEquityInstrumentsOtherThanOptionsOutstandingAggregateIntrinsicValue contextRef="c20141231_AwardTypeAxis_RestrictedStockUnitsRSUMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember" unitRef="U001" decimals="0">25251904</ebs:ShareBasedCompensationArrangementEquityInstrumentsOtherThanOptionsOutstandingAggregateIntrinsicValue>
  <!--Number of stock based employee compensation plans-Emergent Plans [Member]-->
  <ebs:NumberOfStockBasedEmployeeCompensationPlans contextRef="c20141231_PlanNameAxis_EmergentPlansMember" unitRef="U007" decimals="INF">2</ebs:NumberOfStockBasedEmployeeCompensationPlans>
  <!--Share Based Compensation Arrangement by share Based Payment Award, Options, Exercise Period-Emergent BioSolutions Inc. 2006 Stock Incentive Plan [Member]-Stock Options [Member]-->
  <ebs:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePeriod contextRef="c20140101to20141231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember">P10Y</ebs:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePeriod>
  <!--Share Based Compensation Arrangement by share Based Payment Award, Contractual life of awards-Emergent BioSolutions Inc. 2006 Stock Incentive Plan [Member]-Stock Options [Member]-->
  <ebs:ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualLifeOfAwards contextRef="c20140101to20141231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember">P10Y</ebs:ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualLifeOfAwards>
  <!--Restricted stock unit conversion ratio-Emergent BioSolutions Inc. 2006 Stock Incentive Plan [Member]-Restricted Stock Units (RSUs) [Member]-->
  <ebs:RestrictedStockUnitConversionRatio contextRef="c20141231_AwardTypeAxis_RestrictedStockUnitsRSUMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember" unitRef="U005" decimals="INF">2.3000000000000000</ebs:RestrictedStockUnitConversionRatio>
  <!--Exercise price of option as percentage of fair market value at grant date, minimum-Emergent BioSolutions Inc. 2006 Stock Incentive Plan [Member]-Stock Options [Member]-Minimum [Member]-->
  <ebs:ExercisePriceOfOptionAsPercentageOfFairMarketValueAtGrantDateMinimum contextRef="c20141231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember_RangeAxis_MinimumMember" unitRef="U005" decimals="INF">1</ebs:ExercisePriceOfOptionAsPercentageOfFairMarketValueAtGrantDateMinimum>
  <!--Period of contractual agreement-->
  <ebs:PeriodOfContractualAgreement contextRef="c20140101to20141231">P5Y</ebs:PeriodOfContractualAgreement>
  <!--Percentage of total spending in collaboration used to determine the receivable, revenue, payable and expense during period-->
  <ebs:PercentageOfTotalSpendingInCollaborationUsedToDetermineReceivableRevenuePayableAndExpenseDuringPeriod contextRef="c20140101to20141231" unitRef="U005" decimals="0">0</ebs:PercentageOfTotalSpendingInCollaborationUsedToDetermineReceivableRevenuePayableAndExpenseDuringPeriod>
  <!--Number of doses of FDA licensed anthrax vaccine to be supplied under contract-->
  <ebs:NumberOfDosesOfFdaLicensedAnthraxVaccineToBeSuppliedUnderContract contextRef="c20140101to20141231" unitRef="U006" decimals="-4">44750000</ebs:NumberOfDosesOfFdaLicensedAnthraxVaccineToBeSuppliedUnderContract>
  <!--Business Interruption Insurance Revenue-->
  <ebs:BusinessInterruptionInsuranceRevenue contextRef="c20130101to20131231" unitRef="U001" decimals="-5">1700000</ebs:BusinessInterruptionInsuranceRevenue>
  <!--Business Interruption Insurance Recovery [Text Block]-->
  <ebs:BusinessInterruptionInsuranceRecoveryTextBlock contextRef="c20140101to20141231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;18. Business interruption insurance recovery&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;During the year ended December 31, 2012, the Company recorded a $1.7 million in insurance recovery related to a power outage at its Lansing, Michigan facility. The insurance recovery is classified in the Company's statement of operations as other income (expense), net.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</ebs:BusinessInterruptionInsuranceRecoveryTextBlock>
  <!--Finite Lived Intangible Assets Amortization Expense Year Five and After-->
  <ebs:FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveAndAfter contextRef="c20141231" unitRef="U001" decimals="-3">26629000</ebs:FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveAndAfter>
  <!--Operating Leases, Rent Expense, Annual Escalation Percentage-Office and laboratory space, Rockville, Maryland [Member]-->
  <ebs:OperatingLeasesRentExpenseAnnualEscalationPercentage contextRef="c20141231_PropertyPlantAndEquipmentByTypeAxis_OfficeAndLaboratorySpaceRockvilleMarylandMember" unitRef="U005" decimals="2">0.03</ebs:OperatingLeasesRentExpenseAnnualEscalationPercentage>
  <!--Operating Leases, Future Minimum Payments Due Net of Future Sublease Income-->
  <ebs:OperatingLeasesFutureMinimumPaymentsDueNetOfFutureSubleaseIncome contextRef="c20141231" unitRef="U001" decimals="-3">9738000</ebs:OperatingLeasesFutureMinimumPaymentsDueNetOfFutureSubleaseIncome>
  <!--Debt Instrument, covenant, leverage ratio-Credit Agreement [Member]-->
  <ebs:DebtInstrumentCovenantLeverageRatio contextRef="c20140101to20140331_LongtermDebtTypeAxis_CreditAgreementMember" unitRef="U008" decimals="INF">4.00</ebs:DebtInstrumentCovenantLeverageRatio>
  <!--Debt Instrument, covenant, leverage ratio-Credit Agreement [Member]-->
  <ebs:DebtInstrumentCovenantLeverageRatio contextRef="c20140101to20140930_LongtermDebtTypeAxis_CreditAgreementMember" unitRef="U008" decimals="INF">3.75</ebs:DebtInstrumentCovenantLeverageRatio>
  <!--Debt Instrument, covenant, leverage ratio-Credit Agreement [Member]-->
  <ebs:DebtInstrumentCovenantLeverageRatio contextRef="c20140101to20141231_LongtermDebtTypeAxis_CreditAgreementMember" unitRef="U008" decimals="INF">3.50</ebs:DebtInstrumentCovenantLeverageRatio>
  <!--Debt Instrument, covenant, debt coverage ratio-Credit Agreement [Member]-->
  <ebs:DebtInstrumentCovenantDebtCoverageRatio contextRef="c20140101to20141231_LongtermDebtTypeAxis_CreditAgreementMember" unitRef="U008" decimals="INF">2.50</ebs:DebtInstrumentCovenantDebtCoverageRatio>
  <!--Debt instrument covenant, minimum cash and liquid investments balance-Credit Agreement [Member]-->
  <ebs:DebtInstrumentCovenantMinimumCashAndLiquidInvestmentsBalance contextRef="c20141231_LongtermDebtTypeAxis_CreditAgreementMember" unitRef="U001" decimals="-6">50000000</ebs:DebtInstrumentCovenantMinimumCashAndLiquidInvestmentsBalance>
  <!--Proceeds From Borrowings On Long Term Indebtness And Line Of Credit-Revolving Credit Loan dated December 2013, due in December 2018 [Member]-->
  <ebs:ProceedsFromBorrowingsOnLongTermIndebtnessAndLineOfCredit contextRef="c20130101to20131231_LongtermDebtTypeAxis_RevolvingCreditLoanDatedDecember2013DueInDecember2018Member" unitRef="U001" decimals="-5">62000000</ebs:ProceedsFromBorrowingsOnLongTermIndebtnessAndLineOfCredit>
  <!--Number of lending institutions-Credit Agreement [Member]-->
  <ebs:NumberOfLendingInstitutions contextRef="c20140101to20141231_LongtermDebtTypeAxis_CreditAgreementMember" unitRef="U008" decimals="INF">3</ebs:NumberOfLendingInstitutions>
  <!--Debt Instrument, Number of Equity Instruments-Convertible Senior Notes Due 2021 [Member]-->
  <ebs:DebtInstrumentNumberOfEquityInstruments contextRef="c20140101to20140129_LongtermDebtTypeAxis_ConvertibleSeniorNotesDue2021Member" unitRef="U002" decimals="4">30.8821</ebs:DebtInstrumentNumberOfEquityInstruments>
  <!--Debt Instrument, covenant, senior leverage ratio-Credit Agreement [Member]-->
  <ebs:DebtInstrumentCovenantSeniorLeverageRatio contextRef="c20140101to20141231_LongtermDebtTypeAxis_CreditAgreementMember" unitRef="U008" decimals="INF">2.00</ebs:DebtInstrumentCovenantSeniorLeverageRatio>
  <!--Defined Contribution Plan, Percentage of Employee Gross Salary Subject to Employer Matching-->
  <ebs:DefinedContributionPlanPercentageOfEmployeeGrossSalarySubjectToEmployerMatching contextRef="c20140101to20141231" unitRef="U005" decimals="INF">0.06</ebs:DefinedContributionPlanPercentageOfEmployeeGrossSalarySubjectToEmployerMatching>
  <!--Noncontrolling Interest, Noncash development expenses from joint venture-Noncontrolling Interest in Subsidiary [Member]-->
  <ebs:NoncontrollingInterestNoncashDevelopmentExpensesFromJointVenture contextRef="c20120101to20121231_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U001" decimals="-3">3670000</ebs:NoncontrollingInterestNoncashDevelopmentExpensesFromJointVenture>
  <!--Noncontrolling Interest, Noncash development expenses from joint venture-Retained Earnings [Member]-->
  <ebs:NoncontrollingInterestNoncashDevelopmentExpensesFromJointVenture contextRef="c20130101to20131231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3">0</ebs:NoncontrollingInterestNoncashDevelopmentExpensesFromJointVenture>
  <!--Noncontrolling Interest, Noncash development expenses from joint venture-Accumulated Other Comprehensive Loss [Member]-->
  <ebs:NoncontrollingInterestNoncashDevelopmentExpensesFromJointVenture contextRef="c20130101to20131231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3">0</ebs:NoncontrollingInterestNoncashDevelopmentExpensesFromJointVenture>
  <!--Noncontrolling Interest, Noncash development expenses from joint venture-Retained Earnings [Member]-->
  <ebs:NoncontrollingInterestNoncashDevelopmentExpensesFromJointVenture contextRef="c20120101to20121231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3">0</ebs:NoncontrollingInterestNoncashDevelopmentExpensesFromJointVenture>
  <!--Noncontrolling Interest, Noncash development expenses from joint venture-Accumulated Other Comprehensive Loss [Member]-->
  <ebs:NoncontrollingInterestNoncashDevelopmentExpensesFromJointVenture contextRef="c20140101to20141231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3">0</ebs:NoncontrollingInterestNoncashDevelopmentExpensesFromJointVenture>
  <!--Noncontrolling Interest, Noncash development expenses from joint venture-->
  <ebs:NoncontrollingInterestNoncashDevelopmentExpensesFromJointVenture contextRef="c20140101to20141231" unitRef="U001" decimals="-3">453000</ebs:NoncontrollingInterestNoncashDevelopmentExpensesFromJointVenture>
  <!--Noncontrolling Interest, Noncash development expenses from joint venture-->
  <ebs:NoncontrollingInterestNoncashDevelopmentExpensesFromJointVenture contextRef="c20120101to20121231" unitRef="U001" decimals="-3">3670000</ebs:NoncontrollingInterestNoncashDevelopmentExpensesFromJointVenture>
  <!--Noncontrolling Interest, Noncash development expenses from joint venture-Noncontrolling Interest in Subsidiary [Member]-->
  <ebs:NoncontrollingInterestNoncashDevelopmentExpensesFromJointVenture contextRef="c20130101to20131231_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U001" decimals="-3">-347000</ebs:NoncontrollingInterestNoncashDevelopmentExpensesFromJointVenture>
  <!--Noncontrolling Interest, Noncash development expenses from joint venture-Retained Earnings [Member]-->
  <ebs:NoncontrollingInterestNoncashDevelopmentExpensesFromJointVenture contextRef="c20140101to20141231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3">0</ebs:NoncontrollingInterestNoncashDevelopmentExpensesFromJointVenture>
  <!--Noncontrolling Interest, Noncash development expenses from joint venture-->
  <ebs:NoncontrollingInterestNoncashDevelopmentExpensesFromJointVenture contextRef="c20130101to20131231" unitRef="U001" decimals="-3">-347000</ebs:NoncontrollingInterestNoncashDevelopmentExpensesFromJointVenture>
  <!--Noncontrolling Interest, Noncash development expenses from joint venture-Noncontrolling Interest in Subsidiary [Member]-->
  <ebs:NoncontrollingInterestNoncashDevelopmentExpensesFromJointVenture contextRef="c20140101to20141231_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U001" decimals="-3">453000</ebs:NoncontrollingInterestNoncashDevelopmentExpensesFromJointVenture>
  <!--Provision for chargebacks, charged to earnings-->
  <ebs:ProvisionForChargebacksChargedToEarnings contextRef="c20140101to20141231" unitRef="U001" decimals="-3">299000</ebs:ProvisionForChargebacksChargedToEarnings>
  <!--Provision for chargebacks, charged to earnings-->
  <ebs:ProvisionForChargebacksChargedToEarnings contextRef="c20130101to20131231" unitRef="U001" decimals="-3">0</ebs:ProvisionForChargebacksChargedToEarnings>
  <!--Provision for chargebacks, charged to earnings-->
  <ebs:ProvisionForChargebacksChargedToEarnings contextRef="c20120101to20121231" unitRef="U001" decimals="-3">0</ebs:ProvisionForChargebacksChargedToEarnings>
  <!--Write off of bank fees-->
  <ebs:WriteOffOfBankFees contextRef="c20130101to20131231" unitRef="U001" decimals="-3">0</ebs:WriteOffOfBankFees>
  <!--Write off of bank fees-->
  <ebs:WriteOffOfBankFees contextRef="c20120101to20121231" unitRef="U001" decimals="-3">0</ebs:WriteOffOfBankFees>
  <!--Write off of bank fees-->
  <ebs:WriteOffOfBankFees contextRef="c20140101to20141231" unitRef="U001" decimals="-3">1831000</ebs:WriteOffOfBankFees>
  <!--Contingent value right payment-->
  <ebs:ContingentValueRightPayment contextRef="c20120101to20121231" unitRef="U001" decimals="-3">1748000</ebs:ContingentValueRightPayment>
  <!--Contingent value right payment-->
  <ebs:ContingentValueRightPayment contextRef="c20140101to20141231" unitRef="U001" decimals="-3">1579000</ebs:ContingentValueRightPayment>
  <!--Contingent value right payment-->
  <ebs:ContingentValueRightPayment contextRef="c20130101to20131231" unitRef="U001" decimals="-3">348000</ebs:ContingentValueRightPayment>
  <!--Proceeds From Borrowings On Long Term Indebtedness And Line Of Credit-->
  <ebs:ProceedsFromBorrowingsOnLongTermIndebtednessAndLineOfCredit contextRef="c20120101to20121231" unitRef="U001" decimals="-3">13547000</ebs:ProceedsFromBorrowingsOnLongTermIndebtednessAndLineOfCredit>
  <!--Proceeds From Borrowings On Long Term Indebtedness And Line Of Credit-->
  <ebs:ProceedsFromBorrowingsOnLongTermIndebtednessAndLineOfCredit contextRef="c20130101to20131231" unitRef="U001" decimals="-3">62000000</ebs:ProceedsFromBorrowingsOnLongTermIndebtednessAndLineOfCredit>
  <!--Proceeds From Borrowings On Long Term Indebtedness And Line Of Credit-->
  <ebs:ProceedsFromBorrowingsOnLongTermIndebtednessAndLineOfCredit contextRef="c20140101to20141231" unitRef="U001" decimals="-3">1000000</ebs:ProceedsFromBorrowingsOnLongTermIndebtednessAndLineOfCredit>
  <!--Provision For Fair Value Of Contingent Value Rights-->
  <ebs:ProvisionForFairValueOfContingentValueRights contextRef="c20140101to20141231" unitRef="U001" decimals="-3">3133000</ebs:ProvisionForFairValueOfContingentValueRights>
  <!--Provision For Fair Value Of Contingent Value Rights-->
  <ebs:ProvisionForFairValueOfContingentValueRights contextRef="c20130101to20131231" unitRef="U001" decimals="-3">735000</ebs:ProvisionForFairValueOfContingentValueRights>
  <!--Provision For Fair Value Of Contingent Value Rights-->
  <ebs:ProvisionForFairValueOfContingentValueRights contextRef="c20120101to20121231" unitRef="U001" decimals="-3">-3005000</ebs:ProvisionForFairValueOfContingentValueRights>
  <!--Contingent Purchase Consideration Net Of Current Portion-->
  <ebs:ContingentPurchaseConsiderationNetOfCurrentPortion contextRef="c20131231" unitRef="U001" decimals="-3">15278000</ebs:ContingentPurchaseConsiderationNetOfCurrentPortion>
  <!--Contingent Purchase Consideration Net Of Current Portion-->
  <ebs:ContingentPurchaseConsiderationNetOfCurrentPortion contextRef="c20141231" unitRef="U001" decimals="-3">41170000</ebs:ContingentPurchaseConsiderationNetOfCurrentPortion>
  <!--Provision for chargebacks-->
  <ebs:ProvisionForChargebacks contextRef="c20141231" unitRef="U001" decimals="-3">2246000</ebs:ProvisionForChargebacks>
  <!--Provision for chargebacks-->
  <ebs:ProvisionForChargebacks contextRef="c20131231" unitRef="U001" decimals="-3">0</ebs:ProvisionForChargebacks>
  <!--Contingent Value Rights Current Portion-->
  <ebs:ContingentValueRightsCurrentPortion contextRef="c20131231" unitRef="U001" decimals="-3">1341000</ebs:ContingentValueRightsCurrentPortion>
  <!--Contingent Value Rights Current Portion-->
  <ebs:ContingentValueRightsCurrentPortion contextRef="c20141231" unitRef="U001" decimals="-3">6487000</ebs:ContingentValueRightsCurrentPortion>
  <!--Property, Plant and Equipment Useful Lives Table Text Block [Text Block]-->
  <ebs:PropertyPlantAndEquipmentUsefulLivesTableTextBlockTextBlock contextRef="c20140101to20141231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Property, plant and equipment are stated at cost. Depreciation is computed using the straight-line method over the following estimated useful lives:&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td style="width: 50.01%; vertical-align: top;"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Buildings&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 49.99%; vertical-align: top;"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;31-39 years&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width: 50.01%; vertical-align: top;"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Building improvements&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 49.99%; vertical-align: top;"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;10-39 years&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width: 50.01%; vertical-align: top;"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Furniture and equipment&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 49.99%; vertical-align: top;"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;3-15 years&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width: 50.01%; vertical-align: top;"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Software&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 49.99%; vertical-align: top;"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Lesser of 3-5 years or product life&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width: 50.01%; vertical-align: top;"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Leasehold improvements&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 49.99%; vertical-align: top;"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;Lesser of the asset life or lease term&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</ebs:PropertyPlantAndEquipmentUsefulLivesTableTextBlockTextBlock>
  <!--Contingent purchase consideration obligations [Policy Text Block]-->
  <ebs:ContingentPurchaseConsiderationObligationsPolicyTextBlock contextRef="c20140101to20141231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Contingent purchase consideration obligations&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;The Company records contingent purchase obligations at fair value. Obligations are based on sales royalties, primarily for RSDL. The fair value model used to calculate this obligation is based on the income approach (a discounted cash flow model) that has been risk adjusted based on the probability of achievement of net sales.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;The inputs the Company uses for determining the fair value of the contingent purchase consideration are Level 3 fair value measurements. The Company re-evaluates the fair value of the contingent purchase consideration obligation on a quarterly basis. Changes in the fair value can result from adjustments to the discount rates and updates in the assumed timing of or achievement of net sales. Any future increase in the fair value of the contingent purchase consideration obligation is based on an increased likelihood that the underlying net sales will be achieved and the associated payment or payments which will therefore become due and payable. These increases in the fair value of the contingent purchase consideration obligation will result in a charge to cost of product sales in the period in which the increase is determined. Similarly, any future decrease in the fair value of the contingent purchase consideration obligation will result in a reduction in cost of product sales.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</ebs:ContingentPurchaseConsiderationObligationsPolicyTextBlock>
  <!--Risks and uncertainties [Policy Text Block]-->
  <ebs:RisksAndUncertaintiesPolicyTextBlock contextRef="c20140101to20141231">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt; font-weight: bold;"&gt;Certain risks and uncertainties&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-size: 10pt;"&gt;The Company has derived a majority of all of its revenue from sales of BioThrax under contracts with the U.S. government. The Company's CDC contract does not necessarily increase the likelihood that it will secure future comparable contracts with the U.S. government. The Company expects that a significant portion of the business that it will seek in the near future, in particular for BioThrax, will be under government contracts that present a number of risks that are not typically present in the commercial contracting process. U.S. government contracts for BioThrax are subject to unilateral termination or modification by the government. The Company may fail to achieve significant sales of BioThrax to customers in addition to the U.S. government, which would harm its growth opportunities. The Company may not be able to sustain or increase profitability. The Company may not be able to manufacture BioThrax consistently in accordance with FDA specifications.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</ebs:RisksAndUncertaintiesPolicyTextBlock>
  <!--Payment of contingent obligations-->
  <ebs:PaymentOfContingentObligations contextRef="c20130101to20131231" unitRef="U001" xsi:nil="true" />
  <!--Money Market Funds, Fair Value Disclosure-Fair Value, Inputs, Level 1 [Member]-Fair Value, Measurements, Recurring [Member]-->
  <ebs:MoneyMarketFundsFairValueDisclosure contextRef="c20141231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="-3" id="Item-2">111912000</ebs:MoneyMarketFundsFairValueDisclosure>
  <!--Money Market Funds, Fair Value Disclosure-Fair Value, Measurements, Recurring [Member]-->
  <ebs:MoneyMarketFundsFairValueDisclosure contextRef="c20131231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="-3" id="Item-3">37701000</ebs:MoneyMarketFundsFairValueDisclosure>
  <!--Money Market Funds, Fair Value Disclosure-Fair Value, Measurements, Recurring [Member]-Fair Value, Inputs, Level 3 [Member]-->
  <ebs:MoneyMarketFundsFairValueDisclosure contextRef="c20131231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="-3" id="Item-4">0</ebs:MoneyMarketFundsFairValueDisclosure>
  <!--Money Market Funds, Fair Value Disclosure-Fair Value, Measurements, Recurring [Member]-Fair Value, Inputs, Level 3 [Member]-->
  <ebs:MoneyMarketFundsFairValueDisclosure contextRef="c20141231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="-3" id="Item-5">0</ebs:MoneyMarketFundsFairValueDisclosure>
  <!--Money Market Funds, Fair Value Disclosure-Fair Value, Measurements, Recurring [Member]-Fair Value, Inputs, Level 2 [Member]-->
  <ebs:MoneyMarketFundsFairValueDisclosure contextRef="c20141231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="-3" id="Item-6">0</ebs:MoneyMarketFundsFairValueDisclosure>
  <!--Money Market Funds, Fair Value Disclosure-Fair Value, Inputs, Level 1 [Member]-Fair Value, Measurements, Recurring [Member]-->
  <ebs:MoneyMarketFundsFairValueDisclosure contextRef="c20131231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="-3" id="Item-7">37701000</ebs:MoneyMarketFundsFairValueDisclosure>
  <!--Money Market Funds, Fair Value Disclosure-Fair Value, Inputs, Level 2 [Member]-Fair Value, Measurements, Recurring [Member]-->
  <ebs:MoneyMarketFundsFairValueDisclosure contextRef="c20131231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="-3" id="Item-8">0</ebs:MoneyMarketFundsFairValueDisclosure>
  <!--Money Market Funds, Fair Value Disclosure-Fair Value, Measurements, Recurring [Member]-->
  <ebs:MoneyMarketFundsFairValueDisclosure contextRef="c20141231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="-3" id="Item-9">111912000</ebs:MoneyMarketFundsFairValueDisclosure>
  <!--Contingent Value Rights, Fair Value Disclosure-Fair Value, Measurements, Recurring [Member]-Fair Value, Inputs, Level 3 [Member]-->
  <ebs:ContingentValueRightsFairValueDisclosure contextRef="c20131231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="-3">16619000</ebs:ContingentValueRightsFairValueDisclosure>
  <!--Contingent Value Rights, Fair Value Disclosure-Fair Value, Measurements, Recurring [Member]-->
  <ebs:ContingentValueRightsFairValueDisclosure contextRef="c20131231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="-3">16619000</ebs:ContingentValueRightsFairValueDisclosure>
  <!--Contingent Value Rights, Fair Value Disclosure-Fair Value, Measurements, Recurring [Member]-Fair Value, Inputs, Level 3 [Member]-->
  <ebs:ContingentValueRightsFairValueDisclosure contextRef="c20141231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="-3">47657000</ebs:ContingentValueRightsFairValueDisclosure>
  <!--Contingent Value Rights, Fair Value Disclosure-Fair Value, Measurements, Recurring [Member]-->
  <ebs:ContingentValueRightsFairValueDisclosure contextRef="c20141231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="-3">47657000</ebs:ContingentValueRightsFairValueDisclosure>
  <!--Contingent Value Rights, Fair Value Disclosure-Fair Value, Measurements, Recurring [Member]-Fair Value, Inputs, Level 2 [Member]-->
  <ebs:ContingentValueRightsFairValueDisclosure contextRef="c20131231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="-3">0</ebs:ContingentValueRightsFairValueDisclosure>
  <!--Contingent Value Rights, Fair Value Disclosure-Fair Value, Inputs, Level 1 [Member]-Fair Value, Measurements, Recurring [Member]-->
  <ebs:ContingentValueRightsFairValueDisclosure contextRef="c20141231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="-3">0</ebs:ContingentValueRightsFairValueDisclosure>
  <!--Contingent Value Rights, Fair Value Disclosure-Fair Value, Inputs, Level 1 [Member]-Fair Value, Measurements, Recurring [Member]-->
  <ebs:ContingentValueRightsFairValueDisclosure contextRef="c20131231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="-3">0</ebs:ContingentValueRightsFairValueDisclosure>
  <!--Contingent Value Rights, Fair Value Disclosure-Fair Value, Inputs, Level 2 [Member]-Fair Value, Measurements, Recurring [Member]-->
  <ebs:ContingentValueRightsFairValueDisclosure contextRef="c20141231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="-3">0</ebs:ContingentValueRightsFairValueDisclosure>
  <!--Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases, Sales, Issues-->
  <ebs:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssues contextRef="c20130101to20131231" unitRef="U001" decimals="-3">16232000</ebs:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssues>
  <!--Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases, Sales, Issues-->
  <ebs:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssues contextRef="c20140101to20141231" unitRef="U001" decimals="-3">29484000</ebs:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssues>
  <!--Deferred Income Tax Expense (Benefit) before purchase price adjustment-->
  <ebs:DeferredIncomeTaxExpenseBenefitBeforePurchasePriceAdjustment contextRef="c20120101to20121231" unitRef="U001" decimals="-3">3383000</ebs:DeferredIncomeTaxExpenseBenefitBeforePurchasePriceAdjustment>
  <!--Deferred Income Tax Expense (Benefit) before purchase price adjustment-->
  <ebs:DeferredIncomeTaxExpenseBenefitBeforePurchasePriceAdjustment contextRef="c20140101to20141231" unitRef="U001" decimals="-3">5318000</ebs:DeferredIncomeTaxExpenseBenefitBeforePurchasePriceAdjustment>
  <!--Deferred Income Tax Expense (Benefit) before purchase price adjustment-->
  <ebs:DeferredIncomeTaxExpenseBenefitBeforePurchasePriceAdjustment contextRef="c20130101to20131231" unitRef="U001" decimals="-3">13859000</ebs:DeferredIncomeTaxExpenseBenefitBeforePurchasePriceAdjustment>
  <!--Operating Loss Carryforwards, Period of Change in Nature and Conduct of Business for Changing Life of Operating Loss Carryforwards-Foreign Tax Authority [Member]-->
  <ebs:OperatingLossCarryforwardsPeriodOfChangeInNatureAndConductOfBusinessForChangingLifeOfOperatingLossCarryforwards contextRef="c20140101to20141231_IncomeTaxAuthorityAxis_ForeignCountryMember">P3Y</ebs:OperatingLossCarryforwardsPeriodOfChangeInNatureAndConductOfBusinessForChangingLifeOfOperatingLossCarryforwards>
  <!--Adjusted net loss-->
  <ebs:AdjustedNetLoss contextRef="c20140101to20141231" unitRef="U001" decimals="-3">40355000</ebs:AdjustedNetLoss>
  <!--Adjusted net loss-->
  <ebs:AdjustedNetLoss contextRef="c20130101to20131231" unitRef="U001" decimals="-3">31135000</ebs:AdjustedNetLoss>
  <!--Adjusted net loss-->
  <ebs:AdjustedNetLoss contextRef="c20120101to20121231" unitRef="U001" decimals="-3">23524000</ebs:AdjustedNetLoss>
  <!--Unrecognized tax benefits, amount expected to be reversed within next twelve months-->
  <ebs:UnrecognizedTaxBenefitsAmountExpectedToBeReversedWithinNextTwelveMonths contextRef="c20131231" unitRef="U001" decimals="0">152000</ebs:UnrecognizedTaxBenefitsAmountExpectedToBeReversedWithinNextTwelveMonths>
  <!--Unrecognized tax benefits, amount expected to be reversed within next twelve months-->
  <ebs:UnrecognizedTaxBenefitsAmountExpectedToBeReversedWithinNextTwelveMonths contextRef="c20141231" unitRef="U001" decimals="0">140000</ebs:UnrecognizedTaxBenefitsAmountExpectedToBeReversedWithinNextTwelveMonths>
  <!--Unrecognized tax benefits, current-->
  <ebs:UnrecognizedTaxBenefitsCurrent contextRef="c20131231" unitRef="U001" decimals="0">132000</ebs:UnrecognizedTaxBenefitsCurrent>
  <!--Unrecognized tax benefits, current-->
  <ebs:UnrecognizedTaxBenefitsCurrent contextRef="c20141231" unitRef="U001" decimals="0">183000</ebs:UnrecognizedTaxBenefitsCurrent>
  <!--Unrecognized tax benefits, noncurrent-->
  <ebs:UnrecognizedTaxBenefitsNoncurrent contextRef="c20131231" unitRef="U001" decimals="0">991000</ebs:UnrecognizedTaxBenefitsNoncurrent>
  <!--Unrecognized tax benefits, noncurrent-->
  <ebs:UnrecognizedTaxBenefitsNoncurrent contextRef="c20141231" unitRef="U001" decimals="0">1064000</ebs:UnrecognizedTaxBenefitsNoncurrent>
  <!--In process research and development-->
  <ebs:InProcessResearchAndDevelopment contextRef="c20131231" unitRef="U001" decimals="-3">41800000</ebs:InProcessResearchAndDevelopment>
  <!--In process research and development-->
  <ebs:InProcessResearchAndDevelopment contextRef="c20141231" unitRef="U001" decimals="-3">77800000</ebs:InProcessResearchAndDevelopment>
  <!--In process research and development-All Other [Member]-->
  <ebs:InProcessResearchAndDevelopment contextRef="c20141231_StatementBusinessSegmentsAxis_AllOtherSegmentsMember" unitRef="U001" decimals="-3">0</ebs:InProcessResearchAndDevelopment>
  <!--In process research and development-Biosciences [Member]-->
  <ebs:InProcessResearchAndDevelopment contextRef="c20131231_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U001" decimals="-3">41800000</ebs:InProcessResearchAndDevelopment>
  <!--In process research and development-Biodefense [Member]-->
  <ebs:InProcessResearchAndDevelopment contextRef="c20131231_StatementBusinessSegmentsAxis_BiodefenseMember" unitRef="U001" decimals="-3">0</ebs:InProcessResearchAndDevelopment>
  <!--In process research and development-All Other [Member]-->
  <ebs:InProcessResearchAndDevelopment contextRef="c20131231_StatementBusinessSegmentsAxis_AllOtherSegmentsMember" unitRef="U001" decimals="-3">0</ebs:InProcessResearchAndDevelopment>
  <!--In process research and development-Biosciences [Member]-->
  <ebs:InProcessResearchAndDevelopment contextRef="c20121231_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U001" decimals="-3">41800000</ebs:InProcessResearchAndDevelopment>
  <!--In process research and development-Biodefense [Member]-->
  <ebs:InProcessResearchAndDevelopment contextRef="c20141231_StatementBusinessSegmentsAxis_BiodefenseMember" unitRef="U001" decimals="-3">27700000</ebs:InProcessResearchAndDevelopment>
  <!--In process research and development-Biodefense [Member]-->
  <ebs:InProcessResearchAndDevelopment contextRef="c20121231_StatementBusinessSegmentsAxis_BiodefenseMember" unitRef="U001" decimals="-3">0</ebs:InProcessResearchAndDevelopment>
  <!--In process research and development-->
  <ebs:InProcessResearchAndDevelopment contextRef="c20121231" unitRef="U001" decimals="-3">41800000</ebs:InProcessResearchAndDevelopment>
  <!--In process research and development-All Other [Member]-->
  <ebs:InProcessResearchAndDevelopment contextRef="c20121231_StatementBusinessSegmentsAxis_AllOtherSegmentsMember" unitRef="U001" decimals="-3">0</ebs:InProcessResearchAndDevelopment>
  <!--In process research and development-Biosciences [Member]-->
  <ebs:InProcessResearchAndDevelopment contextRef="c20141231_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U001" decimals="-3">50100000</ebs:InProcessResearchAndDevelopment>
  <!--Number of business units-->
  <ebs:NumberOfBusinessUnits contextRef="c20140101to20141231" unitRef="U011" decimals="INF">2</ebs:NumberOfBusinessUnits>
  <!--Contract manufacturing-->
  <ebs:ContractManufacturing contextRef="c20130101to20131231" unitRef="U001" decimals="-3">0</ebs:ContractManufacturing>
  <!--Contract manufacturing-->
  <ebs:ContractManufacturing contextRef="c20140101to20141231" unitRef="U001" decimals="-3">30944000</ebs:ContractManufacturing>
  <!--Contract manufacturing-->
  <ebs:ContractManufacturing contextRef="c20120101to20121231" unitRef="U001" decimals="-3">0</ebs:ContractManufacturing>
  <link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:footnote xlink:label="Footnote-Item-1" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Acquired inventory reflects a $6.2 million adjustment to record inventory at fair value, referred to as a step-up adjustment. The $6.2 million step-up is estimated to be amortized through cost of product sales and contract manufacturing over the next five years based on expected inventory turnover, which will increase cost of product sales and contract manufacturing during such period.</link:footnote>
    <link:loc xlink:href="#Item-1" xlink:label="Item-1_lbl" xlink:type="locator" />
    <link:footnoteArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-1_lbl" xlink:to="Footnote-Item-1" xlink:type="arc" />
    <link:footnote xlink:label="Footnote-Item-2" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Included in cash and cash equivalents in accompanying consolidated balance sheets.</link:footnote>
    <link:loc xlink:href="#Item-2" xlink:label="Item-2_lbl" xlink:type="locator" />
    <link:footnoteArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-2_lbl" xlink:to="Footnote-Item-2" xlink:type="arc" />
    <link:loc xlink:href="#Item-3" xlink:label="Item-3_lbl" xlink:type="locator" />
    <link:footnoteArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-3_lbl" xlink:to="Footnote-Item-2" xlink:type="arc" />
    <link:loc xlink:href="#Item-4" xlink:label="Item-4_lbl" xlink:type="locator" />
    <link:footnoteArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-4_lbl" xlink:to="Footnote-Item-2" xlink:type="arc" />
    <link:loc xlink:href="#Item-5" xlink:label="Item-5_lbl" xlink:type="locator" />
    <link:footnoteArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-5_lbl" xlink:to="Footnote-Item-2" xlink:type="arc" />
    <link:loc xlink:href="#Item-6" xlink:label="Item-6_lbl" xlink:type="locator" />
    <link:footnoteArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-6_lbl" xlink:to="Footnote-Item-2" xlink:type="arc" />
    <link:loc xlink:href="#Item-7" xlink:label="Item-7_lbl" xlink:type="locator" />
    <link:footnoteArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-7_lbl" xlink:to="Footnote-Item-2" xlink:type="arc" />
    <link:loc xlink:href="#Item-8" xlink:label="Item-8_lbl" xlink:type="locator" />
    <link:footnoteArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-8_lbl" xlink:to="Footnote-Item-2" xlink:type="arc" />
    <link:loc xlink:href="#Item-9" xlink:label="Item-9_lbl" xlink:type="locator" />
    <link:footnoteArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-9_lbl" xlink:to="Footnote-Item-2" xlink:type="arc" />
  </link:footnoteLink>
</xbrl>
